Offline copy · daily 10:00 AM PDT · Michigan + Atlanta

Priya Lab Radar

Lab-by-lab fit, funding and hiring odds for Yogapriya Sundaresan

422 Michigan and Atlanta labs holding 430 R01-class awards, 59 of them vision awards (3 vision awards started in the last 30 days), plus 11 directory-sourced lab(s) with no NIH award matched. Every lab is scored on 5 weighted dimensions against her structured profile, with the matching evidence, the gaps, the public roster and the NIH money behind each verdict shown in full. Snapshot 2026-09-23 07:17:51 UTC.

This file is a complete, self-contained copy of the dashboard: no server, no internet, no install. Everything except the outbound source links works offline.

Labs tracked

433

Live lab postings

3

Strong hiring odds

51

Stale or closed

4

Dates unverified

12

Live = posted within 4 months. Measured from the run date 2026-09-23, so anything published before 2026-05-23 is archived rather than counted as current. Postings whose source prints no date are held in a separate "date unverified" state rather than being guessed at.

Scored against her actual CV. Scored from Yogapriya's own documents: a 9-page curriculum vitae dated August 2026 and a one-page research profile dated August 2026, both attached to this workspace. Every term, weight and career-stage judgement below traces to a line in those two files. The terms and weights live in data/profile.json; edit that one file, re-run the generator and every percentage here recomputes.

Act on 2 of 2 postings closing within 14 days

2 postings state a close date inside the next 14 days. The nearest is Postdoctoral Fellow — Landowski Lab (retinal lipid metabolism) (Wayne State University — Landowski Laboratory, Ophthalmology, Visual and Anatomical Sciences), which closes in 7 days on 2026-09-30.

Close dates are whatever the posting's own source states — never inferred. A posting is listed here whether or not it also counts as live, because a stale advert with a close date still ahead can still take an application, and one whose publication date could not be verified can still shut on the day its source prints. Counted from the 2026-09-23 run date.

What the latest refresh found

New = first seen in the most recent refresh run. Anything carried over from an earlier run is not new, however recently it was posted.

Latest run Sep 23, 2026, 07:17 UTC, compared against Sep 23, 2026, 07:03 UTC. 19 run(s) on record, 966 records tracked.

New in this run (0)

No new entries in the latest refresh (last run: Sep 23, 2026, 07:17 UTC). The run found nothing the previous snapshot did not already contain, which is the usual outcome on a quiet day and is reported rather than padded.

Removed since the previous refresh (0)

Nothing disappeared in the latest run.

How the match % is computed

Overall match % is the weighted mean of the five dimension scores below, multiplied by a domain gate that discounts the result when the disease overlap is thin. The three evidence dimensions score by matching their terms against the grant title, abstract, NIH preferred terms and the lab's own public research description; matched term weights are divided by the saturation ceiling (the sum of the top N term weights) so a lab that hits the heaviest few terms reaches 100%. Every card prints the weighted mean, the gate and the final number, and every term carries the CV line that puts it in her profile.

Two percentages, two bodies of text. Posting fit scores the advert's own words — its title, role type and summary. Lab fit scores everything known about the lab: its NIH abstracts, preferred terms and research summary. Employer fit, on an industry posting, scores the employer's own published description of its work. The same opening therefore carries two percentages, and the advert number is usually the lower of the two because there is far less advert text to match against — which is why a score is shown with the amount of text behind it, and why a percentage from too little text is never presented as a fit verdict. The same weighted dimensions and the same domain gate run over both, so the numbers are comparable; what differs is how much the source had to say. Posting entries print both and label each one.

How much text each score came from

How much scorable text a score was actually derived from, measured on the same text the three evidence dimensions read. A match percentage is only a verdict when the text was long enough that a term NOT appearing means the work is absent rather than merely unmentioned. A grant abstract plus NIH preferred terms clears that bar easily; a three-sentence LinkedIn advert does not, and its score is a floor rather than a judgement. Where the bar is not cleared, every surface must print the evidence statement instead of the fit band — never a bare 'Low fit' badge.

A score is called “Scored on enough the text to read as a verdict” once the scored text runs to 120 words or more. Tokens are the alphanumeric words of the scored text, counted after the same normalisation the term matcher uses. 120 is the floor for treating an absence as evidence: it is roughly a full paragraph, it is cleared by every award-derived and directory-derived lab text in this snapshot, and it is cleared by only four of the 37 carried postings — which is the finding, not a tuning accident.

A shorter text is rescued only if it fires at least 4 of her profile terms across all 3 evidence dimensions. A short text can still be scored on if it engaged the profile broadly: saturation needs 10 of the 18 evidence terms, so a text that fires at least 4 of them and touches all three evidence dimensions has given the scorer enough to work with even when it is brief. Both conditions are needed — four terms all inside one dimension leaves two thirds of the profile untested.

Anything below both bars prints “Not enough the text to score reliably” in place of a fit band, and the percentage is presented as a floor set by how little was written. {text} is replaced with the name of the text that was scored — "advert text", "lab text", "employer description" — so a confidence label always says which text it is about and can never read as a statement about her record.

30%

Disease & domain overlap

How close the lab's disease area is to glaucoma, retinal ganglion cell biology and ocular neurodegeneration — the two arms her CV is built on.

20%

Model systems

Whether the lab works in the experimental systems the CV shows her running: transgenic mouse in vivo work, viral-vector delivery and genome editing.

25%

Techniques & readouts

Overlap with the hands-on repertoire listed in the CV's technical skills section: autophagy and organelle quality control, imaging and histology, molecular biochemistry, axonal assays, sequencing and in vivo ocular function.

15%

Seniority & capacity fit

Whether this award looks like it can host someone at her level right now — she is targeting postdoctoral fellow, research associate and staff scientist roles — judged on R01-class money, years of runway left, how recently the award started, and whether a role at that level is actually advertised.

10%

Geography

Target metros are Michigan and the Atlanta area.

The profile being matched

Postdoctoral fellow, ~4 years post-Ph.D.. Postdoctoral Research Fellow, Brunson Center for Translational Vision Research, Department of Ophthalmology and Visual Sciences, Gavin Herbert Eye Institute, University of California, Irvine, with Dr. Gulab S. Zode (August 2022 – present).

13 peer-reviewed articles, 8 of them first-author, plus 3 invited book chapters and 2 funded grants (Gavin Herbert Eye Institute 20/20 Society Pilot Grant as PI, 2023–24; The Glaucoma Foundation Grant as co-investigator with Dr. Zode, 2025). Editorial board member of Eye, 2025–2028.

Roles she is looking for: Postdoctoral Fellow, Research Associate, Staff Scientist. Taken verbatim from the "Positions of interest" block of her August 2026 research profile. Tenure-track faculty and independent PI roles are not among them, so the dashboard does not score faculty searches.

Sources: Yogapriya_Sundaresan_CV_9dde.pdf (August 2026) · Yogapriya_Sundaresan_Research_Profile_8dd2.pdf (August 2026) · https://orcid.org/0000-0002-7983-8249. Profile last edited Sep 21, 2026. ORCID record.

Showing 433 of the 433 labs in this snapshot — 11 directory-sourced — no nih award matched, 79 best fit, 12 lower match, 331 not yet researched. Every heading below prints what it is showing out of what it holds, and the index at the foot of this tab follows the filters unless you untie it there.

Directory-sourced — no NIH award matched (11)

Found by reading department and lab directories rather than by an NIH award sweep, so an eminent PI is not invisible merely because their current funding is a VA merit award, a centre core grant, an R00 or a foundation grant. Each card names the page it was read from and the date. The match % here is scored from a single directory paragraph and carries no seniority credit, so it is a floor and is not comparable with the award-scored labs below.

#1 Lab fit 52% · Not enough lab text to score reliably Hiring: Not enough data Michigan Neuro + ophtho

Thanh Hoang lab

Thanh Hoang · University of Michigan, Ann Arbor MI · lab page ↗

Located at the University of Michigan Kellogg Eye Center, our lab studies fundamental biology of neurodevelopment and regeneration in the brain and retina. We employ large-scale multiomic and genetic approaches in both mouse and human systems. Our ultimate goal is to translate these understandings into therapeutic strategies for treating neurodegenerative diseases. Research focus: regeneration of neurons through cell reprogramming; cell type specification during neurodevelopment; modulating cell interactions for neuroprotection. Published work includes a large-scale CRISPR screen of genetic regulation of retinal ganglion cell regeneration and reprogramming of Müller glia into retinal neurons. (source)

Lab fit breakdown — 52% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 102 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 96% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% = 52%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 96%

    Matched 4 of 6 profile areas (27 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Inherited retinal disease and ocular gene therapy

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Hoang Lab — Neuroscience & Regeneration, University of Michigan Kellogg Eye Center on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#2 Lab fit 36% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Ophthalmology

Andrew J. Feola lab

Andrew J. Feola · Emory University, Atlanta GA

The Feola group investigates how hormonal changes affect visual function and the biomechanical properties of the eye. The team also investigates hormones as neuroprotective against the progression of visual impairment in glaucoma and potentially their benefit in various ocular diseases. (source)

Lab fit breakdown — 36% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 46 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 75% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% = 36%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual function".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 75%

    Matched 3 of 6 profile areas (21 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “visual function”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#3 Lab fit 30% · Not enough lab text to score reliably Hiring: Not enough data Michigan Ophthalmology

Rajesh Rao lab

Rajesh Rao · University of Michigan, Ann Arbor MI · lab page ↗

Blinding diseases including dry age-related macular degeneration, diabetic retinopathy and glaucoma share the feature that critical cells in the retina die and do not regenerate. Our lab uses stem cell biology, genomics and epigenetics to better understand how the retina forms, so that we can learn new ways to generate the retinal cells that die in disease, with the hope of regenerating cells through cell or drug therapies. We also use these technologies to study how eye and orbit cancers develop. (source)

Lab fit breakdown — 30% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 89 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 68% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 30% = 30%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 68%

    Matched 3 of 6 profile areas (19 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Rajesh Rao Lab, University of Michigan on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#4 Lab fit 25% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Ophthalmology

Deepta Ghate lab

Deepta Ghate · Emory University, Atlanta GA

Dr. Ghate's lab focuses on the impact of visual disability on activities of daily living, particularly driving, visual perception, high-level vision, ocular disease and ocular biomarkers for CNS disorders. Current projects include the evaluation of high-level visual functions in glaucoma and the evaluation of the impact of augmented reality cues on driving performance in glaucoma. (source)

Lab fit breakdown — 25% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 64 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 46% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.92 domain gate = 25%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual function".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 46%

    Matched 2 of 6 profile areas (13 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “visual function”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#5 Lab fit 23% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Neuro + ophtho

Sayantan Datta lab

Sayantan Datta · Emory University, Atlanta GA

Using cell and molecular genetics, we study the pathophysiological changes in age-related macular degeneration (AMD), focusing on the mitochondrial and oxidative stress damage in the retinal pigment epithelial cells (RPE). We also use stem-cell-derived RPE cells as a replacement therapy in geographic atrophy, a hallmark feature of late-stage AMD. (source)

Lab fit breakdown — 23% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 59 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 32% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#6 Lab fit 22% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Ophthalmology

John Nickerson lab

John Nickerson · Emory University, Atlanta GA

Dr. Nickerson's research focuses on retinal proteins and their expression in normal animals and in animal models exhibiting characteristics of human eye diseases. (source)

Lab fit breakdown — 22% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 30 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 32% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.82 domain gate = 22%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "eye disease".
  • Mouse / rodent in vivo models Lab text mentions "animal model".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “eye disease”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#7 Lab fit 22% · Not enough lab text to score reliably Hiring: Not enough data Michigan Ophthalmology

Julia E. Richards lab

Julia E. Richards · University of Michigan, Ann Arbor MI · lab page ↗

The research program of Dr. Julia Richards focuses on the underlying causes of hereditary eye disease and the normal processes of ocular aging. Her research has a long-term emphasis on the group of diseases classified as glaucoma, one of the leading causes of irreversible blindness in the United States. Recent breakthroughs in gene mapping and identification of disease genes, disease risk factors, and risk factors associated with endophenotypes have come from collaborations with glaucoma specialists and biostatistical geneticists, and through the International Glaucoma Genetics Consortium. (source)

Lab fit breakdown — 22% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 94 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 46% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.92 domain gate = 22%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "eye disease".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 46%

    Matched 2 of 6 profile areas (13 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “eye disease”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Dr. Julia Richards Ophthalmic Genetics Research Lab, Kellogg Eye Center, University of Michigan on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#8 Lab fit 16% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Ophthalmology

Daniel T. Hass lab

Daniel T. Hass · Emory University, Atlanta GA

Our goal is to understand metabolism in visual tissues, primarily the retina and retinal pigment epithelium. We want to know which cells in the eye carry out particular metabolic processes, what causes a cell to be metabolically wired as it is, and the extent to which degenerative diseases affecting vision are linked to metabolic impairments. (source)

Lab fit breakdown — 16% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 61 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 32% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.82 domain gate = 16%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#9 Lab fit 16% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Neuro + ophtho

Eldon Geisert lab

Eldon Geisert · Emory University, Atlanta GA

Dr. Geisert's research interests include defining the molecular mechanisms governing the response of the retina to injury, and involve a novel molecule that selectively kills the most virulent form of brain cancer, glioblastoma. As the PI for a $1 million grant from the U.S. Army Medical Research Acquisition Activity, he also studies injuries from improvised explosive devices. (source)

Lab fit breakdown — 16% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 65 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 32% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.82 domain gate = 16%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#10 Lab fit 16% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Ophthalmology

P. Michael Iuvone lab

P. Michael Iuvone · Emory University, Atlanta GA

Dr. Iuvone's group provides basic science information relevant to eye diseases such as age-related macular degeneration and diabetic retinopathy, working on retinal function. (source)

Lab fit breakdown — 16% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 31 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 32% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.82 domain gate = 16%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "eye disease".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “eye disease”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

#11 Lab fit 9% · Not enough lab text to score reliably Hiring: Not enough data Atlanta Ophthalmology

Hans Grossniklaus lab

Hans Grossniklaus · Emory University, Atlanta GA

Board certified in both ophthalmology and anatomic pathology, Dr. Grossniklaus and his team conduct research focused on diagnostic ophthalmic pathology, ocular oncology and ophthalmic pathology, including drug delivery. (source)

Lab fit breakdown — 9% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 34 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 11% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 0% · weight 15%
Geography 100% · weight 10%

Weighted mean 13% × 0.7 domain gate = 9%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, project runway unknown, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
unknown
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Project end date missing.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 0%

    No NIH award was matched for this lab, so the 40-point baseline for an active NIH-funded lab is not awarded and none of the 4 capacity conditions can be tested. This score is a floor, not a verdict on the lab's capacity.

    Not found: Active NIH-funded lab; R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot

None. This lab is carried because a faculty directory names the PI in her fields, not because an award was found. Read from Emory School of Medicine — The Emory Eye Center Research Groups on 2026-09-22. This run's R01-class NIH sweep found no award for this person, so no funding figure is shown.

Newest award started date unknown · project period to date unknown · roster/posting last verified date unknown · first seen Sep 22, 2026

Best fit (79)

Match 45% or above against her profile.

#1 Lab fit 83% · Excellent fit Hiring: Moderate Michigan Ophthalmology

Ashok Kumar lab

Ashok Kumar · Wayne State University, Detroit MI

Project Summary Endophthalmitis is a devastating complication caused by a wide range of microorganisms which can result in irreversible vision loss if not diagnosed and treated promptly. The current diagnostic approach heavily relies on microbial culture to determine the etiology of endophthalmitis. However, only ~40% of suspected endophthalmitis cases are culture-positive, leaving many potentially infectious culture-negative cases. Therefore, the discovery of potential biomarkers is urgently needed for both the diagnosis of endophthalmitis and in guiding appropriate antimicrobial therapy. Her

Lab fit breakdown — 83% weighted · Excellent fit

Scored on enough lab text to read as a verdict. 768 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 96% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 83% = 83%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,853,417 in active NIH money across 6 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,853,417
Active projects
6
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,853,417 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years) — 2R01EY032149-05A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 96%

    Matched 4 of 6 profile areas (27 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “uveitis”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035499-03 Vitreous metabolic perturbations during bacterial and fungal endophthalmitis

    R01 · NEI · $447,076 · Sep 30, 2024 to Aug 31, 2028

  • 5R01EY027381-08 Ferroptosis in bacterial endophthalmitis: Mechanisms and Therapeutic targeting

    R01 · NEI · $453,470 · Sep 30, 2017 to Apr 30, 2029

  • 5R01EY026964-10 Targeting NAD metabolism to ameliorate bacterial endophthalmitis

    R01 · NEI · $320,273 · Apr 1, 2017 to Mar 31, 2027

All active NIH projects for Ashok Kumar ($2,853,417)
  • 2R01EY032149-05A1 Defining Host Determinants of Ocular Zika Pathogenesis — $701,983, ends Jun 30, 2030
  • 5R01EY036572-02 Defining Ocular Monkey Pox Pathogenic Mechanisms — $699,615, ends Jun 30, 2030
  • 5R01EY027381-08 Ferroptosis in bacterial endophthalmitis: Mechanisms and Therapeutic targeting — $453,470, ends Apr 30, 2029
  • 5R01EY035499-03 Vitreous metabolic perturbations during bacterial and fungal endophthalmitis — $447,076, ends Aug 31, 2028
  • 5R01EY026964-10 Targeting NAD metabolism to ameliorate bacterial endophthalmitis — $320,273, ends Mar 31, 2027
  • 5R21EY037082-02 Differential impact of acute and chronic opioids on ocular innate immunity and infections — $231,000, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#2 Lab fit 81% · Excellent fit Hiring: Moderate Atlanta Neuro + ophtho Stale / archived posting · posted 23 months ago

Ophthalmic Engineering & Innovation Laboratory (OEIL)

Michael Girard · Emory University, Atlanta GA · lab page ↗

Explainable AI and 3D digital-twin biomechanical models of the optic nerve head to uncover mechanisms of axonal injury in optic neuropathies including glaucoma; in vivo biomechanics, blood perfusion and 3D architecture of retinal and optic nerve head tissues, plus myopia. (source)

Lab fit breakdown — 81% weighted · Excellent fit

Scored on enough lab text to read as a verdict. 333 words of lab text were scored, matching 11 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 100% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 81% = 81%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Neurodegeneration and neuroprotection Lab text mentions "apoptosis".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

The OEIL members page exists but serves no readable roster, and the Emory research-group page names only Girard. Georgia Tech's bio states he has trained 10 postdoctoral fellows and 13 PhD students across his career but does not name the current Atlanta team. Current team size is unknown.

Source: OEIL members page (renders no readable member list); Emory group page lists no team · checked Sep 21, 2026

Posting · Stale / archived posting

Postdoctoral Fellow — AI / Ocular Biomechanics ↗

Stale / archived posting

posted 2024-10-17 · posted 23 months ago · source checked 2026-09-22

Source publication date 2024-10-17 (posted 23 months ago) is older than the 4-month window that opens 2026-05-23, so it is archived rather than presented as current.

iMechanica posting by M.J.A. Girard (Emory Ophthalmology + Georgia Tech BME)

Posted date read from: iMechanica node byline: "Submitted by mgirard on Thu, 10/17/2024 - 03:10".

Applications by email to michael.girard@emory.edu. The iMechanica page is dated 17 Oct 2024 — about 23 months before this run — so it is archived, not a current opening. Nothing on the page has been updated since; contact Girard directly if the AI/ocular-biomechanics project is of interest rather than treating this as live.

Can they afford to hire her?

Moderate Moderate: $1,202,080 in active NIH money across 2 projects, 3.5 years of project period left, lab size unknown, no live opening — the only advert is stale (posted 23 months ago).

Active NIH money
$1,202,080
Active projects
2
Runway left
3.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,202,080 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • 0 Only a stale posting (posted 23 months ago) — Source publication date 2024-10-17 (posted 23 months ago) is older than the 4-month window that opens 2026-05-23, so it is archived rather than presented as current.
  • Unknown: The only posting found for this lab falls outside the 4-month freshness window, so it contributes nothing. Source publication date 2024-10-17 (posted 23 months ago) is older than the 4-month window that opens 2026-05-23, so it is archived rather than presented as current.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 100%

    Matched 5 of 6 profile areas (37 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “apoptosis”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ocular”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Inherited retinal disease and ocular gene therapy

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 4 of 7 profile areas (22 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Axonal transport and neuronal injury assays — lab text says “axonal injury”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY037299-02 AXON: Axonal biomechaniX to unveil injury mechanisms in glaucomatous Optic Neuropathy

    R01 · NEI · $565,218 · Jul 1, 2025 to Mar 31, 2030

All active NIH projects for Michael Girard ($1,202,080)
  • 1R01EY037245-01A1 Optic Nerve Head Morphology and Biomechanics in Glaucoma — $636,862, ends Mar 31, 2030
  • 5R01EY037299-02 AXON: Axonal biomechaniX to unveil injury mechanisms in glaucomatous Optic Neuropathy — $565,218, ends Mar 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2025 · project period to Mar 31, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#3 Lab fit 77% · Strong fit Hiring: Strong Michigan Ophthalmology Live posting · posted 2 months ago Closing soon — closes in 7 days

Landowski Laboratory (retinal lipid metabolism)

Michael Landowski · Wayne State University, Detroit MI · lab page ↗

Mouse models, cell culture systems and human samples to dissect retinal lipid metabolism and polyunsaturated fatty acid pathways in RPE degeneration, Stargardt disease and age-related macular degeneration; retinal phenotyping by ERG, SD-OCT, histology, flatmounts, EM and RNA-seq. (source)

Lab fit breakdown — 77% weighted · Strong fit

Scored on enough lab text to read as a verdict. 283 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 71% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 93% · weight 25%
Seniority & capacity fit 100% · weight 15%
Geography 100% · weight 10%

Weighted mean 77% = 77%. Squarely in her disease area — no discount applied.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "retinitis pigmentosa".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · 6 named members

  • Brianna Klopp — Research assistant, tenure unknown [news/directory]
  • Youde Jiang — Research assistant, tenure unknown [news/directory]
  • Daniela De Andrade — Master's student, tenure unknown [news/directory]
  • Omar Mouchli — Undergraduate researcher, tenure unknown [news/directory]
  • Saydee Jaboro — Undergraduate researcher, tenure unknown [news/directory]
  • Liam LeBlanc — Research assistant, joined 2026 (under a year) [unverified, unconfirmed] Announced joining in a LinkedIn post dated 23 Jul 2026 that Landowski replied to; LinkedIn could not be logged into to confirm.

Roles come from a July 2026 university news caption, not a lab roster page. Lab was founded January 2025, so no member predates that.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Wayne State School of Medicine news, 9 Jul 2026 (team photo caption naming each member and role) · checked Sep 21, 2026

Posting · Live opening

Post-Doctoral Fellow — Ophthalmology, Visual and Anatomical Sciences ↗

Live opening Closing soon — closes in 7 days

posted 2026-07-20 · posted 2 months ago · closes 2026-09-30 · source checked 2026-09-22

Source publication date 2026-07-20 (posted 2 months ago) is inside the 4-month window that opens 2026-05-23. The source states applications close 2026-09-30 — closes in 7 days counting from the 2026-09-23 run date.

Chronicle of Higher Education / Wayne State OVAS

Posted date read from: Chronicle of Higher Education JSON-LD datePosted 2026-07-20 and the visible "Date posted Jul 20, 2026" row.

Stated applications-close date of 30 Sep 2026 comes from the AcademicJobs mirror (https://www.academicjobs.com/university-jobs/post-doctoral-fellow-department-of-ophthalmology-visual-and-anatomical-sciences-ovas-detroit-michigan/764090, "Applications Close: Sep 30, 2026"). The Chronicle listing itself only carries a board expiry of 21 Nov 2026, so treat 30 Sep as the deadline to work to.

Can they afford to hire her?

Strong Strong: $626,683 in active NIH money across 1 project, 4.4 years of project period left, 6 known team members, a live opening (posted 2 months ago).

Active NIH money
$626,683
Active projects
1
Runway left
4.4 yrs
Known lab size
6
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $626,683 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-01.
  • +20 Live opening — posted 2 months ago — Post-Doctoral Fellow — Ophthalmology, Visual and Anatomical Sciences — Source publication date 2026-07-20 (posted 2 months ago) is inside the 4-month window that opens 2026-05-23. The source states applications close 2026-09-30 — closes in 7 days counting from the 2026-09-23 run date.
  • +5 Small team with room to add a senior bench scientist — 6 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 71%

    Matched 3 of 6 profile areas (20 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “retinitis pigmentosa”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 93%

    Matched 4 of 7 profile areas (28 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “rna-seq”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “oct”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 100%

    4 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”
    • Advertised opening at one of her three target levels — lab text says “award record”
  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01EY036795-01A1 Role of Polyunsaturated Fatty Acids in Retinal Pigmented Epithelium Pathology

    R01 · NEI · $626,683 · Jul 1, 2026 to Feb 28, 2031

All active NIH projects for Michael Landowski ($626,683)
  • 1R01EY036795-01A1 Role of Polyunsaturated Fatty Acids in Retinal Pigmented Epithelium Pathology — $626,683, ends Feb 28, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2026 · project period to Feb 28, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#4 Lab fit 77% · Strong fit Hiring: Moderate Michigan Neuro + ophtho

Bruce A. Berkowitz lab

Bruce A. Berkowitz · Wayne State University, Detroit MI

My lab develops and applies next generation imaging biomarkers for diagnosis and treatment before overt neurodegeneration. Diseases studied include Alzheimer's disease, Parkinson's disease, diabetic retinopathy and retinitis pigmentosa, in human, rat and mouse, using optical coherence tomography, MRI and optokinetic tracking. (source)

Lab fit breakdown — 77% weighted · Strong fit

Scored on enough lab text to read as a verdict. 560 words of lab text were scored, matching 10 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 71% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 77% = 77%. Squarely in her disease area — no discount applied.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "retinitis pigmentosa".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,022,619 in active NIH money across 3 projects, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,022,619
Active projects
3
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,022,619 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 71%

    Matched 3 of 6 profile areas (20 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “retinitis pigmentosa”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 100%

    Matched 5 of 7 profile areas (30 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.
    • Calcium and mechanosensitive channel signalling — lab text says “calcium channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY034309-04 Mitigating retinitis pigmentosa based on a non-invasive rod energy-landscape biomarker

    R01 · NEI · $496,155 · Sep 30, 2023 to Jun 30, 2027

  • 5R01AG081981-04 Novel Early Retinal Imaging Biomarkers for Treating Later Spatial Memory Loss in Experimental Alzheimer's Disease

    R01 · NIA · $1,086,201 · Sep 15, 2023 to May 31, 2028

All active NIH projects for Bruce A. Berkowitz ($2,022,619)
  • 5R01AG081981-04 Novel Early Retinal Imaging Biomarkers for Treating Later Spatial Memory Loss in Experimental Alzheimer's Disease — $1,086,201, ends May 31, 2028
  • 5R01EY034309-04 Mitigating retinitis pigmentosa based on a non-invasive rod energy-landscape biomarker — $496,155, ends Jun 30, 2027
  • 1R21EY037416-01A1 Osmotic regulation in the cone dystrophy, CDSRR — $440,263, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#5 Lab fit 77% · Strong fit Hiring: Possible Atlanta Ophthalmology

Jeffrey H Boatright lab

Jeffrey H Boatright · Emory University, Atlanta GA

Dr. Boatright's laboratory conducts research initiatives on gene therapy and neuroprotection in treatment of retinal degenerative diseases, in the expectation that pharmacological neuroprotectants will delay vision loss while gene therapies will provide permanent relief. (source)

Lab fit breakdown — 77% weighted · Strong fit

Scored on enough lab text to read as a verdict. 277 words of lab text were scored, matching 11 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 100% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 30% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 77% = 77%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".

What’s missing

  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $475,841 in active NIH money across 2 projects, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$475,841
Active projects
2
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $475,841 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-01-31 (about 1.3 years) — 5I01RX004563-03, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 100%

    Matched 6 of 6 profile areas (43 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “retinal degenerat”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.
  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 30%

    Matched 2 of 7 profile areas (9 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “electroretinogra”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY031042-05 Modulators for Retinal Ganglion Cell Injury

    R01 · NEI · $475,841 · Mar 1, 2021 to Feb 28, 2027

All active NIH projects for Jeffrey H Boatright ($475,841)
  • 5R01EY031042-05 Modulators for Retinal Ganglion Cell Injury — $475,841, ends Feb 28, 2027
  • 5I01RX004563-03 The Active AMD Study to Improve Function in Veterans with Age Related Macular Degeneration — unknown, ends Jan 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2021 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#6 Lab fit 75% · Strong fit Hiring: Possible Michigan Ophthalmology

Prasov Lab (Ophthalmic Genetics)

Lev Prasov · University of Michigan, Ann Arbor MI · lab page ↗

Human genetics of inherited ocular conditions including pediatric and early-onset glaucoma, nanophthalmos and anterior segment dysgenesis, using mouse and cell culture models to validate disease genes and pathogenic pathways. (source)

Lab fit breakdown — 75% weighted · Strong fit

Scored on enough lab text to read as a verdict. 324 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 100% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 75% = 75%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · 13 named members

  • Michelle Brinkmeier, MS — Research lab specialist — lab manager, tenure unknown [official roster]
  • Dejuan Kong — Research lab specialist, tenure unknown [official roster]
  • Diana Gallego Martinez, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Gabrielle Rozumek, BS — Graduate student (Molecular & Cellular Pathology), tenure unknown [official roster]
  • Hannah Pittman, BS — Graduate student (Genetics & Genomics), tenure unknown [official roster]
  • Mia Brakebill, BS — Graduate student (Genetics & Genomics), tenure unknown [official roster]
  • Bridget Blevins, BS, MPH — Research coordinator, tenure unknown [official roster]
  • Katy Meta, BS — Genetic counseling student, tenure unknown [official roster]
  • Elise Root, BS — Genetic counseling student, tenure unknown [official roster]
  • Rachel Lim — Undergraduate research assistant, tenure unknown [official roster]
  • Danny Soden — Undergraduate research assistant, tenure unknown [official roster]
  • Alayna Aamodt — Undergraduate research assistant, tenure unknown [official roster]
  • Hannah Hu — Undergraduate research assistant, tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Prasov Lab research staff page · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No postdoc or research-scientist requisition on the lab site or U-M Careers ophthalmology listings.

Checked at U-M Careers, Research Fellow listings

Can they afford to hire her?

Possible Possible: $580,496 in active NIH money across 1 project, 3.6 years of project period left, 13 known team members, no advertised opening.

Active NIH money
$580,496
Active projects
1
Runway left
3.6 yrs
Known lab size
13
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $580,496 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • 0 No active posting found — No postdoc or research-scientist requisition on the lab site or U-M Careers ophthalmology listings. Checked 2026-09-21.
Per-dimension evidence
  • Disease & domain overlap — 100%

    Matched 5 of 6 profile areas (37 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “sclera”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY037225-02 Defining the role of RIG-I in glaucoma pathogenesis and response to viral infection

    R01 · NEI · $580,496 · Jul 1, 2025 to Apr 30, 2030

All active NIH projects for Lev Prasov ($580,496)
  • 5R01EY037225-02 Defining the role of RIG-I in glaucoma pathogenesis and response to viral infection — $580,496, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2025 · project period to Apr 30, 2030 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#7 Lab fit 73% · Strong fit Hiring: Moderate Atlanta Neuroscience

Gary J Bassell lab

Gary J Bassell · Emory University, Atlanta GA

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease characterized by motor neuron degeneration and has been linked to mutations in the KIF5A gene, which encodes the motor protein KIF5A. The ALS-associated KIF5A variants result in exon 27 skipping (KIF5AΔE27), generating a novel C- terminal peptide. This study comprehensively investigates the molecular mechanisms underlying KIF5AΔE27's role in ALS pathogenesis through three specific aims. Aim 1 focuses on determining the gain of function in transgenic mice expressing KIF5AΔE27. Preliminary data demonstrate early neuri

Lab fit breakdown — 73% weighted · Strong fit

Scored on enough lab text to read as a verdict. 259 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 64% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 73% = 73%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "axonal transport".
  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,379,006 in active NIH money across 3 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,379,006
Active projects
3
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,379,006 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 64%

    Matched 2 of 6 profile areas (18 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “axonal transport”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 100%

    Matched 5 of 7 profile areas (35 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axonal transport”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS138605-02 Pathogenic mechanisms of KIF5A-associated ALS

    R01 · NINDS · $518,256 · May 1, 2025 to Apr 30, 2030

All active NIH projects for Gary J Bassell ($1,379,006)
  • 5R01NS138605-02 Pathogenic mechanisms of KIF5A-associated ALS — $518,256, ends Apr 30, 2030
  • 1R21NS145545-01 Mechanisms of altered RNA transport dynamics by Kif1C mutations in heterospastic paraplegia — $430,375, ends Jun 30, 2027
  • 1R21NS143271-01A1 Membrane trafficking impairments in fragile x syndrome — $430,375, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2025 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#8 Lab fit 73% · Strong fit Hiring: Possible Atlanta Neuroscience

Jie Jiang lab

Jie Jiang · Emory University, Atlanta GA

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease characterized by motor neuron degeneration and has been linked to mutations in the KIF5A gene, which encodes the motor protein KIF5A. The ALS-associated KIF5A variants result in exon 27 skipping (KIF5AΔE27), generating a novel C- terminal peptide. This study comprehensively investigates the molecular mechanisms underlying KIF5AΔE27's role in ALS pathogenesis through three specific aims. Aim 1 focuses on determining the gain of function in transgenic mice expressing KIF5AΔE27. Preliminary data demonstrate early neuri

Lab fit breakdown — 73% weighted · Strong fit

Scored on enough lab text to read as a verdict. 259 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 64% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 73% = 73%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "axonal transport".
  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $518,256 in active NIH money across 1 project, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$518,256
Active projects
1
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $518,256 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 64%

    Matched 2 of 6 profile areas (18 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “axonal transport”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 100%

    Matched 5 of 7 profile areas (35 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axonal transport”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS138605-02 Pathogenic mechanisms of KIF5A-associated ALS

    R01 · NINDS · $518,256 · May 1, 2025 to Apr 30, 2030

All active NIH projects for Jie Jiang ($518,256)
  • 5R01NS138605-02 Pathogenic mechanisms of KIF5A-associated ALS — $518,256, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2025 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#9 Lab fit 73% · Strong fit Hiring: Moderate Michigan Ophthalmology

Abigail Fahim lab

Abigail Fahim · University of Michigan, Ann Arbor MI

PROJECT SUMMARY: Choroideremia is a blinding inherited retinal disease in which retinal pigment epithelial (RPE) cells contribute significantly to chorioretinal degeneration, but the underlying molecular mechanisms remain largely unclear. A critical barrier to progress in developing therapies is understanding how RPE cells contribute to death of neighboring tissues in choroideremia. Our long-term goal is to determine how RPE dysfunction contributes to chorioretinal degeneration and to develop novel therapies. Choroideremia is caused by mutations in CHM, encoding Rab escort protein 1, which fac

Lab fit breakdown — 73% weighted · Strong fit

Scored on enough lab text to read as a verdict. 275 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 71% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 73% = 73%. Squarely in her disease area — no discount applied.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,041,154 in active NIH money across 2 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,041,154
Active projects
2
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,041,154 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 71%

    Matched 3 of 6 profile areas (20 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY036422-03 Retinal Pigment Epithelium Secreted Matrix Metalloproteinase 2 as a Novel Target in Choroideremia

    R01 · NEI · $506,262 · Sep 30, 2024 to Jul 31, 2029

All active NIH projects for Abigail Fahim ($1,041,154)
  • 5K12EY022299-14 Michigan Vision Clinician Scientist Development Program — $534,892, ends Jun 30, 2028
  • 5R01EY036422-03 Retinal Pigment Epithelium Secreted Matrix Metalloproteinase 2 as a Novel Target in Choroideremia — $506,262, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2024 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#10 Lab fit 73% · Strong fit Hiring: Moderate Michigan Neuro + ophtho

James D Weiland lab

James D Weiland · University of Michigan, Ann Arbor MI

Prosthetic electrical stimulation of inner retinal neurons can restore a sense of vision in patients with outer retinal degeneration, but implant patients to date report artificial vision to be low quality. Clinical studies of retinal prostheses show that long-term implantation and stimulation is safe, and that implant patients can detect large objects and recognize simple forms. But visual acuity is 20/438 at best, and functional vision is limited by rapid (within seconds) fading of electrically elicited percepts. Numerous clinical and animal studies demonstrate that current approaches for re

Lab fit breakdown — 73% weighted · Strong fit

Scored on enough lab text to read as a verdict. 239 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 79% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 73% = 73%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "retinitis pigmentosa".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,460,926 in active NIH money across 4 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,460,926
Active projects
4
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,460,926 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2T32NS115724-06, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 79%

    Matched 3 of 6 profile areas (22 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “retinitis pigmentosa”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 4 of 7 profile areas (22 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035008-03 Intraretinal stimulation for high acuity artificial vision

    R01 · NEI · $581,853 · Jul 1, 2024 to Apr 30, 2028

All active NIH projects for James D Weiland ($1,460,926)
  • 5R01EY035008-03 Intraretinal stimulation for high acuity artificial vision — $581,853, ends Apr 30, 2028
  • 5R61EY037514-02 Multi-modal interface for non-visual navigation — $502,353, ends Jun 30, 2027
  • 2T32NS115724-06 Neural Engineering Training Program (NETP) — $188,917, ends Jun 30, 2031
  • 5P30EY007003-40 Instrument & Electronics Services Core — $187,803, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#11 Lab fit 72% · Strong fit Hiring: Possible Michigan Neuroscience

Hayley S Mcloughlin lab

Hayley S Mcloughlin · University of Michigan, Ann Arbor MI

ABSTRACT Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly inherited ataxia and currently has no effective treatment. This progressive, multisystem disorder is typified by the degeneration of critical parts of the central nervous system including the cerebellum, brainstem, basal ganglia, and spinal cord. Moreover, neuropathological studies show widespread involvement of the peripheral nervous system (PNS). Despite the focus of past research on the central nervous system, peripheral neuropathy symptoms are prominently observed in over half of SCA3 patients. This research aims t

Lab fit breakdown — 72% weighted · Strong fit

Scored on enough lab text to read as a verdict. 285 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 64% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 67% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 72% = 72%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "ganglion cell".
  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $483,494 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$483,494
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $483,494 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 64%

    Matched 2 of 6 profile areas (18 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “ganglion cell”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 67%

    Matched 3 of 7 profile areas (20 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS140063-02 Investigating Peripheral Neuropathy in Spinocerebellar Ataxia Type 3

    R01 · NINDS · $483,494 · Aug 1, 2025 to Jul 31, 2030

All active NIH projects for Hayley S Mcloughlin ($483,494)
  • 5R01NS140063-02 Investigating Peripheral Neuropathy in Spinocerebellar Ataxia Type 3 — $483,494, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#12 Lab fit 72% · Strong fit Hiring: Moderate Atlanta Neuro + ophtho

Machelle T. Pardue lab

Machelle T. Pardue · Emory University, Atlanta GA

The development of life-changing treatments for people with vision loss. Research is focused on the detection and treatment of early-stage diabetic retinopathy; the identification of mechanisms of refractive eye growth and myopia; and the use of neuroprotection to slow retinal disease and preserve visual function. (source)

Lab fit breakdown — 72% weighted · Strong fit

Scored on enough lab text to read as a verdict. 506 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 100% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 72% = 72%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,226,977 in active NIH money across 3 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,226,977
Active projects
3
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,226,977 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years) — 5T32EY007092-40, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 100%

    Matched 5 of 6 profile areas (33 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “retinal degenerat”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “sclera”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY033361-05 Mechanisms of axial elongation in myopia

    R01 · NEI · $556,024 · Mar 1, 2022 to Feb 28, 2027

  • 5R01EY016435-17 Retinal mechanisms of refractive development

    R01 · NEI · $491,512 · Jan 1, 2009 to Apr 30, 2029

All active NIH projects for Machelle T. Pardue ($1,226,977)
  • 5R01EY033361-05 Mechanisms of axial elongation in myopia — $556,024, ends Feb 28, 2027
  • 5R01EY016435-17 Retinal mechanisms of refractive development — $491,512, ends Apr 30, 2029
  • 5T32EY007092-40 VIsion Science Training in Atlanta — $179,441, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2022 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#13 Lab fit 70% · Strong fit Hiring: Moderate Michigan Neuro + ophtho

Wubben Laboratory (retinal cell metabolism)

Thomas Joseph Wubben · University of Michigan, Ann Arbor MI · lab page ↗

Intersection of retinal cell metabolism and retinal disease: metabolic pathways supporting photoreceptor and RPE survival, mass-spectrometry metabolomics, chemical biology and biochemistry across rodent and rabbit models of macular degeneration, inherited retinal disease, retinal detachment and PVR; small-molecule neuroprotection and gene therapy. (source)

Lab fit breakdown — 70% weighted · Strong fit

Scored on enough lab text to read as a verdict. 293 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 82% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 70% = 70%. Squarely in her disease area — no discount applied.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • Non-rodent animal models Lab text mentions "rabbit".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · 3 names from publications — unconfirmed

  • Jason C. Rech — unknown (co-author), tenure unknown [unverified]
  • Mercy Pawar — unknown (co-author), tenure unknown [unverified]
  • Eric Weh — unknown (co-author), tenure unknown [unverified]

The lab has no public people page. These names come from a 2020 lab publication; current membership is not confirmed and designations are unknown.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Co-authors on a Wubben-lab ARVO/IOVS abstract (2020) — no lab roster page exists · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No requisition on U-M Careers ophthalmology listings and no openings page for this lab.

Checked at U-M Careers, Research Fellow listings

Can they afford to hire her?

Moderate Moderate: $519,644 in active NIH money across 1 project, 4.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$519,644
Active projects
1
Runway left
4.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $519,644 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-04-30 (about 4.6 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-01.
  • 0 No active posting found — No requisition on U-M Careers ophthalmology listings and no openings page for this lab. Checked 2026-09-21.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 82%

    Matched 4 of 6 profile areas (23 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “eye disease”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Non-rodent animal models — lab text says “rabbit”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01EY037747-01A1 Metabolic and molecular mechanisms by which glutamine promotes photoreceptor health

    R01 · NEI · $519,644 · Aug 1, 2026 to Apr 30, 2031

All active NIH projects for Thomas Joseph Wubben ($519,644)
  • 1R01EY037747-01A1 Metabolic and molecular mechanisms by which glutamine promotes photoreceptor health — $519,644, ends Apr 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2026 · project period to Apr 30, 2031 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#14 Lab fit 68% · Strong fit Hiring: Moderate Atlanta Neuro + ophtho

Raquel L Lieberman lab

Raquel L Lieberman · Georgia Institute of Technology, Atlanta GA

Glaucoma is a heterogeneous ocular disease that affects nearly 70 million individuals worldwide. Despite the availability of symptomatic treatments and surgeries, ~10% of patients reach permanent blindness, and treatments do not address the underlying cause of the disease. In most glaucoma subtypes, elevated intraocular pressure (IOP) is the causal risk factor. Elevated IOP originates from trabecular meshwork (TM) dysfunction. Neuron-like TM cells maintain the TM extracellular matrix, an anterior eye segment tissue, and TM cell loss an established pathological hallmark of a glaucomatous TM. Ge

Lab fit breakdown — 68% weighted · Strong fit

Scored on enough lab text to read as a verdict. 567 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 100% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 68% = 68%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Retinal ganglion cells and the optic nerve Lab text mentions "optic nerve".
  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "structural biolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,329,881 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,329,881
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,329,881 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 100%

    Matched 5 of 6 profile areas (37 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retinal ganglion cells and the optic nerve — lab text says “optic nerve”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “eye disease”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY036396-03 Molecular determinants of cytotoxicity due to mutant myocilin misfolding

    R01 · NEI · $337,162 · Sep 1, 2024 to Jun 30, 2029

  • 5R01EY021205-14 Characterization of purified myocilin: glaucoma as a protein misfolding disease

    R01 · NEI · $400,952 · Mar 1, 2011 to Feb 28, 2027

All active NIH projects for Raquel L Lieberman ($1,329,881)
  • 5R01EY036107-03 Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma — $591,767, ends Jun 30, 2028
  • 5R01EY021205-14 Characterization of purified myocilin: glaucoma as a protein misfolding disease — $400,952, ends Feb 28, 2027
  • 5R01EY036396-03 Molecular determinants of cytotoxicity due to mutant myocilin misfolding — $337,162, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#15 Lab fit 67% · Strong fit Hiring: Moderate Michigan Ophthalmology New award

Yang group, Center for Advanced Models for Translational Sciences and Therapeutics (CAMTraST)

Dongshan Yang · University of Michigan, Ann Arbor MI · lab page ↗

Gene-edited large-animal disease models: CRISPR/Cas9 knockout and knock-in rabbits for inherited retinal disease (USH2A, CLRN1 / Usher syndrome), progressive retinal degeneration phenotyping, and development of genome-editing therapy for retinal disease, with multimodal in vivo imaging (photoacoustic microscopy, OCT, fluorescence). (source)

Lab fit breakdown — 67% weighted · Strong fit

Scored on enough lab text to read as a verdict. 344 words of lab text were scored, matching 10 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 54% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 53% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 73% × 0.92 domain gate = 67%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "vision loss".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · 3 names from publications — unconfirmed

  • Van Phuc Nguyen — unknown (frequent co-author), tenure unknown [unverified]
  • Yannis M. Paulus — Faculty collaborator (co-corresponding author), tenure unknown [unverified]
  • Y. Eugene Chen — Faculty collaborator (CAMTraST), tenure unknown [unverified]

CAMTraST has no public people page for this group. These are recurring collaborators on Yang's corresponding-author retinal papers, not a confirmed current roster, and several are independent faculty rather than lab staff.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Co-authors on Yang-corresponding retinal imaging papers — CAMTraST publishes no lab roster · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No requisition on U-M Careers ophthalmology listings.

Checked at U-M Careers, Research Fellow listings

Can they afford to hire her?

Moderate Moderate: $709,251 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$709,251
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $709,251 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01EY037712-01A1 is flagged as a new project by NIH.
  • 0 No active posting found — No requisition on U-M Careers ophthalmology listings. Checked 2026-09-21.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 54%

    Matched 3 of 6 profile areas (15 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “vision loss”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection

  • Model systems — 100%

    Matched 4 of 5 profile areas (31 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Non-rodent animal models — lab text says “rabbit”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Human donor tissue, primary and explant culture

  • Techniques & readouts — 53%

    Matched 3 of 7 profile areas (16 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “oct”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01EY037712-01A1 Genome Editing Therapy to Treat Vision Loss in Usher Syndrome Type 2A

    R01 · NEI · $709,251 · Sep 15, 2026 to Jun 30, 2030 · Type 1 (new)

All active NIH projects for Dongshan Yang ($709,251)
  • 1R01EY037712-01A1 Genome Editing Therapy to Treat Vision Loss in Usher Syndrome Type 2A — $709,251, ends Jun 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to Jun 30, 2030 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#16 Lab fit 66% · Strong fit Hiring: Moderate Atlanta Ophthalmology

Ethier Lab (ocular biomechanics — glaucoma and myopia)

C Ross Ethier · Emory University, Atlanta GA · lab page ↗

The Ethier Lab studies vision through a biomedical engineering lens, focused on glaucoma and myopia. Dr. Ethier's work sits at the interface of biomechanics, cell biology and physiology: the biomechanics of aqueous humour drainage in the normal and glaucomatous eye, the mechanical and cellular response of optic nerve tissues to intraocular pressure, and the molecular and cellular mechanisms driving abnormal ocular growth. Current bench projects named on the lab's own people page include the mechanobiology of Schlemm's canal cells and transcellular pore formation in aqueous humour outflow, extraction of trabecular meshwork biomechanical properties from OCT imaging, biomechanical and transcriptional differences between segmental flow regions of the trabecular meshwork, and choroidal pericyte responses to all-trans retinoic acid in myopigenesis. (source)

Lab fit breakdown — 66% weighted · Strong fit

Scored on enough lab text to read as a verdict. 450 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 100% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 66% = 66%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Retinal ganglion cells and the optic nerve Lab text mentions "optic nerve".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • In vivo ocular imaging and functional readouts Lab text mentions "optical coherence tomograph".

What’s missing

  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · 5 named members

  • C. Ross Ethier, PhD — Principal investigator; Professor of Ophthalmology, Emory Eye Center, since 2025 (~1 yr) [official roster] The page states he retired from Georgia Tech in 2025 to take up his current position at the Emory Eye Center; he joined Georgia Tech and Emory in 2012.
  • Haiyan Li, PhD — Postdoctoral researcher — BrightFocus Foundation Postdoctoral Fellow; mechanobiology of Schlemm's canal cells, transcellular pore formation and aqueous humour outflow, since 2022 (~4 yrs) [official roster]
  • Ana Nicolle Strat, MS, PhD — Postdoctoral researcher — all-trans retinoic acid as a regulator of myopigenesis; choroidal pericyte reprogramming, joined 2026 (under a year) [official roster] The page states she began her postdoctoral training in the Ethier Lab in January 2026.
  • Hu Xu, PhD — Postdoctoral researcher — computational biomechanics; physics-informed neural networks to extract trabecular meshwork properties from OCT, tenure unknown [official roster] The page states no joining date for him.
  • Cydney Wong, PhD — Postdoctoral researcher — biomechanical and transcriptional differences between segmental flow regions of the trabecular meshwork, since 2020 (~6 yrs) [official roster] Joined the lab in 2020 as a student and completed her Georgia Tech/Emory BME PhD in 2025.

The Emory page carries the lab as it stands after the 2025 move from Georgia Tech to the Emory Eye Center: the PI and four postdoctoral researchers. The older Georgia Tech lab site (ethier.gatech.edu) lists additional research staff and graduate students but did not respond to requests from this environment on 2026-09-22, so nobody was carried over from it.

Source: Emory School of Medicine — The Ethier Lab, Meet the Lab Group · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No opening was advertised for this lab on 2026-09-22. The lab's own Emory pages (overview, people, research, support, contact) carry no openings or 'join us' section. Emory's faculty applicant site (faculty-emory.icims.com) was searched for 'ophthalmology', 'eye center', 'biomechanics' and 'ethier': the ophthalmology hits are clinical faculty requisitions (comprehensive ophthalmologist, oculoplastics, cornea fellow) and there is no Ethier-lab postdoctoral requisition. The Georgia Tech lab site (ethier.gatech.edu) did not respond to requests from this environment on the same date, so it could not be checked. The roster's own dates show a postdoc joining in January 2026, so the absence of an advert is not evidence that the lab is not recruiting.

Can they afford to hire her?

Moderate Moderate: $1,254,502 in active NIH money across 2 projects, 2.9 years of project period left, 5 known team members, no advertised opening.

Active NIH money
$1,254,502
Active projects
2
Runway left
2.9 yrs
Known lab size
5
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,254,502 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years) — 5R01EY030124-07, which is outside this briefing's scope but is active NIH money for this PI.
  • 0 No active posting found — No opening was advertised for this lab on 2026-09-22. The lab's own Emory pages (overview, people, research, support, contact) carry no openings or 'join us' section. Emory's faculty applicant site (faculty-emory.icims.com) was searched for 'ophthalmology', 'eye center', 'biomechanics' and 'ethier': the ophthalmology hits are clinical faculty requisitions (comprehensive ophthalmologist, oculoplastics, cornea fellow) and there is no Ethier-lab postdoctoral requisition. The Georgia Tech lab site (ethier.gatech.edu) did not respond to requests from this environment on the same date, so it could not be checked. The roster's own dates show a postdoc joining in January 2026, so the absence of an advert is not evidence that the lab is not recruiting. Checked 2026-09-22.
  • +5 Small team with room to add a senior bench scientist — 5 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 100%

    Matched 4 of 6 profile areas (29 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retinal ganglion cells and the optic nerve — lab text says “optic nerve”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “sclera”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY033361-05 Mechanisms of axial elongation in myopia

    R01 · NEI · $556,024 · Mar 1, 2022 to Feb 28, 2027

All active NIH projects for C Ross Ethier ($1,254,502)
  • 5R01EY030124-07 Quantitative assessment of glaucomatous conventional outflow dynamics — $698,478, ends Aug 31, 2029
  • 5R01EY033361-05 Mechanisms of axial elongation in myopia — $556,024, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2022 · project period to Feb 28, 2027 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026

#17 Lab fit 65% · Strong fit Hiring: Possible Michigan Ophthalmology

Jillian Nydam Pearring lab

Jillian Nydam Pearring · University of Michigan, Ann Arbor MI

ABSTRACT Retinal inherited diseases are a leading cause of blindness worldwide. Despite major progress in the discovery of causative genes underlying inherited retinal disease, understanding the natural history and phenotype of a particular molecular diagnosis remains limited. Recently, we found that dominant human mutations in ARL3 cause higher levels of Arl3-GTP activity, resulting in a developmental phenotype that prevents photoreceptor nuclei from translocating properly into the outer nuclear layer of the retina. Arl3 is a small GTPase that regulates the enrichment of lipid proteins into t

Lab fit breakdown — 65% weighted · Strong fit

Scored on enough lab text to read as a verdict. 462 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 43% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 71% × 0.92 domain gate = 65%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "organelle".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "organoid")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $943,535 in active NIH money across 2 projects, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$943,535
Active projects
2
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $943,535 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 43%

    Matched 2 of 6 profile areas (12 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 100%

    Matched 5 of 7 profile areas (33 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “organelle”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY036019-03 Investigating Photoreceptor Nuclear Migration Defects Caused by Loss of Retinitis Pigmentosa 2.

    R01 · NEI · $496,819 · Jul 1, 2024 to Apr 30, 2028

  • 5R01EY032491-05 Understanding Photoreceptor Trafficking Pathways to the Outer Segment

    R01 · NEI · $446,716 · Mar 1, 2022 to Dec 31, 2026

All active NIH projects for Jillian Nydam Pearring ($943,535)
  • 5R01EY036019-03 Investigating Photoreceptor Nuclear Migration Defects Caused by Loss of Retinitis Pigmentosa 2. — $496,819, ends Apr 30, 2028
  • 5R01EY032491-05 Understanding Photoreceptor Trafficking Pathways to the Outer Segment — $446,716, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#18 Lab fit 63% · Strong fit Hiring: Possible Michigan Ophthalmology Standing call — undated

Translational Nanomedicine Research Laboratory

Anjali Sharma · University of Michigan, Ann Arbor MI · lab page ↗

Dendrimer and polymer nanomedicine for target-specific drug and gene delivery to ocular and central nervous system disease: trehalose-based dendrimers that clear corneal and retinal neovascularisation in animal models, 2-deoxyglucose dendrimers for injury-associated neurons, and prostate cancer nanotherapy. Chemistry, engineering and biology interface. (source)

Lab fit breakdown — 63% weighted · Strong fit

Scored on enough lab text to read as a verdict. 377 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 68% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 63% = 63%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "intraocular pressure".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene delivery".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · 2 names from publications — unconfirmed

  • Anubhav Dhull — unknown (frequent co-author, listed at University of Michigan), tenure unknown [unverified]
  • Aqib Iqbal Dar — unknown (frequent co-author, listed at University of Michigan), tenure unknown [unverified]

The lab relocated from Washington State University to U-M Pharmaceutical Sciences in July 2026 and has not yet published a Michigan roster. The WSU site still hosts group photos but no named list. These two names are recurring recent co-authors already listed at Michigan.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: U-M College of Pharmacy announcement; group members named on recent co-authored papers · checked Sep 21, 2026

Posting · Standing call — undated

Graduate students and postdocs — nano-drug delivery ↗

Standing call — undated

posted date: unknown (source prints none) · source checked 2026-09-22

The lab's own page advertises this as a standing open call and prints no publication date. Page re-read 2026-09-22; recorded as unknown rather than guessed, so it is not counted as a live dated opening.

Sharma lab "Open positions" (now directing applicants to anjal@umich.edu)

Posted date read from: Sharma lab Open positions block prints no publication date.

Standing call re-read 22 Sep 2026 on the lab's own page, which now also states the lab moved to the University of Michigan College of Pharmacy on 15 Jul 2026 and directs applicants to anjal@umich.edu. Undated, so not counted as a live dated opening. Two $2.6M R01s (NEI corneal neovascularisation, NINDS brain disorders) both run to 2030.

Can they afford to hire her?

Possible Possible: active NIH award total unknown, 3.8 years of project period left, lab size unknown, an undated standing call rather than a live dated opening.

Active NIH money
unknown
Active projects
unknown
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-15.
  • +5 Brand-new (Type 1) project, not a renewal — 7R01EY037277-02 is flagged as a new project by NIH.
  • +10 Standing open call, no publication date — Graduate students and postdocs — nano-drug delivery — The lab's own page advertises this as a standing open call and prints no publication date. Page re-read 2026-09-22; recorded as unknown rather than guessed, so it is not counted as a live dated opening.
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 68%

    Matched 3 of 6 profile areas (19 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “intraocular pressure”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene delivery”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 7R01EY037277-02 Nanotherapies for Targeted Treatment of Corneal Neovascularization

    R01 · NEI · $543,508 · Jul 15, 2026 to Jun 30, 2030 · Type 1 (new)

Newest award started Jul 15, 2026 · project period to Jun 30, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#19 Lab fit 63% · Strong fit Hiring: Strong Michigan Neuroscience Date unverified

Kaczorowski Lab (cognitive resilience)

Catherine Cook Kaczorowski · University of Michigan, Ann Arbor MI · lab page ↗

Systems genetics of cognitive resilience to ageing and Alzheimer's disease using genetically diverse mouse panels (AD-BXDs), integrating genomics, proteomics, in vivo imaging, electrophysiology, behaviour and computational analysis across mouse and human data. (source)

Lab fit breakdown — 63% weighted · Strong fit

Scored on enough lab text to read as a verdict. 2064 words of lab text were scored, matching 10 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 77% × 0.82 domain gate = 63%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • CRISPR / conditional knockout genetics Lab text mentions "genome editing".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "drug discovery")

Lab composition · 7 named members

  • Stephanie Boas, PhD — Research fellow (postdoc), tenure unknown [official roster]
  • Yiding Cao — Research fellow (postdoc), tenure unknown [official roster]
  • Yu Chen, PhD — Research fellow (postdoc), tenure unknown [official roster]
  • Lauren Fish, PhD — Research fellow (postdoc), tenure unknown [official roster]
  • Elizabeth Litkowski — Research fellow (postdoc), tenure unknown [official roster]
  • Oluwademilade Nuga — Research fellow (postdoc), tenure unknown [official roster]
  • Surjeet Singh, PhD — Research fellow (postdoc), tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Kaczorowski Lab members page · checked Sep 21, 2026

Posting · Date unverified

Research Fellow (postdoctoral) ↗

Date unverified

posted date: unknown (source prints none) · source checked 2026-09-22

The publication date could not be confirmed on the employer's own page. Checked 2026-09-22; treated as unverified rather than live.

Lab site — referenced in search results, requisition URL not retrievable

Posted date read from: no requisition page could be opened, so no publication date exists to record.

Search results referenced a full-time postdoctoral Research Fellow position on ageing interventions in genetically heterogeneous mice, open through 30 Sep 2026, but no verifiable requisition page could be opened on 22 Sep 2026 and the lab-members page prints no posting date. Recorded as date-unverified rather than live; contact kaczoro@med.umich.edu.

Can they afford to hire her?

Strong Strong: $7,950,389 in active NIH money across 7 projects, 4.3 years of project period left, 7 known team members, a posting whose publication date could not be verified.

Active NIH money
$7,950,389
Active projects
7
Runway left
4.3 yrs
Known lab size
7
Show the reasoning and the underlying awards
Hiring signals — 83 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $7,950,389 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 7 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-01.
  • +3 Posting referenced but date unverified — Research Fellow (postdoctoral) — The publication date could not be confirmed on the employer's own page. Checked 2026-09-22; treated as unverified rather than live.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “genome editing”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “postmortem”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 100%

    Matched 5 of 7 profile areas (30 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG094704-01 Utilizing Heterogeneous Mouse Models to Discover Mechanisms Underlying Caloric Restriction (CR) on Cognitive Outcomes

    R01 · NIA · $1,732,842 · Mar 1, 2026 to Jan 31, 2031

  • 5R01AG092459-02 Multimodal Probabilistic Machine Learning for Uncovering Latent Factors of Resilience in Alzheimer’s Disease

    R01 · NIA · $736,793 · Aug 1, 2025 to Apr 30, 2030

  • 5U01AG088407-03 The impact of metals and polygenic risk on multiomics, brain aging, and ADRD outcomes

    U01 · NIA · $1,482,647 · Sep 30, 2024 to Aug 31, 2029

  • 5R01AG076129-05 Systems Genetics Analysis of Alzheimer's Disease-Related Sleep Loss and the Transition to Dementia

    R01 · NIA · $787,595 · Feb 1, 2022 to Jan 31, 2027

  • 5R01NS125742-05 Genetic Mechanisms Controlling Resilience to Huntington's Disease

    R01 · NINDS · $794,548 · Dec 1, 2021 to Nov 30, 2027

  • 5R01AG075818-05 Cell Type-Specific Proteins that Promote Resilience to Cognitive Aging and Alzheimer's Disease

    R01 · NIA · $1,284,306 · Sep 30, 2021 to May 31, 2027

  • 5R01AG074012-05 Systems Genetics Analysis of Sex Differences in Alzheimer's Disease

    R01 · NIA · $1,131,658 · Sep 1, 2021 to Jun 30, 2027

All active NIH projects for Catherine Cook Kaczorowski ($7,950,389)
  • 1R01AG094704-01 Utilizing Heterogeneous Mouse Models to Discover Mechanisms Underlying Caloric Restriction (CR) on Cognitive Outcomes — $1,732,842, ends Jan 31, 2031
  • 5U01AG088407-03 The impact of metals and polygenic risk on multiomics, brain aging, and ADRD outcomes — $1,482,647, ends Aug 31, 2029
  • 5R01AG075818-05 Cell Type-Specific Proteins that Promote Resilience to Cognitive Aging and Alzheimer's Disease — $1,284,306, ends May 31, 2027
  • 5R01AG074012-05 Systems Genetics Analysis of Sex Differences in Alzheimer's Disease — $1,131,658, ends Jun 30, 2027
  • 5R01NS125742-05 Genetic Mechanisms Controlling Resilience to Huntington's Disease — $794,548, ends Nov 30, 2027
  • 5R01AG076129-05 Systems Genetics Analysis of Alzheimer's Disease-Related Sleep Loss and the Transition to Dementia — $787,595, ends Jan 31, 2027
  • 5R01AG092459-02 Multimodal Probabilistic Machine Learning for Uncovering Latent Factors of Resilience in Alzheimer’s Disease — $736,793, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#20 Lab fit 62% · Strong fit Hiring: Strong Atlanta Neuroscience

Matthew J.m. Rowan lab

Matthew J.m. Rowan · Emory University, Atlanta GA

PROJECT SUMMARY BCL11A is a zinc-finger transcription factor that has been well-studied in erythroid biology, but evidence for an important role in the brain is beginning to emerge. Patients with heterozygous loss-of-function BCL11A mutations present with clinical features that can include intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy. BCL11A is identified as a high confidence ASD risk gene in the SFARI database, and multiple lines of evidence also support potential roles in the etiology of schizophrenia (SZ) and Alzheimer’s disease (AD). However, the mechanisms th

Lab fit breakdown — 62% weighted · Strong fit

Scored on enough lab text to read as a verdict. 812 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 76% × 0.82 domain gate = 62%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "proteostasis".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "protein structure")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,704,349 in active NIH money across 4 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,704,349
Active projects
4
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,704,349 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “proteostasis”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146992-01 Understanding the contribution of BCL11A to neuron function and neurological disease

    R01 · NINDS · $575,485 · Feb 1, 2026 to Jan 31, 2031

  • 5R01AG085557-03 Searching for the Goldilocks Zone of Innate Immunity in Alzheimer's Disease

    R01 · NIA · $1,010,081 · Sep 26, 2024 to Jun 30, 2029

  • 5R01AG079269-03 Automated cell-type-specific electrophysiology for understanding circuit dysregulation in Alzheimer's Disease

    R01 · NIA · $688,408 · Aug 17, 2022 to Jul 31, 2027

All active NIH projects for Matthew J.m. Rowan ($2,704,349)
  • 5R01AG085557-03 Searching for the Goldilocks Zone of Innate Immunity in Alzheimer's Disease — $1,010,081, ends Jun 30, 2029
  • 5R01AG079269-03 Automated cell-type-specific electrophysiology for understanding circuit dysregulation in Alzheimer's Disease — $688,408, ends Jul 31, 2027
  • 1R01NS146992-01 Understanding the contribution of BCL11A to neuron function and neurological disease — $575,485, ends Jan 31, 2031
  • 1R21MH142870-01 Precision Targeting of Hippocampal Subfields with AAVs — $430,375, ends Mar 14, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#21 Lab fit 62% · Strong fit Hiring: Strong Atlanta Neuroscience

Zhexing Wen lab

Zhexing Wen · Emory University, Atlanta GA

PROJECT SUMMARY BCL11A is a zinc-finger transcription factor that has been well-studied in erythroid biology, but evidence for an important role in the brain is beginning to emerge. Patients with heterozygous loss-of-function BCL11A mutations present with clinical features that can include intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy. BCL11A is identified as a high confidence ASD risk gene in the SFARI database, and multiple lines of evidence also support potential roles in the etiology of schizophrenia (SZ) and Alzheimer’s disease (AD). However, the mechanisms th

Lab fit breakdown — 62% weighted · Strong fit

Scored on enough lab text to read as a verdict. 891 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 96% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 76% × 0.82 domain gate = 62%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "ipsc")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $5,878,657 in active NIH money across 7 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$5,878,657
Active projects
7
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,878,657 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 7 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years) — 1R01AG095529-01, which is outside this briefing's scope but is active NIH money for this PI.
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 96%

    Matched 4 of 5 profile areas (27 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146992-01 Understanding the contribution of BCL11A to neuron function and neurological disease

    R01 · NINDS · $575,485 · Feb 1, 2026 to Jan 31, 2031

  • 5R01MH139822-02 Leveraging human iPSC technology to understand the role of neuroinflammation in 22q11.2 deletion syndrome

    R01 · NIMH · $549,705 · Apr 4, 2025 to Jan 31, 2030

  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids

    RF1 · NIA · $1,785,477 · Aug 1, 2022 to Jul 31, 2027

All active NIH projects for Zhexing Wen ($5,878,657)
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids — $1,785,477, ends Jul 31, 2027
  • 5R01AG089717-03 Genetics-informed dissection of human brain cell-cell communication in Alzheimer's disease progression — $784,842, ends Apr 30, 2029
  • 5R01AG069900-05 Drug repositioning for Alzheimer's disease via genetics, electronic health records, and human iPSC models — $762,918, ends Dec 31, 2026
  • 5R01AG083628-03 Investigation of active kinome networks in Alzheimer's dementia. — $736,899, ends May 31, 2029
  • 1R01AG095529-01 Harnessing large-scale human omics data to decode novel risk genes for AD and its neuropsychiatric symptoms — $683,331, ends May 31, 2031
  • 1R01NS146992-01 Understanding the contribution of BCL11A to neuron function and neurological disease — $575,485, ends Jan 31, 2031
  • 5R01MH139822-02 Leveraging human iPSC technology to understand the role of neuroinflammation in 22q11.2 deletion syndrome — $549,705, ends Jan 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#22 Lab fit 61% · Moderate fit Hiring: Strong Atlanta Neuroscience Closed · posted date unknown

Golde Lab / Center for Neurodegenerative Disease

Todd E Golde · Emory University, Atlanta GA · lab page ↗

Alzheimer's disease therapeutics and mechanisms with continuous NIH funding since 2000; amyloid and neuroinflammation biology, rAAV delivery to brain, spinal cord and microglia, and translational target discovery extending opportunistically to other neurodegenerative diseases. (source)

Lab fit breakdown — 61% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 572 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 93% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 75% × 0.82 domain gate = 61%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "proteostasis".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "protein structure")
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "innate immun")

Lab composition · 2 named members

  • Kazi Farhana Afroz, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Brenda Moore, PhD — Senior scientist, tenure unknown [official roster]

The lab members page lists only two scientists besides Golde, which is likely incomplete for a centre director of this size; treat lab size as a lower bound.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Golde Lab members page · checked Sep 21, 2026

Posting · Closed

Postdoctoral positions — Alzheimer's Disease Big Data to Biology Training Program (T32AG087922) ↗

Closed

posted date: unknown (source prints none) · closes 2025-07-31 · source checked 2026-09-22

The source states applications closed 2025-07-31, before the 2026-09-23 run date.

Emory Center for Neurodegenerative Disease (T32 co-led by Golde)

Posted date read from: Emory GBHI news page prints no publication date for the announcement.

This call is closed. The Emory announcement states: "Applications are due by 5:00 p.m. ET on Thursday, July 31, 2025." That deadline passed more than a year before this run, so the four funded slots on the Alzheimer's Disease Big Data to Biology T32 (T32AG087922) are not open. Watch for a fresh cycle rather than applying to this page.

Can they afford to hire her?

Strong Strong: $2,250,608 in active NIH money across 3 projects, 4.3 years of project period left, 2 known team members, no live opening — the advert is past its close date.

Active NIH money
$2,250,608
Active projects
3
Runway left
4.3 yrs
Known lab size
2
Show the reasoning and the underlying awards
Hiring signals — 85 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,250,608 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-15.
  • 0 Posting past its stated close date — The source states applications closed 2025-07-31, before the 2026-09-23 run date.
  • +5 Small team with room to add a senior bench scientist — 2 public members on the roster.
  • Unknown: The only posting found for this lab falls outside the 4-month freshness window, so it contributes nothing. The source states applications closed 2025-07-31, before the 2026-09-23 run date.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 93%

    Matched 4 of 7 profile areas (28 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “proteostasis”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG093923-01A1 Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease

    R01 · NIA · $657,222 · Feb 15, 2026 to Jan 31, 2031

  • 5R01AG085557-03 Searching for the Goldilocks Zone of Innate Immunity in Alzheimer's Disease

    R01 · NIA · $1,010,081 · Sep 26, 2024 to Jun 30, 2029

All active NIH projects for Todd E Golde ($2,250,608)
  • 5R01AG085557-03 Searching for the Goldilocks Zone of Innate Immunity in Alzheimer's Disease — $1,010,081, ends Jun 30, 2029
  • 1R01AG093923-01A1 Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease — $657,222, ends Jan 31, 2031
  • 5T32AG087922-03 Alzheimer's Disease Big Data to Biology Training Program (ADBDB-TP) — $583,305, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 15, 2026 · project period to Jan 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#23 Lab fit 61% · Moderate fit Hiring: Moderate Atlanta Neuroscience

Yona R Levites lab

Yona R Levites · Emory University, Atlanta GA

Despite extensive research, the mechanisms through which Aβ aggregates contribute to cellular and tissue dysfunction in Alzheimer’s Disease (AD) are still debated. This debate, centered on mechanisms of toxicity, also extends to other human amyloidoses. Though most efforts have focused on identifying toxic species or conformers (e.g., oligomers, protofibrils, fibrillar conformers) and the effects of these Aβ only assemblies, our latest findings propose an alternative, non-mutually exclusive hypothesis. Based on comprehensive proteomic analyses of human AD and control brains, along with mouse m

Lab fit breakdown — 61% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 538 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 93% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 75% × 0.82 domain gate = 61%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "proteostasis".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "protein structure")
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "innate immun")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,667,303 in active NIH money across 2 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,667,303
Active projects
2
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,667,303 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-15.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 93%

    Matched 4 of 7 profile areas (28 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “proteostasis”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG093923-01A1 Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease

    R01 · NIA · $657,222 · Feb 15, 2026 to Jan 31, 2031

  • 5R01AG085557-03 Searching for the Goldilocks Zone of Innate Immunity in Alzheimer's Disease

    R01 · NIA · $1,010,081 · Sep 26, 2024 to Jun 30, 2029

All active NIH projects for Yona R Levites ($1,667,303)
  • 5R01AG085557-03 Searching for the Goldilocks Zone of Innate Immunity in Alzheimer's Disease — $1,010,081, ends Jun 30, 2029
  • 1R01AG093923-01A1 Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease — $657,222, ends Jan 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 15, 2026 · project period to Jan 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#24 Lab fit 59% · Moderate fit Hiring: Moderate Michigan Neuroscience Live posting · posted 2 months ago

Moore Laboratory (molecular neurodegeneration)

Darren John Moore · Van Andel Institute, Grand Rapids MI · lab page ↗

Molecular pathophysiology of inherited Parkinson's disease genes LRRK2, VPS35, parkin and ATP13A2, with a focus on the endolysosomal pathway, using primary neurons and astrocytes, human iPSC-derived models, rodent genetic models, viral vector technology, neuropathology, proteomics and behaviour. (source)

Lab fit breakdown — 59% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 317 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 100% · weight 15%
Geography 100% · weight 10%

Weighted mean 72% × 0.82 domain gate = 59%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "ipsc")

Lab composition · 9 named members

  • Brandon Meyerink, PhD — Postdoctoral fellow (Moore Laboratory), tenure unknown [official roster]
  • Jordan Rowlands, PhD — Postdoctoral fellow (Moore Laboratory), tenure unknown [official roster]
  • Alexis Bergsma, PhD — Senior laboratory manager (Dept. of Neurodegenerative Science), tenure unknown [official roster]
  • Xi Chen, PhD — Research scientist (Dept. of Neurodegenerative Science), tenure unknown [official roster]
  • Yue Ma, PhD — Research scientist (Dept. of Neurodegenerative Science), tenure unknown [official roster]
  • Maxwell Frye — PhD student, VAI Graduate School (mentor: Moore), tenure unknown [official roster]
  • Vanessa Howland — PhD student, VAI Graduate School (mentor: Moore), tenure unknown [official roster]
  • Alina Offerman — Research technician (Dept. of Neurodegenerative Science), tenure unknown [official roster]
  • Kayla Sipple — Research technician (Dept. of Neurodegenerative Science), tenure unknown [official roster]

Van Andel lists some staff at department level (Department of Neurodegenerative Science, which Moore chairs) rather than strictly under the lab; those are marked as such.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Moore Laboratory site (lab members section) · checked Sep 21, 2026

Posting · Live opening

Postdoctoral Fellow — Parkinson's Disease Mechanisms ↗

Live opening

posted 2026-07-14 · posted 2 months ago · source checked 2026-09-22

Source publication date 2026-07-14 (posted 2 months ago) is inside the 4-month window that opens 2026-05-23.

Van Andel Institute Workday careers site, requisition R1631

Posted date read from: Van Andel Workday requisition R1631 posting start date 2026-07-14.

Confirmed on Van Andel's own Workday board on 22 Sep 2026 (requisition R1631, posted 14 Jul 2026). The ALZFORUM mirror at https://www.alzforum.org/jobs/postdoctoral-fellow-parkinsons-disease-mechanisms reads "Posted 16 Jul 2026". Reviewed on a rolling basis until filled.

Can they afford to hire her?

Moderate Moderate: $582,465 in active NIH money across 1 project, 4.4 years of project period left, 9 known team members, a live opening (posted 2 months ago).

Active NIH money
$582,465
Active projects
1
Runway left
4.4 yrs
Known lab size
9
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $582,465 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-15.
  • +20 Live opening — posted 2 months ago — Postdoctoral Fellow — Parkinson's Disease Mechanisms — Source publication date 2026-07-14 (posted 2 months ago) is inside the 4-month window that opens 2026-05-23.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “primary neuron”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 100%

    4 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”
    • Advertised opening at one of her three target levels — lab text says “award record”
  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS146544-01 Neurodegenerative Mechanisms of ATP13A2-linked Parkinson's Disease and Related Disorders

    R01 · NINDS · $582,465 · Mar 15, 2026 to Feb 28, 2031

All active NIH projects for Darren John Moore ($582,465)
  • 1R01NS146544-01 Neurodegenerative Mechanisms of ATP13A2-linked Parkinson's Disease and Related Disorders — $582,465, ends Feb 28, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 15, 2026 · project period to Feb 28, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#25 Lab fit 58% · Moderate fit Hiring: Strong Michigan Neuroscience

Feldman Lab / NeuroNetwork for Emerging Therapies

Eva Lucille Feldman · University of Michigan, Ann Arbor MI · lab page ↗

ALS, diabetic neuropathy and metabolic drivers of cognitive impairment: glia–neuron metabolic crosstalk, oligodendrocyte biology, rodent models of metabolic syndrome and neurodegeneration, systems biology and multi-omics. (source)

Lab fit breakdown — 58% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 932 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 71% × 0.82 domain gate = 58%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · 13 named members

  • Mohamed Noureldein, PhD — Postdoctoral fellow, tenure unknown [news/directory] Independently confirmed as a U-M postdoctoral fellow in Feldman's lab via Google Scholar profile.
  • Dae-Gyu Jang, PhD — Postdoctoral fellow, tenure unknown [unverified, unconfirmed]
  • Cali McEntee, PhD — Postdoctoral fellow, tenure unknown [unverified, unconfirmed]
  • Jihyun Park, PhD — Postdoctoral fellow, tenure unknown [news/directory, unconfirmed] LinkedIn profile lists postdoctoral research fellow, U-M Medical School.
  • Stacey Jacoby — unknown, tenure unknown [unverified, unconfirmed]
  • Melissa Elafros — unknown (clinical faculty collaborator), tenure unknown [unverified, unconfirmed]
  • Laura DeVault — unknown, tenure unknown [unverified, unconfirmed]
  • Emily Koubek — unknown, tenure unknown [unverified, unconfirmed]
  • Lillia Baird — unknown, tenure unknown [unverified, unconfirmed]
  • Crystal Pacut — unknown, tenure unknown [unverified, unconfirmed]
  • Diana Rigan — unknown, tenure unknown [unverified, unconfirmed]
  • Haley McQuown — unknown, tenure unknown [unverified, unconfirmed]
  • Lavanya Muthukumar — unknown, tenure unknown [unverified, unconfirmed]

No public lab roster page was found. Every name here comes from Feldman's own public LinkedIn posts, which could not be re-verified behind LinkedIn's login. Designations are only known for the four postdocs she named as postdocs.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Public LinkedIn posts by Eva L. Feldman (19 Sep 2025 postdoc list; 11 Feb 2026 lab list) · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No Feldman-lab requisition surfaced on U-M Careers.

Checked at U-M Careers, Research Fellow listings

Can they afford to hire her?

Strong Strong: $5,032,306 in active NIH money across 4 projects, 4.7 years of project period left, 13 known team members, no advertised opening.

Active NIH money
$5,032,306
Active projects
4
Runway left
4.7 yrs
Known lab size
13
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,032,306 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-06.
  • 0 No active posting found — No Feldman-lab requisition surfaced on U-M Careers. Checked 2026-09-21.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 100%

    Matched 4 of 7 profile areas (30 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS148128-01 Transcriptomics of blood samples in ALS: An untapped resource to advance diagnosis, prognosis, and drug discovery and to gain insights into molecular subtypes of disease

    R01 · NINDS · $619,212 · Jul 6, 2026 to May 31, 2031

  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis

    R01 · NIEHS · $3,133,754 · Sep 10, 2025 to Sep 9, 2029

  • 6R01TS000344-03M001 RFA-TS-23-001: ?Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis

    R01 · ATSDR · $59,998 · Sep 30, 2023 to Sep 29, 2027

  • 2R01DK130913-05 Schwann Cell Senescence and the Secretome Provide a Unifying Mechanism for the Onset and Progression of Diabetic Neuropathy

    R01 · NIDDK · $779,340 · Aug 23, 2022 to May 31, 2031

All active NIH projects for Eva Lucille Feldman ($5,032,306)
  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis — $3,133,754, ends Sep 9, 2029
  • 2R01DK130913-05 Schwann Cell Senescence and the Secretome Provide a Unifying Mechanism for the Onset and Progression of Diabetic Neuropathy — $779,340, ends May 31, 2031
  • 1R01NS148128-01 Transcriptomics of blood samples in ALS: An untapped resource to advance diagnosis, prognosis, and drug discovery and to gain insights into molecular subtypes of disease — $619,212, ends May 31, 2031
  • 5R01TS000344-03 RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS) — $500,000, ends Sep 29, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 6, 2026 · project period to May 31, 2031 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#26 Lab fit 58% · Moderate fit Hiring: Possible Michigan Neuro + ophtho

Thummel Lab (zebrafish retinal regeneration)

Ryan Thummel · Wayne State University, Detroit MI · lab page ↗

Zebrafish models of photoreceptor degeneration and retinal regeneration, including chronic and acute light-damage injury, Müller glia responses, Nr2e3 function, histology and quantitative retinal morphology. (source)

Lab fit breakdown — 58% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 288 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 71% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 58% = 58%. Squarely in her disease area — no discount applied.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "retinitis pigmentosa".
  • Non-rodent animal models Lab text mentions "zebrafish".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · 3 named members

  • Xixia Luo — Research staff / lab manager, tenure unknown [official roster]
  • Jennifer Thomas — Graduate student, tenure unknown [official roster]
  • Alexis Steinmetz — Research staff, tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: ZFIN lab registry (Thummel Lab) cross-checked against thummellab.com people page · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No advertised position. The lab people page invites direct enquiries: "Please reach out if you are interested in joining the Thummel Lab."

Checked at Thummel Lab people page

Can they afford to hire her?

Possible Possible: $385,000 in active NIH money across 1 project, 2.8 years of project period left, 3 known team members, no advertised opening.

Active NIH money
$385,000
Active projects
1
Runway left
2.8 yrs
Known lab size
3
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $385,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • 0 No active posting found — No advertised position. The lab people page invites direct enquiries: "Please reach out if you are interested in joining the Thummel Lab." Checked 2026-09-21.
  • +5 Small team with room to add a senior bench scientist — 3 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 71%

    Matched 3 of 6 profile areas (20 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “retinitis pigmentosa”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “zebrafish”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY036575-02 Genetic and glial support mechanisms in acute and chronic models of photoreceptor degeneration

    R01 · NEI · $385,000 · Aug 1, 2025 to Jul 31, 2029

All active NIH projects for Ryan Thummel ($385,000)
  • 5R01EY036575-02 Genetic and glial support mechanisms in acute and chronic models of photoreceptor degeneration — $385,000, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jul 31, 2029 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#27 Lab fit 57% · Moderate fit Hiring: Strong Michigan Neuroscience

Andrew P Lieberman lab

Andrew P Lieberman · University of Michigan, Ann Arbor MI

ABSTRACT: Niemann-Pick disease type C is an invariably fatal autosomal recessive lysosomal disorder affecting all ages. Patients develop a clinically heterogeneous phenotype that includes severe, progressive neurodegeneration and early death. This disease is commonly caused by loss-of-function mutations in the NPC1 gene, encoding a multipass transmembrane glycoprotein required for exporting unesterified cholesterol from late endosomes and lysosomes. Most often, disease-causing missense mutations trigger misfolding of the NPC1 protein in the endoplasmic reticulum, leading to its degradation. De

Lab fit breakdown — 57% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 463 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 70% × 0.82 domain gate = 57%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "gene targeting".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,002,502 in active NIH money across 4 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,002,502
Active projects
4
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,002,502 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-21.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “gene targeting”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS150245-01 NPC1 protein misfolding in Niemann-Pick type C disease

    R01 · NINDS · $640,674 · Aug 21, 2026 to Jul 31, 2031

  • 5R01NS119873-05 Mechanisms of neuromuscular degeneration in SBMA

    R01 · NINDS · $498,416 · Sep 1, 2021 to May 31, 2027

All active NIH projects for Andrew P Lieberman ($2,002,502)
  • 1R01NS150245-01 NPC1 protein misfolding in Niemann-Pick type C disease — $640,674, ends Jul 31, 2031
  • 5R01NS119873-05 Mechanisms of neuromuscular degeneration in SBMA — $498,416, ends May 31, 2027
  • 2P30AG072931-06 Neuropathology Core — $457,791, ends Jun 30, 2031
  • 2T32GM141840-06 Training Program in Translational Research — $405,621, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 21, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#28 Lab fit 57% · Moderate fit Hiring: Possible Michigan Neuro + ophtho

Dao-qi Zhang lab

Dao-qi Zhang · Oakland University, Rochester MI

PROJECT SUMMARY The long-term goal of this project is to determine the neuronal and vascular mechanisms of visual impairment and myopia resulting from prematurity in order to develop preventive and therapeutic strategies. Prenatal and early postnatal vertebrate retinas generate correlated spontaneous neuronal activity, termed “retinal waves,” that are essential for normal neuronal development and vision. Premature retinal wave termination may contribute to preterm birth-associated vision problems and refractive errors. Preterm birth, in combination with postnatal oxy- gen therapy, can also cau

Lab fit breakdown — 57% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 229 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 68% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 57% = 57%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual acuity".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "patch clamp")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $821,937 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$821,937
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $821,937 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 68%

    Matched 3 of 6 profile areas (19 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY033808-04 The Underlying Mechanisms of Visual Impairment and Myopia in Prematurity

    R01 · NEI · $392,921 · Sep 30, 2023 to Jun 30, 2027

All active NIH projects for Dao-qi Zhang ($821,937)
  • 1R15EY034305-01A1 Pacemakers of Cholinergic Wave Activity in the Developing Retina — $429,016, ends Aug 31, 2027
  • 5R01EY033808-04 The Underlying Mechanisms of Visual Impairment and Myopia in Prematurity — $392,921, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2023 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#29 Lab fit 57% · Moderate fit Hiring: Moderate Michigan Neuroscience

Marianna Sadagurski lab

Marianna Sadagurski · Wayne State University, Detroit MI

ABSTRACT Aging is the dominant risk factor for most chronic diseases including neurodegenerative diseases. There is now ample evidence, in mice, that the process of aging can be delayed by pharmacological compounds that target numerous cellular and molecular pathways that have been implicated in the aging process and also delay multiple forms of late-life illness, including Alzheimer's disease (AD). In collaboration with the Intervention Testing Program (ITP), we have recently demonstrated that an FDA-approved anti-diabetes drug, Canagliflozin (Cana), a sodium- glucose transporter 2 (SGLT2) in

Lab fit breakdown — 57% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 590 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 70% × 0.82 domain gate = 57%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "endoplasmic reticulum".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,975,672 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,975,672
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,975,672 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 1R01ES038236-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • +5 Brand-new (Type 1) project, not a renewal — 4RF1AG078170-02 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “endoplasmic reticulum”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4RF1AG078170-02 Canagliflozin as a Neuroprotective Agent to Improve Neuroinflammation and Cognitive Function during Aging

    RF1 · NIA · $818,445 · Sep 1, 2023 to Aug 31, 2028 · Type 1 (new)

  • 5R01ES033171-05 Benzene exposure promotes neuroinflammation and metabolic dysregulation

    R01 · NIEHS · $359,423 · Apr 1, 2022 to Jan 31, 2027

All active NIH projects for Marianna Sadagurski ($1,975,672)
  • 4RF1AG078170-02 Canagliflozin as a Neuroprotective Agent to Improve Neuroinflammation and Cognitive Function during Aging — $818,445, ends Aug 31, 2028
  • 1R01ES038236-01A1 Molecular Mechanisms of Multi-Organ Communication in Response to VOC Exposure Across Aging — $797,804, ends Jun 30, 2031
  • 5R01ES033171-05 Benzene exposure promotes neuroinflammation and metabolic dysregulation — $359,423, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Aug 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#30 Lab fit 57% · Moderate fit Hiring: Unlikely Michigan Ophthalmology

Renu A. Kowluru lab

Renu A. Kowluru · Wayne State University, Detroit MI

Her laboratory investigates the role of mitochondrial dysfunction in the development of diabetic retinopathy, focusing mainly on understanding how diabetes damages retinal mitochondria and how the damaged mitochondria lead to the development of retinopathy. Her work showed that damaged mitochondrial DNA in diabetes leads to a self-propagating vicious cycle of free radicals, contributing to the failure of retinopathy to arrest after hyperglycaemic insult is terminated (the 'metabolic memory' phenomenon), and she was the first to show the role of mitochondrial epigenetics in the development of diabetic retinopathy. (source)

Lab fit breakdown — 57% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 316 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 80% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 62% × 0.92 domain gate = 57%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "apoptosis".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histopatholog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $346,500 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$346,500
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $346,500 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “apoptosis”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 80%

    Matched 3 of 7 profile areas (24 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histopatholog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY033516-05 Diabetic Retinopathy, Mitochondria Damage and Long Non-coding RNAs

    R01 · NEI · $346,500 · Jul 1, 2022 to Jun 30, 2027

All active NIH projects for Renu A. Kowluru ($346,500)
  • 5R01EY033516-05 Diabetic Retinopathy, Mitochondria Damage and Long Non-coding RNAs — $346,500, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#31 Lab fit 57% · Moderate fit Hiring: Possible Michigan Neuroscience

Kathy Steece-collier lab

Kathy Steece-collier · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

Project Summary The often debilitating side-effect of standard pharmacotherapy for Parkinson disease (PD), levodopa-induced dyskinesia (LID) continues to be a serious complication of medical treatment for individuals with PD. Despite eventually occurring in greater than 90% of individuals, there is the only one FDA-approved drug for LID. However, it is only partially effective, works best in cases of mild LID, and can itself produce significant adverse events. Maintaining the motor benefits of PD therapies while avoiding LID remains a significant unmet clinical need. Our research program has b

Lab fit breakdown — 57% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 292 words of lab text were scored, matching 9 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 100% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 69% × 0.82 domain gate = 57%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $935,797 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$935,797
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $935,797 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 100%

    Matched 5 of 7 profile areas (32 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Axonal transport and neuronal injury assays — lab text says “retrograde”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • Calcium and mechanosensitive channel signalling — lab text says “calcium channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Molecular biology, biochemistry and proteomics; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS110398-08 Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD

    R01 · NINDS · $935,797 · Sep 30, 2018 to May 31, 2029

All active NIH projects for Kathy Steece-collier ($935,797)
  • 5R01NS110398-08 Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD — $935,797, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2018 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#32 Lab fit 56% · Moderate fit Hiring: Strong Atlanta Neuroscience Standing call — undated

Mao Lab (neuronal stress response)

Zixu Mao · Emory University, Atlanta GA · lab page ↗

Fundamental mechanisms of neuronal stress response in Alzheimer's and Parkinson's disease: macroautophagy and chaperone-mediated autophagy, lysosomal and mitochondrial function, ER–lysosome stress signalling, proteostasis and miRNA homeostasis, using rodent models and primary neurons. (source)

Lab fit breakdown — 56% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 795 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 68% × 0.82 domain gate = 56%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "primary neuron".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · 4 named members

  • Wenming Li, MD, PhD — Instructor, tenure unknown [official roster]
  • Bo Meng, PhD — Postdoctoral fellow, tenure unknown [official roster] Also listed in the departmental postdoc directory under Mao.
  • Minzheng Wang, MD — Research specialist, lead (rodent models), tenure unknown [official roster]
  • Andy Xiong — Laboratory research assistant, tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Mao Lab members page (Emory Pharmacology & Chemical Biology) · checked Sep 21, 2026

Posting · Standing call — undated

Postdoctoral positions — Mao Lab ↗

Standing call — undated

posted date: unknown (source prints none) · source checked 2026-09-22

The lab's own page advertises this as a standing open call and prints no publication date. Page re-read 2026-09-22; recorded as unknown rather than guessed, so it is not counted as a live dated opening.

Mao Lab "Career Opportunities" section

Posted date read from: Mao lab Career Opportunities section prints no publication date.

Lab page states: "Several postdoctoral positions are available in the laboratory of Zixu Mao." Re-read 22 Sep 2026 and still present, but it is an undated standing advertisement rather than a dated requisition, so it is not counted as a live opening. Apply by email with a CV.

Can they afford to hire her?

Strong Strong: $1,968,616 in active NIH money across 3 projects, 4.2 years of project period left, 4 known team members, an undated standing call rather than a live dated opening.

Active NIH money
$1,968,616
Active projects
3
Runway left
4.2 yrs
Known lab size
4
Show the reasoning and the underlying awards
Hiring signals — 88 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,968,616 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2030-11-30 (about 4.2 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-15.
  • +10 Standing open call, no publication date — Postdoctoral positions — Mao Lab — The lab's own page advertises this as a standing open call and prints no publication date. Page re-read 2026-09-22; recorded as unknown rather than guessed, so it is not counted as a live dated opening.
  • +5 Small team with room to add a senior bench scientist — 4 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “primary neuron”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG092720-01A1 The Role of PML in Oxidative Stress and Alzheimer's Disease

    R01 · NIA · $651,466 · Feb 15, 2026 to Nov 30, 2030

  • 5R01NS125317-04 Chloride Homeostasis in Lysosomal Function and Parkinson's Disease

    R01 · NINDS · $600,311 · Jul 1, 2022 to Apr 30, 2028

  • 5R01AG069253-03 Dysregulation of Multivesicular Body and Exosome Flux in Alzheimer's Disease

    R01 · NIA · $716,839 · May 1, 2021 to Apr 30, 2027

All active NIH projects for Zixu Mao ($1,968,616)
  • 5R01AG069253-03 Dysregulation of Multivesicular Body and Exosome Flux in Alzheimer's Disease — $716,839, ends Apr 30, 2027
  • 1R01AG092720-01A1 The Role of PML in Oxidative Stress and Alzheimer's Disease — $651,466, ends Nov 30, 2030
  • 5R01NS125317-04 Chloride Homeostasis in Lysosomal Function and Parkinson's Disease — $600,311, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 15, 2026 · project period to Nov 30, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#33 Lab fit 55% · Moderate fit Hiring: Moderate Michigan Neuroscience New award

Yang Yang Laboratory (cryo-EM of neurodegeneration)

Yang Yang · Van Andel Institute, Grand Rapids MI · lab page ↗

Cryo-EM and cryo-ET of amyloid filaments in Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies and multiple system atrophy; amyloid assembly, spreading and clearance mechanisms, and amyloid-based therapies including PET ligands and antibodies. (source)

Lab fit breakdown — 55% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 313 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 83% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 67% × 0.82 domain gate = 55%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Axonal transport and neuronal injury assays Lab text mentions "neurite".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "cryo-em")
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "pet ligand")

Lab composition · 8 named members

  • Mohammed Alhadidy, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Tiara Hinton, PhD — Postdoctoral fellow (VAI Inspire fellow), tenure unknown [official roster]
  • Daniel Mendez, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Henry Pan, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Hongwei Zhang, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Katelyn Ernst — PhD student, VAI Graduate School, tenure unknown [official roster]
  • Timothy Bourassa — Assistant research technician (Dept. of Structural Biology), tenure unknown [official roster]
  • Flavia Marcello — Assistant research technician (Dept. of Structural Biology), tenure unknown [official roster]

Lab founded 2024. Technicians and admin are listed at Department of Structural Biology level.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Yang Yang Laboratory site (lab members section) · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

The posting previously recorded here is gone. The Vaia aggregator page now returns "This page is no longer available", and a search of all 23 live requisitions on Van Andel's own Workday board on 22 Sep 2026 found no opening in the Yang lab. Treat as filled or withdrawn; email Yang directly if the cryo-EM/cryo-ET work is of interest.

Checked at Van Andel Institute careers feed

Can they afford to hire her?

Moderate Moderate: $618,967 in active NIH money across 1 project, 4.8 years of project period left, 8 known team members, no advertised opening.

Active NIH money
$618,967
Active projects
1
Runway left
4.8 yrs
Known lab size
8
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $618,967 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-14.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01NS144991-01A1 is flagged as a new project by NIH.
  • 0 No active posting found — The posting previously recorded here is gone. The Vaia aggregator page now returns "This page is no longer available", and a search of all 23 live requisitions on Van Andel's own Workday board on 22 Sep 2026 found no opening in the Yang lab. Treat as filled or withdrawn; email Yang directly if the cryo-EM/cryo-ET work is of interest. Checked 2026-09-22.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 83%

    Matched 4 of 7 profile areas (25 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS144991-01A1 Structural Basis of Plaque Morphogenesis in Alzheimer's Disease

    R01 · NINDS · $618,967 · Sep 14, 2026 to Jun 30, 2031 · Type 1 (new)

All active NIH projects for Yang Yang ($618,967)
  • 1R01NS144991-01A1 Structural Basis of Plaque Morphogenesis in Alzheimer's Disease — $618,967, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 14, 2026 · project period to Jun 30, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#34 Lab fit 55% · Moderate fit Hiring: Moderate Michigan Neuro + ophtho

Michelle L Hastings lab

Michelle L Hastings · University of Michigan, Ann Arbor MI

Abstract Genomic deletion of exons 7 and 8 from the CLN3 gene is the most common cause of CLN3 Batten disease (OMIM #204200), a rare autosomal recessive, lethal, neurodegenerative lysosomal storage disorder. The function of the protein is not known, but the loss of its function and, potentially the consequent production of a toxic protein fragment, is associated with accumulation of auto-fluorescent storage material and glycerophosphodiesters (GPDs) in cells, and progressive vision loss, cognitive decline, motor coordination dysfunction, seizures, dystonia and ultimately death in children and

Lab fit breakdown — 55% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 303 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 39% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 50% · weight 15%
Geography 100% · weight 10%

Weighted mean 67% × 0.82 domain gate = 55%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "vision loss".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histopatholog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,347,673 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,347,673
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,347,673 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-10.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 39%

    Matched 2 of 6 profile areas (11 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “vision loss”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “histopatholog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 50%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • Award started within the last 12 months — lab text says “award record”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1U01NS148918-01 IND-Enabling Studies of an Antisense Oligonucleotide Therapy for CLN3 Batten Disease

    U01 · NINDS · $1,347,673 · Jul 10, 2026 to Jun 30, 2029

All active NIH projects for Michelle L Hastings ($1,347,673)
  • 1U01NS148918-01 IND-Enabling Studies of an Antisense Oligonucleotide Therapy for CLN3 Batten Disease — $1,347,673, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 10, 2026 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#35 Lab fit 55% · Moderate fit Hiring: Strong Atlanta Neuroscience

Blaine Russell Roberts lab

Blaine Russell Roberts · Emory University, Atlanta GA

Despite extensive research, the mechanisms through which Aβ aggregates contribute to cellular and tissue dysfunction in Alzheimer’s Disease (AD) are still debated. This debate, centered on mechanisms of toxicity, also extends to other human amyloidoses. Though most efforts have focused on identifying toxic species or conformers (e.g., oligomers, protofibrils, fibrillar conformers) and the effects of these Aβ only assemblies, our latest findings propose an alternative, non-mutually exclusive hypothesis. Based on comprehensive proteomic analyses of human AD and control brains, along with mouse m

Lab fit breakdown — 55% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 523 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 67% × 0.82 domain gate = 55%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Axonal transport and neuronal injury assays Lab text mentions "neurite".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "monoclonal")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,831,792 in active NIH money across 4 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,831,792
Active projects
4
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,831,792 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-15.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG093923-01A1 Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease

    R01 · NIA · $657,222 · Feb 15, 2026 to Jan 31, 2031

  • 5R01AG085587-03 Deciphering the IgG glycosylation code of Alzheimer's Disease

    R01 · NIA · $547,556 · Feb 1, 2024 to Jan 31, 2029

All active NIH projects for Blaine Russell Roberts ($3,831,792)
  • 1S10OD040085-01 timsTOF Ultra-2 mass spectrometer with Evosep LC for Emory — $1,700,000, ends May 17, 2027
  • 1R61NS142626-01A1 Red Blood Cell Lipid Signatures: A New Approach to Parkinson's Disease Diagnosis — $927,014, ends Jul 31, 2029
  • 1R01AG093923-01A1 Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease — $657,222, ends Jan 31, 2031
  • 5R01AG085587-03 Deciphering the IgG glycosylation code of Alzheimer's Disease — $547,556, ends Jan 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 15, 2026 · project period to Jan 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#36 Lab fit 55% · Moderate fit Hiring: Possible Michigan Ophthalmology

List Lab (cell-surface proteases)

Karin List · Wayne State University, Detroit MI · lab page ↗

Type II transmembrane serine proteases and cell-surface-anchored proteolysis in epithelial development and carcinogenesis, including matriptase in corneal epithelial homeostasis and repair, using knockout and transgenic mouse models plus in vitro cancer models. (source)

Lab fit breakdown — 55% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 378 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 32% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 67% × 0.82 domain gate = 55%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "cre recombinase".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · 2 named members

  • Joseph Lundgren — PhD candidate, tenure unknown [official roster]
  • Michael Flynn — PhD candidate, tenure unknown [official roster] Works on matriptase in corneal epithelial repair.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Wayne State Pharmacology faculty profile, "Current Lab Personnel" · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No advertised postdoc position on the departmental profile.

Checked at Wayne State Pharmacology faculty profile

Can they afford to hire her?

Possible Possible: $477,534 in active NIH money across 1 project, 3.8 years of project period left, 2 known team members, no advertised opening.

Active NIH money
$477,534
Active projects
1
Runway left
3.8 yrs
Known lab size
2
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $477,534 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • 0 No active posting found — No advertised postdoc position on the departmental profile. Checked 2026-09-21.
  • +5 Small team with room to add a senior bench scientist — 2 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “cre recombinase”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY037251-02 Role of matriptase in corneal epithelial homeostasis and repair

    R01 · NEI · $477,534 · Aug 1, 2025 to Jul 31, 2030

All active NIH projects for Karin List ($477,534)
  • 5R01EY037251-02 Role of matriptase in corneal epithelial homeostasis and repair — $477,534, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jul 31, 2030 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#37 Lab fit 55% · Moderate fit Hiring: Moderate Michigan Neuro + ophtho

Watson Lab (brain, behaviour and neural network dynamics)

Brendon O Watson · University of Michigan, Ann Arbor MI · lab page ↗

Neural network dynamics linking brain and behaviour in rodents, using in vivo electrophysiology with silicon probes and long-run behavioural monitoring, at the level of single neurons, networks and whole-organism behaviour. Current themes are the temporal structure of REM sleep, sleep and circadian regulation of cortical firing rates, behavioural and physiological markers of social bonding, and altered sleep architecture in psychiatric and neurodegenerative disease — including increased REM duration and beta power in a mouse model of spinocerebellar ataxia type 3, which the lab links to REM pathology in Alzheimer's and Parkinson's disease. The PI is Associate Professor of Psychiatry and a practising psychiatrist. (source)

Lab fit breakdown — 55% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 853 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.92 domain gate = 55%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Retina, photoreceptors and RPE Lab text mentions "photoreceptor".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · 11 named members

  • Brendon Watson, MD-PhD — Principal Investigator; Associate Professor of Psychiatry, tenure unknown [official roster]
  • Lezio Soares Bueno-Júnior, PhD — Assistant Research Scientist, tenure unknown [official roster]
  • Jeremiah Hartner, PhD — Research Investigator, tenure unknown [official roster]
  • Simeone Marino, PhD — Associate Research Scientist, tenure unknown [official roster]
  • Nicolette Ognjanovski, PhD — Gilmore Postdoctoral Fellow, tenure unknown [official roster]
  • Daniil Berezhnoi, PhD — Senior Researcher, tenure unknown [official roster]
  • Josh Ghimire — Doctoral Student, Neuroscience, tenure unknown [official roster]
  • David Kim — Doctoral Student, Biomedical Engineering, tenure unknown [official roster]
  • Antwan Green — Medical Student and Researcher, tenure unknown [official roster]
  • Avery Johnson — Undergraduate Researcher, tenure unknown [official roster]
  • Aisling Brannock — Undergraduate Researcher, tenure unknown [official roster]

Current members only; the page carries a long separate alumni list.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Watson Lab people page · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No openings page and no advertised vacancy. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at Watson Lab site (home and people pages)

Can they afford to hire her?

Moderate Moderate: $3,285,700 in active NIH money across 4 projects, 3.5 years of project period left, 11 known team members, no advertised opening.

Active NIH money
$3,285,700
Active projects
4
Runway left
3.5 yrs
Known lab size
11
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,285,700 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • 0 No active posting found — No openings page and no advertised vacancy. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “photoreceptor”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS141983-02 Circadian and homeostatic regulation of sleep in a diurnal model of Smith-Magenis Syndrome

    R01 · NINDS · $594,862 · Apr 1, 2025 to Mar 31, 2030

  • 4RF1MH131592-03 Effects of early life sleep disruption on prefrontal cortex electrophysiological state and affiliation/attachment

    RF1 · NIMH · $1,991,026 · Aug 1, 2023 to May 31, 2028

  • 5R01MH126137-05 Digital behavioral phenotyping and multi-region electrophysiology to determine behavioral and neural network changes underlying the stress response in mice

    R01 · NIMH · $504,145 · May 1, 2021 to Feb 28, 2027

All active NIH projects for Brendon O Watson ($3,285,700)
  • 4RF1MH131592-03 Effects of early life sleep disruption on prefrontal cortex electrophysiological state and affiliation/attachment — $1,991,026, ends May 31, 2028
  • 5R01NS141983-02 Circadian and homeostatic regulation of sleep in a diurnal model of Smith-Magenis Syndrome — $594,862, ends Mar 31, 2030
  • 5R01MH126137-05 Digital behavioral phenotyping and multi-region electrophysiology to determine behavioral and neural network changes underlying the stress response in mice — $504,145, ends Feb 28, 2027
  • 5R21NS139668-02 Developing and characterizing sleep-based network homeostasis in a diurnal rodent model for Familial Natural Short Sleep — $195,667, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2025 · project period to Mar 31, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#38 Lab fit 55% · Moderate fit Hiring: Possible Michigan Ophthalmology

Mohamed Al-sayed Al-shabrawey lab

Mohamed Al-sayed Al-shabrawey · Oakland University, Rochester MI

Summary Proliferative diabetic retinopathy is a major cause of vision impairment in diabetic patients due to pathological diabetic macular edema and retinal neovascularization. Our previous research identified bone morphogenetic proteins-2 and -4 (BMP2/4) and their receptors Activin-receptor-Like-Kinases (ALK2 and ALK3) as significant factors in retinal endothelial cell barrier dysfunction associated with diabetic retinopathy and excess fibronectin production. Activation of BMP2/4-ALK in diabetes is associated with activation of both canonical (SMAD) and non-canonical (p38 MAPK) pathways and h

Lab fit breakdown — 55% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 274 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 68% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 55% = 55%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "intraocular pressure".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ocular".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $572,904 in active NIH money across 1 project, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$572,904
Active projects
1
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $572,904 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 68%

    Matched 3 of 6 profile areas (19 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “intraocular pressure”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ocular”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 2R01EY030054-06A1 BMP2/ALKs Signaling System in Diabetic Retinopathy

    R01 · NEI · $572,904 · Feb 1, 2020 to Feb 28, 2030

All active NIH projects for Mohamed Al-sayed Al-shabrawey ($572,904)
  • 2R01EY030054-06A1 BMP2/ALKs Signaling System in Diabetic Retinopathy — $572,904, ends Feb 28, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2020 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#39 Lab fit 54% · Moderate fit Hiring: Moderate Michigan Neuroscience

Anne Watson Draelos lab

Anne Watson Draelos · University of Michigan, Ann Arbor MI

ABSTRACT Systems neuroscience is acquiring exponentially more neural activity data in vivo and is employing richer stimuli to study ethologically relevant behaviors. Models of neural dynamics in low-dimensional spaces (‘neural manifolds’) are increasingly state-of-the-art for describing the underlying neurobiological mechanisms to encode rich stimuli and evoke behavior. However, causally testing these theories remains challenging, as it requires dynamic manipulation of activity across neurons and time, conditioned on the individual brain, task, or environment. Here, we propose to build new mac

Lab fit breakdown — 54% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 418 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 66% × 0.82 domain gate = 54%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • CRISPR / conditional knockout genetics Lab text mentions "gene targeting".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,062,697 in active NIH money across 2 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,062,697
Active projects
2
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,062,697 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (31 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “gene targeting”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Non-rodent animal models — lab text says “zebrafish”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Human donor tissue, primary and explant culture

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DA063389-01 Real-time modeling and perturbation of stimulus-shaped neural manifolds

    R01 · NIDA · $325,904 · Mar 1, 2026 to Dec 31, 2028

  • 5R01AG092459-02 Multimodal Probabilistic Machine Learning for Uncovering Latent Factors of Resilience in Alzheimer’s Disease

    R01 · NIA · $736,793 · Aug 1, 2025 to Apr 30, 2030

All active NIH projects for Anne Watson Draelos ($1,062,697)
  • 5R01AG092459-02 Multimodal Probabilistic Machine Learning for Uncovering Latent Factors of Resilience in Alzheimer’s Disease — $736,793, ends Apr 30, 2030
  • 1R01DA063389-01 Real-time modeling and perturbation of stimulus-shaped neural manifolds — $325,904, ends Dec 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2026 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#40 Lab fit 54% · Moderate fit Hiring: Possible Michigan Neuroscience

Ming Li lab

Ming Li · University of Michigan, Ann Arbor MI

PROJECT SUMMARY The lysosome is an important organelle responsible for digesting and recycling materials, nutrient sensing, and controlling cell proliferation. It is also linked to neurodegenerative diseases, including Alzheimer's, Huntington's, and Parkinson's diseases. Despite its importance, the regulation of lysosomal membrane protein composition and the function of its transporters and ion channels are not well understood. My lab has made significant progress in studying the turnover mechanisms of lysosomal membrane proteins by identifying a conserved ubiquitin- and ESCRT-dependent pathwa

Lab fit breakdown — 54% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 382 words of lab text were scored, matching 8 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 87% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 66% × 0.82 domain gate = 54%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Non-rodent animal models Lab text mentions "zebrafish".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $809,130 in active NIH money across 2 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$809,130
Active projects
2
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $809,130 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Non-rodent animal models — lab text says “zebrafish”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture

  • Techniques & readouts — 87%

    Matched 4 of 7 profile areas (26 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM153356-03 Functional characterization of lysosome membrane and its protein quality control system

    R35 · NIGMS · $384,822 · Sep 1, 2024 to Aug 31, 2029

  • 5R01HD109346-05 Characterization of TMEM251 that causes a new type of severe lysosome storage disease

    R01 · NICHD · $424,308 · Sep 15, 2022 to Aug 31, 2027

All active NIH projects for Ming Li ($809,130)
  • 5R01HD109346-05 Characterization of TMEM251 that causes a new type of severe lysosome storage disease — $424,308, ends Aug 31, 2027
  • 5R35GM153356-03 Functional characterization of lysosome membrane and its protein quality control system — $384,822, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#41 Lab fit 53% · Moderate fit Hiring: Strong Atlanta Neuroscience

Escayg Lab (neurogenetics of epilepsy)

Andrew P Escayg · Emory University, Atlanta GA · lab page ↗

Human and mouse neurogenetics of severe childhood epilepsy and mechanistically related disorders including autism and Alzheimer's disease; transgenic, knock-in/knock-out and conditional knockout mouse lines for voltage-gated ion channels, GPCRs and ATP6V0C, with video/EEG analysis, behavioural analysis, bioinformatics and extracellular vesicle biology. (source)

Lab fit breakdown — 53% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 622 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 77% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 65% × 0.82 domain gate = 53%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "rna-seq".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · 6 named members

  • Jennifer Wong, PhD — Assistant professor (former Escayg postdoc, now runs her own lab), tenure unknown [official roster]
  • Asheebo Rojas, PhD — Instructor, tenure unknown [official roster]
  • Samantha Reed, BS — Neuroscience graduate student, tenure unknown [official roster]
  • Katie James, BS — Neuroscience graduate student, tenure unknown [official roster]
  • Nihar Ettigi — Undergraduate researcher, tenure unknown [official roster]
  • Eesha Faiz — Undergraduate researcher, tenure unknown [official roster]

The page also lists eleven named alumni with their current positions, so the roster is actively maintained.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Escayg Lab people page · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No openings section on the lab site and no postdoc currently listed on the roster.

Checked at Escayg Lab people page

Can they afford to hire her?

Strong Strong: $1,518,781 in active NIH money across 3 projects, 4.3 years of project period left, 6 known team members, no advertised opening.

Active NIH money
$1,518,781
Active projects
3
Runway left
4.3 yrs
Known lab size
6
Show the reasoning and the underlying awards
Hiring signals — 78 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,518,781 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-02-01.
  • 0 No active posting found — No openings section on the lab site and no postdoc currently listed on the roster. Checked 2026-09-21.
  • +5 Small team with room to add a senior bench scientist — 6 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 77%

    Matched 4 of 7 profile areas (23 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “rna-seq”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146992-01 Understanding the contribution of BCL11A to neuron function and neurological disease

    R01 · NINDS · $575,485 · Feb 1, 2026 to Jan 31, 2031

  • 5R01NS126392-04 SCN8A encephalopathy: disease mechanisms and treatment

    R01 · NINDS · $523,154 · Mar 1, 2023 to Feb 29, 2028

All active NIH projects for Andrew P Escayg ($1,518,781)
  • 1R01NS146992-01 Understanding the contribution of BCL11A to neuron function and neurological disease — $575,485, ends Jan 31, 2031
  • 5R01NS126392-04 SCN8A encephalopathy: disease mechanisms and treatment — $523,154, ends Feb 29, 2028
  • 1R21NS145127-01A1 Exploring the contribution of extracellular vesicles to epileptogenesis in TLE and DS — $420,142, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#42 Lab fit 53% · Moderate fit Hiring: Moderate Michigan Ophthalmology

Neera Tewari-singh lab

Neera Tewari-singh · Michigan State University, East Lansing MI

Project Summary Mustard vesicating agent sulfur mustard (SM) is the most extensively used warfare agent in history and remains a potential agent of warfare and terrorism. Eye is the most sensitive organ to SM and its analog nitrogen mustard (NM) exposure, resulting in devastating biphasic injury called Mustard Gas Keratopathy. The dose- and time- related severity of symptoms and the mechanism of this biphasic injury involving damage to the most affected cornea and possibly to other ocular tissues is not well understood. In addition, the extent to which mustard vesicants distribute, transport,

Lab fit breakdown — 53% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 68% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% = 53%. Squarely in her disease area — no discount applied.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "aqueous humor".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,252,083 in active NIH money across 3 projects, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,252,083
Active projects
3
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,252,083 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-22 (about 2.6 years) — 1R01ES036491-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 68%

    Matched 3 of 6 profile areas (19 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “aqueous humor”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY034140-03 Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico Models

    R01 · NEI · $453,286 · Sep 1, 2023 to Aug 31, 2027

All active NIH projects for Neera Tewari-singh ($3,252,083)
  • 1R01ES036491-01A1 Identifying mechanisms of lung toxicity from skin exposure to vesicants — $1,403,056, ends Apr 22, 2029
  • 1R01ES037601-01 Mast Cell Activation as a Common Mechanism of Pulmonary Toxicity by Chemical Threat Agents — $1,395,741, ends Aug 31, 2028
  • 5R01EY034140-03 Understanding Mustard Vesicants Distribution and Toxicity in the Eye Using In Vivo and In Silico Models — $453,286, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#43 Lab fit 53% · Moderate fit Hiring: Unlikely Michigan Ophthalmology

Andrew Fx Goldberg lab

Andrew Fx Goldberg · Oakland University, Rochester MI

Project Summary / Abstract This project investigates the molecular and cellular mechanisms that govern vertebrate photoreceptor outer segment (OS) structure, a fundamental unsolved problem in photoreceptor cell biology. This basic science knowledge gap severely limits clinical understanding of (and treatments for) blinding diseases in humans and animals caused by mutations that disrupt OS structure. A broad variety of inherited retinal degenerations (IRDs) are caused by mutations that disrupt OS organelle structure. Because normal OS structure is required for healthy vision but is not yet unde

Lab fit breakdown — 53% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 221 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 43% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 58% × 0.92 domain gate = 53%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "organelle".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "protein structure")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $385,858 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$385,858
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $385,858 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 43%

    Matched 2 of 6 profile areas (12 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “organelle”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY025291-09 Molecular Basis of Rod and Cone Photoreceptor Outer Segment Structures

    R01 · NEI · $385,858 · May 1, 2016 to Apr 30, 2027

All active NIH projects for Andrew Fx Goldberg ($385,858)
  • 5R01EY025291-09 Molecular Basis of Rod and Cone Photoreceptor Outer Segment Structures — $385,858, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2016 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#44 Lab fit 52% · Moderate fit Hiring: Strong Michigan Neuroscience

Sami Barmada lab

Sami Barmada · University of Michigan, Ann Arbor MI

Neurodegeneration involves complex cellular phenotypes and molecular changes that vary widely among the cells of the nervous system. Current methodologies permit either detailed molecular profiling (e.g., single-cell transcriptomics) or functional phenotyping (e.g., live imaging of neuronal activity), but not both in the same cells. Thus, it is difficult to directly link a neuron's functional state or fate with its gene expression profile. To address this limitation, we developed an innovative technology, VISTA-FISH (Video Imaging with Spatial- Temporal Analysis by FISH), that couples prospect

Lab fit breakdown — 52% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 475 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 63% × 0.82 domain gate = 52%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "protein degradation".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,951,379 in active NIH money across 3 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,951,379
Active projects
3
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,951,379 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-12.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “protein degradation”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS148028-01 Linking Single-Cell Transcriptomic, Morphological, and Temporal Signatures of Vulnerability in Neurodegeneration

    R01 · NINDS · $601,750 · Jun 12, 2026 to Mar 31, 2031

  • 2R37NS113943-06 Regulation and impact of shortened TDP43 isoforms in FTD and ALS

    R37 · NINDS · $1,794,354 · Dec 1, 2019 to Aug 31, 2029

All active NIH projects for Sami Barmada ($2,951,379)
  • 2R37NS113943-06 Regulation and impact of shortened TDP43 isoforms in FTD and ALS — $1,794,354, ends Aug 31, 2029
  • 1R01NS148028-01 Linking Single-Cell Transcriptomic, Morphological, and Temporal Signatures of Vulnerability in Neurodegeneration — $601,750, ends Mar 31, 2031
  • 1R56NS147344-01 Structural interrogation of TDP43 mislocalization and aggregation in aging and disease — $555,275, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 12, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#45 Lab fit 52% · Moderate fit Hiring: Strong Michigan Neuroscience

Joshua Welch lab

Joshua Welch · University of Michigan, Ann Arbor MI

Neurodegeneration involves complex cellular phenotypes and molecular changes that vary widely among the cells of the nervous system. Current methodologies permit either detailed molecular profiling (e.g., single-cell transcriptomics) or functional phenotyping (e.g., live imaging of neuronal activity), but not both in the same cells. Thus, it is difficult to directly link a neuron's functional state or fate with its gene expression profile. To address this limitation, we developed an innovative technology, VISTA-FISH (Video Imaging with Spatial- Temporal Analysis by FISH), that couples prospect

Lab fit breakdown — 52% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 278 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 63% × 0.82 domain gate = 52%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "protein degradation".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $5,633,655 in active NIH money across 5 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$5,633,655
Active projects
5
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,633,655 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-12.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “protein degradation”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS148028-01 Linking Single-Cell Transcriptomic, Morphological, and Temporal Signatures of Vulnerability in Neurodegeneration

    R01 · NINDS · $601,750 · Jun 12, 2026 to Mar 31, 2031

All active NIH projects for Joshua Welch ($5,633,655)
  • 2R01HG010883-06A1 Quantitative definition of cell identity from single-cell multi-omic, spatial, and perturbation data — $2,881,291, ends Feb 28, 2030
  • 5UC2AR081033-05 Immunogenomics and Systems Biology Core — $1,057,514, ends Dec 31, 2026
  • 5R33DA059916-04 Single-cell multi-omic analysis of opioid-mediated HIV disease pathogenesis — $686,641, ends Jul 31, 2028
  • 1R01NS148028-01 Linking Single-Cell Transcriptomic, Morphological, and Temporal Signatures of Vulnerability in Neurodegeneration — $601,750, ends Mar 31, 2031
  • 5R01DE030630-05 Craniofacial skeletal cell lineage plasticity for reconstituting stem cells and their niches — $406,459, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 12, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#46 Lab fit 52% · Moderate fit Hiring: Strong Michigan Neuroscience

Colin Fred Greineder lab

Colin Fred Greineder · University of Michigan, Ann Arbor MI

The ability to selectively modulate microglia activity by increasing or decreasing the expression of one or more target genes is critical for defining and targeting the molecular pathways that govern normal physiology and diverse disease phenotypes. Unfortunately, adeno-associated viruses (AAVs) and other viral vectors – the workhorses of many in vivo studies aimed at modulating gene expression – are limited by immunogenicity and toxicity, as well as their relatively low activity in microglia compared to other CNS cell types. In contrast, antisense oligonucleotides (ASOs) are attractive agents

Lab fit breakdown — 52% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 529 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 63% × 0.82 domain gate = 52%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".
  • Axonal transport and neuronal injury assays Lab text mentions "neurite".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "biologics")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,676,365 in active NIH money across 4 projects, 4.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,676,365
Active projects
4
Runway left
4.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,676,365 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2030-11-30 (about 4.2 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG095417-01 Non-invasive Modulation of Microglia Gene Expression Using Peripherally Administered Antibody Conjugates

    R01 · NIA · $655,198 · Mar 1, 2026 to Nov 30, 2030

  • 3R01AG080016-04S1 CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease

    R01 · NIA · $62,840 · Apr 1, 2023 to Dec 31, 2027

All active NIH projects for Colin Fred Greineder ($2,676,365)
  • 5R01AG080016-04 CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease — $802,009, ends Dec 31, 2027
  • 5R01HL163438-04 Michigan Emergency Department Improvement Collaborative AltERnaTives to admission for Pulmonary Embolism (MEDIC ALERT PE) Study — $774,549, ends Dec 31, 2027
  • 1R01AG095417-01 Non-invasive Modulation of Microglia Gene Expression Using Peripherally Administered Antibody Conjugates — $655,198, ends Nov 30, 2030
  • 5R01AR085170-02 Optimizing bone surface targeting of therapeutic antibodies for osteoporosis — $444,609, ends Mar 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2026 · project period to Nov 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#47 Lab fit 52% · Moderate fit Hiring: Strong Michigan Neuroscience Standing call — undated

Tessier Lab (molecular biotechnology / antibody engineering)

Peter M Tessier · University of Michigan, Ann Arbor MI · lab page ↗

Therapeutic antibody discovery and engineering: protein engineering and directed evolution, biomolecular screening and high-throughput characterization, and machine learning / AI-driven computational prediction, applied to bispecific antibodies, antibody-drug conjugates and antibody-mediated CNS drug delivery for neurodegenerative disease. (source)

Lab fit breakdown — 52% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 1055 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 63% × 0.82 domain gate = 52%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "protein engineering")

Lab composition · 9 named members

  • Bivek Chaulagain, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Alicia Dubinski, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Kozo Yoneda — unknown (role not stated on roster page), tenure unknown [official roster]
  • Yun-Huai (Wade) Kuo — unknown (role not stated on roster page), tenure unknown [official roster]
  • Yunxuan Xie — unknown (role not stated on roster page), tenure unknown [official roster]
  • Namir Khalasawi — unknown (role not stated on roster page), tenure unknown [official roster]
  • Kartik Kher — unknown (role not stated on roster page), tenure unknown [official roster]
  • Kai Rubach — unknown (role not stated on roster page), tenure unknown [official roster]
  • Hyun Jin Lee — unknown (role not stated on roster page), tenure unknown [official roster]

The members page gives research interests but states a role only for some people; roles that were not stated on the page are left as unknown.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Tessier Lab members page · checked Sep 21, 2026

Posting · Standing call — undated

Postdoctoral associates — protein/antibody engineering and CNS delivery ↗

Standing call — undated

posted date: unknown (source prints none) · source checked 2026-09-22

The lab's own page advertises this as a standing open call and prints no publication date. Page re-read 2026-09-22; recorded as unknown rather than guessed, so it is not counted as a live dated opening.

Tessier Lab open positions page

Posted date read from: Tessier lab open-positions page prints only "Page updated" with no date.

Standing call re-read 22 Sep 2026: "The Tessier lab has multiple openings for projects involving protein/antibody engineering, antibody drug discovery and development, antibody-mediated CNS drug delivery, and antibody biophysical and developability analysis." Undated, so not counted as a live dated opening. Email ptessier@umich.edu.

Can they afford to hire her?

Strong Strong: $3,072,304 in active NIH money across 6 projects, 4.2 years of project period left, 9 known team members, an undated standing call rather than a live dated opening.

Active NIH money
$3,072,304
Active projects
6
Runway left
4.2 yrs
Known lab size
9
Show the reasoning and the underlying awards
Hiring signals — 90 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,072,304 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2030-11-30 (about 4.2 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-01.
  • +10 Standing open call, no publication date — Postdoctoral associates — protein/antibody engineering and CNS delivery — The lab's own page advertises this as a standing open call and prints no publication date. Page re-read 2026-09-22; recorded as unknown rather than guessed, so it is not counted as a live dated opening.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG095417-01 Non-invasive Modulation of Microglia Gene Expression Using Peripherally Administered Antibody Conjugates

    R01 · NIA · $655,198 · Mar 1, 2026 to Nov 30, 2030

  • 5R01EB036493-02 Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots

    R01 · NIBIB · $612,347 · Feb 1, 2025 to Jan 31, 2029

  • 5R01NS138455-03 Neuron-specific modulation of gene expression using systemically administered bispecific antibody-ASO conjugates

    R01 · NINDS · $599,383 · Jul 1, 2024 to May 31, 2029

  • 3R01AG080016-04S1 CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease

    R01 · NIA · $62,840 · Apr 1, 2023 to Dec 31, 2027

All active NIH projects for Peter M Tessier ($3,072,304)
  • 5R01AG080016-04 CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease — $802,009, ends Dec 31, 2027
  • 1R01AG095417-01 Non-invasive Modulation of Microglia Gene Expression Using Peripherally Administered Antibody Conjugates — $655,198, ends Nov 30, 2030
  • 5R01EB036493-02 Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots — $612,347, ends Jan 31, 2029
  • 5R01NS138455-03 Neuron-specific modulation of gene expression using systemically administered bispecific antibody-ASO conjugates — $599,383, ends May 31, 2029
  • 5R21AG093031-02 Long-lived Activation of Parenchymal Border Macrophages Using Immunocytokines to Address Aging- and Alzheimer’s Disease-associated Deficits in Cerebrospinal Fluid Dynamics — $208,695, ends Jan 31, 2027
  • 5R21AI190578-02 Efficient and Long-lived Brain Delivery of Neutralizing Antibodies Against Eastern Equine Encephalitis Virus for Post-exposure Therapy — $194,672, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2026 · project period to Nov 30, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#48 Lab fit 52% · Moderate fit Hiring: Unlikely Michigan Neuroscience

Michael Henderson lab

Michael Henderson · Van Andel Institute, Grand Rapids MI

PROJECT SUMMARY/ABSTRACT Over 6.5 million people in the United States currently live with progressive neurodegenerative Alzheimer’s disease (AD) and related dementias including dementia with Lewy bodies (DLB), yet no treatments to stop their progression are available. The presence of aggregated proteins in the brain (tau, amyloid β (Aβ), and α- synuclein) is thought to underlie disease, and clinical overlap in presentation of these diseases associates with the presence of more than one type of pathology. The factors influencing cellular and network vulnerability to each individual pathology or

Lab fit breakdown — 52% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 251 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 83% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 63% × 0.82 domain gate = 52%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunofluoresc".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "neurite".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $440,318 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$440,318
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $440,318 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 83%

    Matched 4 of 7 profile areas (25 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunofluoresc”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG077573-05 Network and cellular vulnerability to pathological protein progression

    R01 · NIA · $440,318 · May 1, 2022 to Apr 30, 2027

All active NIH projects for Michael Henderson ($440,318)
  • 5R01AG077573-05 Network and cellular vulnerability to pathological protein progression — $440,318, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#49 Lab fit 51% · Moderate fit Hiring: Strong Michigan Neuroscience

Bakulski Research group

Kelly Bakulski · University of Michigan, Ann Arbor MI · lab page ↗

Environmental and genetic causes of neurological disorders, using molecular epidemiology and toxicology. Themes are risk of Alzheimer's disease and related dementias from perinatal and life-course heavy-metal exposure (lead, cadmium), DNA methylation and epigenetic clocks against cognitive status, plasma biomarkers for Alzheimer's disease, and cell-type-specific tools for population studies. Associate Professor of Epidemiology with tenure and leader of the Data Management and Statistical Core of the Michigan Alzheimer's Disease Research Center; also co-holder of a Cure Alzheimer's Fund award with Catherine Kaczorowski on caloric restriction and cognition in heterogeneous mouse models. (source)

Lab fit breakdown — 51% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 1801 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 62% × 0.82 domain gate = 51%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • CRISPR / conditional knockout genetics Lab text mentions "genome editing".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · 9 named members

  • Kelly Bakulski, PhD — Principal Investigator; Associate Professor of Epidemiology, tenure unknown [official roster]
  • John Dou, MPH — Research Analyst, tenure unknown [official roster]
  • Mingzhou Fu, MPH, MHI — Research Analyst, tenure unknown [official roster]
  • Lauren Middleton, MPH — Research Analyst and Laboratory Manager, tenure unknown [official roster]
  • Herong Wang, MPH — Research Analyst, tenure unknown [official roster]
  • Freida Blostein, MPH, PhD — Postdoctoral Fellow, tenure unknown [official roster]
  • Kyle Campbell, MPH — Doctoral Candidate, Epidemiology, tenure unknown [official roster]
  • Yike Liu — MPH Candidate, tenure unknown [official roster]
  • Samantha Frech — Undergraduate Researcher, tenure unknown [official roster]

Current members only; the page carries a long separate alumni list. The page's own header calls her Assistant Professor while the School of Public Health faculty profile and U-M Experts both say Associate Professor with tenure, so the group page appears out of date on rank.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Bakulski Research people page · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No openings page and no advertised vacancy. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at Bakulski Research site and SPH faculty profile

Can they afford to hire her?

Strong Strong: $7,714,589 in active NIH money across 7 projects, 4.8 years of project period left, 9 known team members, no advertised opening.

Active NIH money
$7,714,589
Active projects
7
Runway left
4.8 yrs
Known lab size
9
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $7,714,589 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 7 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2P30AG072931-06, which is outside this briefing's scope but is active NIH money for this PI.
  • +10 Award started within the last 12 months — 2 awards in this snapshot started on or after 2026-03-01.
  • 0 No active posting found — No openings page and no advertised vacancy. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “genome editing”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG096517-01 Environmental Exposures and ADRD in the Health and Retirement Study Cohort

    R01 · NIA · $1,703,843 · Apr 1, 2026 to Jan 31, 2031

  • 1R01AG094704-01 Utilizing Heterogeneous Mouse Models to Discover Mechanisms Underlying Caloric Restriction (CR) on Cognitive Outcomes

    R01 · NIA · $1,732,842 · Mar 1, 2026 to Jan 31, 2031

  • 5U01AG088407-03 The impact of metals and polygenic risk on multiomics, brain aging, and ADRD outcomes

    U01 · NIA · $1,482,647 · Sep 30, 2024 to Aug 31, 2029

  • 5R01AG072396-05 Risk of Alzheimer's Disease and Related Dementias from Perinatal Lead Exposure: Brain Region and Cell Type Effects

    R01 · NIA · $762,926 · Feb 15, 2022 to Dec 31, 2026

  • 3R01AG070897-05S1 The Study of the Environment and Alzheimer's disease and related Dementias (SEAD)

    R01 · NIA · $90,357 · Mar 15, 2021 to Feb 28, 2027

  • 5R01AG067592-05 DNA Methylation,Genetics, and Modifiable Risk Factors of Dementia in a Nationally Representative, Multi-Ethnic Cohort

    R01 · NIA · $736,487 · May 15, 2020 to Mar 31, 2027

All active NIH projects for Kelly Bakulski ($7,714,589)
  • 1R01AG094704-01 Utilizing Heterogeneous Mouse Models to Discover Mechanisms Underlying Caloric Restriction (CR) on Cognitive Outcomes — $1,732,842, ends Jan 31, 2031
  • 1R01AG096517-01 Environmental Exposures and ADRD in the Health and Retirement Study Cohort — $1,703,843, ends Jan 31, 2031
  • 5U01AG088407-03 The impact of metals and polygenic risk on multiomics, brain aging, and ADRD outcomes — $1,482,647, ends Aug 31, 2029
  • 5R01AG072396-05 Risk of Alzheimer's Disease and Related Dementias from Perinatal Lead Exposure: Brain Region and Cell Type Effects — $762,926, ends Dec 31, 2026
  • 5R01AG067592-05 DNA Methylation,Genetics, and Modifiable Risk Factors of Dementia in a Nationally Representative, Multi-Ethnic Cohort — $736,487, ends Mar 31, 2027
  • 2P30AG072931-06 Data Management & Statistical Core — $670,005, ends Jun 30, 2031
  • 5R01AG070897-05 The Study of the Environment and Alzheimer's disease and related Dementias (SEAD) — $625,839, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#50 Lab fit 50% · Moderate fit Hiring: Strong Atlanta Neuroscience Date unverified New award

Radiopharmaceutical Discovery Lab

Steven H Liang · Emory University, Atlanta GA · lab page ↗

Discovery of radioactive drugs — PET and theranostic agents — for biologically important but underexplored targets, and the translational radiochemistry needed to carry new fluorine-18 and carbon-11 labelling methods from bench discovery into routine radiopharmaceutical production. Brain targets include cholesterol 24-hydroxylase, giving real-time imaging of brain cholesterol breakdown relevant to Alzheimer's, Parkinson's and Huntington's disease; also histamine H3 receptor, subtype-selective metabotropic glutamate receptors, arginine vasopressin and PARP-1. The PI is Professor of Radiology and Imaging Sciences, directs the Emory PET Imaging Center and holds the endowed directorship of radiochemistry, the cyclotron facility and radiopharmacy. (source)

Lab fit breakdown — 50% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 2171 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 96% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 61% × 0.82 domain gate = 50%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".
  • In vivo ocular imaging and functional readouts Lab text mentions "in vivo imaging".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "radiotracer")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

No roster page is published — the group's own site says a new Emory website is under construction — so lab size is unknown and no team-size credit is given. Emory Radiology's research news feature names Jiahui Chen, PhD as a scientist mentored in the group and winner of a 2025 departmental award, and the facilities description puts the group in one seven-person and two two-person laboratories in HSRB-II. That is not a complete roster, so nobody is listed as a member here.

Source: Group website (states a new Emory site is under construction) · checked Sep 22, 2026

Posting · Date unverified

Opening ↗

Date unverified

posted date: unknown (source prints none) · source checked 2026-09-22

The publication date could not be confirmed on the employer's own page. Checked 2026-09-22; treated as unverified rather than live.

Group website banner

Posted date read from: The group site carries an undated "We are recruiting!" banner and no requisition; on 22 Sep 2026 a re-fetch of scholarblogs.emory.edu returned an AWS WAF human-verification challenge, so no date could be read from the source.

The group's site carries the line "We are recruiting!" with no role, level, date or application route attached, so no specific opening can be confirmed. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. No publication date exists to check, so this is recorded as date-unverified and does not count as a live opening.

Can they afford to hire her?

Strong Strong: $7,899,834 in active NIH money across 10 projects, 4.7 years of project period left, lab size unknown, a posting whose publication date could not be verified.

Active NIH money
$7,899,834
Active projects
10
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 88 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $7,899,834 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 10 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01AG101703-01 is flagged as a new project by NIH.
  • +3 Posting referenced but date unverified — The publication date could not be confirmed on the employer's own page. Checked 2026-09-22; treated as unverified rather than live.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 96%

    Matched 4 of 5 profile areas (27 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG101703-01 Subtype AMPAR ligand discovery for Alzheimer's disease

    R01 · NIA · $657,298 · Sep 15, 2026 to May 31, 2031 · Type 1 (new)

  • 5R01AG094161-02 Poly (ADP-ribose) polymerase ligand discovery for Alzheimer's disease

    R01 · NIA · $780,758 · May 15, 2025 to Jan 31, 2030

  • 5R01AG083084-03 Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients

    R01 · NIA · $755,607 · Sep 1, 2023 to May 31, 2029

  • 4R01AG081401-02 Glycogen synthase kinase 3 ligand discovery for Alzheimer’s disease

    R01 · NIA · $758,831 · May 1, 2023 to Apr 30, 2028

  • 5R01AG079956-03 Subtype-selective phosphodiesterase PET ligands

    R01 · NIA · $747,136 · Jan 1, 2023 to Nov 30, 2028

  • 5R01AG075444-04 Subtype-selective NMDA ligands for Alzheimer's Disease

    R01 · NIA · $762,049 · Apr 1, 2022 to Mar 31, 2028

  • 5R01AG073428-04 AMPAR ligand discovery for Alzheimer's disease

    R01 · NIA · $766,848 · Sep 1, 2021 to Aug 31, 2027

  • 5R01AG070060-06 Ligand discovery for delineating cholesterol homeostasis in the brain

    R01 · NIA · $744,264 · Jan 1, 2021 to Dec 31, 2026

All active NIH projects for Steven H Liang ($7,899,834)
  • 5R01MH128705-05 PET ligand discovery for arginine vasopressin — $1,159,299, ends Apr 30, 2027
  • 5R01AG094161-02 Poly (ADP-ribose) polymerase ligand discovery for Alzheimer's disease — $780,758, ends Jan 31, 2030
  • 5R61NS130128-03 Subtype-Selective Metabotropic Glutamate Receptor PET Ligands — $767,744, ends Mar 31, 2027
  • 5R01AG073428-04 AMPAR ligand discovery for Alzheimer's disease — $766,848, ends Aug 31, 2027
  • 5R01AG075444-04 Subtype-selective NMDA ligands for Alzheimer's Disease — $762,049, ends Mar 31, 2028
  • 4R01AG081401-02 Glycogen synthase kinase 3 ligand discovery for Alzheimer’s disease — $758,831, ends Apr 30, 2028
  • 5R01AG083084-03 Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients — $755,607, ends May 31, 2029
  • 5R01AG079956-03 Subtype-selective phosphodiesterase PET ligands — $747,136, ends Nov 30, 2028
  • 5R01AG070060-06 Ligand discovery for delineating cholesterol homeostasis in the brain — $744,264, ends Dec 31, 2026
  • 1R01AG101703-01 Subtype AMPAR ligand discovery for Alzheimer's disease — $657,298, ends May 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to May 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#51 Lab fit 50% · Moderate fit Hiring: Possible Atlanta Neuro + ophtho

Mazade Lab (visual signalling in myopia)

Reece Mazade · Emory University, Atlanta GA · lab page ↗

Influence of visual input on neuronal signalling in myopia; retinal circuit signalling and single-neuron electrophysiology, building on mouse models of experimental myopia. (source)

Lab fit breakdown — 50% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 222 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 68% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% = 50%. Squarely in her disease area — no discount applied.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "retinal ganglion".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "lens".
  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

Brand-new independent lab: Mazade was a research scientist in the Pardue lab from Feb 2023 and became Assistant Professor of Ophthalmology in Jan 2026 (ORCID employment record). The Emory directory still lists him under the Pardue lab and no independent roster has been published. Effective lab size is unknown but likely minimal.

Source: Emory Eye Center research team directory · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No Mazade-lab requisition on Emory's iCIMS faculty careers site. Emory Ophthalmology's standing NEI T32 route is open to vision postdocs generally.

Checked at Emory Ophthalmology postdoctoral fellowships page

Can they afford to hire her?

Possible Possible: $391,250 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$391,250
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $391,250 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • 0 No active posting found — No Mazade-lab requisition on Emory's iCIMS faculty careers site. Emory Ophthalmology's standing NEI T32 route is open to vision postdocs generally. Checked 2026-09-21.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 68%

    Matched 3 of 6 profile areas (19 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “retinal ganglion”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “lens”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY037296-02 Influence of visual input on neuronal signaling in myopia

    R01 · NEI · $391,250 · Jul 1, 2025 to Jun 30, 2030

All active NIH projects for Reece Mazade ($391,250)
  • 5R01EY037296-02 Influence of visual input on neuronal signaling in myopia — $391,250, ends Jun 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2025 · project period to Jun 30, 2030 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#52 Lab fit 49% · Moderate fit Hiring: Moderate Atlanta Neuroscience New award

Shirley Zhang lab

Shirley Zhang · Emory University, Atlanta GA

Project Summary The blood-brain barrier (BBB) is a critical obstacle to the effective treatment of neurological diseases, as it regulates the passage of nutrients and waste products between the blood and brain and limits the entry of nearly all drugs and biologics into the central nervous system. To overcome this challenge, it is essential to uncover the mechanisms that regulate BBB function. Emerging evidence highlights the role of circadian rhythms, 24-hour oscillations in physiological processes, in regulating BBB function. Our long-term goal is to elucidate how circadian rhythms regulate t

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 281 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "protein degradation".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "biologics")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $457,272 in active NIH money across 1 project, 4.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$457,272
Active projects
1
Runway left
4.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $457,272 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-08-31 (about 4.9 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “protein degradation”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146234-01A1 Circadian rhythm regulation of brain vasculature

    R01 · NINDS · $457,272 · Sep 1, 2026 to Aug 31, 2031

All active NIH projects for Shirley Zhang ($457,272)
  • 1R01NS146234-01A1 Circadian rhythm regulation of brain vasculature — $457,272, ends Aug 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Aug 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#53 Lab fit 49% · Moderate fit Hiring: Possible Atlanta Neuroscience

Angela M Mabb lab

Angela M Mabb · Georgia State University, Atlanta GA

Abstract Protein ubiquitination is a posttranslational modification that is essential for nervous system function. UB requires the utilization of a series of enzymes called E1, E2, and E3 that enable the covalent addition of ubiquitin (UB) to to its cellular targets. Protein ubiquitination is also a highly reversible process which is handled by enzymes called deubiquitinases (DUBs) that cut and/or edit UB chains on substrates. While numerous neurological disorders are associated with mutations in the UB enzyme machinery, the role of protein ubiquitination under non-diseased states and the intr

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 237 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "ubiquitin".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $407,352 in active NIH money across 1 project, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$407,352
Active projects
1
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $407,352 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “ubiquitin”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS136464-02 Protein ubiquitination and deubiquitination in neurological disorders

    R01 · NINDS · $407,352 · Sep 1, 2025 to Aug 31, 2029

All active NIH projects for Angela M Mabb ($407,352)
  • 5R01NS136464-02 Protein ubiquitination and deubiquitination in neurological disorders — $407,352, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2025 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#54 Lab fit 49% · Moderate fit Hiring: Moderate Michigan Neuroscience

Benjamin Neal Combs lab

Benjamin Neal Combs · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

Project Summary/Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the pathological accumulation of the tau protein and amyloid beta (Aβ) peptide. Tau pathology is also present in several other neurodegenerative disorders known as tauopathies. Most cases of these disorders have no clear genetic cause and the disease etiology remains poorly understood. There is growing interest in identifying how exposure to toxic elements in the environment, including heavy metals like cadmium, might help initiate and promote progression of these diseases. The typica

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 293 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,862,804 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,862,804
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,862,804 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG090456-01A1 Modeling effects of cadmium exposure on Alzheimer’s Disease pathology and neurodegeneration

    RF1 · NIA · $2,862,804 · Aug 15, 2025 to Jul 31, 2029

All active NIH projects for Benjamin Neal Combs ($2,862,804)
  • 1RF1AG090456-01A1 Modeling effects of cadmium exposure on Alzheimer’s Disease pathology and neurodegeneration — $2,862,804, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2025 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#55 Lab fit 49% · Moderate fit Hiring: Moderate Michigan Neuroscience

Shreesh Raj Sammi lab

Shreesh Raj Sammi · Michigan State University, East Lansing MI

Project Summary/Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the pathological accumulation of the tau protein and amyloid beta (Aβ) peptide. Tau pathology is also present in several other neurodegenerative disorders known as tauopathies. Most cases of these disorders have no clear genetic cause and the disease etiology remains poorly understood. There is growing interest in identifying how exposure to toxic elements in the environment, including heavy metals like cadmium, might help initiate and promote progression of these diseases. The typica

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 293 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,862,804 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,862,804
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,862,804 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG090456-01A1 Modeling effects of cadmium exposure on Alzheimer’s Disease pathology and neurodegeneration

    RF1 · NIA · $2,862,804 · Aug 15, 2025 to Jul 31, 2029

All active NIH projects for Shreesh Raj Sammi ($2,862,804)
  • 1RF1AG090456-01A1 Modeling effects of cadmium exposure on Alzheimer’s Disease pathology and neurodegeneration — $2,862,804, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2025 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#56 Lab fit 49% · Moderate fit Hiring: Possible Atlanta Neuroscience

Anupam Patgiri lab

Anupam Patgiri · Emory University, Atlanta GA

Project Summary Mitochondria are essential organelles for maintaining cellular redox, energy, and metabolic homeostasis. The hub of mitochondrial function is its electron transport chain (ETC) which is necessary for numerous functions, including ATP generation. There are over 300 inherited mutations that can impair ETC function and lead to devastating neuromuscular disorders (e.g., Leigh syndrome) for which there are no FDA-approved therapies. This is in large part because of our incomplete understanding of the disease pathophysiology. Recent studies have demonstrated that an elevated tissue N

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 224 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "protein engineering")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $405,368 in active NIH money across 1 project, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$405,368
Active projects
1
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $405,368 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS133344-03 Targeting NADH-Reductive Stress in Mitochondrial Disease

    R01 · NINDS · $405,368 · Jul 3, 2024 to Apr 30, 2029

All active NIH projects for Anupam Patgiri ($405,368)
  • 5R01NS133344-03 Targeting NADH-Reductive Stress in Mitochondrial Disease — $405,368, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 3, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#57 Lab fit 49% · Moderate fit Hiring: Unlikely Atlanta Neuroscience

Avanti Gokhale lab

Avanti Gokhale · Emory University, Atlanta GA

Summary: This application focuses on a novel pathogenic mechanism that includes metal homeostasis, mitochondrial proteostasis and onset of neurological adverse effects for cognition and movement. We have identified the mitochondrial RNA granule, as a key initiator of neuronal responses to environmental and/or genetic insults that predispose an individual to disease. This RNA processing pathway in mitochondria resides upstream of the effects that have been attributed to manganese toxicity, including reduced respiratory chain activity, mitochondrial membrane depolarization, mitochondrial oxidati

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 265 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "organoid")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $355,840 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$355,840
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $355,840 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01ES034796-04 Mitochondrial mechanisms and signaling in manganese exposure

    R01 · NIEHS · $355,840 · Aug 16, 2023 to May 31, 2028

All active NIH projects for Avanti Gokhale ($355,840)
  • 5R01ES034796-04 Mitochondrial mechanisms and signaling in manganese exposure — $355,840, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 16, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#58 Lab fit 49% · Moderate fit Hiring: Unlikely Atlanta Neuroscience

Erica Marlis Werner lab

Erica Marlis Werner · Emory University, Atlanta GA

Summary: This application focuses on a novel pathogenic mechanism that includes metal homeostasis, mitochondrial proteostasis and onset of neurological adverse effects for cognition and movement. We have identified the mitochondrial RNA granule, as a key initiator of neuronal responses to environmental and/or genetic insults that predispose an individual to disease. This RNA processing pathway in mitochondria resides upstream of the effects that have been attributed to manganese toxicity, including reduced respiratory chain activity, mitochondrial membrane depolarization, mitochondrial oxidati

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 265 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "organoid")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $355,840 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$355,840
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $355,840 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01ES034796-04 Mitochondrial mechanisms and signaling in manganese exposure

    R01 · NIEHS · $355,840 · Aug 16, 2023 to May 31, 2028

All active NIH projects for Erica Marlis Werner ($355,840)
  • 5R01ES034796-04 Mitochondrial mechanisms and signaling in manganese exposure — $355,840, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 16, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#59 Lab fit 49% · Moderate fit Hiring: Possible Michigan Neuroscience

Richard F Keep lab

Richard F Keep · University of Michigan, Ann Arbor MI

Accumulating evidence suggests that Alzheimer’s disease (AD)-related inflammation progresses in two different but interrelated compartments: the blood and the brain, implying that leukocytes could lead to “brain activation,” while brain inflammation may impact the peripheral system by inflammatory mediators. AD has predominantly chronic neuroinflammation components that drive neurodegeneration and cerebrovascular inflammation. However, recent studies have revealed that factors involved in acute inflammatory response, neutrophils, contribute to pathology and cognitive impairment in AD. Why and

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 305 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "innate immun")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $628,083 in active NIH money across 1 project, 1.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$628,083
Active projects
1
Runway left
1.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $628,083 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-01 (about 1.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG084186-04 Deciphering the role of junctional adhesion molecule-A in neutrophil-driven inflammatory response in Alzheimer disease

    R01 · NIA · $628,083 · Aug 15, 2023 to Apr 1, 2028

All active NIH projects for Richard F Keep ($628,083)
  • 5R01AG084186-04 Deciphering the role of junctional adhesion molecule-A in neutrophil-driven inflammatory response in Alzheimer disease — $628,083, ends Apr 1, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2023 · project period to Apr 1, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#60 Lab fit 49% · Moderate fit Hiring: Moderate Michigan Autophagy / organelle QC

Huilin Li lab

Huilin Li · Van Andel Institute, Grand Rapids MI

Project Summary The objective of this proposal is to gain mechanistic and pathological understanding of human GlcNAc-1- phosphotransferase (PTase), an enzyme which modifies lysosomal hydrolases. Lysosomes contain several dozen acid hydrolases that break down unwanted proteins and lipids. Lysosomal enzymes acquire a mannose- 6-P moiety in the Golgi apparatus by the action of PTase, which uses UDP-GlcNAc as a donor substrate. The mannose-6-P functions like a zip code that guides the delivery of these enzymes to the lysosomes. PTase is encoded by the GNPTAB and GNPTG genes and assembles a 340-kDa

Lab fit breakdown — 49% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 228 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 60% × 0.82 domain gate = 49%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,670,000 in active NIH money across 3 projects, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,670,000
Active projects
3
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,670,000 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years) — 5R35GM131754-08, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS127292-05 Molecular mechanisms for sorting lysosomal proteins

    R01 · NINDS · $475,000 · Jul 10, 2022 to May 31, 2027

All active NIH projects for Huilin Li ($1,670,000)
  • 5R35GM131754-08 Structural mechanism of DNA replication — $720,000, ends May 31, 2029
  • 5R01NS127292-05 Molecular mechanisms for sorting lysosomal proteins — $475,000, ends May 31, 2027
  • 5R01CA231466-09 Molecular mechanisms of protein glycosylation and trafficking — $475,000, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 10, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#61 Lab fit 48% · Moderate fit Hiring: Strong Atlanta Neuroscience

Li Lab — Laboratory of Molecular and Cellular Neurobiology

Lian Li · Emory University, Atlanta GA · lab page ↗

Pathogenic mechanisms of neurological disease — Alzheimer's disease, Parkinson's disease and peripheral neuropathy. The lab works on alpha-synuclein, parkin, UCH-L1 and DJ-1; on parkin-driven K63-linked ubiquitination and autophagy–lysosome degradation of UCH-L1; on oxidative damage to UCH-L1 in idiopathic Parkinson's and Alzheimer's brain; on abnormal vesicular and endosomal trafficking (HAP1 with the Huntington's protein huntingtin); and on sialoglycoproteomic network and target discovery for Alzheimer's disease. Approaches combine proteomics and glycoproteomics, biochemistry, cell biology, molecular genetics, network biology and animal models with human patient specimens. Dr Li is Professor and Vice Chair of Pharmacology and Chemical Biology and a member of the Emory Center for Neurodegenerative Diseases; the lab states continuous NIH funding since 1998. (source)

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 698 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 58% × 0.82 domain gate = 48%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · 3 named members

  • Lian Li, PhD — Lab Director; Professor and Vice Chair, Pharmacology and Chemical Biology, tenure unknown [official roster]
  • Jie Tian, PhD — Assistant Scientist, tenure unknown [official roster]
  • Chang Liu, PhD — Postdoctoral Fellow, tenure unknown [official roster]

The page lists three current members and a long table of former members; only current members are recorded here.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Li Lab members page (Emory Pharmacology & Chemical Biology) · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

The lab's pages carry no openings section and advertise no vacancy. The lab is three people with two active R01s, and the PI's email is published on the members page. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at Li Lab site (index, research and lab-members pages)

Can they afford to hire her?

Strong Strong: $1,391,277 in active NIH money across 2 projects, 4.3 years of project period left, 3 known team members, no advertised opening.

Active NIH money
$1,391,277
Active projects
2
Runway left
4.3 yrs
Known lab size
3
Show the reasoning and the underlying awards
Hiring signals — 73 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,391,277 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-04-01.
  • 0 No active posting found — The lab's pages carry no openings section and advertise no vacancy. The lab is three people with two active R01s, and the PI's email is published on the members page. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • +5 Small team with room to add a senior bench scientist — 3 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG092406-01A1 Novel biomarkers and mechanisms of Alzheimer's disease

    R01 · NIA · $643,613 · Apr 1, 2026 to Jan 31, 2031

  • 5R01AG079836-04 Sialoglycoproteomic network and target discovery for Alzheimer's disease

    R01 · NIA · $747,664 · Aug 15, 2023 to Jun 30, 2028

All active NIH projects for Lian Li ($1,391,277)
  • 5R01AG079836-04 Sialoglycoproteomic network and target discovery for Alzheimer's disease — $747,664, ends Jun 30, 2028
  • 1R01AG092406-01A1 Novel biomarkers and mechanisms of Alzheimer's disease — $643,613, ends Jan 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#62 Lab fit 48% · Moderate fit Hiring: Possible Michigan Neuroscience

Roman Jeno Giger lab

Roman Jeno Giger · University of Michigan, Ann Arbor MI

Abstract: Trauma to the adult mammalian peripheral nervous system (PNS) typically results in motor and sensory deficits. While PNS injury induces a strong regenerative response in axotomized neurons, functional recovery in humans is often incomplete and frequently accompanied by the development of chronic pain. PNS injury also triggers nerve inflammation, with immune cells playing vital roles in tissue healing and functional restoration. To better understand the immune response to sciatic nerve injury in mice, we performed a longitudinal analysis using a combination of flow cytometry and singl

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 317 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 36% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 77% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 59% × 0.82 domain gate = 48%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "nerve crush".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $531,478 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$531,478
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $531,478 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 36%

    Matched 1 of 6 profile areas (10 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “nerve crush”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 77%

    Matched 3 of 7 profile areas (23 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS141351-02 Immune Metabolism of Peripheral Nervous Tissue Degeneration and Regeneration

    R01 · NINDS · $531,478 · Aug 1, 2025 to Jul 31, 2030

All active NIH projects for Roman Jeno Giger ($531,478)
  • 5R01NS141351-02 Immune Metabolism of Peripheral Nervous Tissue Degeneration and Regeneration — $531,478, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#63 Lab fit 48% · Moderate fit Hiring: Moderate Michigan Neuroscience

Swathi Yadlapalli lab

Swathi Yadlapalli · University of Michigan, Ann Arbor MI

Abstract Circadian clocks align our physiological functions with Earth's day-night cycles through rhythmic gene expression. While the genetic framework of circadian clocks has been well characterized, the mechanisms responsible for the crucial long-time delays within circadian feedback loops, necessary for establishing a 24-hour periodicity, remain poorly understood. While the importance of clock protein degradation in generating temporal delays was recognized over two decades ago, the roles of subcellular localization and RNA metabolism regulation in contributing to these delays have yet to b

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 423 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 58% × 0.82 domain gate = 48%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "protein degradation".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "deep sequencing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $780,069 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$780,069
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $780,069 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “protein degradation”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “deep sequencing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS140761-02 Deciphering the Role of mRNA Nuclear Localization in Circadian Rhythms

    R01 · NINDS · $372,696 · Jul 1, 2025 to Jun 30, 2030

  • 5R35GM133737-08 Spatiotemporal mechanisms controlling circadian rhythms

    R35 · NIGMS · $407,373 · Sep 1, 2019 to Aug 31, 2029

All active NIH projects for Swathi Yadlapalli ($780,069)
  • 5R35GM133737-08 Spatiotemporal mechanisms controlling circadian rhythms — $407,373, ends Aug 31, 2029
  • 5R01NS140761-02 Deciphering the Role of mRNA Nuclear Localization in Circadian Rhythms — $372,696, ends Jun 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2025 · project period to Jun 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#64 Lab fit 48% · Moderate fit Hiring: Unlikely Atlanta Neuroscience

Renee D Read lab

Renee D Read · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Glioblastomas (GBMs), neoplasms composed of glial cells and their precursors, are among the deadliest primary brain cancers, and are incurable with current therapies. There is an urgent unmet clinical need for new treatments for GBM and related high-grade malignant gliomas. GBM tumorigenicity is often driven by genetic aberrations in receptor tyrosine kinases (RTKs), such as EGFR, and the Pi-3 kinase (PI3K) signaling pathway. Through our team’s collaborative translational research efforts, we discovered that the YAP and TAZ transcription co- activators, effectors of th

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 316 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.92 domain gate = 48%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Retina, photoreceptors and RPE Lab text mentions "macular".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "organoid")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $582,634 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$582,634
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $582,634 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “macular”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS126348-04 Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma

    R01 · NINDS · $582,634 · Sep 21, 2023 to May 31, 2028

All active NIH projects for Renee D Read ($582,634)
  • 5R01NS126348-04 Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma — $582,634, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 21, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#65 Lab fit 48% · Moderate fit Hiring: Moderate Atlanta Neuroscience

Maria C Alvarado lab

Maria C Alvarado · Emory University, Atlanta GA

Abstract The number of people suffering from age-related cognitive decline is growing at an unprecedented rate as the human lifespan increases. In addition, exposure to social adversity and other stressors increases risk for cognitive deficits which may be exacerbated in aging. Because women are at greater risk for developing cognitive impairment compared to men, a potential role for estradiol is implicated. However, findings from studies assessing the effects of estradiol on cognition are equivocal. Consequently, there is a need to understand whether adverse experiential factors may impact es

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 590 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 77% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 59% × 0.82 domain gate = 48%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,512,905 in active NIH money across 2 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,512,905
Active projects
2
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,512,905 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 77%

    Matched 3 of 7 profile areas (23 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG078248-05 The role of stress exposure on estradiol-induced changes in neuroinflammation and cognition

    R01 · NIA · $745,028 · Sep 1, 2022 to May 31, 2027

  • 2R01AG070704-06 Early Risk Factors of Accelerated Neural Aging Trajectories and Cognitive Decline: A Nonhuman Primate Longitudinal Model

    R01 · NIA · $767,877 · Aug 1, 2021 to May 31, 2031

All active NIH projects for Maria C Alvarado ($1,512,905)
  • 2R01AG070704-06 Early Risk Factors of Accelerated Neural Aging Trajectories and Cognitive Decline: A Nonhuman Primate Longitudinal Model — $767,877, ends May 31, 2031
  • 5R01AG078248-05 The role of stress exposure on estradiol-induced changes in neuroinflammation and cognition — $745,028, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to May 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#66 Lab fit 48% · Moderate fit Hiring: Moderate Atlanta Neuroscience

David Weinshenker lab

David Weinshenker · Emory University, Atlanta GA

Project Summary Alzheimer’s disease (AD) is the most common form of neurodegenerative disease and the leading cause of dementia, affecting over 6 million Americans. While the pathological hallmarks of AD include β-amyloid plaques and tau neurofibrillary tangles, the appearance of hyperphosphorylated (“pretangle”) tau in the noradrenergic locus coeruleus (LC) and loss of LC volume are the first detectable AD-like changes in the human brain, and coincide with the onset of prodromal AD symptoms such as including arousal/sleep disturbances, anxiety, depression, and agitation prior to frank cogniti

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 303 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 58% × 0.82 domain gate = 48%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,259,435 in active NIH money across 3 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,259,435
Active projects
3
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,259,435 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5P30AG066511-07, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG079199-03 Contribution of neuromelanin to selective vulnerability of locus coeruleus neurons in Alzheimer's disease

    R01 · NIA · $505,906 · Aug 1, 2022 to Jul 31, 2027

All active NIH projects for David Weinshenker ($1,259,435)
  • 5T32AG087922-03 Alzheimer's Disease Big Data to Biology Training Program (ADBDB-TP) — $583,305, ends Aug 31, 2029
  • 5R01AG079199-03 Contribution of neuromelanin to selective vulnerability of locus coeruleus neurons in Alzheimer's disease — $505,906, ends Jul 31, 2027
  • 5P30AG066511-07 Research Education Component — $170,224, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#67 Lab fit 48% · Moderate fit Hiring: Unlikely Michigan Neuro + ophtho

Shunbin Xu lab

Shunbin Xu · Wayne State University, Detroit MI

Pseudomonas aeruginosa (PA) keratitis is one of the most rapidly developing and destructive diseases of the cornea and a global cause of visual impairment and blindness. Emergence of antibiotic-resistant strains poses additional challenges for effective disease management. Development of alternative treatment is urgent. In this regard, microRNAs (miRNAs) are small, non-coding RNAs and important regulators of gene expression. miRNAs play critical roles in human diseases and are viable therapeutic targets. However, the roles of miRNAs in PA keratitis remain largely unexplored. Our long-term obje

Lab fit breakdown — 48% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 260 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 39% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 59% × 0.82 domain gate = 48%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "apoptosis".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $419,129 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$419,129
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $419,129 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 39%

    Matched 2 of 6 profile areas (11 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “apoptosis”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY026059-09 The miR-183/96/182 Cluster in Pseudomonas aeruginosa-induced Keratitis

    R01 · NEI · $419,129 · Apr 1, 2017 to Apr 30, 2027

All active NIH projects for Shunbin Xu ($419,129)
  • 5R01EY026059-09 The miR-183/96/182 Cluster in Pseudomonas aeruginosa-induced Keratitis — $419,129, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2017 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#68 Lab fit 47% · Moderate fit Hiring: Strong Atlanta Neuroscience

Papa Laboratory

Stella M Papa · Emory University, Atlanta GA · lab page ↗

Neurodegenerative disease of the motor system, centred on basal ganglia dysfunction in Parkinson's disease and other movement disorders. The lab developed the original methods for a chronic MPTP non-human primate model that reproduces advanced patients, and studies altered striatal projection neuron activity with in vivo electrophysiology and neuropharmacology. Recent work shows that reducing AMPA- or NMDA-receptor signalling in the putamen stabilises the motor response to dopamine replacement and controls levodopa-induced dyskinesia. Based jointly in Emory Neurology and the Yerkes National Primate Research Center. (source)

Lab fit breakdown — 47% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 659 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 96% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 57% × 0.82 domain gate = 47%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "aav".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · 4 named members

  • Stella Papa, MD — Principal Investigator, tenure unknown [official roster]
  • Chris Sinon, PhD — Post-doctoral Fellow, tenure unknown [official roster]
  • Brik Kochoian — Graduate Student, tenure unknown [official roster]
  • Cassie Bure — Research Specialist, tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Papa Laboratory lab team page (Emory Neurology) · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No openings section and no advertised vacancy on the lab's pages. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at Papa Laboratory pages (index and lab team)

Can they afford to hire her?

Strong Strong: $1,048,732 in active NIH money across 2 projects, 4.5 years of project period left, 4 known team members, no advertised opening.

Active NIH money
$1,048,732
Active projects
2
Runway left
4.5 yrs
Known lab size
4
Show the reasoning and the underlying awards
Hiring signals — 73 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,048,732 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-04-15.
  • 0 No active posting found — No openings section and no advertised vacancy on the lab's pages. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • +5 Small team with room to add a senior bench scientist — 4 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 96%

    Matched 4 of 5 profile areas (27 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “aav”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: CRISPR / conditional knockout genetics

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS140702-01A1 Changes in molecular mechanisms of dopamine signaling in advanced Parkinson's disease

    R01 · NINDS · $540,901 · Apr 15, 2026 to Mar 31, 2031

  • 5R01NS126924-05 Gene therapy targeting striatal dysfunction for Parkinson’s disease

    R01 · NINDS · $507,831 · Feb 1, 2022 to Jan 31, 2027

All active NIH projects for Stella M Papa ($1,048,732)
  • 1R01NS140702-01A1 Changes in molecular mechanisms of dopamine signaling in advanced Parkinson's disease — $540,901, ends Mar 31, 2031
  • 5R01NS126924-05 Gene therapy targeting striatal dysfunction for Parkinson’s disease — $507,831, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 15, 2026 · project period to Mar 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#69 Lab fit 47% · Moderate fit Hiring: Moderate Atlanta Neuroscience

Shannon Leigh Gourley lab

Shannon Leigh Gourley · Emory University, Atlanta GA

SUMMARY Social interactions impact everyday decisions, even decisions lacking explicit social content. How mammals process social information is intensively investigated. Still, how prior social experiences influence later decision making is not well-understood, likely due in part to a dearth of assays for use in malleable model organisms. My team developed a task referred to as social incentivization of future choice (SIFC). Mice are trained to respond in operant conditioning chambers for two equally preferred foods, then one food is paired with the opportunity to interact with a novel conspe

Lab fit breakdown — 47% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 724 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 57% × 0.82 domain gate = 47%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Axonal transport and neuronal injury assays Lab text mentions "anterograde".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,535,456 in active NIH money across 3 projects, 2.1 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,535,456
Active projects
3
Runway left
2.1 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,535,456 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-10-31 (about 2.1 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “anterograde”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH133740-04 Understanding how social interactions influence reward-seeking behaviors: Developmental mechanisms

    R01 · NIMH · $447,025 · Aug 1, 2023 to May 31, 2028

  • 5R37MH117103-08 Integrated mechanisms for orbitofrontal cortical control of memory and choice

    R37 · NIMH · $666,266 · Aug 1, 2018 to Oct 31, 2028

  • 5R01DA044297-09 Neurotrophic and ontogenic factors in medial orbitofrontal cortical function

    R01 · NIDA · $422,165 · Mar 1, 2018 to Jul 31, 2028

All active NIH projects for Shannon Leigh Gourley ($1,535,456)
  • 5R37MH117103-08 Integrated mechanisms for orbitofrontal cortical control of memory and choice — $666,266, ends Oct 31, 2028
  • 5R01MH133740-04 Understanding how social interactions influence reward-seeking behaviors: Developmental mechanisms — $447,025, ends May 31, 2028
  • 5R01DA044297-09 Neurotrophic and ontogenic factors in medial orbitofrontal cortical function — $422,165, ends Jul 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2023 · project period to Oct 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#70 Lab fit 47% · Moderate fit Hiring: Possible Michigan Ophthalmology

Ahmed S Ibrahim lab

Ahmed S Ibrahim · Wayne State University, Detroit MI

Project Summary/Abstract Retinal neovascularization (RNV) is a debilitating complication of advanced diabetic retinopathy, which despite the use of anti-VEGF and laser treatments continues to cause blindness. Less is known as to why RNV develops only after patients have had diabetes for decades. Although endothelial cell (EC) angiogenic activation is a hallmark of this transition, how ECs adapt their metabolism to sustain such activation remains a significant gap in our knowledge. Our long-term goal is to determine the bioenergetic mechanisms of RNV. The Warburg effect is a metabolic shift fro

Lab fit breakdown — 47% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 246 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 21% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 70% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 57% × 0.82 domain gate = 47%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual acuity".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $831,300 in active NIH money across 2 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$831,300
Active projects
2
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $831,300 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years) — 1R21EY038411-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 21%

    Matched 1 of 6 profile areas (6 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 70%

    Matched 3 of 7 profile areas (21 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY034964-04 The Warburg Effect and Diabetic Retinopathy

    R01 · NEI · $385,000 · Jun 1, 2023 to May 31, 2028

All active NIH projects for Ahmed S Ibrahim ($831,300)
  • 1R21EY038411-01A1 Toxicity of Benzalkonium Chloride to the Corneal Epithelium — $446,300, ends Aug 31, 2028
  • 5R01EY034964-04 The Warburg Effect and Diabetic Retinopathy — $385,000, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#71 Lab fit 46% · Moderate fit Hiring: Strong Michigan Neuro + ophtho New award

De Lott — neuro-ophthalmology outcomes and ocular pain

Lindsey Blake De Lott · University of Michigan, Ann Arbor MI · lab page ↗

Clinical and patient-centred outcomes in neuro-ophthalmic disease, run jointly out of Ophthalmology and Visual Sciences and Neurology at Michigan. Active threads: early deep phenotyping of optic neuritis to inform medical decision-making and personalised decision-support tools for acute demyelinating optic neuritis; non-arteritic anterior ischaemic optic neuropathy; ocular motility disorders and diplopia; giant cell arteritis decision-making; and central nervous system mechanisms and treatment response in chronic ocular surface pain, the subject of the new R01 on this card. The methods are clinical epidemiology, patient-reported outcomes and decision science — the optic-nerve disease area overlaps her profile, the bench techniques do not. (source)

Lab fit breakdown — 46% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 634 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 46% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% × 0.92 domain gate = 46%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "optic neuropath".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

No lab people page is published, so lab size is unknown. Rank differs between pages: the Kellogg ophthalmology profile says Assistant Professor, the U-M Experts profile says Associate Professor in both Ophthalmology and Visual Sciences and Neurology. Both were read on 22 Sep 2026; the discrepancy is unresolved.

Source: U-M Ophthalmology faculty profile and U-M Experts profile · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No research-fellow requisition for this group. The wider U-M ophthalmology search was already unproductive on the previous run and is unchanged.

Checked at U-M Careers, Ophthalmology and Visual Sciences

Can they afford to hire her?

Strong Strong: $1,236,702 in active NIH money across 2 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,236,702
Active projects
2
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 73 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,236,702 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-30 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01EY039428-01 is flagged as a new project by NIH.
  • 0 No active posting found — No research-fellow requisition for this group. The wider U-M ophthalmology search was already unproductive on the previous run and is unchanged. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 46%

    Matched 2 of 6 profile areas (13 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “optic neuropath”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01EY039428-01 Beyond the Eye: Nociplastic Pain as a Predictor of Treatment Response in Chronic Ocular Surface Pain

    R01 · NEI · $690,677 · Sep 15, 2026 to May 30, 2031 · Type 1 (new)

  • 5R01EY036357-03 Central nervous system mechanisms and treatment response in chronic ocular surface pain

    R01 · NEI · $546,025 · Aug 1, 2024 to Jul 31, 2029

All active NIH projects for Lindsey Blake De Lott ($1,236,702)
  • 1R01EY039428-01 Beyond the Eye: Nociplastic Pain as a Predictor of Treatment Response in Chronic Ocular Surface Pain — $690,677, ends May 30, 2031
  • 5R01EY036357-03 Central nervous system mechanisms and treatment response in chronic ocular surface pain — $546,025, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to May 30, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#72 Lab fit 46% · Moderate fit Hiring: Possible Michigan Neuroscience

Mohammad Ejaz Ahmed lab

Mohammad Ejaz Ahmed · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

Abstract: Traumatic brain injury (TBI) is a significant global public health issue, leading to high mortality rates, disabilities, and substantial socioeconomic burdens. TBI results in the loss of AMPKα activity, disruption in regional metabolism, persistent changes in metabolic rates and energy utilization, and elevated glycolysis which enhance the pentose phosphate pathway and promote inflammation. The association between metabolic changes in the brain tissue and the subsequent neutrophil activation and inflammation remains unclear. In this study, male/female C57BL/6 and AMPK-KO mice were su

Lab fit breakdown — 46% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 215 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 47% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 56% × 0.82 domain gate = 46%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $446,477 in active NIH money across 1 project, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$446,477
Active projects
1
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $446,477 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 47%

    Matched 2 of 7 profile areas (14 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS138370-02 Metabolic regulation of Neutrophil Extracellular Traps (NETs) in TBI

    R01 · NINDS · $446,477 · Jun 1, 2025 to Apr 30, 2030

All active NIH projects for Mohammad Ejaz Ahmed ($446,477)
  • 5R01NS138370-02 Metabolic regulation of Neutrophil Extracellular Traps (NETs) in TBI — $446,477, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2025 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#73 Lab fit 46% · Moderate fit Hiring: Unlikely Michigan Neuroscience

Anna Moszczynska lab

Anna Moszczynska · Wayne State University, Detroit MI

PROJECT SUMMARY / ABSTRACT In the height of the opioid crisis in our country, deaths from methamphetamine (METH) overdose are on the rise, and there is no FDA-approved medication for METH use disorder (MUD). New drug targets are needed, particularly for people who heavily use the drug because they have the most difficulty quitting METH use, suffer from a variety of serious neurological problems, and are at high risk to overdose on the drug. Our work with a rat model of heavy compulsive METH consumption (severe MUD) provided evidence that overexpression of neuroprotective protein parkin in the

Lab fit breakdown — 46% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 56% × 0.82 domain gate = 46%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rat".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $277,787 in active NIH money across 1 project, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$277,787
Active projects
1
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $277,787 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rat”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA057384-04 Investigating Parkin-mediated Neuronal Energy Maintenance in Methamphetamine Use Disorder

    R01 · NIDA · $277,787 · Sep 30, 2023 to Jun 30, 2028

All active NIH projects for Anna Moszczynska ($277,787)
  • 5R01DA057384-04 Investigating Parkin-mediated Neuronal Energy Maintenance in Methamphetamine Use Disorder — $277,787, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#74 Lab fit 45% · Moderate fit Hiring: Possible Michigan Neuroscience New award

Wider Lab (mitochondria in acute brain injury)

Joseph Wider · University of Michigan, Ann Arbor MI · lab page ↗

The role of mitochondria in the brain and the molecular mechanisms of mitochondrial dysfunction in acute brain injury — traumatic brain injury, ischaemic stroke, cardiac arrest and neonatal hypoxic-ischaemic encephalopathy — using in vitro, preclinical and translational models to develop neuroprotective therapies. Dr Wider is Assistant Professor of Emergency Medicine and a member of the Weil Institute for Critical Care Research; he trained with Thomas H. Sanderson, and the two groups' shared programme on the same floor covers mitochondrial dynamics and mitophagy after ischaemia/reperfusion (using MitoQC dual-reporter and MitoTimer mice and conditional knockouts of Drp1, Opa1 and Parkin) and near-infrared modulation of cytochrome c oxidase as a neuroprotective intervention. Funding is from the NIH and the Department of Defense CDMRP. (source)

Lab fit breakdown — 45% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 371 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 75% · weight 15%
Geography 100% · weight 10%

Weighted mean 55% × 0.82 domain gate = 45%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitophag".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

Dr Wider is listed with his own research description on the Sanderson Lab members page, but no separate Wider lab roster is published, so current lab size is unknown. The mouse-model and near-infrared detail in the summary traces to the Sanderson Lab research pages they co-author on, not to a Wider lab page.

Source: Sanderson Lab members page, where Dr Wider's own research is described · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

Neither page advertises an opening. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at U-M Experts profile and Sanderson Lab members page

Can they afford to hire her?

Possible Possible: $573,511 in active NIH money across 1 project, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$573,511
Active projects
1
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $573,511 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5R01NS142271-02, which is outside this briefing's scope but is active NIH money for this PI.
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • 0 No active posting found — Neither page advertises an opening. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 75%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Three or more years left in the project period; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01NS142271-02S1 Mitochondrial modulation therapy after brain trauma

    R01 · NINDS · $60,405 · Sep 1, 2026 to Apr 30, 2027

All active NIH projects for Joseph Wider ($573,511)
  • 5R01NS142271-02 Mitochondrial Modulation Therapy After Brain Trauma — $573,511, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Apr 30, 2027 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#75 Lab fit 45% · Moderate fit Hiring: Moderate Michigan Neuroscience

Ursula H. Jakob lab

Ursula H. Jakob · University of Michigan, Ann Arbor MI

Why do we age and why do some of us stay healthy longer than others? Thanks to the development of shorter-lived aging model organisms, much has been learnt about the processes that contribute to our inevitable demise, and the tight connection between these processes and the development of age-associated diseases, including Alzheimer’s and Parkinson’s Disease. Our recent genetic and biochemical studies in C. elegans have revealed a novel longevity paradigm, triggered by early-in-life oxidative stress and mediated by the redox sensitivity of the histone 3 lysine 4 trimethylating (H3K4me3) COMPAS

Lab fit breakdown — 45% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 448 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 97% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 55% × 0.82 domain gate = 45%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Non-rodent animal models Lab text mentions "c. elegans".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,756,365 in active NIH money across 3 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,756,365
Active projects
3
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,756,365 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “c. elegans”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 97%

    Matched 4 of 7 profile areas (29 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG094801-01 Reactive oxygen species as early-in-life modulators of lifespan

    RF1 · NIA · $2,991,725 · Sep 1, 2025 to Aug 31, 2029

  • 5R35GM122506-10 Exploring New Players in Proteostasis

    R35 · NIGMS · $718,790 · May 1, 2017 to Apr 30, 2027

All active NIH projects for Ursula H. Jakob ($3,756,365)
  • 1RF1AG094801-01 Reactive oxygen species as early-in-life modulators of lifespan — $2,991,725, ends Aug 31, 2029
  • 5R35GM122506-10 Exploring New Players in Proteostasis — $718,790, ends Apr 30, 2027
  • 1R13AG101876-01 Protein Folding in the Cell — $45,850, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2025 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#76 Lab fit 45% · Moderate fit Hiring: Moderate Michigan Neuroscience

Susan V Brooks lab

Susan V Brooks · University of Michigan, Ann Arbor MI

ABSTRACT. Preservation of muscle function through Schwann cell regulation of motor unit expansion The loss of skeletal muscle mass and function with aging, known as sarcopenia, is a universal health challenge for the growing elderly population, contributing to decreased mobility, increased disability, loss of independence, and poor quality of life. Studies from our group and others have shown that disruptions of muscle fiber innervation and a reduction in the number of motor units (MU) are significant factors in sarcopenia. A major compensatory mechanism that preserves muscle under conditions

Lab fit breakdown — 45% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 314 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 36% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 67% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 55% × 0.82 domain gate = 45%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "nerve crush".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".
  • Molecular biology, biochemistry and proteomics Lab text mentions "single-cell rna".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $757,796 in active NIH money across 2 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$757,796
Active projects
2
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $757,796 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years) — 5R25HL108842-12, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 36%

    Matched 1 of 6 profile areas (10 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “nerve crush”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 67%

    Matched 3 of 7 profile areas (20 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “single-cell rna”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG086251-03 Preservation of muscle function through Schwann cell regulation of motor unit expansion

    R01 · NIA · $569,854 · Sep 20, 2024 to May 31, 2029

All active NIH projects for Susan V Brooks ($757,796)
  • 5R01AG086251-03 Preservation of muscle function through Schwann cell regulation of motor unit expansion — $569,854, ends May 31, 2029
  • 5R25HL108842-12 Developing Future Scientists — $187,942, ends Aug 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 20, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#77 Lab fit 45% · Moderate fit Hiring: Unlikely Atlanta Ophthalmology

Richard D Dix lab

Richard D Dix · Georgia State University, Atlanta GA

Program Director/Principal Investigator (Last, First, Middle): Dix, Richard D Project Summary Programmed cell death (PCD) operates during innate immunity to eliminate virus-infected cells and regulate infection-associated inflammation during virus invasion. Little information is available regarding the precise contributions of PCD toward the pathogenesis of retinal diseases of virus origin, especially those caused by herpesviruses including AIDS-related human cytomegalovirus (HCMV) retinitis. A critical barrier to progress in advancing our ability to diagnose, prevent, and/or treat herpesvirus

Lab fit breakdown — 45% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 194 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 61% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% = 45%. Squarely in her disease area — no discount applied.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "eye disease".
  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $387,704 in active NIH money across 1 project, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$387,704
Active projects
1
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $387,704 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 61%

    Matched 3 of 6 profile areas (17 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “eye disease”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY034120-04 Programmed cell death and cytomegalovirus retinitis pathogenesis

    R01 · NEI · $387,704 · Sep 30, 2023 to Mar 31, 2027

All active NIH projects for Richard D Dix ($387,704)
  • 5R01EY034120-04 Programmed cell death and cytomegalovirus retinitis pathogenesis — $387,704, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2023 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#78 Lab fit 45% · Moderate fit Hiring: Moderate Michigan Neuroscience

Jonathan Lifshitz lab

Jonathan Lifshitz · University of Michigan, Ann Arbor MI

Our pathological examination of acquired neurological injury uncovered the rod microglia variant of activated immune cells in the brain. Over a century ago, similar rod microglia were hand drawn to indicate neuropathology in general paresis, typhoid, and chemical exposure, and then largely ignored. Following our 2012 publication, rod microglia have been visualized in post-mortem tissue with clinical and neuropathological confirmation of Alzheimer’s Disease and Related Dementias (ADRD), in addition to epilepsy, mental health disorders, and others. Yet no molecular tools exist for precise molecu

Lab fit breakdown — 45% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 307 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 55% × 0.82 domain gate = 45%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Human donor tissue, primary and explant culture Lab text mentions "post-mortem".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,147,338 in active NIH money across 3 projects, 2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,147,338
Active projects
3
Runway left
2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,147,338 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-09-30 (about 2 years) — 5I01RX004536-03, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “post-mortem”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 7R01AG077768-04 Molecular Tool Development to Identify, Isolate, and Interrogate the Rod Microglia Phenotype in Neurological Disease and Injury

    R01 · NIA · $737,493 · Apr 1, 2023 to Dec 31, 2026

All active NIH projects for Jonathan Lifshitz ($1,147,338)
  • 7R01AG077768-04 Molecular Tool Development to Identify, Isolate, and Interrogate the Rod Microglia Phenotype in Neurological Disease and Injury — $737,493, ends Dec 31, 2026
  • 5R01HD110860-04 Gravida traumatic brain injury (TBI) impacts neurodevelopment of the offspring — $409,845, ends May 31, 2028
  • 5I01RX004536-03 Psychoplastogens to make the injured brain receptive to cognitive rehabilitation during the chronic period ofTBI — unknown, ends Sep 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2023 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#79 Lab fit 45% · Moderate fit Hiring: Possible Michigan Autophagy / organelle QC

Ken Inoki lab

Ken Inoki · University of Michigan, Ann Arbor MI

Project Summary mTORC1 stimulates cell and organ growth mainly by stimulating cellular anabolic processes, including protein, lipid, and nucleotide synthesis, and inhibiting catabolic processes such as autophagy. Aberrant activation of mTORC1 signaling has been linked to many human health problems, including cancer, neurodegenerative diseases, and metabolic disorders such as obesity and diabetes. The activity of mTORC1 is tightly regulated by growth factors and multiple cellular metabolic cues such as amino acids, where amino acids recruit mTORC1 to the lysosome through Rag small GTPases activ

Lab fit breakdown — 45% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 244 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 50% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 55% × 0.82 domain gate = 45%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $972,048 in active NIH money across 2 projects, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$972,048
Active projects
2
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $972,048 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 50%

    Matched 2 of 7 profile areas (15 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK124709-04 Lysosomal cholesterol-dependent anabolic regulation

    R01 · NIDDK · $521,707 · Apr 1, 2022 to Jan 31, 2027

All active NIH projects for Ken Inoki ($972,048)
  • 5R01DK124709-04 Lysosomal cholesterol-dependent anabolic regulation — $521,707, ends Jan 31, 2027
  • 5R01GM145631-04 Molecular mechanism of Rheb-dependent mTORC1 regulation — $450,341, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

Lower match (12)

Below the best-fit line, but researched — the score reflects real lab text, not missing data.

#1 Lab fit 43% · Moderate fit Hiring: Strong Michigan Neuroscience Live posting · posted 1 month ago

Zhu Laboratory (C9ORF72 ALS / FTD)

Qiang Zhu · Van Andel Institute, Grand Rapids MI · lab page ↗

Mechanisms of C9ORF72 hexanucleotide repeat expansion in ALS and frontotemporal dementia, combining gain-of-repeat toxicity and loss-of-function, with cell-type specific toxicity, neuron-glia interactions, genetics and epigenetics; human iPSC culture, rodent models, human nervous system tissue and antisense oligonucleotide therapeutics. (source)

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 326 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 100% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "ipsc")

Lab composition · 5 named members

  • Yingli Gu, MD, PhD — Research associate, tenure unknown [official roster]
  • Jing Jin — Senior research scientist, tenure unknown [official roster]
  • Vera Martin Masegosa, PhD — Postdoctoral fellow, tenure unknown [official roster]
  • Laura Pascoe — Assistant research technician, tenure unknown [official roster]
  • Zhongliang Zou — Research technician, tenure unknown [official roster]

Lab established when Zhu joined VAI in January 2022.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Zhu Laboratory people pages (Van Andel Institute) · checked Sep 21, 2026

Posting · Live opening

Postdoctoral Fellow — Laboratory of Dr. Qiang Zhu (genetics, epigenetics, neuroimmune interactions) ↗

Live opening

posted 2026-08-10 · posted 1 month ago · source checked 2026-09-22

Source publication date 2026-08-10 (posted 1 month ago) is inside the 4-month window that opens 2026-05-23.

Van Andel Institute Workday careers site, requisition R1220

Posted date read from: Van Andel Workday requisition R1220 posting start date 2026-08-10.

Re-checking Van Andel's own Workday board on 22 Sep 2026 turned up a postdoctoral requisition for this lab that the earlier aggregator-only check missed: R1220, posted 10 Aug 2026, on disease mechanisms and therapeutics for dementia and motor neuron disease using genome-modified animals, human iPSCs and 3D organoids, epigenetic modification, behavioural neuroscience and neuronal electrophysiology. The bachelor's-level Research Technician requisition R1512 (also posted 10 Aug 2026) is still open alongside it.

Can they afford to hire her?

Strong Strong: $555,128 in active NIH money across 1 project, 4.3 years of project period left, 5 known team members, a live opening (posted 1 month ago).

Active NIH money
$555,128
Active projects
1
Runway left
4.3 yrs
Known lab size
5
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $555,128 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-01.
  • +20 Live opening — posted 1 month ago — Postdoctoral Fellow — Laboratory of Dr. Qiang Zhu (genetics, epigenetics, neuroimmune interactions) — Source publication date 2026-08-10 (posted 1 month ago) is inside the 4-month window that opens 2026-05-23.
  • +5 Small team with room to add a senior bench scientist — 5 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 100%

    4 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”
    • Advertised opening at one of her three target levels — lab text says “award record”
  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS142598-01A1 Mechanisms of gain-of-repeat-toxicity and loss-of-C9ORF72-function in FTD and ALS

    R01 · NINDS · $555,128 · Mar 1, 2026 to Jan 31, 2031

All active NIH projects for Qiang Zhu ($555,128)
  • 1R01NS142598-01A1 Mechanisms of gain-of-repeat-toxicity and loss-of-C9ORF72-function in FTD and ALS — $555,128, ends Jan 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#2 Lab fit 42% · Moderate fit Hiring: Moderate Michigan Ophthalmology

Padovani-Claudio Lab

Dolly Ann Padovani-claudio · University of Michigan, Ann Arbor MI · lab page ↗

Neuro-inflammation, glial activation and angiogenesis in diabetic retinopathy and retinopathy of prematurity; multiomic blood biomarkers of diabetic retinopathy, human retinal microvascular endothelial and Müller cell models, and mouse retina. (source)

Lab fit breakdown — 42% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 705 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 32% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 53% · weight 25%
Seniority & capacity fit 75% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.82 domain gate = 42%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "uveitis".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".
  • In vivo ocular imaging and functional readouts Lab text mentions "optical coherence tomograph".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "predictive model")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

No lab website or people page exists. Her U-M Experts profile describes mentoring but names no current lab members, so lab size is unknown.

Source: Michigan Research Experts profile (no lab people page published) · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No requisition on U-M Careers ophthalmology listings.

Checked at U-M Careers, Research Fellow listings

Can they afford to hire her?

Moderate Moderate: $1,174,302 in active NIH money across 2 projects, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,174,302
Active projects
2
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,174,302 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • +10 Award started within the last 12 months — 2 awards in this snapshot started on or after 2026-03-16.
  • +5 Brand-new (Type 1) project, not a renewal — 7R01EY036473-03 is flagged as a new project by NIH.
  • 0 No active posting found — No requisition on U-M Careers ophthalmology listings. Checked 2026-09-21.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “uveitis”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 53%

    Matched 3 of 7 profile areas (16 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 75%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Three or more years left in the project period; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 7R01EY036473-03 Biobank phenotyping tools for improved understanding and management of eye diseases and disparities

    R01 · NEI · $437,501 · Mar 20, 2026 to Apr 30, 2029 · Type 1 (new)

  • 7R01EY036258-03 Integrative multi-omics for discovery of molecular pathways associated with diabetic retinopathy

    R01 · NEI · $736,801 · Mar 16, 2026 to Apr 30, 2029 · Type 1 (new)

All active NIH projects for Dolly Ann Padovani-claudio ($1,174,302)
  • 7R01EY036258-03 Integrative multi-omics for discovery of molecular pathways associated with diabetic retinopathy — $736,801, ends Apr 30, 2029
  • 7R01EY036473-03 Biobank phenotyping tools for improved understanding and management of eye diseases and disparities — $437,501, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 20, 2026 · project period to Apr 30, 2029 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#3 Lab fit 40% · Adjacent Hiring: Strong Atlanta Neuroscience Date unverified New award

Miocinovic Lab (human motor circuits and deep brain stimulation)

Svjetlana Miocinovic · Emory University, Atlanta GA · lab page ↗

How disruption of brain network activity produces movement disorders — Parkinson's disease, dystonia and tremor — and how to treat them by modulating neural activity, primarily with deep brain stimulation. Methods are intracranial recordings during DBS surgery, high-resolution subdural cortical strips to measure stimulation-evoked potentials in the cortico-subthalamic hyperdirect pathway, MRI tractography, three-dimensional biophysical computational models, non-invasive EEG, EMG and kinematic recording in clinic, and closed-loop DBS programming driven by smartwatch accelerometry and machine learning. The PI is Associate Professor of Neurology at Emory with program faculty appointments in Biomedical Engineering at Georgia Tech. (source)

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 594 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "computational model")

Lab composition · 6 named members

  • Svjetlana Miocinovic, MD, PhD — Principal Investigator; Associate Professor of Neurology, Emory, tenure unknown [official roster]
  • Bailey Kern, BS — Clinical Research Coordinator, tenure unknown [official roster]
  • Bahram Borgheai, PhD — Postdoctoral Fellow, tenure unknown [official roster]
  • Yuji Han, MS — PhD Student, tenure unknown [official roster]
  • Aryaman Gala, BS — PhD Student, tenure unknown [official roster]
  • Xiangtiange (Tina) Li — Undergraduate Student, Emory, tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Miocinovic Lab people page · checked Sep 22, 2026

Posting · Date unverified

Postdoctoral researcher — intelligent deep brain stimulation (neuroscience, machine learning and clinical neural engineering) ↗

Date unverified

posted date: unknown (source prints none) · closes 2026-11-28 · source checked 2026-09-22

The publication date could not be confirmed on the employer's own page. Checked 2026-09-22; treated as unverified rather than live.

Emory faculty iCIMS requisition 172199 (SOM: Neurology: Movement Disorders) — the employer's own posting for the same role the lab jobs page advertises

Posted date read from: Emory's iCIMS portal stamps every requisition with the same boilerplate JSON-LD datePosted of 2024-09-22T06:12 — requisitions 168793, 169978, 172199 and 173296 all carry it — so the portal publishes no real publication date. The lab's own jobs page prints none either, and a re-fetch of movement.bme.gatech.edu on 22 Sep 2026 failed with an HTTP/2 protocol error.

The page advertises a postdoctoral fellow to build an automated DBS programming platform from operating-room electrophysiology, in collaboration with Matthew Gombolay at Georgia Tech's School of Computing. Applications go by email to svjetlana.miocinovic@emory.edu with CV, cover letter and three references. The page carries no publication or closing date, so its age is unknown. Because the page carries no publication date, this is recorded as date-unverified and does not count as a live opening. The same role is carried on Emory's own faculty portal as requisition 172199, whose structured data gives a close date of 28 Nov 2026 but no trustworthy publication date, so the posting's age cannot be verified and it does not count as a live opening. The requisition text confirms the project: automated DBS programming from operating-room electrophysiology with Matthew Gombolay at Georgia Tech.

Can they afford to hire her?

Strong Strong: $1,127,882 in active NIH money across 2 projects, 4.8 years of project period left, 6 known team members, a posting whose publication date could not be verified.

Active NIH money
$1,127,882
Active projects
2
Runway left
4.8 yrs
Known lab size
6
Show the reasoning and the underlying awards
Hiring signals — 76 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,127,882 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • +3 Posting referenced but date unverified — Postdoctoral researcher — intelligent deep brain stimulation (neuroscience, machine learning and clinical neural engineering) — The publication date could not be confirmed on the employer's own page. Checked 2026-09-22; treated as unverified rather than live.
  • +5 Small team with room to add a senior bench scientist — 6 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146703-01A1 Automated programming for personalized deep brain stimulation in Parkinsons disease

    R01 · NINDS · $635,512 · Sep 1, 2026 to Jun 30, 2031

  • 5R01NS125143-05 Optimizing Patient-Specific Deep Brain Stimulation Models Using Electrophysiology

    R01 · NINDS · $492,370 · Jan 1, 2022 to Dec 31, 2026

All active NIH projects for Svjetlana Miocinovic ($1,127,882)
  • 1R01NS146703-01A1 Automated programming for personalized deep brain stimulation in Parkinsons disease — $635,512, ends Jun 30, 2031
  • 5R01NS125143-05 Optimizing Patient-Specific Deep Brain Stimulation Models Using Electrophysiology — $492,370, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Jun 30, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#4 Lab fit 36% · Adjacent Hiring: Moderate Michigan Ophthalmology

Newman-Casey eHealth Lab

Paula Anne Newman-casey · University of Michigan, Ann Arbor MI · lab page ↗

Technology-enabled glaucoma care delivery: personalised glaucoma coaching trials (SEE), telemedicine screening (SIGHT, MI-SIGHT), eye-drop adherence monitoring, health services research and clinical trial operations. (source)

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 709 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 46% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.92 domain gate = 36%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cataract".
  • In vivo ocular imaging and functional readouts Lab text mentions "optical coherence tomograph".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · 12 named members

  • Maria Woodward, MD, MSc — Associate professor; co-strategic director, tenure unknown [official roster]
  • Patrice Hicks, PhD — Research fellow (postdoc), tenure unknown [official roster]
  • Suzanne Winter, MS, CCRC — Clinical research project manager, tenure unknown [official roster]
  • Leslie Niziol, MS — Senior statistician, tenure unknown [official roster]
  • Ming-Chen (Amy) Lu, MS — Senior statistician, tenure unknown [official roster]
  • Tianyun Zhang, MS — Senior software developer, tenure unknown [official roster]
  • Jade Livingston, BS — Clinical research coordinator, tenure unknown [official roster]
  • Phalatha McHaney-Conner, BS, CCRC — Clinical research coordinator, tenure unknown [official roster]
  • Asia Priester — Clinical research coordinator, tenure unknown [official roster]
  • Mildred Silva-Zuccaro, MBBS — Clinical subjects coordinator, tenure unknown [official roster]
  • Thy Nguyen, BS — Research administrative associate, tenure unknown [official roster]
  • Norma Del Risco, MD — Research intern, tenure unknown [official roster]

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Newman-Casey eHealth Lab members page · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No requisition listed on the lab site or U-M Careers ophthalmology listings.

Checked at U-M Careers, Research Fellow listings

Can they afford to hire her?

Moderate Moderate: $2,054,420 in active NIH money across 3 projects, 3.5 years of project period left, 12 known team members, no advertised opening.

Active NIH money
$2,054,420
Active projects
3
Runway left
3.5 yrs
Known lab size
12
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,054,420 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • 0 No active posting found — No requisition listed on the lab site or U-M Careers ophthalmology listings. Checked 2026-09-21.
Per-dimension evidence
  • Disease & domain overlap — 46%

    Matched 2 of 6 profile areas (13 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cataract”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “optical coherence tomograph”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY036082-02 Leveraging technology to enhance eye disease detection: a pragmatic randomized trial

    R01 · NEI · $695,323 · Aug 1, 2025 to Mar 31, 2030

  • 5U01DP006826-02 DP24-081 Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT) Program: A Pragmatic Randomized Trial

    U01 · NCCDPHP · $750,000 · Sep 30, 2024 to Sep 29, 2029

  • 2R01EB032328-05 Quantifying and Understanding Glaucoma Eye Drop Medication Instillation and Adherence

    R01 · NIBIB · $609,097 · Jul 1, 2022 to Mar 31, 2030

All active NIH projects for Paula Anne Newman-casey ($2,054,420)
  • 5U01DP006826-02 DP24-081 Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT) Program: A Pragmatic Randomized Trial — $750,000, ends Sep 29, 2029
  • 5R01EY036082-02 Leveraging technology to enhance eye disease detection: a pragmatic randomized trial — $695,323, ends Mar 31, 2030
  • 2R01EB032328-05 Quantifying and Understanding Glaucoma Eye Drop Medication Instillation and Adherence — $609,097, ends Mar 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Mar 31, 2030 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#5 Lab fit 35% · Adjacent Hiring: Moderate Atlanta Neuroscience New award

Rathore — AI and multimodal imaging for neurodegeneration

Saima Rathore · Emory University, Atlanta GA · lab page ↗

Computational and AI methods that turn medical images into personalised-medicine decisions, across neurodegeneration and neuro-oncology. Alzheimer's work integrates deep CSF proteomic profiling with neuroimaging to build prognostic models, and predicts regional tau accumulation from tau-PET and radiomics. Neuro-oncology work covers glioma and glioblastoma segmentation, molecular subtyping, peritumoral infiltration, recurrence and survival prediction, and separating true progression from pseudo-progression, with tools including CaPTk and GLISTRboost. Assistant Professor in Biomedical Informatics and Neurology; previously Senior Advisor of Imaging Sciences in the Neurodegeneration Biomarker Group at Eli Lilly. (source)

Lab fit breakdown — 35% weighted · Adjacent

Scored on enough lab text to read as a verdict. 396 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.82 domain gate = 35%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Axonal transport and neuronal injury assays Lab text mentions "synaptic loss".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

No lab people page could be found, so lab size is unknown. An Emory departmental faculty page for her was not located on 22 Sep 2026; the two foundation profiles are the citable sources for her appointment.

Source: Michael J. Fox Foundation researcher profile and BrightFocus grantee page · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No opening advertised on either page. Non-NIH funding worth noting for capacity: BrightFocus Foundation lists her as principal investigator on an Alzheimer's award running 1 Jul 2026 to 30 Jun 2029. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at BrightFocus grantee page and MJFF researcher profile

Can they afford to hire her?

Moderate Moderate: $765,444 in active NIH money across 1 project, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$765,444
Active projects
1
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $765,444 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01AG095057-01A1 is flagged as a new project by NIH.
  • 0 No active posting found — No opening advertised on either page. Non-NIH funding worth noting for capacity: BrightFocus Foundation lists her as principal investigator on an Alzheimer's award running 1 Jul 2026 to 30 Jun 2029. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “synaptic loss”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG095057-01A1 Uncovering Pathophysiology in Alzheimer's Disease and Related Dementias (ADRD) Through Integrative AI of Biofluid Proteomics and Imaging

    R01 · NIA · $765,444 · Sep 15, 2026 to May 31, 2031 · Type 1 (new)

All active NIH projects for Saima Rathore ($765,444)
  • 1R01AG095057-01A1 Uncovering Pathophysiology in Alzheimer's Disease and Related Dementias (ADRD) Through Integrative AI of Biofluid Proteomics and Imaging — $765,444, ends May 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to May 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#6 Lab fit 31% · Adjacent Hiring: Moderate Atlanta Neuroscience New award

Kulshreshtha — cardiovascular health and cognitive ageing

Ambar Kulshreshtha · Emory University, Atlanta GA · lab page ↗

Physician-epidemiologist working on the heart–brain link: how poor cardiovascular health leads to cognitive decline and dementia, and how behavioural and lifestyle interventions can improve cognitive health and reduce disparities. Published work includes cardiovascular-health metrics against cognitive performance in the Vietnam Era Twin Registry and longitudinal National Alzheimer's Coordinating Center analyses of cardiovascular disease and dementia risk. Appointments in Family and Preventive Medicine and in Epidemiology, with community outreach on dementia risk factors in greater Atlanta. Population epidemiology, with no laboratory overlap with her profile. (source)

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 420 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.82 domain gate = 31%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

No research-group people page, so group size is unknown. Rank is inconsistent on Emory's own pages: the Rollins profile header reads Assistant Professor while its body text reads Associate Professor in Family and Preventive Medicine and Epidemiology. Both read on 22 Sep 2026.

Source: Emory Family and Preventive Medicine profile and Rollins faculty profile · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No opening advertised on either profile. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at Emory faculty profiles

Can they afford to hire her?

Moderate Moderate: $961,619 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$961,619
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $961,619 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01AG100363-01 is flagged as a new project by NIH.
  • 0 No active posting found — No opening advertised on either profile. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG100363-01 Multidimensional Stress Measures and Cognition: Cause, Consequence, or Catalyst

    R01 · NIA · $782,231 · Sep 15, 2026 to Jun 30, 2031 · Type 1 (new)

All active NIH projects for Ambar Kulshreshtha ($961,619)
  • 1R01AG100363-01 Multidimensional Stress Measures and Cognition: Cause, Consequence, or Catalyst — $782,231, ends Jun 30, 2031
  • 5K23AG066931-05 Association of Perceived Stress and Cognition — $179,388, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to Jun 30, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#7 Lab fit 30% · Adjacent Hiring: Moderate Atlanta Ophthalmology New award

Shantha — uveitis, medical retina and ocular fluid diagnostics

Jessica Shantha · Emory University, Atlanta GA · lab page ↗

Infectious and non-infectious uveitis and medical retina. Work covers the ophthalmic spectrum of Ebola virus disease and other emerging infections in survivors, viral persistence in eye fluid, cataract surgery in survivors (the EVICT study), international surveillance of infectious uveitis and endophthalmitis using metagenomic deep sequencing to characterise causative pathogens, and tears as a non-invasive diagnostic biomarker in uveitis. A clinician-scientist programme aimed at ocular fluid diagnostics and biomarker identification rather than animal or molecular bench work. (source)

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 331 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 32% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "uveitis".
  • Sequencing, variant and splicing analysis Lab text mentions "deep sequencing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

A clinician-scientist with no lab people page, so lab size is unknown. Affiliation needs care: NIH RePORTER records the award at Emory University and the Emory Eye Center profile is live, while the UCSF F. I. Proctor Foundation also lists her as an Associate Professor on its faculty pages (https://proctor.ucsf.edu/jessica-shantha-md, checked 22 Sep 2026). Which post is primary today could not be established from public pages, so treat the Atlanta location as unconfirmed.

Source: Emory Healthcare provider profile · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

Neither profile advertises a research opening. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at Emory Healthcare provider profile and UCSF Proctor faculty page

Can they afford to hire her?

Moderate Moderate: $1,180,265 in active NIH money across 2 projects, 4.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,180,265
Active projects
2
Runway left
4.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,180,265 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-08-31 (about 4.9 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • 0 No active posting found — Neither profile advertises a research opening. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 32%

    Matched 2 of 6 profile areas (9 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “uveitis”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “deep sequencing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01EY038199-01 Therapeutic Drug Monitoring in Uveitis for Long-term Individualized Patient Care

    R01 · NEI · $667,544 · Sep 1, 2026 to Aug 31, 2031

All active NIH projects for Jessica Shantha ($1,180,265)
  • 1R01EY038199-01 Therapeutic Drug Monitoring in Uveitis for Long-term Individualized Patient Care — $667,544, ends Aug 31, 2031
  • 5R01EY036058-03 Multi-omics Strategies to Improve Clinical Outcomes in Uveitis — $512,721, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Aug 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#8 Lab fit 30% · Adjacent Hiring: Moderate Michigan Neuro + ophtho

Cognition, Control and Action (CoCoA) Lab

Taraz G. Lee · University of Michigan, Ann Arbor MI · lab page ↗

The interaction between higher-level cognition and lower-level visual and motor processing: cognitive control, motivation, motor skill acquisition, and why skilled performance collapses under pressure. Human studies combining behavioural experiments, computational modelling, functional MRI, transcranial magnetic stimulation and work with neurological patients. The PI holds a Parkinson's Foundation Young Investigator Award. No animal, molecular or ocular work — the overlap with her profile is the disease area only. (source)

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 300 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 39% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ocular".
  • Non-rodent animal models Lab text mentions "nonhuman primate".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "computational model")

Lab composition · 4 named members

  • Taraz Lee — Principal Investigator; Assistant Professor of Psychology, tenure unknown [official roster]
  • James Brissenden — Postdoctoral Fellow, tenure unknown [news/directory]
  • Rupsha Panda — Graduate Student, Psychology (Cognition and Cognitive Neuroscience), tenure unknown [official roster]
  • Alice Yin — Undergraduate Researcher, Cognitive Science, tenure unknown [official roster]

The members page rendered only partially when read on 22 Sep 2026: these four entries were legible under current headings, but further graduate-student entries could not be read cleanly, so this roster is incomplete and lab size should be treated as a floor. The PI is listed as Assistant Professor on the LSA Psychology faculty page and as Associate Professor on his own public profile; the departmental page is taken as authoritative here.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: CoCoA Lab members page · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No opening in this lab could be confirmed. The PI's own 100 most recent Bluesky posts, read through the public API (app.bsky.feed.getAuthorFeed) on 22 Sep 2026, contain no recruiting statement; the recruiting posts that appear on his profile page are reposts of adverts by other laboratories (KU Leuven, 23 Mar 2026; University of Iowa, 13 Feb 2026), which are their openings and not his. The lab's own site (sites.lsa.umich.edu/tarazlee-lab) could not be read from here — Cloudflare returns a bot challenge — and the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at PI's public Bluesky profile — no advert of his own on it

Can they afford to hire her?

Moderate Moderate: $342,349 in active NIH money across 1 project, 3.6 years of project period left, 4 known team members, no advertised opening.

Active NIH money
$342,349
Active projects
1
Runway left
3.6 yrs
Known lab size
4
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $342,349 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-01.
  • 0 No active posting found — No opening in this lab could be confirmed. The PI's own 100 most recent Bluesky posts, read through the public API (app.bsky.feed.getAuthorFeed) on 22 Sep 2026, contain no recruiting statement; the recruiting posts that appear on his profile page are reposts of adverts by other laboratories (KU Leuven, 23 Mar 2026; University of Iowa, 13 Feb 2026), which are their openings and not his. The lab's own site (sites.lsa.umich.edu/tarazlee-lab) could not be read from here — Cloudflare returns a bot challenge — and the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • +5 Small team with room to add a senior bench scientist — 4 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 39%

    Matched 2 of 6 profile areas (11 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ocular”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01EY038943-01 Investigating the computational and neural mechanisms of visuocognitive adaptation

    R01 · NEI · $342,349 · Aug 1, 2026 to Apr 30, 2030

All active NIH projects for Taraz G. Lee ($342,349)
  • 1R01EY038943-01 Investigating the computational and neural mechanisms of visuocognitive adaptation — $342,349, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2026 · project period to Apr 30, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#9 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuroscience New award

Brouwer — mathematical and statistical modelling in epidemiology

Andrew Frederick Brouwer · University of Michigan, Ann Arbor MI · lab page ↗

Mathematical and statistical modelling for epidemiologic inference, with a speciality in parameter identifiability, estimation and uncertainty. Application areas are infectious-disease transmission and outbreak response (Michigan hepatitis A and COVID-19), environmental pathogens and wastewater surveillance, HPV-related cancer incidence and survival, tobacco-use transitions and gender-minority health, using differential-equation, multistate-transition and age–period–cohort models. Assistant Professor of Epidemiology. No neuroscience or ophthalmology overlap with her profile beyond the brain-health framing of the award on this card. (source)

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 327 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 39% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

No research-group people page is published, so group size is unknown.

Source: U-M School of Public Health faculty profile and U-M Experts profile · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No opening advertised on either page. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at U-M SPH faculty profile and U-M Experts profile

Can they afford to hire her?

Moderate Moderate: $567,557 in active NIH money across 1 project, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$567,557
Active projects
1
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $567,557 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01AG100051-01 is flagged as a new project by NIH.
  • 0 No active posting found — No opening advertised on either page. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 39%

    Matched 2 of 6 profile areas (11 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG100051-01 Predictors of transitions to cognitive impairment and dementia across the cognitive status trajectory

    R01 · NIA · $567,557 · Sep 15, 2026 to May 31, 2031 · Type 1 (new)

All active NIH projects for Andrew Frederick Brouwer ($567,557)
  • 1R01AG100051-01 Predictors of transitions to cognitive impairment and dementia across the cognitive status trajectory — $567,557, ends May 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to May 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#10 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuro + ophtho

Berger Laboratory (corneal inflammation and repair)

Elizabeth Berger · Wayne State University, Detroit MI · lab page ↗

Mechanisms of corneal disease, inflammation and repair, and peptide-based therapies: thymosin beta-4 and VIP combination therapy for diabetes-induced corneal complications, eosinophils in microbial keratitis, antibacterial and regenerative effects in Pseudomonas and Staphylococcus infection, and high/low-capacity-runner models of aging and metabolic syndrome. (source)

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 537 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 47% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 42% × 0.7 domain gate = 29%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · 6 named members

  • Ebrahim Abdul Shukkur, PhD — Researcher (as of 2021), tenure unknown [unverified]
  • Tommy Carion — Lab manager (as of 2021), tenure unknown [unverified]
  • Yuxin Wang — Graduate student (as of 2021), tenure unknown [unverified]
  • Ashten Stambersky — Graduate student (as of 2021), tenure unknown [unverified]
  • Jeff Win — Medical student (as of 2021), tenure unknown [unverified]
  • Thanzeela Ebrahim — Undergraduate student (as of 2021), tenure unknown [unverified]

This roster is from December 2021 and is the most recent named list published. Students named then have very likely graduated; treat as stale. No current roster page exists.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: Wayne State School of Medicine news, 17 Dec 2021 (named lab team) · checked Sep 21, 2026

Posting · No posting advertised

No active posting found (checked Sep 21, 2026).

No postdoc advert. The faculty profile solicits undergraduate and medical students able to commit a year or more, not postdocs.

Checked at Wayne State faculty profile

Can they afford to hire her?

Moderate Moderate: $1,158,893 in active NIH money across 2 projects, 2.6 years of project period left, 6 known team members, no advertised opening.

Active NIH money
$1,158,893
Active projects
2
Runway left
2.6 yrs
Known lab size
6
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,158,893 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • 0 No active posting found — No postdoc advert. The faculty profile solicits undergraduate and medical students able to commit a year or more, not postdocs. Checked 2026-09-21.
  • +5 Small team with room to add a senior bench scientist — 6 public members on the roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 47%

    Matched 2 of 7 profile areas (14 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY036697-02 The Role of Eosinophils in Modulating the Corneal Response to Infection

    R01 · NEI · $586,258 · Jul 1, 2025 to Apr 30, 2029

  • 5R01EY035494-02 Restoration of Structure and Function in the Diabetic Cornea

    R01 · NEI · $572,635 · May 1, 2025 to Feb 28, 2029

All active NIH projects for Elizabeth Berger ($1,158,893)
  • 5R01EY036697-02 The Role of Eosinophils in Modulating the Corneal Response to Infection — $586,258, ends Apr 30, 2029
  • 5R01EY035494-02 Restoration of Structure and Function in the Diabetic Cornea — $572,635, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2025 · project period to Apr 30, 2029 · roster/posting last verified Sep 21, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#11 Lab fit 26% · Adjacent Hiring: Moderate Michigan Neuroscience New award

BRAIN Lab, Cognitive Imaging Research Center (CIRC)

Norman Scheel · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI · lab page ↗

Computational and artificial-intelligence methods that turn multimodal brain imaging into biomarkers of ageing, resilience and neurodegeneration. The core line is resting-state fMRI dimensional complexity and temporal decomposition of brain signals, validated clinically and biologically as a marker of cognitive resilience under Michigan Alzheimer's Disease Research Center funding, and applied across ADNI, HCP, rrAD and UM-MAP datasets with machine and deep learning. The lab also leads the neuroimaging analysis for large NIH trials linking cardiovascular health to brain ageing. The PI is Assistant Professor of Radiology and Director of CIRC. (source)

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 326 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · No public roster — size unknown

Unknown — this lab publishes no roster.

The lab publishes no roster page, so size is unknown. Institution needs care: NIH RePORTER records this award under "Henry Ford Health + Michigan State University Health Sciences", while his own pages place him in the MSU Department of Radiology in East Lansing as Director of CIRC. The lab site is served over plain HTTP only.

Source: BRAIN Lab site (no people page; /brain-lab/people.php returns 404) · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

The page states plainly: "The BRAIN Lab has no open positions or active searches at this time." It still invites prospective postdoctoral researchers with an interest in computational neuroimaging and AI to email a brief note, so this is a documented no rather than silence.

Checked at BRAIN Lab contact page

Can they afford to hire her?

Moderate Moderate: $624,029 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$624,029
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $624,029 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • 0 No active posting found — The page states plainly: "The BRAIN Lab has no open positions or active searches at this time." It still invites prospective postdoctoral researchers with an interest in computational neuroimaging and AI to email a brief note, so this is a documented no rather than silence. Checked 2026-09-22.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG102936-01 Dimensional Complexity as a Biomarker for Resilience in Aging and Dementia (DC-RAD)

    R01 · NIA · $624,029 · Sep 1, 2026 to Jun 30, 2030

All active NIH projects for Norman Scheel ($624,029)
  • 1R01AG102936-01 Dimensional Complexity as a Biomarker for Resilience in Aging and Dementia (DC-RAD) — $624,029, ends Jun 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Jun 30, 2030 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

#12 Lab fit 26% · Adjacent Hiring: Moderate Atlanta Neuroscience New award

ViTAL Lab — Computational Behaviour and Health Analytics

Hyeokhyen Kwon · Emory University, Atlanta GA · lab page ↗

Accessible, scalable and privacy-preserving machine learning on ambient, mobile, wearable and video sensing, aimed at brain and mental health, and validated in real clinics and everyday environments. Current work includes an NIH NINDS R01 (1R01NS146515-01A1) developing AI-driven clinical decision support that scores motor symptoms and mental health in Parkinson's disease from video, wearables and remote interviews; estimating clinician-rated cognition and balance (MoCA, Mini-BESTest) from waist-worn IMU data in older adults with mild cognitive impairment; freezing-of-gait scoring; and multimodal mental-health digital biomarkers. The PI is Assistant Professor of Biomedical Informatics and co-director of the Center for Brain and Behavior AI for Neurohealth Science and Support. (source)

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 490 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · 8 named members

  • Hyeokhyen Kwon, PhD — Director; Assistant Professor, Biomedical Informatics, tenure unknown [official roster]
  • Bolaji Omofojoye — Clinical Research Coordinator, Biomedical Informatics, Emory, tenure unknown [official roster]
  • Jangwon Lim — PhD Student, Computer Science and Informatics, Emory, tenure unknown [official roster]
  • Lauhitya Reddy — PhD Student, Computer Science and Informatics, Emory, tenure unknown [official roster]
  • Merna Bibars — PhD Student, Machine Learning, Georgia Tech, tenure unknown [official roster]
  • Yadhu Kartha — PhD Student, Machine Learning, Georgia Tech, tenure unknown [official roster]
  • Lucy Lyu — MS Student, Computer Science and Informatics, Emory, tenure unknown [official roster]
  • Seuyoung Chung — Visiting Student, Biomedical Informatics, Emory, tenure unknown [official roster]

Current members only; the page also carries an alumni list. The group is large and mostly students, so there is no small-team capacity credit.

Start years are not published on this source, so tenure shows as unknown rather than being estimated.

Source: ViTAL Lab team page · checked Sep 22, 2026

Posting · No posting advertised

No active posting found (checked Sep 22, 2026).

No openings page or advertised vacancy, although a postdoc left the group in 2026 according to the alumni list. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out.

Checked at ViTAL Lab site (home and team pages)

Can they afford to hire her?

Moderate Moderate: $618,523 in active NIH money across 1 project, 4.9 years of project period left, 8 known team members, no advertised opening.

Active NIH money
$618,523
Active projects
1
Runway left
4.9 yrs
Known lab size
8
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $618,523 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-08-31 (about 4.9 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • 0 No active posting found — No openings page or advertised vacancy, although a postdoc left the group in 2026 according to the alumni list. Check covered the lab's own public pages only; the university's central job board was not searched for this lab, so an unadvertised requisition cannot be ruled out. Checked 2026-09-22.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146515-01A1 Scalable and Affordable Artificial Intelligence-driven Clinical Decision Support for Movement Disorders

    R01 · NINDS · $618,523 · Sep 1, 2026 to Aug 31, 2031

All active NIH projects for Hyeokhyen Kwon ($618,523)
  • 1R01NS146515-01A1 Scalable and Affordable Artificial Intelligence-driven Clinical Decision Support for Movement Disorders — $618,523, ends Aug 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Aug 31, 2031 · roster/posting last verified Sep 22, 2026 · first seen Sep 22, 2026 (baseline snapshot)

Not yet researched (331)

Scored on grant text alone because no roster or posting research has been run for them yet, so the match % here is a floor rather than a verdict. Listed in full so nothing is hidden.

#1 Lab fit 44% · Moderate fit Hiring: Moderate Atlanta Autophagy / organelle QC

Mijin Kim lab

Mijin Kim · Georgia Institute of Technology, Atlanta GA

Autophagy is a process that controls cellular homeostasis and is implicated in a number of diseases and conditions. Lysosomes have emerged as essential signaling centers that govern cell growth, division, and differentiation, as well as catabolic activity, and play a large role in autophagy. Dysregulated lysosomal function affects cell survival, invasion, immune evasion, and drug resistance. While elucidation of the role of autophagy and lysosomal dysregulation on cell signaling would facilitate a greater understanding of diseases and guide new therapeutic strategies, there is a dearth of robu

Lab fit breakdown — 44% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 212 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 54% × 0.82 domain gate = 44%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $664,994 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$664,994
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $664,994 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R35GM166288-01 Biointerface quantum and nanosensing technologies to investigate autophagic pathways

    R35 · NIGMS · $421,857 · Aug 1, 2026 to Jul 31, 2031

All active NIH projects for Mijin Kim ($664,994)
  • 1R35GM166288-01 Biointerface quantum and nanosensing technologies to investigate autophagic pathways — $421,857, ends Jul 31, 2031
  • 5R00EB033580-05 Machine Perception Nanosensor Array Platform to Capture Whole Disease Fingerprints of Early Stage Pancreatic Cancer — $243,137, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#2 Lab fit 44% · Moderate fit Hiring: Moderate Michigan Neuroscience

Wenjing Wang lab

Wenjing Wang · University of Michigan, Ann Arbor MI

Summary Lewy Body Dementias (LBDs) are a series of neurodegenerative disorders characterized by accumulation of misfolded α‐synuclein (αS), including Dementia with Lewy Body (DLB), Parkinson’s Disease with Dementia (PDD), and 1/3 of Alzheimer’s Disease (AD). DLB is the 2nd most common dementia after AD accounting for 30% of dementia cases; approximately 30% of AD cases suffer from α‐synucleinopathy resulting in a more rapid and severe cognitive decline than AD alone. In brief, αS pathology is highly associated with AD and related dementias (ADRD). Braak et al. identified that αS pathology spre

Lab fit breakdown — 44% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 644 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 54% × 0.82 domain gate = 44%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "protein degradation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "protein engineering")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,056,147 in active NIH money across 4 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,056,147
Active projects
4
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,056,147 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years) — 5T32GM132046-08, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “protein degradation”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1NS137428-01 Novel fibril-selective nanobody-based agents targeting intracellular and extracellular α-synuclein aggregates and prion-like propagation induced dementia

    RF1 · NINDS · $2,280,379 · Sep 19, 2024 to Aug 31, 2027

  • 5R01DA053200-05 Design of genetically encoded sensors for detecting endogenous opioid peptides

    R01 · NIDA · $335,097 · Sep 1, 2022 to Jun 30, 2027

  • 4DP2MH132939-02 New classes of optogenetic and chemogenetic tools with a feedback control

    DP2 · NIMH · $900,000 · Aug 15, 2022 to Aug 14, 2027

All active NIH projects for Wenjing Wang ($4,056,147)
  • 1RF1NS137428-01 Novel fibril-selective nanobody-based agents targeting intracellular and extracellular α-synuclein aggregates and prion-like propagation induced dementia — $2,280,379, ends Aug 31, 2027
  • 4DP2MH132939-02 New classes of optogenetic and chemogenetic tools with a feedback control — $900,000, ends Aug 14, 2027
  • 5T32GM132046-08 Michigan Chemistry-Biology Interface Training Program — $540,671, ends Jun 30, 2029
  • 5R01DA053200-05 Design of genetically encoded sensors for detecting endogenous opioid peptides — $335,097, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 19, 2024 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#3 Lab fit 44% · Moderate fit Hiring: Possible Atlanta Neuroscience

Adriana Galvan lab

Adriana Galvan · Emory University, Atlanta GA

SUMMARY The basal ganglia serve many behavioral functions, ranging from the regulation of movements and cognition to the modulation of valence and mood. This functional heterogeneity is reflected in the composition of the principal output nucleus of the primate basal ganglia, the internal pallidal segment (GPi). This nucleus contains two distinct populations of projection neurons. A major group of cells in the core of GPi projects to the ventral thalamus (and other targets) and is known to be involved in motor functions. Much less explored is a second population of neurons that is confined to

Lab fit breakdown — 44% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 522 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 54% × 0.82 domain gate = 44%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Calcium and mechanosensitive channel signalling Lab text mentions "ion channel".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $950,195 in active NIH money across 2 projects, 2.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$950,195
Active projects
2
Runway left
2.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $950,195 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-12-31 (about 2.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS134941-03 The Pallidohabenular System in Parkinsonism

    R01 · NINDS · $495,195 · Jan 4, 2024 to Dec 31, 2028

  • 5R01NS130551-05 Chemogenetic Inactivation of the Primate Internal Globus Pallidus as a Treatment for Parkinsonism

    R01 · NINDS · $455,000 · Sep 27, 2022 to Aug 31, 2027

All active NIH projects for Adriana Galvan ($950,195)
  • 5R01NS134941-03 The Pallidohabenular System in Parkinsonism — $495,195, ends Dec 31, 2028
  • 5R01NS130551-05 Chemogenetic Inactivation of the Primate Internal Globus Pallidus as a Treatment for Parkinsonism — $455,000, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 4, 2024 · project period to Dec 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#4 Lab fit 44% · Moderate fit Hiring: Possible Michigan Neuroscience

Carl J Koschmann lab

Carl J Koschmann · University of Michigan, Ann Arbor MI

PROJECT SUMMARY / ABSTRACT Background and long-term objectives: Children and young adults with diffuse midline glioma (DMG) harboring H3K27M mutation rarely survive longer than two years and have no proven therapies beyond radiation. The dopamine receptor DRD2 antagonist ONC201 induces transcription of TNF-related apoptosis- inducing ligand (TRAIL), leading to apoptosis in multiple tumor cell types. ONC201 additionally binds and activates the mitochondrial protease ClpP, resulting in mitochondrial-mediated cell death in breast cancer cells with active oxidative phosphorylation (OXPHOS). ONC201

Lab fit breakdown — 44% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 233 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 54% × 0.82 domain gate = 44%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $684,100 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$684,100
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $684,100 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS124607-05 Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma

    R01 · NINDS · $473,500 · Feb 1, 2022 to Jan 31, 2027

All active NIH projects for Carl J Koschmann ($684,100)
  • 5R01NS124607-05 Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma — $473,500, ends Jan 31, 2027
  • 5UH2CA302680-02 Analytical and Clinical Validation of an H3K27M ctDNA Assay for Diffuse Midline Glioma (DMG) Surveillance — $210,600, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#5 Lab fit 43% · Moderate fit Hiring: Possible Atlanta Neuroscience

Seong Su Kang lab

Seong Su Kang · Emory University, Atlanta GA

Even though so many risk factors and the related hypotheses for Alzheimer’s disease (AD) have been proposed, the exact disease-modifying therapies have not been established. The female predominance in the development of AD also has been well demonstrated as a risk factor. Therefore, understanding sex-specific differences in AD and identifying the underlying mechanisms are important for the treatment and intervention of sex-related AD. It is well known that Apolipoprotein E4 (APOE4) is a major genetic risk factor for developing late-onset AD. Furthermore, there is a correlation between APOE4 an

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 271 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Human donor tissue, primary and explant culture Lab text mentions "primary cell".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $559,052 in active NIH money across 1 project, 3.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$559,052
Active projects
1
Runway left
3.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $559,052 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-11-30 (about 3.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “primary cell”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG087190-02 Impact of APOE4 on sex-specific mechanism for Alzheimer's disease

    R01 · NIA · $559,052 · Dec 15, 2024 to Nov 30, 2029

All active NIH projects for Seong Su Kang ($559,052)
  • 5R01AG087190-02 Impact of APOE4 on sex-specific mechanism for Alzheimer's disease — $559,052, ends Nov 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 15, 2024 · project period to Nov 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#6 Lab fit 43% · Moderate fit Hiring: Strong Michigan Neuroscience

Justin Adam Colacino lab

Justin Adam Colacino · University of Michigan, Ann Arbor MI

Abstract. The goal of this project is to use genetically heterogeneous mice that better model humans to determine the sex-specific consequences of exposure to toxic metals/metalloids (Pb, Cd, As, hereafter referred to as “metals”) on molecular, pathologic, and behavioral changes linked to Alzheimer’s Disease and Related Dementias (ADRD). While ADRD has a substantial genetic component, emerging research shows exposures, such as metals, are likely important modifiable risk factors. Exposures to Pb, Cd, and As are associated with cognitive decline or ADRD in epidemiology studies or ADRD-associate

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 558 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "gene targeting".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,409,730 in active NIH money across 4 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,409,730
Active projects
4
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,409,730 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2T32ES007062-42, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “gene targeting”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01AG088407-03 The impact of metals and polygenic risk on multiomics, brain aging, and ADRD outcomes

    U01 · NIA · $1,482,647 · Sep 30, 2024 to Aug 31, 2029

  • 5R01AG072396-05 Risk of Alzheimer's Disease and Related Dementias from Perinatal Lead Exposure: Brain Region and Cell Type Effects

    R01 · NIA · $762,926 · Feb 15, 2022 to Dec 31, 2026

All active NIH projects for Justin Adam Colacino ($3,409,730)
  • 5U01AG088407-03 The impact of metals and polygenic risk on multiomics, brain aging, and ADRD outcomes — $1,482,647, ends Aug 31, 2029
  • 5R01AG072396-05 Risk of Alzheimer's Disease and Related Dementias from Perinatal Lead Exposure: Brain Region and Cell Type Effects — $762,926, ends Dec 31, 2026
  • 5R01ES028802-09 Developmental Exposures, Stem Cell Reprogramming, and Breast Cancer Disparities — $601,223, ends Oct 31, 2027
  • 2T32ES007062-42 Environmental Toxicology and Epidemiology Pre- and Post-Doctoral Research T32 Training Program — $562,934, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#7 Lab fit 43% · Moderate fit Hiring: Possible Atlanta Neuroscience

Annabelle Catherine Singer lab

Annabelle Catherine Singer · Georgia Institute of Technology, Atlanta GA

Remembering precise locations of importance is a key component of spatial memory. Over the past few decades, extensive prior work has shown that excitatory pyramidal cells in hippocampus code for various spatially relevant cues. Hippocampal inhibitory interneurons have been ascribed important roles in generating oscillations and maintaining optimal levels of excitatory activity, but their role in spatial memory formation is unclear. Understanding the role of interneurons in memory formation processes is crucial because several studies have revealed deficits in inhibition due to Alzheimer’s dis

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 477 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,639,996 in active NIH money across 2 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,639,996
Active projects
2
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,639,996 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4RF1AG078736-02 Hippocampal interneurons in novel memory formation in health and Alzheimer's disease

    RF1 · NIA · $984,291 · Sep 1, 2022 to Aug 31, 2027

  • 4R01NS109226-07 Gamma Sensory Flicker as an Early Intervention for Alzheimer’s Disease: Mechanisms and Protective Effects

    R01 · NINDS · $655,705 · Sep 15, 2018 to Aug 31, 2028

All active NIH projects for Annabelle Catherine Singer ($1,639,996)
  • 4RF1AG078736-02 Hippocampal interneurons in novel memory formation in health and Alzheimer's disease — $984,291, ends Aug 31, 2027
  • 4R01NS109226-07 Gamma Sensory Flicker as an Early Intervention for Alzheimer’s Disease: Mechanisms and Protective Effects — $655,705, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to Aug 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#8 Lab fit 43% · Moderate fit Hiring: Possible Atlanta Neuroscience

Andreas S Bommarius lab

Andreas S Bommarius · Georgia Institute of Technology, Atlanta GA

While the AD etiology remains largely unknown, with no effective strategy to arrest the relentless progression of the disease, current evidence connects amyloid-β (Aβ), a 40/42 amino acid peptide, to early disease progression. How folding of this peptide might create the heterogeneous assemblies (strains) that propagate as a prion-like infection throughout the brain remains a central question. Accordingly, we propose to connect the mechanisms of diversification and propagation of proteopathic Aβ strains to their biochemical manifestation to connect the structural foundation of strain patterns

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 307 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,785,477 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,785,477
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 33 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,785,477 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids

    RF1 · NIA · $1,785,477 · Aug 1, 2022 to Jul 31, 2027

All active NIH projects for Andreas S Bommarius ($1,785,477)
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids — $1,785,477, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#9 Lab fit 43% · Moderate fit Hiring: Possible Atlanta Neuroscience

David Gilbert Lynn lab

David Gilbert Lynn · Emory University, Atlanta GA

While the AD etiology remains largely unknown, with no effective strategy to arrest the relentless progression of the disease, current evidence connects amyloid-β (Aβ), a 40/42 amino acid peptide, to early disease progression. How folding of this peptide might create the heterogeneous assemblies (strains) that propagate as a prion-like infection throughout the brain remains a central question. Accordingly, we propose to connect the mechanisms of diversification and propagation of proteopathic Aβ strains to their biochemical manifestation to connect the structural foundation of strain patterns

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 307 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,785,477 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,785,477
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 33 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,785,477 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids

    RF1 · NIA · $1,785,477 · Aug 1, 2022 to Jul 31, 2027

All active NIH projects for David Gilbert Lynn ($1,785,477)
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids — $1,785,477, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#10 Lab fit 43% · Moderate fit Hiring: Moderate Atlanta Neuroscience

Bo Liang lab

Bo Liang · Emory University, Atlanta GA

While the AD etiology remains largely unknown, with no effective strategy to arrest the relentless progression of the disease, current evidence connects amyloid-β (Aβ), a 40/42 amino acid peptide, to early disease progression. How folding of this peptide might create the heterogeneous assemblies (strains) that propagate as a prion-like infection throughout the brain remains a central question. Accordingly, we propose to connect the mechanisms of diversification and propagation of proteopathic Aβ strains to their biochemical manifestation to connect the structural foundation of strain patterns

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 307 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,176,727 in active NIH money across 2 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,176,727
Active projects
2
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,176,727 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-07-31 (about 1.8 years) — 5R01GM130950-08, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids

    RF1 · NIA · $1,785,477 · Aug 1, 2022 to Jul 31, 2027

All active NIH projects for Bo Liang ($2,176,727)
  • 4RF1AG079256-02 Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoids — $1,785,477, ends Jul 31, 2027
  • 5R01GM130950-08 Structure and Regulation of The Respiratory Syncytial Virus Polymerase — $391,250, ends Jul 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#11 Lab fit 43% · Moderate fit Hiring: Unlikely Michigan Neuro + ophtho

Ryan David Mohan lab

Ryan David Mohan · Wayne State University, Detroit MI

Abstract Although many studies have demonstrated correlations between cytoskeletal dynamics, genome organization, and gene expression, the underlying mechanisms linking them remain unclear. Recently, we discovered crosstalk between the Wiskott-Aldrich syndrome protein family verprolin homolog (WAVE) regulatory complex (WRC), which promotes actin polymerization, and the Spt-Ada-Gcn5-acetyltransferase (SAGA) complex, a transcriptional coactivator. Their relationship is established through the sharing of subunits comprising the SAGA deubiquitinase module, including the deubiquitinase Non-stop. De

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 217 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 21% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "ubiquitin".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $385,000 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$385,000
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $385,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 21%

    Matched 1 of 6 profile areas (6 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “ubiquitin”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS117539-05 Mechanism and effects of communication between actin and gene regulatory complexes

    R01 · NINDS · $385,000 · Jul 1, 2021 to Jun 30, 2027

All active NIH projects for Ryan David Mohan ($385,000)
  • 5R01NS117539-05 Mechanism and effects of communication between actin and gene regulatory complexes — $385,000, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#12 Lab fit 43% · Moderate fit Hiring: Possible Michigan Neuroscience

Sokol Todi lab

Sokol Todi · Wayne State University, Detroit MI

PROJECT SUMMARY The goal of this resubmitted, competitive renewal R01 application is to execute an unprecedented, com- prehensive, parallel and rigorous examination of the processing of each polyglutamine (polyQ) disease protein through a novel, isogenic series of transgenic animals and approaches that span Drosophila ge- netics, physiology, mass spectrometry, mammalian cell biology and biochemistry. The polyQ family of proteins is linked to nine incurable neurodegenerative maladies: Spinocerebellar Ataxias (SCAs) 1, 2, 3, 6, 7 and 17, Huntington's disease, Dentatorubral-pallidoluysian atrophy

Lab fit breakdown — 43% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.82 domain gate = 43%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $475,722 in active NIH money across 1 project, 2.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$475,722
Active projects
1
Runway left
2.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $475,722 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-11-30 (about 2.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS086778-12 MOLECULAR MECHANISMS OF NEUROPROTECTION IN POLYGLUTAMINE-DEPENDENT DEGENERATION

    R01 · NINDS · $475,722 · Apr 1, 2014 to Nov 30, 2028

All active NIH projects for Sokol Todi ($475,722)
  • 5R01NS086778-12 MOLECULAR MECHANISMS OF NEUROPROTECTION IN POLYGLUTAMINE-DEPENDENT DEGENERATION — $475,722, ends Nov 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2014 · project period to Nov 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#13 Lab fit 42% · Moderate fit Hiring: Moderate Michigan Neuroscience

Dawen Cai lab

Dawen Cai · University of Michigan, Ann Arbor MI

Abstract Knowing the molecular signature of distinct brain cell types in the human brain is relevant for basic neuroscience research and understanding neurological disease. While past and ongoing large-scale scRNAseq and spatial transcriptomics efforts have provided a comprehensive mRNA expression atlas, there lacks a similar proteomics atlas due to the limited profiling throughput of current methods. Additionally, studies have shown expression discrepancy between the transcription and translation levels, especially during development. Therefore, mapping proteomes, not just transcriptomes, is

Lab fit breakdown — 42% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 247 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.82 domain gate = 42%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "monoclonal")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $7,080,112 in active NIH money across 3 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$7,080,112
Active projects
3
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $7,080,112 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5P41EB035084-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4R01MH134803-02 Scalable high-plex pipeline for whole-brain proteomics profiling

    R01 · NIMH · $3,061,628 · Aug 1, 2025 to Jul 31, 2028

All active NIH projects for Dawen Cai ($7,080,112)
  • 4UC2AR082197-02 Neural Architecture of the Murine and Human Temporomandibular Joint — $3,749,330, ends Aug 31, 2027
  • 4R01MH134803-02 Scalable high-plex pipeline for whole-brain proteomics profiling — $3,061,628, ends Jul 31, 2028
  • 5P41EB035084-02 TR&D3 — $269,154, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jul 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#14 Lab fit 42% · Moderate fit Hiring: Moderate Atlanta Neuroscience

Deqiang Qiu lab

Deqiang Qiu · Emory University, Atlanta GA

Project Summary Poststroke cognitive impairment (PSCI) was found to be common in various research studies. PSCI is ideally recognized through cognitive screening and test but they are not standard clinical practices and hence stroke recovery and prevention of recurrent strokes may be undermined by concurrent but poorly recognized cognitive issues, e.g., patient compliance to follow blood pressure control medication may be poorer among those with PSCI. Therefore, a significant unmet need for optimizing poststroke care is to recognize patients at high risk of PSCI to tailor for them an appropria

Lab fit breakdown — 42% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 810 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.82 domain gate = 42%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,934,231 in active NIH money across 4 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,934,231
Active projects
4
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,934,231 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5P30AG066511-07, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3RF1NS139325-01S1 Using AI on Routine Clinical and Imaging Data from Acute Stroke Encounter to Predict Post-Stroke Vascular Contributions to Cognitive Impairment (AI - RESPECT)

    RF1 · NINDS · $234,750 · Sep 1, 2024 to Jul 31, 2027

  • 5R01AG089806-03 Explainable and Ethical AI for Studying Alzheimer's Disease

    R01 · NIA · $679,906 · Aug 1, 2024 to Apr 30, 2029

  • 5R01AG072603-05 Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's Disease

    R01 · NIA · $585,060 · Feb 1, 2022 to Jan 31, 2027

All active NIH projects for Deqiang Qiu ($3,934,231)
  • 1RF1NS139325-01 Using AI on Routine Clinical and Imaging Data from Acute Stroke Encounter to Predict Post-Stroke Vascular Contributions to Cognitive Impairment (AI - RESPECT) — $2,340,263, ends Jul 31, 2027
  • 5R01AG089806-03 Explainable and Ethical AI for Studying Alzheimer's Disease — $679,906, ends Apr 30, 2029
  • 5R01AG072603-05 Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's Disease — $585,060, ends Jan 31, 2027
  • 5P30AG066511-07 Imaging Core — $329,002, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#15 Lab fit 42% · Moderate fit Hiring: Moderate Atlanta Neuroscience

Bing Yao lab

Bing Yao · Emory University, Atlanta GA

Project Summary AD is an age-related progressive neurodegenerative disorder affecting millions of Americans without effective interventions. The gradual accumulation of neurofibrillary tangles formed by abnormal protein aggregation, such as tau and amyloid-β (Aβ) protein, serves as the neuropathological hallmark of AD. In recent years, the role of TAR DNA-binding protein 43 (TDP-43), a DNA and RNA-binding protein that has been heavily studied in amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar degeneration (FTLD-TDP), has drawn increasing interest for AD pathogenesis. The patholog

Lab fit breakdown — 42% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 545 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.82 domain gate = 42%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "splicing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,410,302 in active NIH money across 3 projects, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,410,302
Active projects
3
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,410,302 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG078937-05 Elucidating the Roles of Transposable Elements in Alzheimer's and related dementias

    R01 · NIA · $716,852 · Aug 15, 2022 to Apr 30, 2027

  • 5R01NS118819-05 Regulation and function of human neural circular RNAs

    R01 · NINDS · $472,174 · Mar 15, 2021 to Dec 31, 2026

All active NIH projects for Bing Yao ($2,410,302)
  • 1R61AG094646-01 In vivo single-cell analysis of Alzheimer's disease-associated regulatory elements — $1,221,276, ends Jul 31, 2027
  • 5R01AG078937-05 Elucidating the Roles of Transposable Elements in Alzheimer's and related dementias — $716,852, ends Apr 30, 2027
  • 5R01NS118819-05 Regulation and function of human neural circular RNAs — $472,174, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#16 Lab fit 42% · Moderate fit Hiring: Possible Michigan Neuroscience

Min-hao Kuo lab

Min-hao Kuo · Michigan State University, East Lansing MI

Hyperphosphorylated tau and the molecular mechanisms of tauopathy Tauopathies are neurodegenerative disorders sharing the common pathology of the tau protein in the central nervous system. The most prominent tauopathy is Alzheimer’s disease (AD) that affects nearly 6 million Americans and more than 30 million people worldwide. Animal and cell studies demonstrated that soluble, oligomeric hyperphosphorylated tau is toxic to cells, and can transmit in a prion-like fashion in the brain. However, how hyperphosphorylation converts tau into a cytotoxic species, and how hyperphosphorylated tau exerts

Lab fit breakdown — 42% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 256 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.82 domain gate = 42%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "allele".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,009,107 in active NIH money across 2 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,009,107
Active projects
2
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,009,107 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years) — 5R01NS135693-04, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG077475-03 Hyperphosphorylated tau and the molecular mechanisms of tauopathy

    R01 · NIA · $411,452 · Jun 1, 2022 to May 31, 2027

All active NIH projects for Min-hao Kuo ($1,009,107)
  • 5R01NS135693-04 Treating neurotoxicity and cognitive deficits due to hyperphosphorylated tau. — $597,655, ends Aug 31, 2028
  • 5R01AG077475-03 Hyperphosphorylated tau and the molecular mechanisms of tauopathy — $411,452, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#17 Lab fit 42% · Moderate fit Hiring: Possible Atlanta Neuroscience

Yue Feng lab

Yue Feng · Emory University, Atlanta GA

Project Summary Circular RNAs (circRNAs) are a novel class of covalently closed RNA species derived from “back splicing” of pre-mRNAs. Mounting evidence suggests the essential roles of circRNAs in governing healthy brain development and their abnormalities in neurological and neuropsychiatric disorders. Many circRNAs are unique and highly abundant in the human brain, which are thought to underlie the sophisticated function of human brains and the fragility of various brain diseases. Mechanistically, circRNAs can function through sponging microRNAs or RNA-binding proteins, which broadly regulat

Lab fit breakdown — 42% weighted · Moderate fit

Scored on enough lab text to read as a verdict. 232 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.82 domain gate = 42%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "splicing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,019,924 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,019,924
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,019,924 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS118819-05 Regulation and function of human neural circular RNAs

    R01 · NINDS · $472,174 · Mar 15, 2021 to Dec 31, 2026

All active NIH projects for Yue Feng ($1,019,924)
  • 1R56NS146174-01A1 Human-specific mechanisms for miR-124 to control neuronal development — $547,750, ends Aug 31, 2027
  • 5R01NS118819-05 Regulation and function of human neural circular RNAs — $472,174, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 15, 2021 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#18 Lab fit 41% · Adjacent Hiring: Moderate Michigan Neuroscience

Michelle Suzanne Mazei-robison lab

Michelle Suzanne Mazei-robison · Michigan State University, East Lansing MI

Summary Opioid use and abuse are a major health and economic concern, with reduction of abused prescription opioids shifted to cheaper, illicit opioids like fentanyl. Thus, development of non-opioid treatments is crucial, but requires additional understanding of the neurobiological underpinnings. Dysregulation of the reward circuitry contributes to opioid-induced plasticity and addictive-like behavior, including altered function of ventral tegmental area (VTA) dopamine (DA) neurons. Given the powerful and unique roles that activity of these neurons play in a multitude of behaviors, it is unsur

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 480 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 59% × 0.7 domain gate = 41%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "allele".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,090,987 in active NIH money across 2 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,090,987
Active projects
2
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,090,987 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DA066149-01 Ventral tegmental area neuromedin s expression and signaling in opioid responses

    R01 · NIDA · $495,345 · Jun 1, 2026 to Mar 31, 2031

  • 5R01MH111604-10 Projection-specific gene expression in resilience to chronic stress

    R01 · NIMH · $595,642 · Sep 8, 2016 to Jun 30, 2027

All active NIH projects for Michelle Suzanne Mazei-robison ($1,090,987)
  • 5R01MH111604-10 Projection-specific gene expression in resilience to chronic stress — $595,642, ends Jun 30, 2027
  • 1R01DA066149-01 Ventral tegmental area neuromedin s expression and signaling in opioid responses — $495,345, ends Mar 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#19 Lab fit 41% · Adjacent Hiring: Strong Michigan Neuroscience

Alfred J Robison lab

Alfred J Robison · Michigan State University, East Lansing MI

Summary Opioid use and abuse are a major health and economic concern, with reduction of abused prescription opioids shifted to cheaper, illicit opioids like fentanyl. Thus, development of non-opioid treatments is crucial, but requires additional understanding of the neurobiological underpinnings. Dysregulation of the reward circuitry contributes to opioid-induced plasticity and addictive-like behavior, including altered function of ventral tegmental area (VTA) dopamine (DA) neurons. Given the powerful and unique roles that activity of these neurons play in a multitude of behaviors, it is unsur

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 480 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 59% × 0.7 domain gate = 41%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "allele".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,711,978 in active NIH money across 5 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,711,978
Active projects
5
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,711,978 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DA066149-01 Ventral tegmental area neuromedin s expression and signaling in opioid responses

    R01 · NIDA · $495,345 · Jun 1, 2026 to Mar 31, 2031

  • 5R01MH111604-10 Projection-specific gene expression in resilience to chronic stress

    R01 · NIMH · $595,642 · Sep 8, 2016 to Jun 30, 2027

All active NIH projects for Alfred J Robison ($2,711,978)
  • 5R01DA040621-10 Small molecule modulators of ΔFosB — $609,024, ends Mar 31, 2027
  • 5R01MH111604-10 Projection-specific gene expression in resilience to chronic stress — $595,642, ends Jun 30, 2027
  • 5R01AI168014-05 Transcriptional mechanisms in mast cells underlying immune function and disease — $580,217, ends Jul 31, 2027
  • 1R01DA066149-01 Ventral tegmental area neuromedin s expression and signaling in opioid responses — $495,345, ends Mar 31, 2031
  • 1R21NS142826-01 Whole brain, PET-based molecular neuroimaging of fos expression – a new tool for imaging neurocircuitry involved in complex behavior — $431,750, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#20 Lab fit 41% · Adjacent Hiring: Moderate Atlanta Neuroscience

Thomas L Kukar lab

Thomas L Kukar · Emory University, Atlanta GA

The long-term goal of this project is to understand how loss of progranulin (PGRN) causes neurodegeneration in frontotemporal degeneration (FTD) and neuronal ceroid lipofuscinosis (NCL), commonly called Batten’s disease. FTD and NCL are fatal and currently incurable. FTD and NCL have distinct clinical manifestations but share a causative genetic factor, the GRN gene, which encodes PGRN. PGRN is an 80 kDa secreted glycoprotein composed of 7.5 tandem proteins called granulins. Heterozygous GRN mutations decrease PGRN levels and are a common cause of FTD, the most frequent dementia before the age

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 463 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% × 0.82 domain gate = 41%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,990,519 in active NIH money across 2 projects, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,990,519
Active projects
2
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,990,519 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-03-12.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146190-01 Determining the therapeutic potential and mechanism of granulins to treat Batten disease and frontotemporal dementia

    R01 · NINDS · $616,690 · Mar 12, 2026 to Feb 28, 2031

  • 4RF1AG079318-02 Resolving the function of progranulin in lysosomal lipid metabolism and the etiology of Alzheimer's disease and frontotemporal dementia

    RF1 · NIA · $1,373,829 · Sep 1, 2022 to Aug 31, 2027

All active NIH projects for Thomas L Kukar ($1,990,519)
  • 4RF1AG079318-02 Resolving the function of progranulin in lysosomal lipid metabolism and the etiology of Alzheimer's disease and frontotemporal dementia — $1,373,829, ends Aug 31, 2027
  • 1R01NS146190-01 Determining the therapeutic potential and mechanism of granulins to treat Batten disease and frontotemporal dementia — $616,690, ends Feb 28, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 12, 2026 · project period to Feb 28, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#21 Lab fit 41% · Adjacent Hiring: Moderate Atlanta Neuroscience

Allan I Levey lab

Allan I Levey · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT While it is widely acknowledged that Alzheimer’s disease and related dementias (AD/ADRD) have an extended preclinical phase, there are sparse data on the cognitive and pathobiological changes in middle-ages, a critical window for preventative intervention in people likely to progress to full-blown clinical disease. South Asians, a population with heightened risk of AD/ADRD and vascular/metabolic risks at younger ages, offer a unique opportunity to investigate preclinical AD/ADRD and related modifiable risk factors of its progression. Predictive models leveraging multim

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 650 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.92 domain gate = 41%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $16,882,208 in active NIH money across 4 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$16,882,208
Active projects
4
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $16,882,208 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5P30AG066511-07, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01AG089759-03S3 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India

    R01 · NIA · $106,846 · Sep 15, 2024 to Aug 31, 2029

  • 5U01NS128433-04 Novel Protein Biomarkers of Corticolimbic Pathophysiology in Lewy body Dementia

    U01 · NINDS · $1,794,006 · Sep 15, 2022 to Jun 30, 2028

All active NIH projects for Allan I Levey ($16,882,208)
  • 5U54AG065187-08 TREAT AD — $8,264,544, ends Aug 31, 2029
  • 5P30AG066511-07 Goizueta Alzheimer's Disease Research Center — $4,428,495, ends Apr 30, 2030
  • 5R01AG089759-03 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India — $2,395,163, ends Aug 31, 2029
  • 5U01NS128433-04 Novel Protein Biomarkers of Corticolimbic Pathophysiology in Lewy body Dementia — $1,794,006, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#22 Lab fit 41% · Adjacent Hiring: Moderate Atlanta Neuroscience

Yoland Smith lab

Yoland Smith · Emory University, Atlanta GA

SUMMARY The basal ganglia serve many behavioral functions, ranging from the regulation of movements and cognition to the modulation of valence and mood. This functional heterogeneity is reflected in the composition of the principal output nucleus of the primate basal ganglia, the internal pallidal segment (GPi). This nucleus contains two distinct populations of projection neurons. A major group of cells in the core of GPi projects to the ventral thalamus (and other targets) and is known to be involved in motor functions. Much less explored is a second population of neurons that is confined to

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 237 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% × 0.82 domain gate = 41%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $841,767 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$841,767
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $841,767 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2T32NS096050-31, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS134941-03 The Pallidohabenular System in Parkinsonism

    R01 · NINDS · $495,195 · Jan 4, 2024 to Dec 31, 2028

All active NIH projects for Yoland Smith ($841,767)
  • 5R01NS134941-03 The Pallidohabenular System in Parkinsonism — $495,195, ends Dec 31, 2028
  • 2T32NS096050-31 Training In Systems And Integrative Biology Neuroscience — $346,572, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 4, 2024 · project period to Dec 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#23 Lab fit 41% · Adjacent Hiring: Moderate Atlanta Neuroscience

Thomas Wichmann lab

Thomas Wichmann · Emory University, Atlanta GA

SUMMARY The basal ganglia serve many behavioral functions, ranging from the regulation of movements and cognition to the modulation of valence and mood. This functional heterogeneity is reflected in the composition of the principal output nucleus of the primate basal ganglia, the internal pallidal segment (GPi). This nucleus contains two distinct populations of projection neurons. A major group of cells in the core of GPi projects to the ventral thalamus (and other targets) and is known to be involved in motor functions. Much less explored is a second population of neurons that is confined to

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 237 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% × 0.82 domain gate = 41%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,828,150 in active NIH money across 2 projects, 2.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,828,150
Active projects
2
Runway left
2.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,828,150 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-12-31 (about 2.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS134941-03 The Pallidohabenular System in Parkinsonism

    R01 · NINDS · $495,195 · Jan 4, 2024 to Dec 31, 2028

All active NIH projects for Thomas Wichmann ($2,828,150)
  • 5P50NS123103-05 Morris K. Udall Centers of Excellence for Parkinson's Disease Research at Emory University — $2,332,955, ends Jul 31, 2027
  • 5R01NS134941-03 The Pallidohabenular System in Parkinsonism — $495,195, ends Dec 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 4, 2024 · project period to Dec 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#24 Lab fit 41% · Adjacent Hiring: Possible Atlanta Neuroscience

Lih-shen Chin lab

Lih-shen Chin · Emory University, Atlanta GA

Project Summary / Abstract Lewy body dementia (LBD), which includes Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB), is a major form of Alzheimer disease (AD)-related dementia, accounting for up to 30% of all dementia cases. Patients with LBD suffer from cognitive impairment, neuropsychiatric symptoms, and a fraction of LBD patients have Parkinsonian motor symptoms. Clinical differentiation of DLB from PDD is based on an arbitrarily defined “one-year rule”, and whether DLB and PDD are the same or different clinical syndromes remains unclear. Our current knowledge of the mo

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 262 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% × 0.82 domain gate = 41%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $711,297 in active NIH money across 1 project, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$711,297
Active projects
1
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $711,297 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG065282-03 Molecular and Network Analyses of Lewy Body Dementia Pathogenesis

    R01 · NIA · $711,297 · Sep 5, 2021 to Aug 31, 2027

All active NIH projects for Lih-shen Chin ($711,297)
  • 5R01AG065282-03 Molecular and Network Analyses of Lewy Body Dementia Pathogenesis — $711,297, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 5, 2021 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#25 Lab fit 41% · Adjacent Hiring: Possible Michigan Neuroscience

Jun Hee Kim lab

Jun Hee Kim · University of Michigan, Ann Arbor MI

ABSTRACT Auditory processing abnormalities are common and prominent features of neurodevelopmental disorders such as autism spectrum disorder (ASD). A central challenge of autism research is to identify common mechanisms that underlie sensory processing abnormalities including auditory dysfunction. One prevalent hypothesis is that the behavioral phenotypes in ASD arise from altered functional connectivity in the brain. Neuroimaging studies and the transcriptional profile in human ASD indicate that altered myelination and white matter integrity could be a common pathophysiology that impairs fun

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 476 words of lab text were scored, matching 7 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 83% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 58% × 0.7 domain gate = 41%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,002,866 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,002,866
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,002,866 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 83%

    Matched 4 of 7 profile areas (25 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DC019371-06 Role of SCN2A in Myelination and Neural Circuit Development in Autism Spectrum Disorder

    R01 · NIDCD · $491,576 · Sep 1, 2021 to Aug 31, 2027

  • 5R01DC018797-05 Role of Adaptive Myelination in Auditory Brain Plasticity

    R01 · NIDCD · $511,290 · Apr 1, 2021 to Jul 31, 2027

All active NIH projects for Jun Hee Kim ($1,002,866)
  • 5R01DC018797-05 Role of Adaptive Myelination in Auditory Brain Plasticity — $511,290, ends Jul 31, 2027
  • 5R01DC019371-06 Role of SCN2A in Myelination and Neural Circuit Development in Autism Spectrum Disorder — $491,576, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#26 Lab fit 41% · Adjacent Hiring: Moderate Michigan Neuroscience

Peter K Todd lab

Peter K Todd · University of Michigan, Ann Arbor MI

Hexanucleotide repeat translation in ALS and Frontotemporal Dementia The most common genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD) is an intronic GGGGCC (G4C2) hexanucleotide repeat expansion in the gene C9orf72 (C9FTD/ALS). Despite its position within an intron, the C9orf72 repeat triggers synthesis of dipeptide repeat proteins (DPRs) via a process known as Repeat Associated Non-AUG (RAN) Translation. Studies by our group and others over the past decade have defined key mechanistic parameters that regulate RAN translational initiation and identified se

Lab fit breakdown — 41% weighted · Adjacent

Scored on enough lab text to read as a verdict. 206 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 50% × 0.82 domain gate = 41%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "ubiquitin".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,308,906 in active NIH money across 3 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,308,906
Active projects
3
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,308,906 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years) — 5P50HD118707-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “ubiquitin”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS099280-09 Hexanucleotide repeat translation in ALS and Frontotemporal Dementia

    R01 · NINDS · $640,460 · Sep 1, 2016 to Mar 31, 2028

All active NIH projects for Peter K Todd ($3,308,906)
  • 5P50HD118707-02 Fragile X Premutations, Mechanisms and Modifiers — $1,575,127, ends Aug 31, 2030
  • 5U01NS143225-02 Clinical Outcome Assessment and Treatment Monitoring Markers for Clinical Trial Readiness in FXTAS — $1,093,319, ends Jun 30, 2030
  • 5R01NS099280-09 Hexanucleotide repeat translation in ALS and Frontotemporal Dementia — $640,460, ends Mar 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2016 · project period to Mar 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#27 Lab fit 40% · Adjacent Hiring: Moderate Atlanta Neuroscience

Erik C.b. Johnson lab

Erik C.b. Johnson · Emory University, Atlanta GA

PROJECT SUMMARY Alzheimer’s disease (AD) is commonly considered a disease exclusive to the elderly. While aging is the largest risk factor for the development of AD, approximately 5 to 10 percent of AD develops in people younger than age 65. In most early-onset AD cases there is no clearly identifiable genetic mutation that causes the disease, and therefore such cases have been termed sporadic early-onset AD (sEOAD). Compared to late-onset AD (LOAD) or autosomal dominant forms of AD (ADAD), little is known about the pathophysiology of sEOAD. In contrast to LOAD and ADAD, sEOAD more often prese

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 284 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,984,943 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,984,943
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,984,943 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG089497-02 A Proteomic Comparison of Sporadic Early-Onset, Late-Onset, and Autosomal Dominant Alzheimer's Disease

    R01 · NIA · $2,984,943 · Sep 30, 2024 to Jul 31, 2030

All active NIH projects for Erik C.b. Johnson ($2,984,943)
  • 5R01AG089497-02 A Proteomic Comparison of Sporadic Early-Onset, Late-Onset, and Autosomal Dominant Alzheimer's Disease — $2,984,943, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2024 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#28 Lab fit 40% · Adjacent Hiring: Moderate Atlanta Neuroscience

James J Lah lab

James J Lah · Emory University, Atlanta GA

Alzheimer's Disease (AD) is increasingly becoming an immense economic and social challenge. By 2050, it's projected that 13.8 million Americans will be living with AD, and the total annual expenditures for health, long- term care, and hospice services for those with AD and other dementias could surge to $1.2 trillion. Developing predictive artificial intelligent (AI) models to assist in the diagnosis and prognosis of the disease is critically important for patient management. However, current AI models for studying Alzheimer’s Disease often suffer from explainability challenges, and the effect

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 881 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 53% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".
  • In vivo ocular imaging and functional readouts Lab text mentions "in vivo imaging".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "stiffness")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $8,944,663 in active NIH money across 4 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$8,944,663
Active projects
4
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $8,944,663 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5P30AG066511-07, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 53%

    Matched 3 of 7 profile areas (16 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG089806-03 Explainable and Ethical AI for Studying Alzheimer's Disease

    R01 · NIA · $679,906 · Aug 1, 2024 to Apr 30, 2029

  • 5R01AG083084-03 Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients

    R01 · NIA · $755,607 · Sep 1, 2023 to May 31, 2029

  • 5R01AG070937-05 The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease

    R01 · NIA · $6,871,445 · Feb 15, 2021 to Jan 31, 2027

All active NIH projects for James J Lah ($8,944,663)
  • 5R01AG070937-05 The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease — $6,871,445, ends Jan 31, 2027
  • 5R01AG083084-03 Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients — $755,607, ends May 31, 2029
  • 5R01AG089806-03 Explainable and Ethical AI for Studying Alzheimer's Disease — $679,906, ends Apr 30, 2029
  • 5P30AG066511-07 Clinical Core — $637,705, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#29 Lab fit 40% · Adjacent Hiring: Possible Michigan Neuroscience

Ana Marie Daugherty lab

Ana Marie Daugherty · Wayne State University, Detroit MI

The hippocampus and the parahippocampal region of the medial temporal lobe (MTL) consist of anatomically and functionally distinct subregions that are selectively targeted by different pathological processes in neurodegenerative disorders, such as Alzheimer's disease (AD) and semantic variant Primary Progressive Aphasia (svPPA). In AD, in vivo MRI studies investigating MTL subregions have often shown mixed findings that are inconsistent with post-mortem pathology studies. These inconsistencies likely result from the lack of validity and standardization in MTL segmentation approaches. In svPPA,

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 244 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Human donor tissue, primary and explant culture Lab text mentions "post-mortem".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $583,863 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$583,863
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $583,863 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2P30AG072931-06, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “post-mortem”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG070592-05S2 A harmonized medial temporal lobe subregion segmentation protocol: an essential element for dementia research

    R01 · NIA · $112,180 · Mar 1, 2022 to Feb 28, 2027

All active NIH projects for Ana Marie Daugherty ($583,863)
  • 7R01AG070592-05 A harmonized medial temporal lobe subregion segmentation protocol: an essential element for dementia research — $428,043, ends Feb 28, 2027
  • 2P30AG072931-06 Research Education Component — $155,820, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2022 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#30 Lab fit 40% · Adjacent Hiring: Unlikely Michigan Neuroscience

Laura Elske Maria Wisse lab

Laura Elske Maria Wisse · Wayne State University, Detroit MI

The hippocampus and the parahippocampal region of the medial temporal lobe (MTL) consist of anatomically and functionally distinct subregions that are selectively targeted by different pathological processes in neurodegenerative disorders, such as Alzheimer's disease (AD) and semantic variant Primary Progressive Aphasia (svPPA). In AD, in vivo MRI studies investigating MTL subregions have often shown mixed findings that are inconsistent with post-mortem pathology studies. These inconsistencies likely result from the lack of validity and standardization in MTL segmentation approaches. In svPPA,

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 244 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Human donor tissue, primary and explant culture Lab text mentions "post-mortem".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $428,043 in active NIH money across 1 project, 0.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$428,043
Active projects
1
Runway left
0.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $428,043 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-02-28.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “post-mortem”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG070592-05S2 A harmonized medial temporal lobe subregion segmentation protocol: an essential element for dementia research

    R01 · NIA · $112,180 · Mar 1, 2022 to Feb 28, 2027

All active NIH projects for Laura Elske Maria Wisse ($428,043)
  • 7R01AG070592-05 A harmonized medial temporal lobe subregion segmentation protocol: an essential element for dementia research — $428,043, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2022 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#31 Lab fit 40% · Adjacent Hiring: Possible Michigan Neuro + ophtho

Tomomi Ichinose lab

Tomomi Ichinose · Wayne State University, Detroit MI

Abstract Retinal neurons utilize multiple antagonistic mechanisms to shape visual signal processing, such as ON and OFF signaling, antagonistic center-surround, rod- and cone-signaling, and transient and sustained signaling. Among those signaling mechanisms, ON vs. OFF signaling is coded to morphologically distinct groups of retinal neurons, bipolar, amacrine, and ganglion cells. Retinal neurons that ramify in the inner region of the inner plexiform layer (IPL) respond to the onset of a light stimulus, called ON cells. In contrast, OFF cells ramify in the outer region of the IPL and respond to

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 354 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 57% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.92 domain gate = 40%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retinal ganglion cells and the optic nerve Lab text mentions "ganglion cell".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $846,599 in active NIH money across 2 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$846,599
Active projects
2
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $846,599 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 57%

    Matched 2 of 6 profile areas (16 of 28 weight to saturation).

    • Retinal ganglion cells and the optic nerve — lab text says “ganglion cell”Her side: First-author Cell Death & Disease 2026 and Autophagy Reports 2026 on RGC homeostasis; co-author on axonal transport in myocilin glaucoma (JCI Insight 2025).
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY032917-05 ON and OFF visual signaling in the retinal interneurons

    R01 · NEI · $369,337 · Aug 1, 2021 to Apr 30, 2027

  • 5R01EY028915-08 Mechanisms of Motion Detection in Retinal Neural Network

    R01 · NEI · $477,262 · Sep 30, 2018 to Jun 30, 2028

All active NIH projects for Tomomi Ichinose ($846,599)
  • 5R01EY028915-08 Mechanisms of Motion Detection in Retinal Neural Network — $477,262, ends Jun 30, 2028
  • 5R01EY032917-05 ON and OFF visual signaling in the retinal interneurons — $369,337, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2021 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#32 Lab fit 40% · Adjacent Hiring: Moderate Michigan Neuroscience

Sidhartha Tan lab

Sidhartha Tan · Wayne State University, Detroit MI

PROJECT SUMMARY/ABSTRACT Children with movement disorders are a big burden to society. The burden of disease is very high because of the life-long consequences to the patient, caretakers, and social institutions. Currently there are no cures or preventative treatments for cerebral palsy (CP), as the mechanisms of disease remain poorly defined. Human mutations in key enzymatic pathways constitute genetic causes of childhood movement disorders. With the advent of transgenic rabbit models, a golden opportunity has arisen to study the pathogenetic mechanisms in brain leading to movement disorders,

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 333 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Non-rodent animal models Lab text mentions "rabbit".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,786,102 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,786,102
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,786,102 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years) — 1R01NS146896-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Non-rodent animal models — lab text says “rabbit”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS117146-05 Probing Role of Tetrahydrobiopterin in Cerebral Palsy by Using Transgenic Rabbits

    R01 · NINDS · $564,648 · Dec 15, 2020 to Nov 30, 2026

All active NIH projects for Sidhartha Tan ($1,786,102)
  • 1R01NS146896-01A1 Aldo-keto reductase’s mechanism in brain injury from hypoxia-ischemia and tetrahydrobiopterin deficiency — $625,792, ends Jul 31, 2031
  • 5R01NS130258-04 Ferroptosis in knock-in sepiapterin reductase mutation rabbits — $595,662, ends Jul 31, 2028
  • 5R01NS117146-05 Probing Role of Tetrahydrobiopterin in Cerebral Palsy by Using Transgenic Rabbits — $564,648, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 15, 2020 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#33 Lab fit 40% · Adjacent Hiring: Moderate Michigan Neuroscience

Jie Xu lab

Jie Xu · University of Michigan, Detroit MI

PROJECT SUMMARY/ABSTRACT Children with movement disorders are a big burden to society. The burden of disease is very high because of the life-long consequences to the patient, caretakers, and social institutions. Currently there are no cures or preventative treatments for cerebral palsy (CP), as the mechanisms of disease remain poorly defined. Human mutations in key enzymatic pathways constitute genetic causes of childhood movement disorders. With the advent of transgenic rabbit models, a golden opportunity has arisen to study the pathogenetic mechanisms in brain leading to movement disorders,

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 333 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Non-rodent animal models Lab text mentions "rabbit".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,777,690 in active NIH money across 3 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,777,690
Active projects
3
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,777,690 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-07-31 (about 1.8 years) — 5R01NS130258-04, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Non-rodent animal models — lab text says “rabbit”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS117146-05 Probing Role of Tetrahydrobiopterin in Cerebral Palsy by Using Transgenic Rabbits

    R01 · NINDS · $564,648 · Dec 15, 2020 to Nov 30, 2026

All active NIH projects for Jie Xu ($1,777,690)
  • 5R01DK134361-04 Targeting SGLTs for liver disease in a rabbit model of cystic fibrosis — $617,380, ends Apr 30, 2027
  • 5R01NS130258-04 Ferroptosis in knock-in sepiapterin reductase mutation rabbits — $595,662, ends Jul 31, 2028
  • 5R01NS117146-05 Probing Role of Tetrahydrobiopterin in Cerebral Palsy by Using Transgenic Rabbits — $564,648, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 15, 2020 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#34 Lab fit 40% · Adjacent Hiring: Moderate Atlanta Neuroscience

Stanislav Y Emelianov lab

Stanislav Y Emelianov · Georgia Institute of Technology, Atlanta GA

ABSTRACT Spinal cord diseases and disorders such as spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS) are debilitating, often resulting in loss of mobility and decreased quality of life for those affected. One promising treatment involves the transplantation of neural progenitor cells (NPC) into the spinal cord, which has been shown to have neuroprotective properties. However, most NPC-based therapies fail after reaching clinical trials, and without a method to monitor the injected cells and viability, locating injected NPCs is limited to postmortem histology. The ability to tra

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 287 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Human donor tissue, primary and explant culture Lab text mentions "postmortem".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • In vivo ocular imaging and functional readouts Lab text mentions "in vivo imaging".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,497,877 in active NIH money across 4 projects, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,497,877
Active projects
4
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,497,877 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years) — 1R01HL187527-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “postmortem”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS117613-05 Trimodal Vitality Imaging of Neural Progenitor Cells in the Spinal Cord

    R01 · NINDS · $618,303 · Aug 1, 2020 to Apr 30, 2027

All active NIH projects for Stanislav Y Emelianov ($2,497,877)
  • 1R01HL187527-01 Hydrogel delivery of stem cells to dystrophic diaphragm — $736,461, ends May 31, 2030
  • 5R01EB032822-04 Image-guided cancer therapy using heat activatable CAR T cells — $636,385, ends Jun 30, 2027
  • 5R01NS117613-05 Trimodal Vitality Imaging of Neural Progenitor Cells in the Spinal Cord — $618,303, ends Apr 30, 2027
  • 5R01AR082523-03 Damage Modeling and Vascular Imaging Correlation with Implant Induced Skin Necrosis — $506,728, ends Jan 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2020 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#35 Lab fit 40% · Adjacent Hiring: Possible Atlanta Neuroscience

Stephen F Traynelis lab

Stephen F Traynelis · Emory University, Atlanta GA

This R35 Research Program proposal will use electrophysiological, molecular, and structural approaches to probe multiple aspects of excitatory synaptic function that are relevant for neurological disease. We will focus on the elucidation and modulation of the functional properties of postsynaptic glutamate receptors. We will take advantage of coincident advances in cryoEM, genetics, robotics, and receptor biology to address questions that were previously inaccessible. Four approaches will address critical gaps in our understanding of synaptic function and provide therapeutically-relevant insig

Lab fit breakdown — 40% weighted · Adjacent

Scored on enough lab text to read as a verdict. 217 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 53% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 49% × 0.82 domain gate = 40%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".
  • Calcium and mechanosensitive channel signalling Lab text mentions "ion channel".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $992,303 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$992,303
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $992,303 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 53%

    Matched 3 of 7 profile areas (16 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R35NS111619-08 Glutamate receptors and human neurological disease

    R35 · NINDS · $992,303 · May 1, 2019 to Apr 30, 2027

All active NIH projects for Stephen F Traynelis ($992,303)
  • 5R35NS111619-08 Glutamate receptors and human neurological disease — $992,303, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2019 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#36 Lab fit 39% · Adjacent Hiring: Moderate Michigan Neuroscience

Joanna H Mattis lab

Joanna H Mattis · University of Michigan, Ann Arbor MI

ABSTRACT Epilepsy is characterized by recurrent seizures, but its associated comorbidities – including attention deficits, mood disorders, cognitive impairment, and sleep disorders – are prevalent and often highly detrimental to quality of life. Current treatments do not specifically prevent or reverse these epilepsy-associated comorbidities, and progress in developing targeted therapies has been hampered by an incomplete mechanistic understanding of how seizures remodel relevant networks. Cholinergic neurons, located in discrete nuclei within the brainstem and basal forebrain, play critical r

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 456 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.82 domain gate = 39%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $951,358 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$951,358
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $951,358 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS143722-02 Seizure-Induced Remodeling of Cholinergic Networks in Dravet Syndrome

    R01 · NINDS · $415,813 · Aug 7, 2025 to Jul 31, 2030

  • 5R01NS137222-03 Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome

    R01 · NINDS · $535,545 · Jul 1, 2024 to May 31, 2029

All active NIH projects for Joanna H Mattis ($951,358)
  • 5R01NS137222-03 Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome — $535,545, ends May 31, 2029
  • 5R01NS143722-02 Seizure-Induced Remodeling of Cholinergic Networks in Dravet Syndrome — $415,813, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 7, 2025 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#37 Lab fit 39% · Adjacent Hiring: Possible Michigan Neuroscience

Ryan Insolera lab

Ryan Insolera · Wayne State University, Detroit MI

Project Summary/Abstract The long-term goal of our research program is to explore how mitophagy promotes tissue health. Mitochondria generate cellular energy, and a natural byproduct of executing this essential function is susceptibility to damage. A wide assortment of human diseases, including metabolic and neurodegenerative diseases, shares the pathological feature of improper accumulation of damaged mitochondria. Mitophagy, a type of mitochondrial quality control (MQC), degrades damaged mitochondria to prevent their inappropriate accumulation; and therefore, represents a critical mechanism

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 163 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.82 domain gate = 39%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitophag".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $373,129 in active NIH money across 1 project, 3.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$373,129
Active projects
1
Runway left
3.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $373,129 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-11-30 (about 3.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM156765-02 Mechanisms of mitophagy in tissue health and homeostasis

    R35 · NIGMS · $373,129 · Dec 15, 2024 to Nov 30, 2029

All active NIH projects for Ryan Insolera ($373,129)
  • 5R35GM156765-02 Mechanisms of mitophagy in tissue health and homeostasis — $373,129, ends Nov 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 15, 2024 · project period to Nov 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#38 Lab fit 39% · Adjacent Hiring: Possible Atlanta Neuroscience

Zachary Thomas Mceachin lab

Zachary Thomas Mceachin · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Expanded GGGGCC (G4C2) hexanucleotide repeats in the C9orf72 gene were recently identified as the most common genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two neurodegenerative disorders with genetic and pathological overlap. Despite being located in a non-coding region of the gene, expanded G4C2 repeats can promote translation in both the sense and antisense direction to produce five different aggregating dipeptide repeat proteins (DPRs) which are thought to play a key role in c9ALS/FTD pathogenesis. Translation across the ex

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 225 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.82 domain gate = 39%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $620,736 in active NIH money across 1 project, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$620,736
Active projects
1
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $620,736 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS137434-03 Mechanisms of chimeric DPR production and toxicity in c9ALS/FTD

    R01 · NINDS · $620,736 · Jul 1, 2024 to Apr 30, 2029

All active NIH projects for Zachary Thomas Mceachin ($620,736)
  • 5R01NS137434-03 Mechanisms of chimeric DPR production and toxicity in c9ALS/FTD — $620,736, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#39 Lab fit 39% · Adjacent Hiring: Possible Michigan Neuroscience

Bing Ye lab

Bing Ye · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Down syndrome (DS), which is caused by full or partial trisomy of human chromosome 21 (Hsa21), presents various neurological features, including intellectual disability, epilepsy, and Alzheimer’s disease (AD). Although some Hsa21 genes have been identified as key contributors to some of these diseases, the pathogenetic mechanisms that link the triplication of HSA21 genes to most DS-related diseases remain unknown. Particularly, very little is known about whether any of these diseases share common mechanisms. For example, we do not know whether the increased risk for epilepsy an

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 423 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.82 domain gate = 39%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $930,005 in active NIH money across 2 projects, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$930,005
Active projects
2
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $930,005 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS137222-03 Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome

    R01 · NINDS · $535,545 · Jul 1, 2024 to May 31, 2029

  • 5R01NS128500-04 The assembly of population coding networks

    R01 · NINDS · $394,460 · Apr 1, 2023 to Feb 29, 2028

All active NIH projects for Bing Ye ($930,005)
  • 5R01NS137222-03 Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome — $535,545, ends May 31, 2029
  • 5R01NS128500-04 The assembly of population coding networks — $394,460, ends Feb 29, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#40 Lab fit 39% · Adjacent Hiring: Possible Michigan Ophthalmology

Sherry Day lab

Sherry Day · University of Michigan, Ann Arbor MI

Abstract The distinct phenotypes making up inherited retinal degenerations (IRDs) affect all forms of functional vision, and therefore, provide an illustrative disease model for low vision and blindness. Usual care for individuals with IRDs consists of low vision rehabilitation (LVR). Patients experience variable effectiveness with LVR that is often accompanied by elevations in depression and anxiety, which can complicate the delivery, impact, and efficacy of LVR. There remains a critical need to develop an individualized treatment approach for patients with IRDs addressing vision related anxi

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 291 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 43% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 42% × 0.92 domain gate = 39%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual acuity".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $700,286 in active NIH money across 1 project, 2.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$700,286
Active projects
1
Runway left
2.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $700,286 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-02-28 (about 2.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 43%

    Matched 2 of 6 profile areas (12 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: Mouse / rodent in vivo models; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035016-03 Determining optimal vision care for emotionally distressed patients with inherited retinal diseases

    R01 · NEI · $700,286 · Mar 1, 2024 to Feb 28, 2029

All active NIH projects for Sherry Day ($700,286)
  • 5R01EY035016-03 Determining optimal vision care for emotionally distressed patients with inherited retinal diseases — $700,286, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2024 · project period to Feb 28, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#41 Lab fit 39% · Adjacent Hiring: Possible Michigan Ophthalmology

Kanishka Thiran Jayasundera lab

Kanishka Thiran Jayasundera · University of Michigan, Ann Arbor MI

Abstract The distinct phenotypes making up inherited retinal degenerations (IRDs) affect all forms of functional vision, and therefore, provide an illustrative disease model for low vision and blindness. Usual care for individuals with IRDs consists of low vision rehabilitation (LVR). Patients experience variable effectiveness with LVR that is often accompanied by elevations in depression and anxiety, which can complicate the delivery, impact, and efficacy of LVR. There remains a critical need to develop an individualized treatment approach for patients with IRDs addressing vision related anxi

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 291 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 43% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 42% × 0.92 domain gate = 39%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Inherited retinal disease and ocular gene therapy Lab text mentions "inherited retinal".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual acuity".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $700,286 in active NIH money across 1 project, 2.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$700,286
Active projects
1
Runway left
2.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $700,286 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-02-28 (about 2.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 43%

    Matched 2 of 6 profile areas (12 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.
    • Inherited retinal disease and ocular gene therapy — lab text says “inherited retinal”Her side: 19-month Hadassah fellowship on molecular genetics of inherited retinal diseases; first-author KIZ variant paper (Genes 2024) and Progress in Retinal and Eye Research review.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: Mouse / rodent in vivo models; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035016-03 Determining optimal vision care for emotionally distressed patients with inherited retinal diseases

    R01 · NEI · $700,286 · Mar 1, 2024 to Feb 28, 2029

All active NIH projects for Kanishka Thiran Jayasundera ($700,286)
  • 5R01EY035016-03 Determining optimal vision care for emotionally distressed patients with inherited retinal diseases — $700,286, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2024 · project period to Feb 28, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#42 Lab fit 39% · Adjacent Hiring: Possible Michigan Autophagy / organelle QC

Daniel J. Klionsky lab

Daniel J. Klionsky · University of Michigan, Ann Arbor MI

Autophagy represents a complex pathway of cellular homeostasis that functions in cytoprotection, but if dysregulated can cause cell death; a complete knowledge of regulation is critical for the potential modulation of this process for therapeutic purposes, and to increase our basic understanding of membrane dynamics and organelle biogenesis. Autophagy occurs in all eukaryotes, and the protein components of the autophagic machinery are conserved from yeast to mammals. The hallmark of this process is the formation of double- membrane cytosolic vesicles, autophagosomes, that contain cytoplasmic c

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 171 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 73% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 47% × 0.82 domain gate = 39%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $774,289 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$774,289
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $774,289 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 73%

    Matched 3 of 7 profile areas (22 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM131919-08 The mechanism and regulation of autophagy

    R35 · NIGMS · $774,289 · Jun 1, 2019 to May 31, 2029

All active NIH projects for Daniel J. Klionsky ($774,289)
  • 5R35GM131919-08 The mechanism and regulation of autophagy — $774,289, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2019 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#43 Lab fit 39% · Adjacent Hiring: Possible Michigan Neuroscience

Matthew Richard Chapman lab

Matthew Richard Chapman · University of Michigan, Ann Arbor MI

Escherichia coli (E.coli) and other enteric bacteria are a major cause of human diseases. Biofilm formation contributes greatly to bacterial persistence and antimicrobial resistance in the host. A striking aspect of biofilms is the “division of labor” that drives unique subpopulation development. Many Enterobacteriaceae, such as E. coli, produce functional amyloid fibers called curli as a major proteinaceous component of their biofilm extracellular matrix. It is now clear that functional amyloids are widespread, with examples found throughout cellular life. The curli system in E. coli provides

Lab fit breakdown — 39% weighted · Adjacent

Scored on enough lab text to read as a verdict. 272 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 47% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 47% × 0.82 domain gate = 39%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $311,175 in active NIH money across 1 project, 2.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$311,175
Active projects
1
Runway left
2.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $311,175 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-03-31 (about 2.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 47%

    Matched 2 of 7 profile areas (14 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01GM118651-10 Controlling Bacterial Amyloid Formation and the Influence of Curli Subunits on Pathogenic Alpha-synuclein Aggregation

    R01 · NIGMS · $311,175 · Apr 1, 2016 to Mar 31, 2029

All active NIH projects for Matthew Richard Chapman ($311,175)
  • 5R01GM118651-10 Controlling Bacterial Amyloid Formation and the Influence of Curli Subunits on Pathogenic Alpha-synuclein Aggregation — $311,175, ends Mar 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2016 · project period to Mar 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#44 Lab fit 38% · Adjacent Hiring: Moderate Michigan Autophagy / organelle QC

Phyllis I Hanson lab

Phyllis I Hanson · University of Michigan, Ann Arbor MI

SUMMARY Lysosomes are central players in cellular catabolism that play a pivotal role in regulating metabolism and signaling. Cellular and environmental stressors that damage the lysosomal membrane compromise organelle function and release toxic content into the cytoplasm that ultimately drives cell death. Building on our discovery that the ESCRT machinery is rapidly deployed to repair lysosomal membrane damage, there has been much interest in defining how cells sense acute changes in membrane structure and organization to coordinate among a growing array of restorative responses. Our goals ov

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 146 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "lysosom".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $425,916 in active NIH money across 1 project, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$425,916
Active projects
1
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $425,916 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “lysosom”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R35GM163790-01 Mechanisms of Lysosomal Resilience, Repair and Removal

    R35 · NIGMS · $425,916 · Jun 1, 2026 to Mar 31, 2031

All active NIH projects for Phyllis I Hanson ($425,916)
  • 1R35GM163790-01 Mechanisms of Lysosomal Resilience, Repair and Removal — $425,916, ends Mar 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#45 Lab fit 38% · Adjacent Hiring: Possible Michigan Neuroscience

Ye Xiong lab

Ye Xiong · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

Abstract Veterans and the general public with traumatic brain injury (TBI) have a high risk of developing posttraumatic stress disorder (PTSD) and other psychiatric disorders, such as anxiety and depression. The pathophysiological basis that contributes to comorbid PTSD and other psychiatric disorders following TBI is not yet understood, and there are currently few effective treatments for comorbid TBI/PTSD. Serotonergic dysfunction and neuroinflammation are strongly associated with TBI and psychiatric disorders. Gut microbiota dysfunction induces inflammation and affects tryptophan metabolism

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 518 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $894,476 in active NIH money across 2 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$894,476
Active projects
2
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $894,476 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS133347-03 Investigating the role of gut-derived extracellular vesicles in PTSD following TBI

    R01 · NINDS · $463,308 · Sep 5, 2024 to Aug 31, 2029

  • 5R01NS132772-03 AcSDKP as a novel treatment for traumatic brain injury

    R01 · NINDS · $431,168 · May 1, 2024 to Feb 28, 2029

All active NIH projects for Ye Xiong ($894,476)
  • 5R01NS133347-03 Investigating the role of gut-derived extracellular vesicles in PTSD following TBI — $463,308, ends Aug 31, 2029
  • 5R01NS132772-03 AcSDKP as a novel treatment for traumatic brain injury — $431,168, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 5, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#46 Lab fit 38% · Adjacent Hiring: Possible Michigan Neuroscience

Joongkyu Park lab

Joongkyu Park · Wayne State University, Detroit MI

PROJECT SUMMARY/ABSTRACT Alzheimer's disease is a progressive, age-related, degenerative brain disease. The most notable symptom is a significant cognitive impairment accompanying a substantial loss of dendritic spines and, eventually, neurons themselves. Since these end-stages are mostly irreversible, it is critical to identify appropriate molecular targets for intervention before the synaptic dysfunction and neuronal loss become permanent. Brains with Alzheimer's disease display the presence of increased protein accumulations, such as intracellular tau inclusions (neurofibrillary tangles) an

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 245 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $372,838 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$372,838
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $372,838 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG089566-03 Local protein synthesis in tau pathology neurodegeneration

    R01 · NIA · $372,838 · Sep 1, 2024 to Jun 30, 2029

All active NIH projects for Joongkyu Park ($372,838)
  • 5R01AG089566-03 Local protein synthesis in tau pathology neurodegeneration — $372,838, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#47 Lab fit 38% · Adjacent Hiring: Moderate Atlanta Neuroscience

Shina Caroline Lynn Kamerlin lab

Shina Caroline Lynn Kamerlin · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY In Alzheimer's disease (AD) research, much focus has been on oligomeric assemblies of the amyloid-β (Aβ) peptide (a small protein). Oligomers are small nanoparticles produced by the aggregation of 50 or fewer peptide molecules. Peptide aggregation most readily produces amyloid fibrils, and it is a mystery what prevents some oligomers from aggregating further into fibrils. Even within oligomeric and fibrillar aggregate classes, peptide aggregates with a range of structures have been detected. Nevertheless, structural biology methods require stable and structurally homogeneous sa

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 251 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $916,610 in active NIH money across 2 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$916,610
Active projects
2
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $916,610 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years) — 1R35GM161177-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG073434-03 Characterizing Alzheimer's Amyloid-beta Oligomer Structures by Solid-State NMR and Cryo-Electron Microscopy

    R01 · NIA · $483,760 · May 1, 2022 to Apr 30, 2027

All active NIH projects for Shina Caroline Lynn Kamerlin ($916,610)
  • 5R01AG073434-03 Characterizing Alzheimer's Amyloid-beta Oligomer Structures by Solid-State NMR and Cryo-Electron Microscopy — $483,760, ends Apr 30, 2027
  • 1R35GM161177-01 Harnessing Biomolecular Simulations to Understand Protein Dynamics and Allostery — $432,850, ends Jan 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#48 Lab fit 38% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Anant Krishna Paravastu lab

Anant Krishna Paravastu · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY In Alzheimer's disease (AD) research, much focus has been on oligomeric assemblies of the amyloid-β (Aβ) peptide (a small protein). Oligomers are small nanoparticles produced by the aggregation of 50 or fewer peptide molecules. Peptide aggregation most readily produces amyloid fibrils, and it is a mystery what prevents some oligomers from aggregating further into fibrils. Even within oligomeric and fibrillar aggregate classes, peptide aggregates with a range of structures have been detected. Nevertheless, structural biology methods require stable and structurally homogeneous sa

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 251 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $483,760 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$483,760
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $483,760 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG073434-03 Characterizing Alzheimer's Amyloid-beta Oligomer Structures by Solid-State NMR and Cryo-Electron Microscopy

    R01 · NIA · $483,760 · May 1, 2022 to Apr 30, 2027

All active NIH projects for Anant Krishna Paravastu ($483,760)
  • 5R01AG073434-03 Characterizing Alzheimer's Amyloid-beta Oligomer Structures by Solid-State NMR and Cryo-Electron Microscopy — $483,760, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#49 Lab fit 38% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Terrone L Rosenberry lab

Terrone L Rosenberry · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY In Alzheimer's disease (AD) research, much focus has been on oligomeric assemblies of the amyloid-β (Aβ) peptide (a small protein). Oligomers are small nanoparticles produced by the aggregation of 50 or fewer peptide molecules. Peptide aggregation most readily produces amyloid fibrils, and it is a mystery what prevents some oligomers from aggregating further into fibrils. Even within oligomeric and fibrillar aggregate classes, peptide aggregates with a range of structures have been detected. Nevertheless, structural biology methods require stable and structurally homogeneous sa

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 251 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $483,760 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$483,760
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $483,760 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG073434-03 Characterizing Alzheimer's Amyloid-beta Oligomer Structures by Solid-State NMR and Cryo-Electron Microscopy

    R01 · NIA · $483,760 · May 1, 2022 to Apr 30, 2027

All active NIH projects for Terrone L Rosenberry ($483,760)
  • 5R01AG073434-03 Characterizing Alzheimer's Amyloid-beta Oligomer Structures by Solid-State NMR and Cryo-Electron Microscopy — $483,760, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#50 Lab fit 38% · Adjacent Hiring: Moderate Atlanta Neuroscience

Jonathan K. Stiles lab

Jonathan K. Stiles · Morehouse School of Medicine, Atlanta GA

Human cerebral malaria (HCM) is a severe form of Plasmodium falciparum (P.f.) malaria associated with ~500,000 deaths in children annually and impaired brain function in some survivors. HCM is characterized by sequestration of parasitized red blood cells (pRBCs) in cerebral micro-circulation and induction of inflammatory mediators, brain swelling and impaired consciousness with unarousable coma. We have determined that circulating free heme and parasite histidine rich protein 2 (HRP2), by-products of pRBC lysis, are major causes of brain inflammation, blood-brain barrier (BBB) dysfunction, and

Lab fit breakdown — 38% weighted · Adjacent

Scored on enough lab text to read as a verdict. 346 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.82 domain gate = 38%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,824,117 in active NIH money across 4 projects, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,824,117
Active projects
4
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,824,117 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years) — 5T32GM152760-03, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS125775-04 Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae

    R01 · NINDS · $555,227 · Jan 1, 2022 to Dec 31, 2027

All active NIH projects for Jonathan K. Stiles ($2,824,117)
  • 5D43TW009340-15 UJMT LAUNCH: Training the next generation of leaders in global health research — $1,082,700, ends Jun 30, 2027
  • 5T32GM152760-03 Educating and Training Tomorrow’s Biomedical Workforce — $1,008,690, ends Apr 30, 2029
  • 5R01NS125775-04 Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae — $555,227, ends Dec 31, 2027
  • 5R21AI185572-02 Role of ASIC1a activation in ECM associated brain injury and mortality — $177,500, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 1, 2022 · project period to Dec 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#51 Lab fit 37% · Adjacent Hiring: Strong Michigan Neuroscience

Stephen Goutman lab

Stephen Goutman · University of Michigan, Ann Arbor MI

ABSTRACT Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, non-curable neurodegenerative disease with a median survival of only 2-4 years from diagnosis. ALS is heterogenous and symptoms and signs can resemble more common illnesses, rendering it difficult to identify in routine clinical practice. As a result, ALS diagnoses are typically delayed over a year from the onset of clinical symptoms. Moreover, patients often lack information regarding their personal anticipated disease course. There is a critical need to improve ALS diagnosis, prognosis, and treatment. Whole blood transcrip

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 985 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.82 domain gate = 37%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $5,268,649 in active NIH money across 5 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$5,268,649
Active projects
5
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,268,649 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 2 awards in this snapshot started on or after 2025-09-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS148128-01 Transcriptomics of blood samples in ALS: An untapped resource to advance diagnosis, prognosis, and drug discovery and to gain insights into molecular subtypes of disease

    R01 · NINDS · $619,212 · Jul 6, 2026 to May 31, 2031

  • 1U01TS000351-01 Spectral flow cytometry identifies new immune signatures that provide personalized ALS risk and progression biomarkers and therapeutic targets

    U01 · ATSDR · $500,000 · Sep 30, 2025 to Sep 29, 2028

  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis

    R01 · NIEHS · $3,133,754 · Sep 10, 2025 to Sep 9, 2029

  • 6R01TS000344-03M001 RFA-TS-23-001: ?Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis

    R01 · ATSDR · $59,998 · Sep 30, 2023 to Sep 29, 2027

  • 5R01NS120926-05 Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures

    R01 · NINDS · $515,683 · May 15, 2021 to Feb 28, 2027

All active NIH projects for Stephen Goutman ($5,268,649)
  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis — $3,133,754, ends Sep 9, 2029
  • 1R01NS148128-01 Transcriptomics of blood samples in ALS: An untapped resource to advance diagnosis, prognosis, and drug discovery and to gain insights into molecular subtypes of disease — $619,212, ends May 31, 2031
  • 5R01NS120926-05 Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures — $515,683, ends Feb 28, 2027
  • 5R01TS000344-03 RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS) — $500,000, ends Sep 29, 2026
  • 1U01TS000351-01 Spectral flow cytometry identifies new immune signatures that provide personalized ALS risk and progression biomarkers and therapeutic targets — $500,000, ends Sep 29, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 6, 2026 · project period to May 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#52 Lab fit 37% · Adjacent Hiring: Possible Atlanta Neuroscience

Claire-anne N Gutekunst lab

Claire-anne N Gutekunst · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Epilepsy is one of the most prevalent neurological disorders. Patients with epilepsy experience abnormal brain activity causing seizures or periods of unusual behavior, sensations, and often loss of awareness or consciousness. Deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) is an approved therapy that effectively reduces seizures in many patients with drug resistant epilepsy, but very rarely leads to all-important complete freedom from disabling seizures. This gap in treatment effectiveness may stem from limited understanding of the mechanism u

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 471 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 77% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.7 domain gate = 37%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "adeno-associated".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $907,125 in active NIH money across 2 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$907,125
Active projects
2
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $907,125 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “adeno-associated”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 77%

    Matched 3 of 7 profile areas (23 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS129984-03 Deconstructing Antiseizure Mechanisms of Anterior Thalamic Nucleus Electrical Stimulation

    R01 · NINDS · $515,875 · Aug 20, 2024 to Jun 30, 2029

  • 3R01NS138733-02S1 Collaborative Research Fund: A CompreheNSive Study of Temporal Interference Mechanisms (CNS-STIM)

    R01 · NINDS · $39,125 · Aug 14, 2024 to Jul 31, 2027

All active NIH projects for Claire-anne N Gutekunst ($907,125)
  • 5R01NS129984-03 Deconstructing Antiseizure Mechanisms of Anterior Thalamic Nucleus Electrical Stimulation — $515,875, ends Jun 30, 2029
  • 5R01NS138733-03 Advancing non-invasive brain stimulation: A CompreheNSive Study of Temporal Interference Mechanisms (CNS-STIM) — $391,250, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 2024 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#53 Lab fit 37% · Adjacent Hiring: Moderate Michigan Neuroscience

Michael Mark Alexander Sutton lab

Michael Mark Alexander Sutton · University of Michigan, Ann Arbor MI

Abstract One of the long-held mysteries in chromatin signaling is the excessive number of enzymes that install or remove a single chromatin mark. The most extreme case is histone H3 lysine 4 (H3K4me) methylation, a hallmark of transcriptionally active chromatin areas. H3K4me can be placed by six writer enzymes and removed by six eraser enzymes, most of which are expressed broadly in all cell types of the brain and other tissues. Strikingly, 10 of these 12 enzymes are responsible for monogenic forms of neurodevelopmental disorders. These enzymes thus have non-redundant yet poorly understood rol

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 697 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.7 domain gate = 37%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "lentivir".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,097,258 in active NIH money across 4 projects, 2.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,097,258
Active projects
4
Runway left
2.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,097,258 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-01-31 (about 2.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “lentivir”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH133632-03 Dissecting Histone H3K4 Methylation Enzymes in Neuroplasticity

    R01 · NIMH · $659,441 · Jul 12, 2024 to Jan 31, 2029

  • 5R01NS129562-04 Dissecting Cell Type Specific Functions of CHD7 in Development of the Neocortex

    R01 · NINDS · $516,297 · Jul 1, 2023 to Jun 30, 2028

  • 5R01NS129198-05 Regulation of parallel recycling pathways at synaptic sites

    R01 · NINDS · $492,520 · Jul 15, 2022 to May 31, 2027

All active NIH projects for Michael Mark Alexander Sutton ($2,097,258)
  • 5R01MH133632-03 Dissecting Histone H3K4 Methylation Enzymes in Neuroplasticity — $659,441, ends Jan 31, 2029
  • 5R01NS129562-04 Dissecting Cell Type Specific Functions of CHD7 in Development of the Neocortex — $516,297, ends Jun 30, 2028
  • 5R01NS129198-05 Regulation of parallel recycling pathways at synaptic sites — $492,520, ends May 31, 2027
  • 1R21MH144311-01 Gene dosage, synaptic neotony, and neurodevelopmental disorders — $429,000, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 12, 2024 · project period to Jan 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#54 Lab fit 37% · Adjacent Hiring: Possible Michigan Neuroscience

Brett Andrew Mccray lab

Brett Andrew Mccray · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT TRPV4 (transient receptor potential vanilloid 4) is a calcium-permeable ion channel whose activation has been implicated in both hereditary and acquired neurological diseases. Gain-of-function mutations cause debilitating forms of hereditary motor neuron disease and neuropathy/neuronopathy for which no treatment exists. In addition, increased TRPV4 ion channel activity is implicated in multiple other neurological diseases. While the association of TRPV4 with disease and the availability of TRPV4 antagonist drugs make TRPV4 a promising therapeutic target, fundamental as

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 271 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 77% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.7 domain gate = 37%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $491,284 in active NIH money across 1 project, 2.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$491,284
Active projects
1
Runway left
2.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $491,284 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-02-28 (about 2.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 77%

    Matched 4 of 7 profile areas (23 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • Calcium and mechanosensitive channel signalling — lab text says “trpv4”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS131402-03 Defining TRPV4-mediated cytoskeletal changes that trigger pathological blood-neural barrier disruption

    R01 · NINDS · $491,284 · May 1, 2024 to Feb 28, 2029

All active NIH projects for Brett Andrew Mccray ($491,284)
  • 5R01NS131402-03 Defining TRPV4-mediated cytoskeletal changes that trigger pathological blood-neural barrier disruption — $491,284, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2024 · project period to Feb 28, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#55 Lab fit 37% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Christina Donata Cota lab

Christina Donata Cota · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY/ABSTRACT The regulation of transient cell behaviors and regulatory “states” is indispensable for the development of multicellular organisms. Knowledge of the genetic architecture and emergent properties of these processes is also key to developing therapies for congenital diseases and neurodevelopmental syndromes based on cellular reprogramming or genome editing. The objective of this proposal is to characterize the regulation and functions of potentially important genes that control polarized neuronal migration and axon outgrowth in the Ciona larval nervous system, which share

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 258 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 80% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.7 domain gate = 37%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $311,320 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$311,320
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $311,320 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 80%

    Matched 4 of 7 profile areas (24 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01HD104825-05 Regulation of neurodevelopmental cell behaviors in Ciona

    R01 · NICHD · $311,320 · Sep 12, 2022 to Jun 30, 2027

All active NIH projects for Christina Donata Cota ($311,320)
  • 5R01HD104825-05 Regulation of neurodevelopmental cell behaviors in Ciona — $311,320, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 12, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#56 Lab fit 37% · Adjacent Hiring: Moderate Atlanta Neuroscience

Alberto Stolfi lab

Alberto Stolfi · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY/ABSTRACT The regulation of transient cell behaviors and regulatory “states” is indispensable for the development of multicellular organisms. Knowledge of the genetic architecture and emergent properties of these processes is also key to developing therapies for congenital diseases and neurodevelopmental syndromes based on cellular reprogramming or genome editing. The objective of this proposal is to characterize the regulation and functions of potentially important genes that control polarized neuronal migration and axon outgrowth in the Ciona larval nervous system, which share

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 258 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 80% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 53% × 0.7 domain gate = 37%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $697,448 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$697,448
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $697,448 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years) — 5R35GM158421-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 80%

    Matched 4 of 7 profile areas (24 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01HD104825-05 Regulation of neurodevelopmental cell behaviors in Ciona

    R01 · NICHD · $311,320 · Sep 12, 2022 to Jun 30, 2027

All active NIH projects for Alberto Stolfi ($697,448)
  • 5R35GM158421-02 Leveraging the biphasic life cycle of a non-vertebrate chordate to investigate developmental transitions and phenotypic plasticity — $386,128, ends Jun 30, 2030
  • 5R01HD104825-05 Regulation of neurodevelopmental cell behaviors in Ciona — $311,320, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 12, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#57 Lab fit 37% · Adjacent Hiring: Moderate Atlanta Neuroscience

Mar M Sanchez lab

Mar M Sanchez · Emory University, Atlanta GA

Abstract A strong link between chronic social stress, especially starting early in life (ELS/ELA), and age-related disorders has been established mostly based on retrospective human reports. Prospective, longitudinal, studies across the lifespan are critical to identify biomarkers of ELA risk embedded earlier in life, the cumulative effects of chronic stress risk, and to develop early intervention strategies. Short-lived animal models (e.g. rodents) have significant limitations to inform about human aging, and therapeutics developed from them have failed in clinical trials. Longitudinal primat

Lab fit breakdown — 37% weighted · Adjacent

Scored on enough lab text to read as a verdict. 610 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.82 domain gate = 37%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,649,109 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,649,109
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,649,109 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +5 Brand-new (Type 1) project, not a renewal — 2R01DA052909-06A1 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 2R01AG070704-06 Early Risk Factors of Accelerated Neural Aging Trajectories and Cognitive Decline: A Nonhuman Primate Longitudinal Model

    R01 · NIA · $767,877 · Aug 1, 2021 to May 31, 2031

  • 2R01DA052909-06A1 Early experience and neurobiological risks of adult cocaine use disorder

    R01 · NIDA · $881,232 · Apr 1, 2021 to Jun 30, 2031 · Type 1 (new)

All active NIH projects for Mar M Sanchez ($1,649,109)
  • 2R01DA052909-06A1 Early experience and neurobiological risks of adult cocaine use disorder — $881,232, ends Jun 30, 2031
  • 2R01AG070704-06 Early Risk Factors of Accelerated Neural Aging Trajectories and Cognitive Decline: A Nonhuman Primate Longitudinal Model — $767,877, ends May 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2021 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#58 Lab fit 36% · Adjacent Hiring: Strong Michigan Neuroscience

Jayanth Ramadoss lab

Jayanth Ramadoss · Wayne State University, Detroit MI

PROJECT SUMMARY Electronic cigarette (e-cig) use during pregnancy has become a major health concern in recent years and is perpetuated by the perception that e-cigs are less harmful than traditional combustible cigarettes. Recent estimates show 7% of women use e-cigs in pregnancy, and 45% view them as less harmful and may help them quit or reduce combustible cigarettes in pregnancy. An extensive knowledge gap persists regarding their health impact when aerosolized, especially during pregnancy. Using our well-established pregnant rat model, we obtained preliminary data utilizing a state-of-the-

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 557 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 80% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.7 domain gate = 36%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunofluoresc".
  • Molecular biology, biochemistry and proteomics Lab text mentions "western blot".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,630,453 in active NIH money across 5 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,630,453
Active projects
5
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,630,453 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years) — 1U54ES038382-01, which is outside this briefing's scope but is active NIH money for this PI.
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 80%

    Matched 3 of 7 profile areas (24 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “immunofluoresc”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “western blot”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01ES037921-01A1 Novel Approaches for Gestational E-Cigarette Vaping-Induced Neuronal Adaptations

    R01 · NIEHS · $2,147,837 · Jun 1, 2026 to May 31, 2030

  • 5R01AA023520-11 A Novel Mechanistic Framework for FASD Etiology.

    R01 · NIAAA · $400,234 · Apr 15, 2015 to Sep 30, 2026

All active NIH projects for Jayanth Ramadoss ($3,630,453)
  • 1R01ES037921-01A1 Novel Approaches for Gestational E-Cigarette Vaping-Induced Neuronal Adaptations — $2,147,837, ends May 31, 2030
  • 1R01ES038818-01 Impact of Acid, Base, and Salt Components of E-cigarettes in Pregnancy — $473,313, ends Jun 30, 2031
  • 5R01AA023520-11 A Novel Mechanistic Framework for FASD Etiology. — $400,234, ends Sep 30, 2026
  • 5R01HL151497-05 ELECTRONIC CIGARETTE VAPING & VASCULAR SEQUELAE IN THE UTERUS DURING PREGNANCY. — $346,030, ends Dec 31, 2026
  • 1U54ES038382-01 Sex-Dependent E-cig Impact on Fetal Lungs: The Role of Benzoic acid and Freebase Nicotine — $263,039, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2026 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#59 Lab fit 36% · Adjacent Hiring: Moderate Michigan Neuroscience

Michael Roland Williams lab

Michael Roland Williams · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

PROJECT SUMMARY The ground-truth definition, experimental control, and therapeutic treatment of neuronal circuits requires technologies that perform well in vivo. Powerful tools that control and report signal transduction, neuronal activity, and gene expression continue to emerge, but the field lacks robust technologies to deliver those tools throughout long-distance neuronal circuits in the mammalian brain. The state-of-the-art relies on viruses that spread from neurons to their retrograde (e.g. rabies) or anterograde (e.g. HSV1) partners. However, these viruses are pathogens that can exhibit

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 286 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 83% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 52% × 0.7 domain gate = 36%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Non-rodent animal models Lab text mentions "zebrafish".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Axonal transport and neuronal injury assays Lab text mentions "anterograde".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,182,944 in active NIH money across 2 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,182,944
Active projects
2
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,182,944 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “zebrafish”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 83%

    Matched 4 of 7 profile areas (25 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “anterograde”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS149478-02 I/O Tags: Genetically Encoded Tags for Trans-Neuronal Control Across Specific Synapse Classes

    R01 · NINDS · $751,194 · Sep 10, 2025 to Aug 31, 2030

All active NIH projects for Michael Roland Williams ($1,182,944)
  • 5R01NS149478-02 I/O Tags: Genetically Encoded Tags for Trans-Neuronal Control Across Specific Synapse Classes — $751,194, ends Aug 31, 2030
  • 1R21MH138988-01A1 Transgenic Access to Semilunar Granule of the Dentate Gyrus — $431,750, ends Mar 9, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 10, 2025 · project period to Aug 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#60 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Gregory Stephen Sawicki lab

Gregory Stephen Sawicki · Georgia Institute of Technology, Atlanta GA

Mobility serves as a surrogate for well-being with age-related limits to walking function that include: increased energy cost and decreased speed. In 2021, the National Institute on Aging convened interdisciplinary scientists to identify multi-scale mechanisms for mobility impairments in aging and identified multiple factors contributing to elevated metabolic cost and reduced walking speed. A foundational age-related difference in walking function emerged - the so called ‘distal to proximal shift’ in neuromechanical effort. Older walkers rely more on proximal hip rather than distal ankle muscl

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 478 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,319,778 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,319,778
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,319,778 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1RF1AG096055-01 Identifying Multi-Scale Mechanisms for Age-Related Increase in Metabolic Cost of Walking

    RF1 · NIA · $3,224,215 · Aug 15, 2025 to Jul 31, 2029

  • 5R01HD090642-10 Multiscale models of proprioceptive encoding to reveal mechanisms of impaired sensorimotor control

    R01 · NICHD · $582,364 · Sep 16, 2016 to Mar 31, 2027

All active NIH projects for Gregory Stephen Sawicki ($4,319,778)
  • 1RF1AG096055-01 Identifying Multi-Scale Mechanisms for Age-Related Increase in Metabolic Cost of Walking — $3,224,215, ends Jul 31, 2029
  • 5R01HD090642-10 Multiscale models of proprioceptive encoding to reveal mechanisms of impaired sensorimotor control — $582,364, ends Mar 31, 2027
  • 5R01HD113598-03 Personalized Hip vs Ankle Exoskeleton Assistance with Biofeedback to Enhance Mobility Post-Stroke — $513,199, ends Jan 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2025 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#61 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Jennifer C Felger lab

Jennifer C Felger · Emory University, Atlanta GA

Project Summary This project will test the hypothesis that signaling through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways is a key mechanism mediating the effects of inflammation on corticostriatal circuits related to motivation and motor activity as well as symptoms of anhedonia and psychomotor slowing in patients with major depression (MD). The role of JAK/STAT pathways will be examined using a FDA-approved JAK inhibitor, baricitinib, and an innovative biomarker-driven, brain-targeted approach. MD is a disabling disorder, with over 1/3 of MD patient

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 638 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,942,724 in active NIH money across 3 projects, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,942,724
Active projects
3
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,942,724 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH140180-02 JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression

    R01 · NIMH · $627,566 · May 1, 2025 to Feb 28, 2030

  • 5R01MH128872-05 The Role of Inflammation in CNS Mechanisms of Anhedonia and Psychomotor Slowing in Depressed PWH as Determined using a Next Generation TNF Antagonist

    R01 · NIMH · $618,864 · Sep 10, 2021 to Aug 31, 2027

All active NIH projects for Jennifer C Felger ($1,942,724)
  • 5R33MH121625-04 Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression — $696,294, ends Jul 31, 2027
  • 5R01MH140180-02 JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression — $627,566, ends Feb 28, 2030
  • 5R01MH128872-05 The Role of Inflammation in CNS Mechanisms of Anhedonia and Psychomotor Slowing in Depressed PWH as Determined using a Next Generation TNF Antagonist — $618,864, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#62 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Andrew H Miller lab

Andrew H Miller · Emory University, Atlanta GA

Project Summary This project will test the hypothesis that signaling through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways is a key mechanism mediating the effects of inflammation on corticostriatal circuits related to motivation and motor activity as well as symptoms of anhedonia and psychomotor slowing in patients with major depression (MD). The role of JAK/STAT pathways will be examined using a FDA-approved JAK inhibitor, baricitinib, and an innovative biomarker-driven, brain-targeted approach. MD is a disabling disorder, with over 1/3 of MD patient

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 638 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,445,822 in active NIH money across 3 projects, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,445,822
Active projects
3
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,445,822 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH140180-02 JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression

    R01 · NIMH · $627,566 · May 1, 2025 to Feb 28, 2030

  • 5R01MH128872-05 The Role of Inflammation in CNS Mechanisms of Anhedonia and Psychomotor Slowing in Depressed PWH as Determined using a Next Generation TNF Antagonist

    R01 · NIMH · $618,864 · Sep 10, 2021 to Aug 31, 2027

All active NIH projects for Andrew H Miller ($1,445,822)
  • 5R01MH140180-02 JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression — $627,566, ends Feb 28, 2030
  • 5R01MH128872-05 The Role of Inflammation in CNS Mechanisms of Anhedonia and Psychomotor Slowing in Depressed PWH as Determined using a Next Generation TNF Antagonist — $618,864, ends Aug 31, 2027
  • 5R25MH101079-10 Emory Psychiatry Clinical Scientist Training Program (CSTP) — $199,392, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#63 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Suvarna Alladi lab

Suvarna Alladi · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT While it is widely acknowledged that Alzheimer’s disease and related dementias (AD/ADRD) have an extended preclinical phase, there are sparse data on the cognitive and pathobiological changes in middle-ages, a critical window for preventative intervention in people likely to progress to full-blown clinical disease. South Asians, a population with heightened risk of AD/ADRD and vascular/metabolic risks at younger ages, offer a unique opportunity to investigate preclinical AD/ADRD and related modifiable risk factors of its progression. Predictive models leveraging multim

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 366 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.92 domain gate = 36%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,329,952 in active NIH money across 2 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,329,952
Active projects
2
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,329,952 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01AG089759-03S3 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India

    R01 · NIA · $106,846 · Sep 15, 2024 to Aug 31, 2029

All active NIH projects for Suvarna Alladi ($3,329,952)
  • 5R01AG089759-03 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India — $2,395,163, ends Aug 31, 2029
  • 5R01AG080469-04 The impact of bilingualism on cognitive reserve/resilience using socio-demographically and linguistically diverse populations — $934,789, ends Mar 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#64 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Viswanathan Mohan lab

Viswanathan Mohan · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT While it is widely acknowledged that Alzheimer’s disease and related dementias (AD/ADRD) have an extended preclinical phase, there are sparse data on the cognitive and pathobiological changes in middle-ages, a critical window for preventative intervention in people likely to progress to full-blown clinical disease. South Asians, a population with heightened risk of AD/ADRD and vascular/metabolic risks at younger ages, offer a unique opportunity to investigate preclinical AD/ADRD and related modifiable risk factors of its progression. Predictive models leveraging multim

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 366 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.92 domain gate = 36%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,395,163 in active NIH money across 1 project, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,395,163
Active projects
1
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,395,163 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01AG089759-03S3 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India

    R01 · NIA · $106,846 · Sep 15, 2024 to Aug 31, 2029

All active NIH projects for Viswanathan Mohan ($2,395,163)
  • 5R01AG089759-03 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India — $2,395,163, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#65 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Kabayam M Venkat Narayan lab

Kabayam M Venkat Narayan · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT While it is widely acknowledged that Alzheimer’s disease and related dementias (AD/ADRD) have an extended preclinical phase, there are sparse data on the cognitive and pathobiological changes in middle-ages, a critical window for preventative intervention in people likely to progress to full-blown clinical disease. South Asians, a population with heightened risk of AD/ADRD and vascular/metabolic risks at younger ages, offer a unique opportunity to investigate preclinical AD/ADRD and related modifiable risk factors of its progression. Predictive models leveraging multim

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 366 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.92 domain gate = 36%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,151,956 in active NIH money across 3 projects, 3.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,151,956
Active projects
3
Runway left
3.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,151,956 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-12-31 (about 3.3 years) — 5R01DK139632-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01AG089759-03S3 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India

    R01 · NIA · $106,846 · Sep 15, 2024 to Aug 31, 2029

All active NIH projects for Kabayam M Venkat Narayan ($4,151,956)
  • 5R01AG089759-03 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India — $2,395,163, ends Aug 31, 2029
  • 5P01HL154996-05 Precision Cardiovascular Diseases Phenotyping and Pathophysiological Pathways in the CARRS Cohort (Precision-CARRS) — $1,545,788, ends Feb 28, 2027
  • 5R01DK139632-02 Molecular Prediction, Disease Progression, and Type 2 Diabetes (T2D) Phenotypes in South Asians — $211,005, ends Dec 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#66 Lab fit 36% · Adjacent Hiring: Moderate Atlanta Neuroscience

Dorairaj Prabhakaran lab

Dorairaj Prabhakaran · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT While it is widely acknowledged that Alzheimer’s disease and related dementias (AD/ADRD) have an extended preclinical phase, there are sparse data on the cognitive and pathobiological changes in middle-ages, a critical window for preventative intervention in people likely to progress to full-blown clinical disease. South Asians, a population with heightened risk of AD/ADRD and vascular/metabolic risks at younger ages, offer a unique opportunity to investigate preclinical AD/ADRD and related modifiable risk factors of its progression. Predictive models leveraging multim

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 366 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 50% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.92 domain gate = 36%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,856,818 in active NIH money across 3 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,856,818
Active projects
3
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,856,818 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 50%

    Matched 2 of 6 profile areas (14 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01AG089759-03S3 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India

    R01 · NIA · $106,846 · Sep 15, 2024 to Aug 31, 2029

All active NIH projects for Dorairaj Prabhakaran ($2,856,818)
  • 5R01AG089759-03 P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in India — $2,395,163, ends Aug 31, 2029
  • 5U01TW010097-11 1/2-GEOHealth Health Effects of Selected Environmental Exposomes Across the Life CourSe (HEALS)-India — $317,445, ends Feb 28, 2027
  • 5P01HL154996-05 Cardiovascular Disease (CVD) Phenotyping Core — $144,210, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#67 Lab fit 36% · Adjacent Hiring: Possible Michigan Neuroscience

Maik Huettemann lab

Maik Huettemann · Wayne State University, Detroit MI

Currently, there are no approved interventions that significantly attenuate the acute injury and inflammatory response in the initial early (< 24 h) phase following SCI which leads to neuronal death. Following the initial trauma of spinal cord injury (SCI), a secondary cascade of events characterized by damage to the vasculature of the spinal cord occurs, triggering mitochondrial dysfunction. The main source of ROS (reactive oxygen species; free radicals) production is the mitochondria. During tissue injury, calcium is released which activates mitochondrial proteins. The hyperactivate mitochon

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 249 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $549,221 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$549,221
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $549,221 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS134695-03 Non-invasive infrared light therapy and medical device to treat spinal cord injury

    R01 · NINDS · $549,221 · Aug 15, 2024 to May 31, 2029

All active NIH projects for Maik Huettemann ($549,221)
  • 5R01NS134695-03 Non-invasive infrared light therapy and medical device to treat spinal cord injury — $549,221, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#68 Lab fit 36% · Adjacent Hiring: Possible Michigan Neuroscience

Tzumin Lee lab

Tzumin Lee · University of Michigan, Ann Arbor MI

Temporal patterning is an evolutionarily conserved means to generate the proper complement of neurons during brain development. Our long-term goals are to resolve temporal fate specification in the Drosophila brain and discern which mechanisms are evolutionarily conserved in mammals. Temporal patterning has been best studied in Drosophila, where temporal features of the cycling neural stem cells (NSC) are passed to the progeny. Despite decades of study on temporal pattering of the mouse neocortex, the mechanisms that drive temporal progression of cortical fates are not well understood. The Dro

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 246 words of lab text were scored, matching 6 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 79% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 51% × 0.7 domain gate = 36%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $550,404 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$550,404
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $550,404 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 79%

    Matched 3 of 5 profile areas (22 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS134890-03 Mechanisms of Neuronal Temporal Fate

    R01 · NINDS · $550,404 · Jul 1, 2024 to May 31, 2029

All active NIH projects for Tzumin Lee ($550,404)
  • 5R01NS134890-03 Mechanisms of Neuronal Temporal Fate — $550,404, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#69 Lab fit 36% · Adjacent Hiring: Possible Michigan Ophthalmology

Fu-shin X Yu lab

Fu-shin X Yu · Wayne State University, Detroit MI

PROJECT ABSTRACT Diabetic patients are known to have a higher incidence of infection, with increased disease severity and an increased rate of multi-drug resistance. In the diabetic (DM) cornea, this results in increased susceptibility to and the rapid progression of microbial keratitis. To date, the mechanisms underlying this are unknown. To address this critical and understudied question, Pseudomonas (P.) aeruginosa and Staphylococcus (S.) aureus keratitis models with Streptozotocin-induced type 1 (T1) and db/db type 2 (T2) DM mice were established. In our models, higher inocula of both P. a

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 298 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 39% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $433,576 in active NIH money across 1 project, 2.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$433,576
Active projects
1
Runway left
2.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $433,576 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-02-28 (about 2.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 39%

    Matched 2 of 6 profile areas (11 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035785-03 Role of Programmed Cell Death Pathways in Bacterial Keratitis

    R01 · NEI · $433,576 · Mar 1, 2024 to Feb 28, 2029

All active NIH projects for Fu-shin X Yu ($433,576)
  • 5R01EY035785-03 Role of Programmed Cell Death Pathways in Bacterial Keratitis — $433,576, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2024 · project period to Feb 28, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#70 Lab fit 36% · Adjacent Hiring: Possible Atlanta Neuroscience

Timothy C Cope lab

Timothy C Cope · Georgia Institute of Technology, Atlanta GA

Abstract The toxic effects of platinum-based compounds (PBCs) commonly used in chemotherapy weigh against their usefulness as the major option for successfully combating lethal cancers. The decision to opt for survival leaves people worldwide to suffer with PBC neurotoxicity that reduces quality of life by causing neurological disorders both during and long after treatment. Pain, strange sensations, fatigue, and difficulty with balance and walking are common symptoms, collectively known as chemotherapy-induced neuropathy (CIN). During treatment, both sensory and motor neurons are observed to f

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 498 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Calcium and mechanosensitive channel signalling Lab text mentions "ion channel".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,053,909 in active NIH money across 2 projects, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,053,909
Active projects
2
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,053,909 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 2 of 7 profile areas (10 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01CA268125-05 Mechanisms underlying spontaneous firing by motoneurons with acute neurotoxicity

    R01 · NCI · $471,545 · Feb 11, 2022 to Jan 31, 2027

  • 5R01HD090642-10 Multiscale models of proprioceptive encoding to reveal mechanisms of impaired sensorimotor control

    R01 · NICHD · $582,364 · Sep 16, 2016 to Mar 31, 2027

All active NIH projects for Timothy C Cope ($1,053,909)
  • 5R01HD090642-10 Multiscale models of proprioceptive encoding to reveal mechanisms of impaired sensorimotor control — $582,364, ends Mar 31, 2027
  • 5R01CA268125-05 Mechanisms underlying spontaneous firing by motoneurons with acute neurotoxicity — $471,545, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 11, 2022 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#71 Lab fit 36% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Timothy Robert Sampson lab

Timothy Robert Sampson · Emory University, Atlanta GA

Project Summary Pesticide exposures are a significant risk factor for many neurodegenerative diseases, including Parkinson’s disease (PD). Sporadic PD, with no known etiology accounts for ~90% of disease incidences, as highly penetrant genetic risks are not very prevalent. Experimental models have largely elucidated molecular mechanisms of pesticide exposures directly on those neurons vulnerable during PD. For instance, exposures to rotenone and MPTP are used to induce nigrostriatal neuron loss in rodents. While the effects of these exposures on the central nervous system (CNS) have been explo

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 274 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $346,685 in active NIH money across 1 project, 0.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$346,685
Active projects
1
Runway left
0.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $346,685 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-11-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01ES032440-05 Interaction of Pyrethroid Exposure and the Microbiome on Parkinson's Disease related Pathologies

    R01 · NIEHS · $346,685 · Feb 9, 2022 to Nov 30, 2026

All active NIH projects for Timothy Robert Sampson ($346,685)
  • 5R01ES032440-05 Interaction of Pyrethroid Exposure and the Microbiome on Parkinson's Disease related Pathologies — $346,685, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 9, 2022 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#72 Lab fit 36% · Adjacent Hiring: Not enough data Atlanta Neuroscience

Shanthi K Srinivasan lab

Shanthi K Srinivasan · Emory University, Atlanta GA

Enteric neuronal loss is responsible for intestinal dysmotility in significant clinical conditions including aging, diabetes mellitus, and constipation. The overarching goal of this renewal application is to further delineate the neuronal degeneration pathway triggered by a Western fat diet (WD). Preliminary data demonstrate that primary mouse enteric neurons and isolated human enteric neurons exposed to PA have increased cellular iron levels and increased ferritin expression. PA-induced ferroptosis is prevented by the ferroptosis inhibitor, ferrostatin 1. Free iron catalyzes the increase in n

Lab fit breakdown — 36% weighted · Adjacent

Scored on enough lab text to read as a verdict. 227 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.82 domain gate = 36%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuronal loss".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 5 of 100 points
  • +5 One to two years of project period left — Longest project period runs to 2028-07-31 (about 1.8 years).
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuronal loss”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4R01DK080684-15 Mechanism of Enteric Neuropathy

    R01 · NIDDK · $891,735 · Aug 1, 2009 to Jul 31, 2028

Newest award started Aug 1, 2009 · project period to Jul 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#73 Lab fit 35% · Adjacent Hiring: Strong Michigan Neuroscience

Benjamin Michael Hampstead lab

Benjamin Michael Hampstead · University of Michigan, Ann Arbor MI

Abstract This is the first study to evaluate the effects of personalized brain stimulation as a potential treatment for those with posterior cortical atrophy (PCA), a condition that is most often caused by Alzheimer’s disease (AD). Individuals with PCA generally have intact vision but, as pathology spreads through the brain, have increasing difficulty “making sense” of what they see. Examples of this visuospatial impairment include difficulty locating objects in crowded environments (e.g., locating items in a full refrigerator) or traveling from one location to another (i.e., spatial navigatio

Lab fit breakdown — 35% weighted · Adjacent

Scored on enough lab text to read as a verdict. 482 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 30% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.82 domain gate = 35%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual acuity".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $5,398,368 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$5,398,368
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,398,368 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2P30AG072931-06, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 30%

    Matched 2 of 7 profile areas (9 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.
    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG093689-01A1 Network-based neuromodulation for posterior cortical atrophy

    RF1 · NIA · $3,664,645 · Aug 1, 2025 to Jul 31, 2029

  • 5R35AG072262-05 Research Program on Cognition and Neuromodulation Based Interventions (RP-CNBI)

    R35 · NIA · $818,448 · Apr 15, 2021 to Mar 31, 2027

All active NIH projects for Benjamin Michael Hampstead ($5,398,368)
  • 1RF1AG093689-01A1 Network-based neuromodulation for posterior cortical atrophy — $3,664,645, ends Jul 31, 2029
  • 2P30AG072931-06 Clinical Core — $915,275, ends Jun 30, 2031
  • 5R35AG072262-05 Research Program on Cognition and Neuromodulation Based Interventions (RP-CNBI) — $818,448, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#74 Lab fit 35% · Adjacent Hiring: Moderate Atlanta Neuroscience

Jingjing Yang lab

Jingjing Yang · Emory University, Atlanta GA

PROJECT SUMMARY Although genome-wide association studies (GWAS) have discovered ~75 significant risk genes associated with AD/ADRD, the underlying molecular mechanisms remain elusive. This gap has been partially filled by integrating different omics data together with GWAS data. For example, tools developed can integrate transcriptome-wide association study (TWAS) and proteome-wide association study (PWAS) with GWAS data to detect additional AD risk genes and inform on their mediation via transcriptome or proteome with AD dementia. Yet, recent TWAS and PWAS analyses for AD dementia have only c

Lab fit breakdown — 35% weighted · Adjacent

Scored on enough lab text to read as a verdict. 232 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.82 domain gate = 35%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "drug discovery")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $919,819 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$919,819
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $919,819 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years) — 1R35GM161732-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG089703-02 Investigating Cis- and Trans-Genetic Regulation of Brain Transcriptomics and Proteomics Associated with AD/ADRD

    R01 · NIA · $499,101 · Jun 1, 2025 to Mar 31, 2030

All active NIH projects for Jingjing Yang ($919,819)
  • 5R01AG089703-02 Investigating Cis- and Trans-Genetic Regulation of Brain Transcriptomics and Proteomics Associated with AD/ADRD — $499,101, ends Mar 31, 2030
  • 1R35GM161732-01 Enhancing Transcriptome-Wide Association Studies of Complex Human Diseases through Innovative Statistical Methods — $420,718, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2025 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#75 Lab fit 35% · Adjacent Hiring: Possible Michigan Neuroscience

Ravi Allada lab

Ravi Allada · University of Michigan, Ann Arbor MI

Project Summary Understanding why we sleep remains one of the most enduring mysteries in science. Nearly every organism examined, even jellyfish that lack a centralized nervous system, exhibits a restorative sleep-like state. While asleep, we cannot eat, mate, defend ourselves from predators or care for our young. Inadequate sleep contributes to brain disease such as Alzheimer's and depression, and even diseases outside of the brain, such as diabetes and obesity. Sleep is homeostatically regulated, i.e., sleep is driven by the duration and intensity of prior waking experience. However, the mec

Lab fit breakdown — 35% weighted · Adjacent

Scored on enough lab text to read as a verdict. 173 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.82 domain gate = 35%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $784,115 in active NIH money across 2 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$784,115
Active projects
2
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $784,115 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years) — 1R21HL188991-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35NS132223-05 The Molecular and Cellular Basis of the Sleep Homeostat

    R35 · NINDS · $550,115 · Sep 1, 2023 to Apr 30, 2028

All active NIH projects for Ravi Allada ($784,115)
  • 5R35NS132223-05 The Molecular and Cellular Basis of the Sleep Homeostat — $550,115, ends Apr 30, 2028
  • 1R21HL188991-01 Circadian Regulation of Disease Risk Genes and Its Implications for Chronotherapy and Biomarker Discovery — $234,000, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#76 Lab fit 34% · Adjacent Hiring: Moderate Atlanta Neuroscience New award

Hang Shi lab

Hang Shi · Georgia State University, Atlanta GA

Project Abstract Obesity results from a sustained energy imbalance where energy intake surpasses expenditure. While white adipose tissue (WAT) stores excess energy, brown adipose tissue (BAT) dissipates energy as heat. Two types of brown adipocytes exist in the rodents. Classic brown adipocytes are confined to anatomically discrete areas, whereas “inducible” beige adipocytes are sporadically dispersed in WAT and can be induced by cold. Increasing brown/beige adipocyte thermogenesis has been shown to alleviate obesity in rodents. The sympathetic nervous system (SNS) is a driving force for brown

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 247 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.7 domain gate = 34%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,272,299 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,272,299
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,272,299 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-25.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01DK145617-01A1 Reprogramming of sympathetic innervation in response to environmental cues by DNA methylation

    R01 · NIDDK · $715,511 · Aug 25, 2026 to Jun 30, 2031

All active NIH projects for Hang Shi ($1,272,299)
  • 1R01DK145617-01A1 Reprogramming of sympathetic innervation in response to environmental cues by DNA methylation — $715,511, ends Jun 30, 2031
  • 5R01DK130342-05 HDAC1 as a nutrient sensor in the development and progression of NAFLD — $556,788, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 25, 2026 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#77 Lab fit 34% · Adjacent Hiring: Moderate Atlanta Neuroscience New award

Bingzhong Xue lab

Bingzhong Xue · Georgia State University, Atlanta GA

Project Abstract Obesity results from a sustained energy imbalance where energy intake surpasses expenditure. While white adipose tissue (WAT) stores excess energy, brown adipose tissue (BAT) dissipates energy as heat. Two types of brown adipocytes exist in the rodents. Classic brown adipocytes are confined to anatomically discrete areas, whereas “inducible” beige adipocytes are sporadically dispersed in WAT and can be induced by cold. Increasing brown/beige adipocyte thermogenesis has been shown to alleviate obesity in rodents. The sympathetic nervous system (SNS) is a driving force for brown

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 247 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.7 domain gate = 34%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $715,511 in active NIH money across 1 project, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$715,511
Active projects
1
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $715,511 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-25.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01DK145617-01A1 Reprogramming of sympathetic innervation in response to environmental cues by DNA methylation

    R01 · NIDDK · $715,511 · Aug 25, 2026 to Jun 30, 2031

All active NIH projects for Bingzhong Xue ($715,511)
  • 1R01DK145617-01A1 Reprogramming of sympathetic innervation in response to environmental cues by DNA methylation — $715,511, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 25, 2026 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#78 Lab fit 34% · Adjacent Hiring: Moderate Michigan Neuroscience

Li Zhang lab

Li Zhang · Henry Ford Health System, East Lansing MI

ABSTRACT The objectives of this proposal are to optimize and validate detection of microvessels in the cerebral vascular, glymphatic and meningeal lymphatic (ML) systems using superparamagnetic iron oxide (SPIO)-enhanced susceptibility weighted imaging (SWI, SPIO-SWI), and then to investigate the cerebral waste clearance in the vascular, glymphatic and ML systems during progression of Alzheimer’s Disease (AD). Emerging data indicate that the waste clearance from the brain parenchyma plays an important role in neurological diseases, especially neurodegenerative diseases1-9. Waste clearance from

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 731 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,485,819 in active NIH money across 4 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,485,819
Active projects
4
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,485,819 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG094722-01 Efflux Route Responses of Cerebral Waste Clearance During Progression of Alzheimer’s Disease

    RF1 · NIA · $3,062,355 · Sep 15, 2025 to Aug 31, 2029

  • 5R01NS132772-03 AcSDKP as a novel treatment for traumatic brain injury

    R01 · NINDS · $431,168 · May 1, 2024 to Feb 28, 2029

  • 5R01AG068072-05 Cerebral endothelial cells derived exosomes as a therapy for cognitive impairment in aged diabetic rats

    R01 · NIA · $379,316 · Apr 1, 2021 to Mar 31, 2027

All active NIH projects for Li Zhang ($4,485,819)
  • 1RF1AG094722-01 Efflux Route Responses of Cerebral Waste Clearance During Progression of Alzheimer’s Disease — $3,062,355, ends Aug 31, 2029
  • 5R01DK136843-03 Imaging cerebral waste clearance responses during exosome treatment of diabetes — $612,980, ends Mar 31, 2029
  • 5R01NS132772-03 AcSDKP as a novel treatment for traumatic brain injury — $431,168, ends Feb 28, 2029
  • 5R01AG068072-05 Cerebral endothelial cells derived exosomes as a therapy for cognitive impairment in aged diabetic rats — $379,316, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2025 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#79 Lab fit 34% · Adjacent Hiring: Moderate Atlanta Neuroscience

Christina Gavegnano lab

Christina Gavegnano · Emory University, Atlanta GA

Project Summary This project will test the hypothesis that signaling through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways is a key mechanism mediating the effects of inflammation on corticostriatal circuits related to motivation and motor activity as well as symptoms of anhedonia and psychomotor slowing in patients with major depression (MD). The role of JAK/STAT pathways will be examined using a FDA-approved JAK inhibitor, baricitinib, and an innovative biomarker-driven, brain-targeted approach. MD is a disabling disorder, with over 1/3 of MD patient

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 609 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 42% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,992,830 in active NIH money across 3 projects, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,992,830
Active projects
3
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,992,830 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH140180-02 JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression

    R01 · NIMH · $627,566 · May 1, 2025 to Feb 28, 2030

  • 5R01MH128158-05 Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system

    R01 · NIMH · $619,562 · Aug 10, 2022 to Jun 30, 2027

All active NIH projects for Christina Gavegnano ($1,992,830)
  • 5R01HL166004-04 Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV — $745,702, ends Jun 30, 2027
  • 5R01MH140180-02 JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression — $627,566, ends Feb 28, 2030
  • 5R01MH128158-05 Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system — $619,562, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#80 Lab fit 34% · Adjacent Hiring: Strong Michigan Neuroscience

James J. Moon lab

James J. Moon · University of Michigan, Ann Arbor MI

Neuroinflammation is linked to diverse acute and chronic disorders. Regulatory T cells (Tregs) have long been recognized to suppress inflammation and effector T cell (Teff) activation in the periphery, but their role in the CNS has only been fully realized in the last few years. Notably, selective expression of IL-2 in the CNS is effective at differentiating CNS-resident T cells into Tregs and preventing neuropathology in multiple models of neuroinflammation, including traumatic brain injury (TBI), stroke, and multiple sclerosis (MS). However, there has been little clinical translation of thes

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 241 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $4,291,447 in active NIH money across 7 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,291,447
Active projects
7
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,291,447 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 7 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 1R01CA316043-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EB036493-02 Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots

    R01 · NIBIB · $612,347 · Feb 1, 2025 to Jan 31, 2029

All active NIH projects for James J. Moon ($4,291,447)
  • 5R01DE031951-05 Engineered Nano-formulations for STING Activation — $692,603, ends Feb 28, 2027
  • 1R01CA316043-01 Innate-Immune Activating Nanoparticles for Cancer Treatment — $669,421, ends Jun 30, 2031
  • 1R01DK144842-01A1 Biomaterials for Treatment of Type-1 Diabetes — $616,132, ends Jun 30, 2031
  • 5R01EB036493-02 Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots — $612,347, ends Jan 31, 2029
  • 5R01CA271799-05 Biomaterials for modulating the gut microbiome for immune activation — $594,867, ends Apr 30, 2027
  • 5R01DE026728-09 Restoring the Immunogenicity of Head and Neck Cancer — $553,305, ends Jun 30, 2028
  • 1R01EB039718-01 New Drug Delivery Strategy for Gut Microbiome — $552,772, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2025 · project period to Jan 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#81 Lab fit 34% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Ken Berglund lab

Ken Berglund · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Temporal interference (TI) electrical stimulation is an innovative non-invasive brain stimulation technique that holds great promise. It utilizes two high-frequency electrical currents with a slight offset (e.g., 1,000 Hz and 1,010 Hz) to achieve deep and precise brain stimulation. This combination results in the creation of an amplitude modulation only at a depth where the waves interfere. However, despite its theoretical potential and successful application in the peripheral nervous system, there are significant gaps in our understanding of how TI truly functions wit

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 244 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.7 domain gate = 34%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "adeno-associated".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $391,250 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$391,250
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $391,250 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “adeno-associated”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01NS138733-02S1 Collaborative Research Fund: A CompreheNSive Study of Temporal Interference Mechanisms (CNS-STIM)

    R01 · NINDS · $39,125 · Aug 14, 2024 to Jul 31, 2027

All active NIH projects for Ken Berglund ($391,250)
  • 5R01NS138733-03 Advancing non-invasive brain stimulation: A CompreheNSive Study of Temporal Interference Mechanisms (CNS-STIM) — $391,250, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 14, 2024 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#82 Lab fit 34% · Adjacent Hiring: Moderate Michigan Neuroscience

Gabriel Corfas lab

Gabriel Corfas · University of Michigan, Ann Arbor MI

Abstract There is increasing evidence that alterations in myelin contribute to cognitive and behavioral defects and that this is partly mediated through myelin plasticity, but the cellular and molecular mechanisms by which this occurs remain poorly understood. One example of the crucial role of myelin plasticity in mental health is the long-term impact of juvenile social isolation (JSI). Children subjected to JSI suffer from dramatic long-term behavioral and cognitive defects that persist after fostering and intervention. Imaging studies indicate that affected children have defects in the myel

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 243 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 83% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.7 domain gate = 34%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "patch clamp")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,391,630 in active NIH money across 4 projects, 2.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,391,630
Active projects
4
Runway left
2.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,391,630 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-01-31 (about 2.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 83%

    Matched 4 of 7 profile areas (25 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH135425-03 Mechanisms of Social Isolation-Induced Alterations in Prefrontal Cortex Myelin, Neural Circuits and Behavior

    R01 · NIMH · $785,029 · Jul 1, 2024 to Jan 31, 2029

All active NIH projects for Gabriel Corfas ($2,391,630)
  • 5R01MH135425-03 Mechanisms of Social Isolation-Induced Alterations in Prefrontal Cortex Myelin, Neural Circuits and Behavior — $785,029, ends Jan 31, 2029
  • 5R01DC000188-45 Cochlear synaptopathy in noise-induced and age-related hearing loss: mechanisms and treatments — $671,763, ends Feb 29, 2028
  • 5R01DC014832-10 Enhancing Atoh1 function in hair cell regeneration — $648,034, ends Jul 31, 2027
  • 5R25DC020262-04 Michigan Otolaryngology Research Education (MORE) — $286,804, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to Jan 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#83 Lab fit 34% · Adjacent Hiring: Moderate Michigan Neuroscience

Kenneth Yu-chung Kwan lab

Kenneth Yu-chung Kwan · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT The aim of this proposal is to determine how heterozygous mutation of the chromatin remodeler CHD7 (Chromodomain Helicase DNA-binding protein 7) disrupts development of the neocortex, leading to the neurodevelopmental anomalies associated with CHARGE syndrome. CHARGE syndrome is characterized by substantial behavioral and cognitive problems, including executive dysfunction and Autism Spectrum Disorder (ASD). The proposed research team recently identified abnormalities in the neocortex of Chd7 heterozygous mice, implicating CHD7 in key, temporally distinct developmental

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 486 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 83% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 48% × 0.7 domain gate = 34%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".
  • Molecular biology, biochemistry and proteomics Lab text mentions "rna-seq".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,528,296 in active NIH money across 3 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,528,296
Active projects
3
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,528,296 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 83%

    Matched 4 of 7 profile areas (25 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “rna-seq”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS129562-04 Dissecting Cell Type Specific Functions of CHD7 in Development of the Neocortex

    R01 · NINDS · $516,297 · Jul 1, 2023 to Jun 30, 2028

  • 5R01NS125313-05 Subplate-dependent mechanisms of cortical circuit assembly

    R01 · NINDS · $464,547 · Aug 9, 2022 to Jul 31, 2027

All active NIH projects for Kenneth Yu-chung Kwan ($1,528,296)
  • 5R01MH126287-05 Distinct roles of chromatin regulation in transcriptome and genome maintenance in corticogenesis — $547,452, ends Jun 30, 2027
  • 5R01NS129562-04 Dissecting Cell Type Specific Functions of CHD7 in Development of the Neocortex — $516,297, ends Jun 30, 2028
  • 5R01NS125313-05 Subplate-dependent mechanisms of cortical circuit assembly — $464,547, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#84 Lab fit 34% · Adjacent Hiring: Moderate Michigan Neuroscience

Kin Sing Stephen Lee lab

Kin Sing Stephen Lee · Michigan State University, East Lansing MI

Abstract Alzheimer’s disease affects 6 million Americans, is the 6th leading cause of death in the nation and substantially impacts patients’ quality of life with no effective cure available. As the population over the age of 65 is projected to triple by 2035, the number of Alzheimer’s disease patients is expected to increase by at least two-fold. Therefore, there is an unmet medical need to develop novel treatments to prevent and or cure Alzheimer’s disease. Recent studies indicate that soluble epoxide hydrolase (sEH) is a novel therapeutic target for Alzheimer’s disease. Although the newer s

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 290 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 42% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "drug discovery")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,894,690 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,894,690
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,894,690 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 1R01DK146036-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG080186-04 Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease

    R01 · NIA · $635,155 · Feb 1, 2023 to Jan 31, 2028

All active NIH projects for Kin Sing Stephen Lee ($1,894,690)
  • 1R01DK146036-01A1 Investigating the Mechanistic Role of Brown Fat-derived Lipid Mediators and Their Analogs in Metabolic Health — $868,285, ends Jun 30, 2031
  • 5R01AG080186-04 Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease — $635,155, ends Jan 31, 2028
  • 5R35GM146983-05 Ferroptosis and Polyunsaturated Fatty Acid Metabolism — $391,250, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2023 · project period to Jan 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#85 Lab fit 34% · Adjacent Hiring: Possible Atlanta Neuroscience

Craig Forest lab

Craig Forest · Georgia Institute of Technology, Atlanta GA

Project Summary Over 150 million people are projected to be living with dementia worldwide by 2050. Alzheimer’s disease (AD) is the most common form of dementia, responsible for ~70% of dementia cases. A hallmark pathological feature of Alzheimer’s disease (AD) is progressive neurodegeneration, which is thought to initiate and track progressive cognitive decline in AD patients. While increasingly sensitive biochemical markers are available to diagnose AD in individuals, treatments to stall the disease in its early stages remain elusive. Increasing evidence in AD patients models indicates that

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 262 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $688,408 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$688,408
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $688,408 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG079269-03 Automated cell-type-specific electrophysiology for understanding circuit dysregulation in Alzheimer's Disease

    R01 · NIA · $688,408 · Aug 17, 2022 to Jul 31, 2027

All active NIH projects for Craig Forest ($688,408)
  • 5R01AG079269-03 Automated cell-type-specific electrophysiology for understanding circuit dysregulation in Alzheimer's Disease — $688,408, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 17, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#86 Lab fit 34% · Adjacent Hiring: Moderate Atlanta Neuroscience

Peng Jin lab

Peng Jin · Emory University, Atlanta GA

Project Summary AD is an age-related progressive neurodegenerative disorder affecting millions of Americans without effective interventions. The gradual accumulation of neurofibrillary tangles formed by abnormal protein aggregation, such as tau and amyloid-β (Aβ) protein, serves as the neuropathological hallmark of AD. In recent years, the role of TAR DNA-binding protein 43 (TDP-43), a DNA and RNA-binding protein that has been heavily studied in amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar degeneration (FTLD-TDP), has drawn increasing interest for AD pathogenesis. The patholog

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 471 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,998,633 in active NIH money across 3 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,998,633
Active projects
3
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,998,633 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-07-31 (about 1.8 years) — 1R21MH143162-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG078937-05 Elucidating the Roles of Transposable Elements in Alzheimer's and related dementias

    R01 · NIA · $716,852 · Aug 15, 2022 to Apr 30, 2027

  • 5R35NS111602-08 Dynamic DNA Modifications in Brain and Diseases

    R35 · NINDS · $851,406 · Aug 15, 2019 to Jul 31, 2027

All active NIH projects for Peng Jin ($1,998,633)
  • 5R35NS111602-08 Dynamic DNA Modifications in Brain and Diseases — $851,406, ends Jul 31, 2027
  • 5R01AG078937-05 Elucidating the Roles of Transposable Elements in Alzheimer's and related dementias — $716,852, ends Apr 30, 2027
  • 1R21MH143162-01 Spatial Translational Dysregulation in Fragile X Syndrome — $430,375, ends Jul 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#87 Lab fit 34% · Adjacent Hiring: Possible Michigan Neuroscience

Benjamin Herschel Singer lab

Benjamin Herschel Singer · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT Sepsis survivors carry over a 3-fold risk of new chronic brain dysfunction, including long-term cognitive and mood disorders, but risk factors for brain dysfunction in sepsis survivors remain poorly understood. Amyloid beta (Aβ) pathology is present in 20-50% of cognitively normal individuals over age 60 and is thus a common risk factor even in sepsis survivors without a preexisting Alzheimer’s disease diagnosis. Alzheimer’s disease in humans and Aβ pathology in mice increase brain levels of complement receptors which are critical to innate immunity. The complement sys

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 252 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $645,496 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$645,496
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $645,496 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-12-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG074968-05 Enhancement of Brain Dysfunction in Sepsis Survivors by Alzheimer’s Disease Neuropathology

    R01 · NIA · $645,496 · Jan 15, 2022 to Dec 31, 2026

All active NIH projects for Benjamin Herschel Singer ($645,496)
  • 5R01AG074968-05 Enhancement of Brain Dysfunction in Sepsis Survivors by Alzheimer’s Disease Neuropathology — $645,496, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 15, 2022 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#88 Lab fit 34% · Adjacent Hiring: Moderate Michigan Neuroscience

Daniel A Lawrence lab

Daniel A Lawrence · University of Michigan, Ann Arbor MI

ABSTRACT The pathophysiology of Alzheimer’s disease (AD) is complex and represents one of the most difficult and pressing challenges facing modern neuroscience. Intracellular neurofibrillary tangles (NFTs) comprised of hyperphosphorylated tau and senile plaques consisting of aggregated extracellular amyloid beta (Aβ) are the hallmark pathological features of AD. However, it is clear that other factors likely contribute to the neural system failure and cognitive impairments associated with AD. Mounting clinical and experimental data suggest that cardiovascular disease (CVD) risk factors that pr

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,009,438 in active NIH money across 3 projects, 1.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,009,438
Active projects
3
Runway left
1.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,009,438 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-03-31 (about 1.5 years) — 5R01HL055374-26, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG074552-05 The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology

    R01 · NIA · $674,476 · Sep 1, 2021 to Jun 30, 2027

All active NIH projects for Daniel A Lawrence ($2,009,438)
  • 5R01HL163870-04 A Novel PAI-1 Function Drives Lung Fibrosis — $692,404, ends Nov 30, 2026
  • 5R01AG074552-05 The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology — $674,476, ends Jun 30, 2027
  • 5R01HL055374-26 Unraveling the role of tPA in the neurovascular unit — $642,558, ends Mar 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#89 Lab fit 34% · Adjacent Hiring: Possible Michigan Neuroscience

Geoffrey G Murphy lab

Geoffrey G Murphy · University of Michigan, Ann Arbor MI

ABSTRACT The pathophysiology of Alzheimer’s disease (AD) is complex and represents one of the most difficult and pressing challenges facing modern neuroscience. Intracellular neurofibrillary tangles (NFTs) comprised of hyperphosphorylated tau and senile plaques consisting of aggregated extracellular amyloid beta (Aβ) are the hallmark pathological features of AD. However, it is clear that other factors likely contribute to the neural system failure and cognitive impairments associated with AD. Mounting clinical and experimental data suggest that cardiovascular disease (CVD) risk factors that pr

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $674,476 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$674,476
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $674,476 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG074552-05 The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology

    R01 · NIA · $674,476 · Sep 1, 2021 to Jun 30, 2027

All active NIH projects for Geoffrey G Murphy ($674,476)
  • 5R01AG074552-05 The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology — $674,476, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#90 Lab fit 34% · Adjacent Hiring: Possible Michigan Neuroscience

Norbert E Kaminski lab

Norbert E Kaminski · Michigan State University, East Lansing MI

PROJECT SUMMARY/ABSTRACT An estimated 37 million people worldwide are infected with human immunodeficiency virus (HIV). Combined antiretroviral therapy (ART) has turned HIV into a chronic infection with significantly longer life expectancy. New health issues have surfaced as HIV patients live longer. Specifically, 50% of HIV-infected (HIV+) individuals exhibit neurocognitive impairment, termed HIV-associated neurocognitive disorder (HAND). A key event leading to HAND is persistent low-level chronic inflammation resulting in neuronal damage and cell death. A major contributor to HIV-induced neu

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 192 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "cell death".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $828,956 in active NIH money across 2 projects, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$828,956
Active projects
2
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $828,956 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “cell death”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA053047-05 Cannabis use frequency and its impact on monocyte-mediated inflammation in HIV patients

    R01 · NIDA · $514,512 · Sep 1, 2021 to Jul 31, 2027

All active NIH projects for Norbert E Kaminski ($828,956)
  • 5R01DA053047-05 Cannabis use frequency and its impact on monocyte-mediated inflammation in HIV patients — $514,512, ends Jul 31, 2027
  • 5P42ES004911-31 Project 1 - Dioxin-like Compounds Suppress IgM Responses by Targeting CD5+ (Innate-like) B cells, which can Serve as a Biomarker of Susceptibility to Environmental AHR Ligands — $314,444, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#91 Lab fit 34% · Adjacent Hiring: Moderate Michigan Neuroscience

S. Alexandra Burt lab

S. Alexandra Burt · Michigan State University, East Lansing MI

ABSTRACT Mitochondria are bacteria-like organelles with their own DNA (mtDNA). They reside in our cellular cytoplasm, and provide nearly all of the energy we use to sustain life. It thus stands to reason that inherited mtDNA dysfunction is an important element of diseases characterized by low energy. The field has yet to broadly examine this hypothesis, however, in large part because the biometric or family models we use to estimate the effects of nuclear DNA are totally incompatible with the study of mtDNA due to its unique characteristics and pattern of inheritance (e.g., mtDNA reproduces it

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 246 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 50% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,680,140 in active NIH money across 3 projects, 3.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,680,140
Active projects
3
Runway left
3.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,680,140 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-11-30 (about 3.2 years) — 5R01ES035740-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 50%

    Matched 2 of 7 profile areas (15 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG073189-03 Quantifying the contributions of mitochondrial DNA to Alzheimer's Disease and related conditions of aging

    R01 · NIA · $451,781 · Aug 15, 2021 to Apr 30, 2027

All active NIH projects for S. Alexandra Burt ($1,680,140)
  • 5R01ES035740-02 Illuminating the role of historical structural racism in the neighborhood exposome and modern-day child mental health — $656,030, ends Nov 30, 2029
  • 5R01HD104297-05 The methylomic consequences of neighborhood disadvantage for youth risk-taking behaviors. — $572,329, ends May 31, 2027
  • 5R01AG073189-03 Quantifying the contributions of mitochondrial DNA to Alzheimer's Disease and related conditions of aging — $451,781, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2021 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#92 Lab fit 34% · Adjacent Hiring: Strong Michigan Neuroscience

Henry L Paulson lab

Henry L Paulson · University of Michigan, Ann Arbor MI

This R35 proposal builds on the principal investigator’s longstanding success seeking the causes of age- related neurodegenerative diseases and developing treatments for these devastating and largely fatal disorders. The proposal’s unifying theme is a focus on proteins that participate in ubiquitin-linked quality control pathways and that are prone, in neurodegenerative diseases, to phase-separate and aggregate. Building on our recent discoveries in polyglutamine-mediated neurodegeneration and brain-expressed ubiquilins (a class of proteins implicated in various neurodegenerative diseases), we

Lab fit breakdown — 34% weighted · Adjacent

Scored on enough lab text to read as a verdict. 156 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 50% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.82 domain gate = 34%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "ubiquitin".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $5,879,134 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$5,879,134
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,879,134 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2P30AG072931-06, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 50%

    Matched 2 of 7 profile areas (15 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “ubiquitin”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35NS122302-06 Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways

    R35 · NINDS · $1,087,708 · May 1, 2021 to Apr 30, 2029

All active NIH projects for Henry L Paulson ($5,879,134)
  • 2P30AG072931-06 Michigan Alzheimer's Disease Research Center — $4,493,639, ends Jun 30, 2031
  • 5R35NS122302-06 Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways — $1,087,708, ends Apr 30, 2029
  • 5T32NS007222-44 Training in Clinical and Basic Neuroscience — $297,787, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2021 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#93 Lab fit 33% · Adjacent Hiring: Strong Atlanta Neuroscience

Ken W Hepburn lab

Ken W Hepburn · Emory University, Atlanta GA

The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population Abstract. Americans living in rural areas, compared to their urban and suburban counterparts, are disproportionately affected by shortages of health care resources, resulting in poorer health status and health outcomes. The prevalence and impact of dementia and other chronic illnesses is and will continue to be higher in rural America. Rural-dwelling persons living with dementia illnesses (PLWD) and the friends and family (caregivers)

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 798 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,258,685 in active NIH money across 4 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,258,685
Active projects
4
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,258,685 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-18.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG099377-01 The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population

    R01 · NIA · $651,391 · Aug 18, 2026 to Jul 31, 2031

  • 3R01AG087216-02S1 Effect of Cognitive Empathy Training on Dementia Caregivers

    R01 · NIA · $48,509 · Sep 15, 2024 to Aug 31, 2029

  • 5R01AG082833-04 Caregiver as Navigator-Developing Skills Online (CAN-DO): Developing Dementia Family Caregiver Mastery for Navigating Complex Health, Social Service, Legal, Financial, and Family Systems

    R01 · NIA · $713,371 · Sep 1, 2023 to May 31, 2028

All active NIH projects for Ken W Hepburn ($3,258,685)
  • 5P30AG064200-08 Roybal Center for Dementia Family Caregiver Mastery — $1,170,181, ends May 31, 2029
  • 5R01AG087216-03 Effect of Cognitive Empathy Training on Dementia Caregivers — $723,742, ends Aug 31, 2029
  • 5R01AG082833-04 Caregiver as Navigator-Developing Skills Online (CAN-DO): Developing Dementia Family Caregiver Mastery for Navigating Complex Health, Social Service, Legal, Financial, and Family Systems — $713,371, ends May 31, 2028
  • 1R01AG099377-01 The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population — $651,391, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 18, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#94 Lab fit 33% · Adjacent Hiring: Possible Michigan Neuroscience

Jailson Brito Querido lab

Jailson Brito Querido · University of Michigan, Ann Arbor MI

Expansion of a hexanucleotide GGGGCC repeat within the first intron of the C9orf72 gene is the primary monogenic cause for both Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Despite its intronic location, expanded GGGGCC repeat is retained in the mature mRNA, supporting a non-canonical translation initiation mechanism known as repeat- associated non-AUG (RAN) translation. RAN translation of C9orf72 mRNA generates toxic dipeptide repeat (DPR) proteins. These DPR proteins aggregate in the brains of affected individuals and have been shown to induce neurodegeneration in m

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 234 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 47% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $606,736 in active NIH money across 1 project, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$606,736
Active projects
1
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $606,736 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 47%

    Matched 2 of 7 profile areas (14 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS140149-03 Deciphering the structural basis of repeat-associated non-AUG (RAN) translation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    R01 · NINDS · $606,736 · Sep 18, 2024 to Aug 31, 2029

All active NIH projects for Jailson Brito Querido ($606,736)
  • 5R01NS140149-03 Deciphering the structural basis of repeat-associated non-AUG (RAN) translation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia — $606,736, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 18, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#95 Lab fit 33% · Adjacent Hiring: Moderate Atlanta Neuroscience

Candace C. Fleischer lab

Candace C. Fleischer · Emory University, Atlanta GA

Project Summary Brain temperature regulation is crucial for neurologic function and recovery after ischemia and injury. Local brain temperature increases as small as 1-2°C significantly contribute to the extent of ischemia-induced brain damage, and dissociation of brain and body temperatures is a strong predictor of poor prognosis. While brain temperature is well-recognized as an important clinical parameter for neuroprotection, current brain thermometry has been limited to invasive temperature probes surgically implanted at a single location, making it impractical in most patient cohorts. Sev

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 264 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Non-rodent animal models Lab text mentions "porcine".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "predictive model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,538,528 in active NIH money across 2 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,538,528
Active projects
2
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,538,528 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “porcine”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS138044-02 Synergistic Advancements in MR Thermometry and Predictive Thermal Modeling Towards Improved Characterization of Human Brain Temperature

    R01 · NINDS · $599,528 · Sep 17, 2024 to Aug 31, 2030

All active NIH projects for Candace C. Fleischer ($1,538,528)
  • 4DP2NS127704-02 A novel framework for quantifying metabolic brain health — $939,000, ends Aug 31, 2027
  • 5R01NS138044-02 Synergistic Advancements in MR Thermometry and Predictive Thermal Modeling Towards Improved Characterization of Human Brain Temperature — $599,528, ends Aug 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 17, 2024 · project period to Aug 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#96 Lab fit 33% · Adjacent Hiring: Possible Michigan Neuroscience

Sara J Aton lab

Sara J Aton · University of Michigan, Ann Arbor MI

Disrupted sleep is a major predictor of disordered cognition and affect, yet many questions regarding sleep's role in brain function remain unanswered. For example, why is sleep critical for memory consolidation? Why is there ubiquitous (presumably, evolutionarily conserved) wake-non-rapid eye movement (NREM)-REM sleep state ordering across species, and what are the differential roles of the two sleep states? How do brain circuit-wide dynamics change during these states, and how do those transitions affect the process of memory consolidation? Wake, NREM, and REM states generate distinct patter

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 499 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Sequencing, variant and splicing analysis Lab text mentions "segregation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,042,292 in active NIH money across 2 projects, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,042,292
Active projects
2
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,042,292 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “segregation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH135565-02 CRCNS: Acetylcholine and state-dependent neural network reorganization

    R01 · NIMH · $318,986 · Jun 13, 2023 to Apr 30, 2028

  • 4RF1MH135565-04 CRCNS: Acetylcholine and state-dependent neural network reorganization

    RF1 · NIMH · $622,372 · Jun 13, 2023 to Apr 30, 2028

All active NIH projects for Sara J Aton ($1,042,292)
  • 4RF1MH135565-04 CRCNS: Acetylcholine and state-dependent neural network reorganization — $622,372, ends Apr 30, 2028
  • 1R21NS143254-01A1 Neocortical-hippocampal coordination and plasticity in sleep-dependent memory storage — $419,920, ends Jan 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 13, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#97 Lab fit 33% · Adjacent Hiring: Possible Michigan Neuroscience

Michal R Zochowski lab

Michal R Zochowski · University of Michigan, Ann Arbor MI

Disrupted sleep is a major predictor of disordered cognition and affect, yet many questions regarding sleep's role in brain function remain unanswered. For example, why is sleep critical for memory consolidation? Why is there ubiquitous (presumably, evolutionarily conserved) wake-non-rapid eye movement (NREM)-REM sleep state ordering across species, and what are the differential roles of the two sleep states? How do brain circuit-wide dynamics change during these states, and how do those transitions affect the process of memory consolidation? Wake, NREM, and REM states generate distinct patter

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 499 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Sequencing, variant and splicing analysis Lab text mentions "segregation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $622,372 in active NIH money across 1 project, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$622,372
Active projects
1
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $622,372 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “segregation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH135565-02 CRCNS: Acetylcholine and state-dependent neural network reorganization

    R01 · NIMH · $318,986 · Jun 13, 2023 to Apr 30, 2028

  • 4RF1MH135565-04 CRCNS: Acetylcholine and state-dependent neural network reorganization

    RF1 · NIMH · $622,372 · Jun 13, 2023 to Apr 30, 2028

All active NIH projects for Michal R Zochowski ($622,372)
  • 4RF1MH135565-04 CRCNS: Acetylcholine and state-dependent neural network reorganization — $622,372, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 13, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#98 Lab fit 33% · Adjacent Hiring: Possible Michigan Ophthalmology

Stephen Matthew Cain lab

Stephen Matthew Cain · University of Michigan, Ann Arbor MI

Project Abstract Despite the availability of effective treatments, glaucoma remains a leading cause of irreversible blindness in the United States. Non-adherence to daily prescribed eye drop medications – the treatment for 89% of glaucoma patients - is a key modifiable driver of vision loss in glaucoma. In current practice, patients are diagnosed with glaucoma and simply given a prescription, with only 1 in 8 prescribing physicians teaching patients how to use eye drops. Glaucoma patients fail to use drops about half of the time and 20% of patients do not successfully get the drops into their

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 268 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 46% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.92 domain gate = 33%. Partial disease overlap — weighted mean discounted 8%.

What matches

  • Glaucoma, IOP and trabecular meshwork Lab text mentions "glaucoma".
  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".

What’s missing

  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of neurodegeneration and neuroprotection Nothing in the grant text or lab description touches neurodegeneration and neuroprotection, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $609,097 in active NIH money across 1 project, 3.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$609,097
Active projects
1
Runway left
3.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $609,097 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 46%

    Matched 2 of 6 profile areas (13 of 28 weight to saturation).

    • Glaucoma, IOP and trabecular meshwork — lab text says “glaucoma”Her side: Ph.D. dissertation on trabecular meshwork stem cells in glaucomatous human eyes; three first-author TM papers; current UCI work on TM calcium channels and outflow.
    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 2R01EB032328-05 Quantifying and Understanding Glaucoma Eye Drop Medication Instillation and Adherence

    R01 · NIBIB · $609,097 · Jul 1, 2022 to Mar 31, 2030

All active NIH projects for Stephen Matthew Cain ($609,097)
  • 2R01EB032328-05 Quantifying and Understanding Glaucoma Eye Drop Medication Instillation and Adherence — $609,097, ends Mar 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2022 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#99 Lab fit 33% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Thackery Ian Brown lab

Thackery Ian Brown · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY | Spatial navigation is fundamental to survival, and entorhinal cortex (EC) function may be fundamental to forming and remembering cognitive maps. The Nobel Prize-winning discovery that EC neurons map environments with grid-like signals has given rise to a class of theories that grid-like metrics from EC facilitate spatial orientation, planning, and navigation to goals. Deficits in these same navigational abilities are a hallmark of both healthy aging and Alzheimer’s-related dementia (ADRD), and EC dysfunction is one of the earliest effects of Alzheimer’s disease and is associa

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 245 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Sequencing, variant and splicing analysis Lab text mentions "segregation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $436,091 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$436,091
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $436,091 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “segregation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG073250-05 Influences of Environmental Geometry and Aging on Cognitive Mapping Mechanisms

    R01 · NIA · $436,091 · May 15, 2022 to Apr 30, 2027

All active NIH projects for Thackery Ian Brown ($436,091)
  • 5R01AG073250-05 Influences of Environmental Geometry and Aging on Cognitive Mapping Mechanisms — $436,091, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 15, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#100 Lab fit 33% · Adjacent Hiring: Unlikely Michigan Neuroscience

Wei Li lab

Wei Li · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

PROJECT SUMMARY/ABSTRACT Rett syndrome (RTT) is the leading cause of severe intellectual disability in girls and women. Individuals with RTT develop typically until 6-­18 months, when autism-­like behaviors and deficits in purposeful hand use and speech start to develop. Loss-­of-­function mutations in the transcriptional regulator methyl-­CpG-­binding protein 2 (MECP2) occur in >95% of RTT cases. Initially, researchers regarded MeCP2 deficiency in neurons as the exclusive cause of RTT. However, recent studies have revealed that glia have a pathological role in RTT etiology. Studies have not y

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 47% × 0.7 domain gate = 33%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $340,297 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$340,297
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $340,297 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-12-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS121542-06 The Pathophysiological Role of Cerebellar Glia in Rett Syndrome

    R01 · NINDS · $340,297 · Apr 1, 2021 to Dec 31, 2026

All active NIH projects for Wei Li ($340,297)
  • 5R01NS121542-06 The Pathophysiological Role of Cerebellar Glia in Rett Syndrome — $340,297, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2021 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#101 Lab fit 33% · Adjacent Hiring: Possible Michigan Neuroscience

Sung Kyun Park lab

Sung Kyun Park · University of Michigan, Ann Arbor MI

PROJECT SUMMARY The rising prevalence of Alzheimer's disease and related dementias (ADRD) is a major public health and clinical challenge in the United States. Identification of ADRD causes to inform prevention and policy is the most efficient way to address these challenges. Most research to date has focused on identifying genetic causes of ADRD, however, recent population-scale studies have shown that environmental exposures, such as lead and cadmium, also contribute to ADRD risk and etiology. Initial findings on environmental factors linked to ADRD risk is promising, but human evidence is l

Lab fit breakdown — 33% weighted · Adjacent

Scored on enough lab text to read as a verdict. 285 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.82 domain gate = 33%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,206,899 in active NIH money across 2 projects, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,206,899
Active projects
2
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,206,899 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2027-12-31 (about 1.3 years) — 5R01ES035087-04, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG070897-05S1 The Study of the Environment and Alzheimer's disease and related Dementias (SEAD)

    R01 · NIA · $90,357 · Mar 15, 2021 to Feb 28, 2027

All active NIH projects for Sung Kyun Park ($1,206,899)
  • 5R01AG070897-05 The Study of the Environment and Alzheimer's disease and related Dementias (SEAD) — $625,839, ends Feb 28, 2027
  • 5R01ES035087-04 Integrated exposome profiling to identify environmental risk factors of metabolic disease in mid- and late-life — $581,060, ends Dec 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 15, 2021 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#102 Lab fit 32% · Adjacent Hiring: Moderate Michigan Neuroscience

Philip D King lab

Philip D King · University of Michigan, Ann Arbor MI

The Ras-Mitogen-activated protein kinase (MAPK) signaling pathway is a critical regulator of blood vascular development and function. Dysregulated Ras-MAPK signaling in blood vascular endothelial cells (EC) leads to different types of vascular malformations, including arteriovenous malformations in which arteries connect di- rectly with veins. Ras is a small GTP-binding protein that cycles between inactive GDP-bound and active GTP- bound states in response to growth factor stimulation. Ras cycling is mediated by Ras guanine nucleotide exchange factors that exchange Ras-bound GDP for GTP, and R

Lab fit breakdown — 32% weighted · Adjacent

Scored on enough lab text to read as a verdict. 310 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.7 domain gate = 32%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "structural biolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,887,325 in active NIH money across 3 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,887,325
Active projects
3
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,887,325 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS139796-02 A Novel Mechanism of Ras Regulation Necessary for Normal Vascular Development

    R01 · NINDS · $584,589 · Aug 1, 2025 to Jun 30, 2030

All active NIH projects for Philip D King ($1,887,325)
  • 2R01HL120888-09A1 Ras-MAPK Regulation of Lymphatic Vessel Valve Development — $660,214, ends Mar 31, 2030
  • 5R01AI165381-04 Roles of Macropinocytosis in HIV-1 infection of CD4+ T Cells — $642,522, ends May 31, 2027
  • 5R01NS139796-02 A Novel Mechanism of Ras Regulation Necessary for Normal Vascular Development — $584,589, ends Jun 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jun 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#103 Lab fit 32% · Adjacent Hiring: Moderate Michigan Neuroscience

Greg Thurber lab

Greg Thurber · University of Michigan, Ann Arbor MI

The ability to selectively modulate the expression of one or more neuronal genes is critical for defining pathways that govern normal brain physiology and diverse disease phenotypes. Anti-sense oligonucleotides (ASOs) are attractive agents for manipulating neuronal gene expression, especially given their clear advantages relative to gene therapy, including that ASO therapy is reversible, nonimmunogenic, and independent of gene size. However, progress has been limited by the need for invasive routes of administration [e.g., intracerebroventricular (ICV) injection], limited cellular uptake, and

Lab fit breakdown — 32% weighted · Adjacent

Scored on enough lab text to read as a verdict. 246 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.7 domain gate = 32%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "single-cell rna".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,642,220 in active NIH money across 3 projects, 4.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,642,220
Active projects
3
Runway left
4.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,642,220 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-04-30 (about 4.6 years) — 1R01CA292699-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “single-cell rna”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS138455-03 Neuron-specific modulation of gene expression using systemically administered bispecific antibody-ASO conjugates

    R01 · NINDS · $599,383 · Jul 1, 2024 to May 31, 2029

All active NIH projects for Greg Thurber ($1,642,220)
  • 1R01CA292699-01A1 Payload Selection to Maximize Multiple Mechanisms of Action for High Avidity Low Affinity Antibody Drug Conjugates — $646,671, ends Apr 30, 2031
  • 5R01NS138455-03 Neuron-specific modulation of gene expression using systemically administered bispecific antibody-ASO conjugates — $599,383, ends May 31, 2029
  • 5R35GM128819-08 Designing Antibody Drug Conjugates for Durable and Complete Therapeutic Responses — $396,166, ends Nov 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#104 Lab fit 32% · Adjacent Hiring: Possible Michigan Neuroscience

Lois S Weisman lab

Lois S Weisman · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT Phosphoinositide signaling lipids are key regulators of endomembrane trafficking and are critical for synaptic function and plasticity. Notably, many synapse-specific trafficking pathways are highly similar to cognate pathways in non-neuronal cells. The specialized trafficking at synapses is largely achieved via modest alterations to generic trafficking pathways. Due to the high demand of traffic at synapses, very minor mutations in these pathways specifically impact the nervous system and underlie a wide range of neurological disorders. PIKfyve and its regulatory prot

Lab fit breakdown — 32% weighted · Adjacent

Scored on enough lab text to read as a verdict. 187 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 50% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 46% × 0.7 domain gate = 32%. No real disease overlap — weighted mean discounted 30%.

What matches

  • AAV / lentiviral delivery and gene therapy Lab text mentions "lentivir".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $938,769 in active NIH money across 2 projects, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$938,769
Active projects
2
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $938,769 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 50%

    Matched 2 of 5 profile areas (14 of 28 weight to saturation).

    • AAV / lentiviral delivery and gene therapy — lab text says “lentivir”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Mouse / rodent in vivo models; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS129198-05 Regulation of parallel recycling pathways at synaptic sites

    R01 · NINDS · $492,520 · Jul 15, 2022 to May 31, 2027

All active NIH projects for Lois S Weisman ($938,769)
  • 5R01NS129198-05 Regulation of parallel recycling pathways at synaptic sites — $492,520, ends May 31, 2027
  • 5R01GM062261-27 Regulation of myosin V interaction with cargo — $446,249, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#105 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience New award

Paulette B. Goforth lab

Paulette B. Goforth · University of Michigan, Ann Arbor MI

Abstract Dysregulated energy balance profoundly impacts human health, as evidenced by the prevalence of obesity with co-morbidities, eating disorders, disease-associated anorexia/cachexia, and the interplay between mood disorders and nutritional status. The dorsal vagal complex (DVC), which includes the area postrema (AP) and nucleus of the solitary tract (NTS), integrates visceral input from the gut and circulating peripheral factors to modulate feeding and energy balance. Current obesity treatments that engage DVC neurons and restrain food intake often have undesirable gastrointestinal side

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 485 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,426,496 in active NIH money across 2 projects, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,426,496
Active projects
2
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,426,496 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-14.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01DK142653-01A1 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DK142653-01A1 Neurobiological mechanisms of energy balance control by hindbrain Prlh-expressing neurons

    R01 · NIDDK · $752,267 · Sep 14, 2026 to May 31, 2030 · Type 1 (new)

  • 5R01DK132008-04 Defining roles for area postrema neuron cell types in food intake and nausea

    R01 · NIDDK · $674,229 · Mar 10, 2023 to Jan 31, 2027

All active NIH projects for Paulette B. Goforth ($1,426,496)
  • 1R01DK142653-01A1 Neurobiological mechanisms of energy balance control by hindbrain Prlh-expressing neurons — $752,267, ends May 31, 2030
  • 5R01DK132008-04 Defining roles for area postrema neuron cell types in food intake and nausea — $674,229, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 14, 2026 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#106 Lab fit 31% · Adjacent Hiring: Strong Michigan Neuroscience New award

David P Olson lab

David P Olson · University of Michigan, Ann Arbor MI

Abstract Dysregulated energy balance profoundly impacts human health, as evidenced by the prevalence of obesity with co-morbidities, eating disorders, disease-associated anorexia/cachexia, and the interplay between mood disorders and nutritional status. The dorsal vagal complex (DVC), which includes the area postrema (AP) and nucleus of the solitary tract (NTS), integrates visceral input from the gut and circulating peripheral factors to modulate feeding and energy balance. Current obesity treatments that engage DVC neurons and restrain food intake often have undesirable gastrointestinal side

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 256 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • CRISPR / conditional knockout genetics Lab text mentions "knockout".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $1,079,035 in active NIH money across 3 projects, 4.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,079,035
Active projects
3
Runway left
4.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 78 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,079,035 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-04-30 (about 4.6 years) — 2T32DK071212-21, which is outside this briefing's scope but is active NIH money for this PI.
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-14.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01DK142653-01A1 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 4 of 5 profile areas (33 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DK142653-01A1 Neurobiological mechanisms of energy balance control by hindbrain Prlh-expressing neurons

    R01 · NIDDK · $752,267 · Sep 14, 2026 to May 31, 2030 · Type 1 (new)

All active NIH projects for David P Olson ($1,079,035)
  • 1R01DK142653-01A1 Neurobiological mechanisms of energy balance control by hindbrain Prlh-expressing neurons — $752,267, ends May 31, 2030
  • 2T32DK071212-21 Developmental Origins of Endocrine and Metabolic Disorders — $203,882, ends Apr 30, 2031
  • 5P30DK020572-49 Molecular Genetics Core — $122,886, ends Nov 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 14, 2026 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#107 Lab fit 31% · Adjacent Hiring: Strong Michigan Neuroscience

Maureen Agnes Sartor lab

Maureen Agnes Sartor · University of Michigan, Ann Arbor MI

ABSTRACT Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, non-curable neurodegenerative disease with a median survival of only 2-4 years from diagnosis. ALS is heterogenous and symptoms and signs can resemble more common illnesses, rendering it difficult to identify in routine clinical practice. As a result, ALS diagnoses are typically delayed over a year from the onset of clinical symptoms. Moreover, patients often lack information regarding their personal anticipated disease course. There is a critical need to improve ALS diagnosis, prognosis, and treatment. Whole blood transcrip

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 481 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.82 domain gate = 31%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,976,923 in active NIH money across 3 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,976,923
Active projects
3
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,976,923 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-06.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS148128-01 Transcriptomics of blood samples in ALS: An untapped resource to advance diagnosis, prognosis, and drug discovery and to gain insights into molecular subtypes of disease

    R01 · NINDS · $619,212 · Jul 6, 2026 to May 31, 2031

  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis

    R01 · NIEHS · $3,133,754 · Sep 10, 2025 to Sep 9, 2029

All active NIH projects for Maureen Agnes Sartor ($3,976,923)
  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis — $3,133,754, ends Sep 9, 2029
  • 1R01NS148128-01 Transcriptomics of blood samples in ALS: An untapped resource to advance diagnosis, prognosis, and drug discovery and to gain insights into molecular subtypes of disease — $619,212, ends May 31, 2031
  • 5P30ES017885-14 Pan Omics and Data Science Core — $223,957, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 6, 2026 · project period to May 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#108 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience

Saravanan Venkatachalam lab

Saravanan Venkatachalam · Wayne State University, Detroit MI

PROJECT SUMMARY Electronic cigarette (e-cig) use during pregnancy has become a major health concern in recent years and is perpetuated by the perception that e-cigs are less harmful than traditional combustible cigarettes. Recent estimates show 7% of women use e-cigs in pregnancy, and 45% view them as less harmful and may help them quit or reduce combustible cigarettes in pregnancy. An extensive knowledge gap persists regarding their health impact when aerosolized, especially during pregnancy. Using our well-established pregnant rat model, we obtained preliminary data utilizing a state-of-the-

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 278 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "autophag".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,147,837 in active NIH money across 1 project, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,147,837
Active projects
1
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,147,837 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “autophag”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01ES037921-01A1 Novel Approaches for Gestational E-Cigarette Vaping-Induced Neuronal Adaptations

    R01 · NIEHS · $2,147,837 · Jun 1, 2026 to May 31, 2030

All active NIH projects for Saravanan Venkatachalam ($2,147,837)
  • 1R01ES037921-01A1 Novel Approaches for Gestational E-Cigarette Vaping-Induced Neuronal Adaptations — $2,147,837, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2026 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#109 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience

Erica Sawyer Levitt lab

Erica Sawyer Levitt · University of Michigan, Ann Arbor MI

Sudden Unexpected Death in Epilepsy (SUDEP) is a leading cause of death in patients with epilepsy. SUDEP mechanisms are not understood, although there is evidence to implicate apnea, autonomic dysfunction, and cardiac arrhythmias. Genes encoding voltage-gated sodium channel subunits are high SUDEP risk genes. Loss- of-function variants in SCN1A are linked to the Developmental and Epileptic Encephalopathy (DEE) Dravet syndrome (DS). Importantly, SCN1A is expressed in both heart and brain. Thus, we proposed that cardiac arrhythmias contribute to the mechanism of SUDEP in channelopathy-linked gen

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 715 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,751,384 in active NIH money across 3 projects, 3.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,751,384
Active projects
3
Runway left
3.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,751,384 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01HL178516-01A1 Neuro-cardiac Mechanisms of Sudden Unexpected Death in Epilepsy

    R01 · NHLBI · $765,515 · May 1, 2026 to Mar 31, 2030

  • 5R01HL174547-03 Brainstem mechanisms of opioid-induced respiratory depression

    R01 · NHLBI · $526,445 · Jul 15, 2024 to Apr 30, 2028

  • 5R01DA061320-03 Serotonin mechanisms in fentanyl-induced respiratory depression

    R01 · NIDA · $459,424 · Jun 15, 2024 to Apr 30, 2027

All active NIH projects for Erica Sawyer Levitt ($1,751,384)
  • 1R01HL178516-01A1 Neuro-cardiac Mechanisms of Sudden Unexpected Death in Epilepsy — $765,515, ends Mar 31, 2030
  • 5R01HL174547-03 Brainstem mechanisms of opioid-induced respiratory depression — $526,445, ends Apr 30, 2028
  • 5R01DA061320-03 Serotonin mechanisms in fentanyl-induced respiratory depression — $459,424, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2026 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#110 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience

Dana M Spence lab

Dana M Spence · Michigan State University, East Lansing MI

PROJECT SUMMARY It is well-established that damage to the myelin sheath, the protein-based substance that surrounds nerve fiber, is a hallmark feature of Multiple Sclerosis (MS), a disease that ~ affects 1 in 800 people in the United States, and females at a higher ratio (~2:1) than males. The neurovascular unit (NVU), a concept in neuroscience that describes the relationship between brain cells, the extracellular matrix (ECM), basement membrane, and associated blood vessels, is at the center of MS pathology. The exact mechanism leading to an attack on the myelin sheath is not known, although

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 601 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • In vivo ocular imaging and functional readouts Lab text mentions "in vivo imaging".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "radiotracer")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,088,185 in active NIH money across 2 projects, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,088,185
Active projects
2
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,088,185 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS137462-02 An Enhanced Neurovascular Model with Scanning Conductance Imaging of Cell Junctions to Determine the Role of Matrix Metalloproteases in Multiple Sclerosis

    R01 · NINDS · $507,292 · Jul 1, 2025 to May 31, 2030

  • 5R01NS105888-08 From single molecule to microfluidic 3D tissue platforms: novel multiscale tools to investigate hyper-stimulated immune cells in the circulation

    R01 · NINDS · $580,893 · Apr 1, 2018 to May 31, 2029

All active NIH projects for Dana M Spence ($1,088,185)
  • 5R01NS105888-08 From single molecule to microfluidic 3D tissue platforms: novel multiscale tools to investigate hyper-stimulated immune cells in the circulation — $580,893, ends May 31, 2029
  • 5R01NS137462-02 An Enhanced Neurovascular Model with Scanning Conductance Imaging of Cell Junctions to Determine the Role of Matrix Metalloproteases in Multiple Sclerosis — $507,292, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2025 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#111 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience

Martin G Myers lab

Martin G Myers · University of Michigan, Ann Arbor MI

Abstract Early models of food intake control held that hypothalamic circuits integrate information about energy storage and utilization to regulate long-term energy balance, while the brainstem dorsal vagal complex (DVC) receives signals from the gut and inflammation (among other stimuli) to modulate only short-term parameters of food intake (e.g., meal size). We now understand that the DVC plays important roles in long-term energy balance, however. The nucleus of the solitary tract (NTS), a component of the DVC, integrates circulating and vagal sensory signals to modulate food intake. We and

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 452 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "cre recombinase".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "rna-seq".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,405,005 in active NIH money across 3 projects, 3.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,405,005
Active projects
3
Runway left
3.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,405,005 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-11-30 (about 3.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “cre recombinase”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “rna-seq”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK141495-02 NTS Neuron Populations that Mediate the Aversive and Non-Aversive Suppression of Food Intake

    R01 · NIDDK · $502,233 · Feb 1, 2025 to Nov 30, 2029

  • 5R01DK132008-04 Defining roles for area postrema neuron cell types in food intake and nausea

    R01 · NIDDK · $674,229 · Mar 10, 2023 to Jan 31, 2027

All active NIH projects for Martin G Myers ($1,405,005)
  • 5R01DK132008-04 Defining roles for area postrema neuron cell types in food intake and nausea — $674,229, ends Jan 31, 2027
  • 5R01DK141495-02 NTS Neuron Populations that Mediate the Aversive and Non-Aversive Suppression of Food Intake — $502,233, ends Nov 30, 2029
  • 5P30DK020572-49 Administrative Core — $228,543, ends Nov 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2025 · project period to Nov 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#112 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience

Shigeki Iwase lab

Shigeki Iwase · University of Michigan, Ann Arbor MI

Abstract One of the long-held mysteries in chromatin signaling is the excessive number of enzymes that install or remove a single chromatin mark. The most extreme case is histone H3 lysine 4 (H3K4me) methylation, a hallmark of transcriptionally active chromatin areas. H3K4me can be placed by six writer enzymes and removed by six eraser enzymes, most of which are expressed broadly in all cell types of the brain and other tissues. Strikingly, 10 of these 12 enzymes are responsible for monogenic forms of neurodevelopmental disorders. These enzymes thus have non-redundant yet poorly understood rol

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 472 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 45% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "splicing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,834,059 in active NIH money across 4 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,834,059
Active projects
4
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,834,059 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH133632-03 Dissecting Histone H3K4 Methylation Enzymes in Neuroplasticity

    R01 · NIMH · $659,441 · Jul 12, 2024 to Jan 31, 2029

  • 5R01NS116008-07 A Neuron-specific Methyl-histone Regulatory Complex

    R01 · NINDS · $598,988 · Jun 1, 2020 to Jul 31, 2030

All active NIH projects for Shigeki Iwase ($1,834,059)
  • 5R01MH133632-03 Dissecting Histone H3K4 Methylation Enzymes in Neuroplasticity — $659,441, ends Jan 31, 2029
  • 5R01NS116008-07 A Neuron-specific Methyl-histone Regulatory Complex — $598,988, ends Jul 31, 2030
  • 1R21MH144311-01 Gene dosage, synaptic neotony, and neurodevelopmental disorders — $429,000, ends Aug 31, 2028
  • 1R03NS148802-01 Identifying the substrates of the PHF21A-containing neuron-specific demethylase complex — $146,630, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 12, 2024 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#113 Lab fit 31% · Adjacent Hiring: Possible Michigan Neuroscience

Sarah L Veatch lab

Sarah L Veatch · University of Michigan, Ann Arbor MI

PROJECT SUMMARY The plasma membrane dictates how cells sense and respond to their environment, informing cellular decisions to, for example, proliferate, mature into other cell types, respond to pathogens, transmit electrical signals, or strengthen neuronal connections in the brain. Lipids and proteins within membranes act collectively to provide both a physical barrier to the extracellular space and the ability to selectively transmit information and materials to the cell. Defects in these processes lead to diverse human diseases ranging from cancer to immunodeficiency to neurodegeneration. W

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 199 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.82 domain gate = 31%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Calcium and mechanosensitive channel signalling Lab text mentions "ion channel".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $565,488 in active NIH money across 1 project, 2.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$565,488
Active projects
1
Runway left
2.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $565,488 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-11-30 (about 2.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM152150-03 Functional Roles of the Membrane Phase Transition in Cellular Physiology

    R35 · NIGMS · $565,488 · Jan 1, 2024 to Nov 30, 2028

All active NIH projects for Sarah L Veatch ($565,488)
  • 5R35GM152150-03 Functional Roles of the Membrane Phase Transition in Cellular Physiology — $565,488, ends Nov 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 1, 2024 · project period to Nov 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#114 Lab fit 31% · Adjacent Hiring: Possible Atlanta Neuroscience

Irene Yang lab

Irene Yang · Emory University, Atlanta GA

Abstract Alzheimer’s disease (AD) affects 6.5 million Americans inflicting tremendous burden on our society both economically and in terms of human suffering, yet the etiology of AD is not fully understood. Risk factors for AD are numerous and include demographic, genetic, lifestyle, medical, environmental, psychiatric, and infectious factors. Among the infectious factors known to be associated with AD is periodontal disease (PerioD). PerioD is a polymicrobial infection of the gingival tissue and one of the most common conditions of the oral cavity. There is a growing interest in the connectio

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 333 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.82 domain gate = 31%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "allele".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $774,368 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$774,368
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $774,368 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS133809-03 The Contribution of the Oral Microbiome to Alzheimer’s Disease Risk

    R01 · NINDS · $774,368 · Sep 12, 2023 to May 31, 2029

All active NIH projects for Irene Yang ($774,368)
  • 5R01NS133809-03 The Contribution of the Oral Microbiome to Alzheimer’s Disease Risk — $774,368, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 12, 2023 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#115 Lab fit 31% · Adjacent Hiring: Moderate Michigan Neuroscience

Rebecca Knickmeyer lab

Rebecca Knickmeyer · Michigan State University, East Lansing MI

PROJECT SUMMARY Prenatal exposure to maternal psychosocial stress and environmental contaminants is associated with reduced cognitive performance in children. However, efforts to support cognitive development in exposed children are hindered by limited understanding of the mechanisms underlying these epidemiological associations. Our project will address this gap by focusing on 2 potential mechanistic pathways (inflammation and the gut microbiome), which are potentially modifiable. Our central hypothesis is that these pathways alter neurodevelopmental processes (including neurogenesis, neural

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 598 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.82 domain gate = 31%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Axonal transport and neuronal injury assays Lab text mentions "neurite".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,780,079 in active NIH money across 4 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,780,079
Active projects
4
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,780,079 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years) — 1R21HD121237-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01HD107019-04 Prenatal Maternal Stress, Exposure to Environmental Chemicals, and Cognitive Development: Potential Roles for Inflammation and the Developing Gut Microbiome

    R01 · NICHD · $644,271 · Aug 22, 2022 to Jan 31, 2028

  • 5R01MH123716-05 Genetic Influences on Infant Brain Development: Understanding the Developmental Origins of Mental Illness

    R01 · NIMH · $1,011,745 · May 17, 2021 to Mar 31, 2027

All active NIH projects for Rebecca Knickmeyer ($2,780,079)
  • 5R01MH123716-05 Genetic Influences on Infant Brain Development: Understanding the Developmental Origins of Mental Illness — $1,011,745, ends Mar 31, 2027
  • 5R01MH122526-05 The Development of Gut Microbiota and Behavioral Inhibition in Childhood: The Role of Early Stress and Brain Development — $692,313, ends Jun 30, 2027
  • 5R01HD107019-04 Prenatal Maternal Stress, Exposure to Environmental Chemicals, and Cognitive Development: Potential Roles for Inflammation and the Developing Gut Microbiome — $644,271, ends Jan 31, 2028
  • 1R21HD121237-01A1 Impact of Urbanicity on Infant Brain Structure and Function via the Gut-Brain Axis — $431,750, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 22, 2022 · project period to Jan 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#116 Lab fit 31% · Adjacent Hiring: Moderate Atlanta Neuroscience

Anita H. Corbett lab

Anita H. Corbett · Emory University, Atlanta GA

Project Summary Post-transcriptional control of mRNAs plays a key role in regulating important developmental events via RNA binding proteins (RBPs) that modulate key aspects of RNA fate, including splicing, stability, and translation. Developmental roles of RBPs are particularly evident in the nervous system, where their loss is linked to an array of diseases. Understanding how individual RBPs contribute to tissue-specific developmental events is complicated by their generally ubiquitous expression and by the insufficiency of consensus RBP-binding sites to predict in vivo occupancy or regulati

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 260 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "splicing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,404,635 in active NIH money across 6 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,404,635
Active projects
6
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,404,635 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years) — 5T32GM135060-07, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS125768-05 A Conserved RNA Binding Protein Required for Control of Key Developmental Pathways

    R01 · NINDS · $379,161 · Feb 1, 2022 to Jan 31, 2027

All active NIH projects for Anita H. Corbett ($2,404,635)
  • 5T32GM148391-04 IMSD at Emory University — $669,996, ends Jan 31, 2028
  • 5T32GM135060-07 Training Program in Biochemistry, Cell and Development Biology — $431,337, ends Jun 30, 2030
  • 5R01NS125768-05 A Conserved RNA Binding Protein Required for Control of Key Developmental Pathways — $379,161, ends Jan 31, 2027
  • 5R25AI175048-03 INfectious Diseases Summer Program Integrating Research at Emory (INSPIRE) — $378,762, ends Apr 30, 2029
  • 5T34GM149511-04 MARC at Emory University — $349,754, ends May 31, 2028
  • 1R21AI193385-01A1 Role of the DEAH-Box RNA helicase DHX29 during Class Switch Recombination in B-cells — $195,625, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#117 Lab fit 31% · Adjacent Hiring: Possible Atlanta Neuroscience

Kenneth H Moberg lab

Kenneth H Moberg · Emory University, Atlanta GA

Project Summary Post-transcriptional control of mRNAs plays a key role in regulating important developmental events via RNA binding proteins (RBPs) that modulate key aspects of RNA fate, including splicing, stability, and translation. Developmental roles of RBPs are particularly evident in the nervous system, where their loss is linked to an array of diseases. Understanding how individual RBPs contribute to tissue-specific developmental events is complicated by their generally ubiquitous expression and by the insufficiency of consensus RBP-binding sites to predict in vivo occupancy or regulati

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 260 words of lab text were scored, matching 5 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 60% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "splicing".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $760,183 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$760,183
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $760,183 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 60%

    Matched 3 of 7 profile areas (18 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “splicing”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS125768-05 A Conserved RNA Binding Protein Required for Control of Key Developmental Pathways

    R01 · NINDS · $379,161 · Feb 1, 2022 to Jan 31, 2027

All active NIH projects for Kenneth H Moberg ($760,183)
  • 1R56AG085250-01A1 Control of Drosophila intestinal homeostasis by RhoGap15b — $381,022, ends Aug 31, 2027
  • 5R01NS125768-05 A Conserved RNA Binding Protein Required for Control of Key Developmental Pathways — $379,161, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#118 Lab fit 31% · Adjacent Hiring: Unlikely Michigan Neuroscience

Miriam H Meisler lab

Miriam H Meisler · University of Michigan, Ann Arbor MI

ABSTRACT During the previous funding period, we generated a conditional mouse model of the recurrent sodium channel mutation SCN8A-p.R1872W that is responsible for the rare, devastating disorder Developmental Epileptic Encephalopathy (DEE). We demonstrated that expression of the mutant channel in excitatory neurons of the forebrain reproduces the seizures and sudden death of the human disorder. We also developed an effective treatment for Scn8a-DEE by intracerebroventricular administration of an antisense oligonucleotide (ASO) that reduced both mutant and wildtype transcript level throughout t

Lab fit breakdown — 31% weighted · Adjacent

Scored on enough lab text to read as a verdict. 286 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 100% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 44% × 0.7 domain gate = 31%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "adeno-associated".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Sequencing, variant and splicing analysis Lab text mentions "exome".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $465,915 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$465,915
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $465,915 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-01-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 100%

    Matched 3 of 5 profile areas (28 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “adeno-associated”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “exome”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS034509-29 Functional Genetics of the Neuronal Sodium Channel Gene SCN8A

    R01 · NINDS · $465,915 · May 1, 1996 to Jan 31, 2027

All active NIH projects for Miriam H Meisler ($465,915)
  • 5R01NS034509-29 Functional Genetics of the Neuronal Sodium Channel Gene SCN8A — $465,915, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 1996 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#119 Lab fit 30% · Adjacent Hiring: Strong Michigan Neuroscience

Soo-eun Chang lab

Soo-eun Chang · University of Michigan, Ann Arbor MI

Treatment options for stuttering remain severely limited, with reported success rates of current interventions for children who stutter failing to exceed natural (unassisted) recovery rates. There is a significant need to develop novel treatments informed by an updated neuroscientific understanding of stuttering. Systematic empirical work as well as theoretical perspectives have pointed to an association between deficits in the basal ganglia thalamocortical (BGTC) network and the onset and persistence of stuttering. A key function supported by the BGTC network is timing and initiation of speec

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 646 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $1,897,290 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,897,290
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 73 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,897,290 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-20.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DC023753-01 Digital rhythm games for stuttering intervention

    R01 · NIDCD · $648,923 · Jul 20, 2026 to Jun 30, 2031

  • 5R01DC022763-02 Organization and development of motor cortical circuits for speech production in stuttering

    R01 · NIDCD · $616,719 · Apr 1, 2025 to Mar 31, 2030

  • 5R01DC011277-16 A longitudinal study of neural network development in children who stutter

    R01 · NIDCD · $631,648 · Sep 29, 2010 to Jan 31, 2027

All active NIH projects for Soo-eun Chang ($1,897,290)
  • 1R01DC023753-01 Digital rhythm games for stuttering intervention — $648,923, ends Jun 30, 2031
  • 5R01DC011277-16 A longitudinal study of neural network development in children who stutter — $631,648, ends Jan 31, 2027
  • 5R01DC022763-02 Organization and development of motor cortical circuits for speech production in stuttering — $616,719, ends Mar 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 20, 2026 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#120 Lab fit 30% · Adjacent Hiring: Moderate Atlanta Neuroscience

Shella D Keilholz lab

Shella D Keilholz · Emory University, Atlanta GA

Resting state functional magnetic resonance imaging (rs-fMRI) contains a wealth of information about the large-scale structure of intrinsic neural activity in the brain and is widely used to study alterations in neurological or psychiatric disorders. Our prior work demonstrates that intrinsic brain activity is dominated by a few whole- brain spatiotemporal patterns that occur repeatedly over time, but little is known about the mechanisms that coordinate these patterns and therefore about how altered patterns in brain disorders should be interpreted. The spatiotemporal patterns exhibit features

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 199 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $994,811 in active NIH money across 2 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$994,811
Active projects
2
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $994,811 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2030-12-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-01-23.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS140219-01A1 Contribution of cell-specific activity to functional MRI

    R01 · NINDS · $577,611 · Jan 23, 2026 to Dec 31, 2030

All active NIH projects for Shella D Keilholz ($994,811)
  • 1R01NS140219-01A1 Contribution of cell-specific activity to functional MRI — $577,611, ends Dec 31, 2030
  • 1R21MH140191-01 Characterizing and manipulating large-scale activity in the brain — $417,200, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 23, 2026 · project period to Dec 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#121 Lab fit 30% · Adjacent Hiring: Moderate Michigan Neuroscience

Quan Jiang lab

Quan Jiang · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

ABSTRACT The objectives of this proposal are to optimize and validate detection of microvessels in the cerebral vascular, glymphatic and meningeal lymphatic (ML) systems using superparamagnetic iron oxide (SPIO)-enhanced susceptibility weighted imaging (SWI, SPIO-SWI), and then to investigate the cerebral waste clearance in the vascular, glymphatic and ML systems during progression of Alzheimer’s Disease (AD). Emerging data indicate that the waste clearance from the brain parenchyma plays an important role in neurological diseases, especially neurodegenerative diseases1-9. Waste clearance from

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 240 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "animal model".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,675,335 in active NIH money across 2 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,675,335
Active projects
2
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,675,335 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG094722-01 Efflux Route Responses of Cerebral Waste Clearance During Progression of Alzheimer’s Disease

    RF1 · NIA · $3,062,355 · Sep 15, 2025 to Aug 31, 2029

All active NIH projects for Quan Jiang ($3,675,335)
  • 1RF1AG094722-01 Efflux Route Responses of Cerebral Waste Clearance During Progression of Alzheimer’s Disease — $3,062,355, ends Aug 31, 2029
  • 5R01DK136843-03 Imaging cerebral waste clearance responses during exosome treatment of diabetes — $612,980, ends Mar 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2025 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#122 Lab fit 30% · Adjacent Hiring: Moderate Michigan Neuroscience

Stuart A Batterman lab

Stuart A Batterman · University of Michigan, Ann Arbor MI

ABSTRACT Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no cure or meaningful treat- ments. ALS is mostly sporadic, and for most, evidence supports a gene-time-environment hypothesis of ALS triggered by a confluence of nonmodifiable risk factors (age, sex, and genetics) and modifiable risk factors from the exposome (a person’s cumulative lifetime exposures). Exposures imprint on the epigenome via DNA meth- ylation (DNAm) marks, which change with age, modifying cellular response to environmental insults. Compre- hensive knowledge of all these factors is needed to

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 230 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "survey")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,295,554 in active NIH money across 2 projects, 3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,295,554
Active projects
2
Runway left
3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,295,554 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-09-09 (about 3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis

    R01 · NIEHS · $3,133,754 · Sep 10, 2025 to Sep 9, 2029

All active NIH projects for Stuart A Batterman ($3,295,554)
  • 1R01ES037968-01 Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis — $3,133,754, ends Sep 9, 2029
  • 5P30ES017885-14 Exposure Assessment Core — $161,800, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 10, 2025 · project period to Sep 9, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#123 Lab fit 30% · Adjacent Hiring: Moderate Michigan Neuroscience

Maria G Castro lab

Maria G Castro · University of Michigan, Ann Arbor MI

Molecular profiling of gliomas led to their genetic classification and a better understanding of their pathophysiology. Adult mutant IDH1 gliomas are characterized by a mutation in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) at active site residue R132. The mutation imparts a gain-of-function catalytic activity which leads to the conversion of α-ketoglutarate (αKG) to (R)-2-hydroxyglutarate (2HG). 2HG is a competitive inhibitor of histone 3 (H3) lysine-specific demethylases (KDMs) and of DNA demethylation by ten-eleven translocation methylcytosine dioxygenases (TETs). KDM and TET in

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 255 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "gene therapy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,080,628 in active NIH money across 5 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,080,628
Active projects
5
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,080,628 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years) — 5T32CA009676-33, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “gene therapy”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R37NS144573-02 Neuro-immune mechanisms in mutant IDH1 gliomas

    R37 · NINDS · $648,065 · Aug 1, 2025 to Jun 30, 2029

All active NIH projects for Maria G Castro ($2,080,628)
  • 5R37NS144573-02 Neuro-immune mechanisms in mutant IDH1 gliomas — $648,065, ends Jun 30, 2029
  • 5R01NS122165-05 Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma. — $505,859, ends Dec 31, 2026
  • 5R01NS124167-05 Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics — $465,399, ends Feb 28, 2027
  • 5T32CA009676-33 Training Program in Tumor Microenvironment — $346,694, ends Aug 31, 2029
  • 5P30CA046592-37 Immunologic Monitoring (IM) — $114,611, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#124 Lab fit 30% · Adjacent Hiring: Possible Atlanta Neuroscience

Firas Kobaissy lab

Firas Kobaissy · Morehouse School of Medicine, Atlanta GA

Abstract Summary We hypothesize that we can increase systemically develop a progressive murine TBI-ADRD model with internal and external validity with a “Team-Science”-based two-phase ADRD-relevant phenotype enrichment strategy. This 'Team Science' framework allows us to leverage and integrate the complementary experience and expertise our 5-site multidisciplinary animal model testing team. This collaborative design aims to improve model reproducibility by testing each model at two sites, and the use of standard operation procedure (SOP), common data elements, (CDE) for method/data collection

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 235 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $2,283,334 in active NIH money across 1 project, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,283,334
Active projects
1
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,283,334 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1RF1NS138029-01 TBI-ADRD Modeling with a Team Science Approach (TBI-ADRD Team Science)

    RF1 · NINDS · $2,283,334 · Sep 18, 2024 to Aug 31, 2027

All active NIH projects for Firas Kobaissy ($2,283,334)
  • 1RF1NS138029-01 TBI-ADRD Modeling with a Team Science Approach (TBI-ADRD Team Science) — $2,283,334, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 18, 2024 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#125 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuroscience

Yu Wang lab

Yu Wang · University of Michigan, Ann Arbor MI

ABSTRACT mTORopathies, such as focal cortical dysplasia type II (FCDII), is the most common underlying pathology in children with drug-resistant epilepsies. However, the underlying mechanisms of epileptogenesis, hyperexcitability, and disease progression remain largely elusive. In this proposal, we combine animal models and resected human tissues to understand the cellular and molecular logic networks in the dysplastic cortex. We use cutting-edge technologies in molecular genetics, electrophysiology, transgenics, and RNA sequencing to provide conceptual insights broadly relevant to understandi

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 237 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $519,825 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$519,825
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $519,825 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS136181-03 Decoding the cellular and molecular mechanisms of epileptogenesis and disease progression in mTORopathies

    R01 · NINDS · $519,825 · Jul 1, 2024 to May 31, 2029

All active NIH projects for Yu Wang ($519,825)
  • 5R01NS136181-03 Decoding the cellular and molecular mechanisms of epileptogenesis and disease progression in mTORopathies — $519,825, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#126 Lab fit 30% · Adjacent Hiring: Moderate Michigan Neuroscience

Donovan T Maust lab

Donovan T Maust · University of Michigan, Ann Arbor MI

PROJECT ABSTRACT In 2016, nearly 800,000 Americans were long-stay nursing home (NH) residents. While 45% have dementia, over 30% have a psychiatric diagnosis. In fact, NHs are the most important institutional setting of care for adults with bipolar disorder, schizophrenia, or other psychotic disorders (“serious mental illness” [SMI] hereafter). Individuals with SMI are more likely to spend time in a NH than counterparts without SMI, and the proportion of NH residents with SMI has nearly doubled over the past decade, growing to 18.6% by 2017. However, understanding NH care for SMI requires also

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 509 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "health services")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $18,470,307 in active NIH money across 3 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$18,470,307
Active projects
3
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $18,470,307 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4RF1AG082011-02 The Impact of Alzheimer’s Disease and Related Dementias on Nursing Home Care and Quality for Persons with Serious Mental Illness

    RF1 · NIA · $1,546,956 · Sep 30, 2023 to Aug 31, 2028

  • 5R01AG074957-05 Prescribing without a guide: A national study of psychotropic and opioid polypharmacy among persons living with dementia

    R01 · NIA · $724,326 · Apr 15, 2022 to Dec 31, 2026

All active NIH projects for Donovan T Maust ($18,470,307)
  • 5U54AG084520-04 The National Dementia Workforce Study — $16,199,025, ends Aug 31, 2028
  • 4RF1AG082011-02 The Impact of Alzheimer’s Disease and Related Dementias on Nursing Home Care and Quality for Persons with Serious Mental Illness — $1,546,956, ends Aug 31, 2028
  • 5R01AG074957-05 Prescribing without a guide: A national study of psychotropic and opioid polypharmacy among persons living with dementia — $724,326, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2023 · project period to Aug 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#127 Lab fit 30% · Adjacent Hiring: Possible Atlanta Neuroscience

Carolyn Kay Clevenger lab

Carolyn Kay Clevenger · Emory University, Atlanta GA

Abstract The costs and management of Alzheimer’s disease and related disorders are borne by families, the backbone of the care system for persons living with dementia (PLWD). More than 11 million informal caregivers currently guide the daily lives, fortunes, and care system interactions of PLWD. Promoting effective coping behaviors by strengthening caregivers’ capacities for navigating interactions with systems and structures that provide needed care for PLWD may reduce the high levels of caregiver stress. Ensuring that these systems and structures are effectively accessed and deployed may ben

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 276 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $713,371 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$713,371
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $713,371 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG082833-04 Caregiver as Navigator-Developing Skills Online (CAN-DO): Developing Dementia Family Caregiver Mastery for Navigating Complex Health, Social Service, Legal, Financial, and Family Systems

    R01 · NIA · $713,371 · Sep 1, 2023 to May 31, 2028

All active NIH projects for Carolyn Kay Clevenger ($713,371)
  • 5R01AG082833-04 Caregiver as Navigator-Developing Skills Online (CAN-DO): Developing Dementia Family Caregiver Mastery for Navigating Complex Health, Social Service, Legal, Financial, and Family Systems — $713,371, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#128 Lab fit 30% · Adjacent Hiring: Possible Atlanta Neuroscience

Ebrahim Haroon lab

Ebrahim Haroon · Emory University, Atlanta GA

Project Summary: Chronic inflammation and glutamate dysregulation are pathological processes that precede and hasten brain aging and degeneration in major depression (MD). Herein, we propose the kynurenine (KYN) pathway as a mediator of the association between inflammation and glutamate pathologies. Kynurenines are neuroactive molecules that readily access the brain from the periphery via dedicated transporters known as large neutral amino acid transporters (LAT-1) located in the blood-brain barrier. Once inside the brain, KYN is converted by activated microglial cells into metabolites such as

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 333 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Mouse / rodent in vivo models Lab text mentions "rodent".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $682,162 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$682,162
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $682,162 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH132059-04 Leucine as a Probe of Kynurenine-Induced Glutamate and Neural Circuit Dysfunction in Midlife Depression

    R01 · NIMH · $682,162 · Jul 17, 2023 to May 31, 2028

All active NIH projects for Ebrahim Haroon ($682,162)
  • 5R01MH132059-04 Leucine as a Probe of Kynurenine-Induced Glutamate and Neural Circuit Dysfunction in Midlife Depression — $682,162, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 17, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#129 Lab fit 30% · Adjacent Hiring: Moderate Michigan Neuroscience

Donna M. Martin lab

Donna M. Martin · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT The aim of this proposal is to determine how heterozygous mutation of the chromatin remodeler CHD7 (Chromodomain Helicase DNA-binding protein 7) disrupts development of the neocortex, leading to the neurodevelopmental anomalies associated with CHARGE syndrome. CHARGE syndrome is characterized by substantial behavioral and cognitive problems, including executive dysfunction and Autism Spectrum Disorder (ASD). The proposed research team recently identified abnormalities in the neocortex of Chd7 heterozygous mice, implicating CHD7 in key, temporally distinct developmental

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 264 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "confocal".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,531,942 in active NIH money across 3 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,531,942
Active projects
3
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,531,942 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “confocal”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS129562-04 Dissecting Cell Type Specific Functions of CHD7 in Development of the Neocortex

    R01 · NINDS · $516,297 · Jul 1, 2023 to Jun 30, 2028

All active NIH projects for Donna M. Martin ($1,531,942)
  • 5R01EY035110-04 Functions of chromatin remodeler Chd7 in retinal cell development — $607,143, ends Jul 31, 2027
  • 5R01NS129562-04 Dissecting Cell Type Specific Functions of CHD7 in Development of the Neocortex — $516,297, ends Jun 30, 2028
  • 5K12HD028820-34 Advancing Child Health Through Cellular and Molecular Biology — $408,502, ends Nov 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#130 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuroscience

Jin He lab

Jin He · Michigan State University, East Lansing MI

Project Abstract ASH1L (Absent, Small, or Homeotic discs 1-Like) is a histone methyltransferase facilitating gene expression through its-mediated chromatin modification. Recent genetic studies on large cohorts of autism spectrum disorder (ASD) patients identify ASH1L is one of top ASD risk genes. The genetic findings are further supported by many clinical reports that children diagnosed with ASD acquire various de novo ASH1L mutations. To understand the pathogenic role of disruptive ASH1L mutations in ASD pathogenesis, we used the Ash1l conditional knockout (cKO) mice to show that deletion of

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 507 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "conditional knockout".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,036,458 in active NIH money across 1 project, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,036,458
Active projects
1
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,036,458 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “conditional knockout”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH130544-02 Epigenetic mechanisms of histone methyltransferase ASH1L in autism spectrum disorder

    R01 · NIMH · $518,229 · Jun 15, 2023 to Apr 30, 2028

  • 4RF1MH130544-04 Epigenetic mechanisms of histone methyltransferase ASH1L in autism spectrum disorder

    RF1 · NIMH · $1,036,458 · Jun 15, 2023 to Apr 30, 2028

All active NIH projects for Jin He ($1,036,458)
  • 4RF1MH130544-04 Epigenetic mechanisms of histone methyltransferase ASH1L in autism spectrum disorder — $1,036,458, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 15, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#131 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuroscience

Manojkumar A Puthenveedu lab

Manojkumar A Puthenveedu · University of Michigan, Ann Arbor MI

This proposal addresses an exciting aspect of the biology of the delta opioid receptor (DOR), a prototypical and clinically relevant G protein-coupled receptor (GPCR) that has long been considered a promising target for treating pain and opioid addiction - two highly prevalent and comorbid diseases. Pain, one of the most common symptoms presented at hospitals, is currently managed primarily by opioid analgesics that target the mu-opioid receptor. While effective, their use is highly limited due to extensive side effects and a high potential for addiction. DOR activation is a promising alternat

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,050,120 in active NIH money across 2 projects, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,050,120
Active projects
2
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,050,120 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-01-31 (about 1.3 years) — 5R01DA008863-31, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA055026-05 Regulated trafficking and compartmentalized signaling of opioid receptors

    R01 · NIDA · $461,789 · Sep 15, 2022 to Jul 31, 2027

All active NIH projects for Manojkumar A Puthenveedu ($1,050,120)
  • 5R01DA008863-31 Regulation Of Opioid Receptor Signaling by Endogenous Peptides — $588,331, ends Jan 31, 2028
  • 5R01DA055026-05 Regulated trafficking and compartmentalized signaling of opioid receptors — $461,789, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#132 Lab fit 30% · Adjacent Hiring: Unlikely Michigan Neuroscience

Amanda Noel Leggett lab

Amanda Noel Leggett · Wayne State University, Detroit MI

ABSTRACT Caregivers of persons living with dementia (PLwD) do not act in isolation and are typically involved in broader networks of family and friends who also assist with care, and yet this expanded caregiver network is largely neglected in research. Theories of mutual influence and empirical work suggest that caregivers’ stress and mental health have a negative impact on both caregivers and PLwD, yet recent reports and meta-analyses suggest disappointingly small effects of care-related behavioral interventions. Given that PLwD typically have broad networks involved in care, an exclusive foc

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $441,160 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$441,160
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $441,160 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG079097-04 Profiling Psychosocial Dementia Caregiving Networks: The Impact of Dementia Care Networks on Care Outcomes of Medicare Enrollee Persons Living with Dementia

    R01 · NIA · $441,160 · Sep 1, 2022 to May 31, 2027

All active NIH projects for Amanda Noel Leggett ($441,160)
  • 5R01AG079097-04 Profiling Psychosocial Dementia Caregiving Networks: The Impact of Dementia Care Networks on Care Outcomes of Medicare Enrollee Persons Living with Dementia — $441,160, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#133 Lab fit 30% · Adjacent Hiring: Moderate Atlanta Neuroscience

Vasiliki Michopoulos lab

Vasiliki Michopoulos · Emory University, Atlanta GA

Abstract The number of people suffering from age-related cognitive decline is growing at an unprecedented rate as the human lifespan increases. In addition, exposure to social adversity and other stressors increases risk for cognitive deficits which may be exacerbated in aging. Because women are at greater risk for developing cognitive impairment compared to men, a potential role for estradiol is implicated. However, findings from studies assessing the effects of estradiol on cognition are equivocal. Consequently, there is a need to understand whether adverse experiential factors may impact es

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 259 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Non-rodent animal models Lab text mentions "nonhuman primate".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,772,225 in active NIH money across 5 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,772,225
Active projects
5
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,772,225 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years) — 5K12AR084234-13, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG078248-05 The role of stress exposure on estradiol-induced changes in neuroinflammation and cognition

    R01 · NIA · $745,028 · Sep 1, 2022 to May 31, 2027

All active NIH projects for Vasiliki Michopoulos ($4,772,225)
  • 5U54AG062334-07 Emory Specialized Center of Research Excellence (SCORE) on Sex Differences — $1,498,001, ends Jul 31, 2030
  • 5TL1TR002382-10 J. NRSA Training Core — $928,815, ends Jul 31, 2027
  • 5K12AR084234-13 Emory University BIRCWH Program — $907,200, ends Aug 31, 2030
  • 5R01AG078248-05 The role of stress exposure on estradiol-induced changes in neuroinflammation and cognition — $745,028, ends May 31, 2027
  • 5R01MH128244-05 Neuroendocrine Mechanisms Underlying Perimenopausal Risk for Trauma-Related Hyperarousal in Black Women — $693,181, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#134 Lab fit 30% · Adjacent Hiring: Possible Atlanta Neuroscience

Garrett B. Stanley lab

Garrett B. Stanley · Georgia Institute of Technology, Atlanta GA

Feedback and feedforward gating of sensory signaling through timing in the thalamocortical loop Nearly all sensory experience begins in the periphery, generating sensory signals travelling through the thalamus before reaching neocortex. Despite numerous anatomical and functional investigations into the feedforward projections from thalamus to primary sensory cortex (TC), significantly less is known about the extensive reciprocal corticothalamic (CT) feedback pathway that provides ~40% of input to the thalamus. One proposed role of CT feedback is to control the salience of ascending sensory sig

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 199 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $742,072 in active NIH money across 2 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$742,072
Active projects
2
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $742,072 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years) — 5T32EB025816-08, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS128896-03 Feedback and feedforward gating of sensory signaling through timing in the thalamocortical loop

    R01 · NINDS · $480,840 · Aug 19, 2022 to Jul 31, 2027

All active NIH projects for Garrett B. Stanley ($742,072)
  • 5R01NS128896-03 Feedback and feedforward gating of sensory signaling through timing in the thalamocortical loop — $480,840, ends Jul 31, 2027
  • 5T32EB025816-08 Training in Computational Neural Engineering — $261,232, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 19, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#135 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuroscience

Omar Jamil Ahmed lab

Omar Jamil Ahmed · University of Michigan, Ann Arbor MI

ABSTRACT / PROJECT SUMMARY Chronic stress is thought to play a role in multiple neuropsychiatric disorders. Standard pharmacological treatments for stress-related disorders can take up to several months to elicit a therapeutic response and can produce long-term undesirable off-target effects. A single dose of the psychedelic drug psilocybin has been shown to rapidly promote long-lasting therapeutic effects in humans and in chronically stressed rodents. However, the neural circuit mechanisms underlying the lasting changes induced by psilocybin in healthy and chronically stressed brains remain u

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 204 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 86% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $819,000 in active NIH money across 2 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$819,000
Active projects
2
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $819,000 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-07-31 (about 1.8 years) — 1R21MH144686-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 86%

    Matched 3 of 5 profile areas (24 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH129282-05 Circuit Mechanisms of Psilocybin Following Chronic Stress

    R01 · NIMH · $390,000 · Jun 10, 2022 to Apr 30, 2027

All active NIH projects for Omar Jamil Ahmed ($819,000)
  • 1R21MH144686-01 Psychedelic neuroplastogen rescue of cognitive flexibily in autism spectrum disorder — $429,000, ends Jul 31, 2028
  • 5R01MH129282-05 Circuit Mechanisms of Psilocybin Following Chronic Stress — $390,000, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 10, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#136 Lab fit 30% · Adjacent Hiring: Unlikely Michigan Neuroscience

Carrie Ferrario lab

Carrie Ferrario · University of Michigan, Ann Arbor MI

PROJECT SUMMARY: 40% of U.S. adults are obese. Obesity produces type II diabetes, which increases the risk for cardiovascular disease, many cancers, and Alzheimer's. The NIH strategic plan for obesity research provides “a blueprint (to) encourage the research community to examine the epidemic of obesity from diverse perspectives…in order to develop and evaluate new prevention and treatment strategies”. Further, the NIDDK Cognitive and Clinical Neuroscience of Obesity Program was formed to promote studies of “non-homeostatic brain-behavior mechanisms (to prevent) obesity”. This proposal directl

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 285 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "rat".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "patch clamp")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $523,013 in active NIH money across 1 project, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$523,013
Active projects
1
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $523,013 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rat”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK130246-04 Striatal glutamatergic plasticity and junk-food induced enhancements in cue-triggered food-craving

    R01 · NIDDK · $523,013 · May 3, 2022 to Mar 31, 2027

All active NIH projects for Carrie Ferrario ($523,013)
  • 5R01DK130246-04 Striatal glutamatergic plasticity and junk-food induced enhancements in cue-triggered food-craving — $523,013, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 3, 2022 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#137 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuroscience

Sarah Elizabeth Vordenberg lab

Sarah Elizabeth Vordenberg · University of Michigan, Ann Arbor MI

PROJECT ABSTRACT The U.S. health care system is poorly equipped to deal with the growing number of persons living with dementia (PLWD) in the U.S. and their complex medical and psychosocial needs. While memory impairment is the cardinal feature of Alzheimer’s disease and related dementias (ADRD), behavioral and psychological symptoms (e.g., apathy, delusions, agitation) are common during all stages of illness and cause significant caregiver distress. Despite limited high-quality evidence of efficacy for pharmacological treatment, our work has shown that clinicians prescribe psychotropic medica

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 236 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "er stress".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $724,326 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$724,326
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $724,326 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-12-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “er stress”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG074957-05 Prescribing without a guide: A national study of psychotropic and opioid polypharmacy among persons living with dementia

    R01 · NIA · $724,326 · Apr 15, 2022 to Dec 31, 2026

All active NIH projects for Sarah Elizabeth Vordenberg ($724,326)
  • 5R01AG074957-05 Prescribing without a guide: A national study of psychotropic and opioid polypharmacy among persons living with dementia — $724,326, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 15, 2022 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#138 Lab fit 30% · Adjacent Hiring: Possible Atlanta Neuroscience

Richard David Wainford lab

Richard David Wainford · Emory University, Atlanta GA

ABSTRACT Hypertension is a key risk factor for the development of cerebral small vessel disease, the foremost source of vascular cognitive impairment which is the second most common cause of dementia after Alzheimer’s disease. There is increasing evidence that blood brain barrier dysfunction and neuroinflammation play a pivotal role in the pathophysiology of hypertension and contribute to the development of vascular cognitive impairment. While Angiotensin II Type 1 receptor antagonists are first line therapy to treat hypertension they have recently been demonstrated to improve neurocognitive f

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 239 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Mouse / rodent in vivo models Lab text mentions "rodent".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $757,009 in active NIH money across 1 project, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$757,009
Active projects
1
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $757,009 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-01-31 (about 1.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG075963-04 Age-related Hypertension and Vascular Cognitive Impairment

    R01 · NIA · $757,009 · Feb 1, 2022 to Jan 31, 2028

All active NIH projects for Richard David Wainford ($757,009)
  • 5R01AG075963-04 Age-related Hypertension and Vascular Cognitive Impairment — $757,009, ends Jan 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2022 · project period to Jan 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#139 Lab fit 30% · Adjacent Hiring: Moderate Michigan Autophagy / organelle QC

Matthias Christof Truttmann lab

Matthias Christof Truttmann · University of Michigan, Ann Arbor MI

ABSTRACT The primary goal of this MIRA R35 project is to define the molecular mechanisms by which protein AMPylation regulates proteostasis in normal physiology and in the context of protein misfolding-associated diseases. Protein AMPylation is conferred by dedicated enzymes (AMPylases), which are increasingly recognized to control proteostasis and the degradation of misfolded proteins in metazoans. Despite growing evidence linking protein AMPylation to diabetes, motor neuron degeneration, and mental disorders, our knowledge of AMPylase regulation, the compendium of target proteins, and the co

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 168 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 57% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "proteostasis".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,695,019 in active NIH money across 3 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,695,019
Active projects
3
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,695,019 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years) — 1R01DK148498-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 57%

    Matched 2 of 7 profile areas (17 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “proteostasis”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 2R35GM142561-06 Conserved regulation of proteostasis by post-translational protein AMPylation

    R35 · NIGMS · $466,141 · Sep 15, 2021 to Apr 30, 2031

All active NIH projects for Matthias Christof Truttmann ($1,695,019)
  • 1R01DK148498-01 Chemical Activation of Beta-Cell BiP for Treatment of Type 2 Diabetes — $810,438, ends May 31, 2031
  • 2R35GM142561-06 Conserved regulation of proteostasis by post-translational protein AMPylation — $466,141, ends Apr 30, 2031
  • 1R21NS151155-01 Targeting the ER-resident AMPylase FICD to Ameliorate Spinocerebellar Ataxia Type 3 — $418,440, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2021 · project period to Apr 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#140 Lab fit 30% · Adjacent Hiring: Moderate Atlanta Neuroscience

Randy A. Hall lab

Randy A. Hall · Emory University, Atlanta GA

Project Summary Epilepsy and migraine have long been recognized as being linked in certain families, but the genetic basis of this comorbidity in not well understood. We and others have recently found evidence in human genetic studies that variation in GPR37L1 is a major contributor to epilepsy and migraine risk, especially in cases where epilepsy and migraine are comorbid. GPR37L1 is expressed predominantly in astrocytes, and thus studies on this receptor may lead to more general insights into how astrocyte dysfunction contributes to epilepsy and migraine. The goal of this project is to eluci

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 219 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 43% × 0.7 domain gate = 30%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-in".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Sequencing, variant and splicing analysis Lab text mentions "exome".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,109,550 in active NIH money across 3 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,109,550
Active projects
3
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,109,550 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years) — 5T32GM145445-04, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-in”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “exome”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS123447-05 Control of Seizure and Migraine Susceptibility by GPR37L1

    R01 · NINDS · $482,588 · Jul 15, 2021 to Jun 30, 2027

All active NIH projects for Randy A. Hall ($1,109,550)
  • 5R01NS123447-05 Control of Seizure and Migraine Susceptibility by GPR37L1 — $482,588, ends Jun 30, 2027
  • 5T32GM145445-04 Graduate Training in the Pharmacological Sciences — $431,337, ends Jun 30, 2028
  • 5R21NS142860-02 GPR123 Activation by Steroid Ligands — $195,625, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#141 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuroscience

Jiayu Zhou lab

Jiayu Zhou · University of Michigan, Ann Arbor MI

Project Summary Recent estimates indicate that Alzheimer’s disease (AD) may rank as the third leading cause of death for older people in the United States, just behind heart disease and cancer. While scientists know that AD involves a progressive brain cell failure, the reason why cells fail is still not clear. To understand the progression of the disease, one of the keys is to investigate the cognitive changes in patients with mild cognitive impairment (MCI). Even though biomarkers such as imaging and clinical functions are found to be outstanding in differentiating AD patients from those wit

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 287 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,119,779 in active NIH money across 2 projects, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,119,779
Active projects
2
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,119,779 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG072449-03 Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior Markers

    R01 · NIA · $698,972 · Apr 15, 2021 to Mar 31, 2027

All active NIH projects for Jiayu Zhou ($1,119,779)
  • 5R01AG072449-03 Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior Markers — $698,972, ends Mar 31, 2027
  • 5R01GM145700-04 virtual compound screening using gene expression — $420,807, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 15, 2021 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#142 Lab fit 30% · Adjacent Hiring: Moderate Atlanta Neuroscience

Lena H Ting lab

Lena H Ting · Emory University, Atlanta GA

PROJECT SUMMARY Our long-term goal is to identify neural mechanisms and the functional roles of sensorimotor signals in health and disease as needed to guide mechanistically targeted diagnoses, assessments, and treatments for neurological movement disorders. Here we address the scientific barriers to understanding and treating a broad class of movement disorder symptoms recently defined as joint hyper-resistance, which encompass spasticity in stroke, spinal cord injury, or cerebral palsy; parkinsonian rigidity, and hypertonia. The objective of this collaborative, interdisciplinary proposal is

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 483 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,246,577 in active NIH money across 5 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,246,577
Active projects
5
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,246,577 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01HD090642-10 Multiscale models of proprioceptive encoding to reveal mechanisms of impaired sensorimotor control

    R01 · NICHD · $582,364 · Sep 16, 2016 to Mar 31, 2027

  • 5R01HD046922-18 Neuromechanical modeling of postural responses: Cortical mechanisms of balance impairments in Parkinson's disease

    R01 · NICHD · $637,313 · Apr 1, 2004 to Aug 31, 2029

All active NIH projects for Lena H Ting ($2,246,577)
  • 5R01HD046922-18 Neuromechanical modeling of postural responses: Cortical mechanisms of balance impairments in Parkinson's disease — $637,313, ends Aug 31, 2029
  • 5R01HD090642-10 Multiscale models of proprioceptive encoding to reveal mechanisms of impaired sensorimotor control — $582,364, ends Mar 31, 2027
  • 5R01AG072756-05 Individual-specific engagement of cortical resources for standing balance control in aging and post stroke — $570,043, ends Mar 31, 2027
  • 5T32EB025816-08 Training in Computational Neural Engineering — $261,232, ends Jun 30, 2029
  • 5R21HD117352-02 Context-dependent turning of muscle spindles — $195,625, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 16, 2016 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#143 Lab fit 30% · Adjacent Hiring: Possible Michigan Neuro + ophtho

Carolyn A Harris lab

Carolyn A Harris · Wayne State University, Detroit MI

PROJECT SUMMARY Hydrocephalus, an imbalance between cerebrospinal fluid production and absorption, is diagnosed in more than 1 in 500 people in the United States. Approximately 80% of these patients will suffer long-term neurological deficits. Genetic diseases, meningitis, subarachnoid hemorrhage, stroke, traumatic brain injury, or tumors cause hydrocephalus. The common treatment for all hydrocephalus patients is CSF drainage by shunting. Despite all our efforts, shunts still have the highest failure rate of any neurological device. A shocking 85% of shunts fail after just ten years. Failed sh

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 257 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 21% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "choroid".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $831,310 in active NIH money across 2 projects, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$831,310
Active projects
2
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $831,310 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 21%

    Matched 1 of 6 profile areas (6 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “choroid”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS094570-09 Investigating the source and the action behind shunt obstruction in the treatment of pediatric hydrocephalus

    R01 · NINDS · $524,995 · Jun 1, 2016 to May 31, 2028

All active NIH projects for Carolyn A Harris ($831,310)
  • 5R01NS094570-09 Investigating the source and the action behind shunt obstruction in the treatment of pediatric hydrocephalus — $524,995, ends May 31, 2028
  • 1R44NS139774-01A1 Reducing infections and blockage associated with long-term implantation of ventriculoperitoneal and related shunts — $306,315, ends Oct 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2016 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#144 Lab fit 30% · Adjacent Hiring: Strong Michigan Neuroscience

Alexandre Dasilva lab

Alexandre Dasilva · University of Michigan, Ann Arbor MI

Abstract Episodic migraine (EM) sufferers can develop a progressive state of their disease with more than 15 attacks per month. This state is referred to as chronic migraine (CM), a disorder that significantly impacts a patient’s daily life with more frequent sensory and emotional suffering and potential for substance abuse, especially opiates. Built on rigorous scientific data from our initial R01 on EM, our next goal is to expand the investigation and modulation of endogenous µ-opioid neurotransmission to more complex CM patients. We will investigate how this µ-opioid dysfunction impacts oth

Lab fit breakdown — 30% weighted · Adjacent

Scored on enough lab text to read as a verdict. 259 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.82 domain gate = 30%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".
  • Mouse / rodent in vivo models Lab text mentions "in vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "radiotracer")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,518,023 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,518,023
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,518,023 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 1U54DE035412-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS094413-10 Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in vivo)

    R01 · NINDS · $85,070 · Sep 30, 2015 to Nov 30, 2026

All active NIH projects for Alexandre Dasilva ($3,518,023)
  • 1U54DE035412-01 360° Collaborative Hub for AI in TMD Research (360° Chat-TMD) — $3,017,704, ends Jun 30, 2031
  • 1R21NS145442-01 Predicting Migraine Attack Onset with Real-Time Individualized Autonomic Patterns — $415,249, ends Jul 31, 2027
  • 5R01NS094413-10 Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in vivo) — $85,070, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2015 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#145 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuroscience

Kamran Diba lab

Kamran Diba · University of Michigan, Ann Arbor MI

Abstract/Project Summary The circadian rhythm has strong effects on cognition and memory. There is also strong evidence that the activities of neurons during sleep are important for the memory function of the brain. Until recently, little was known about why delaying these activities for a prolonged period of wakefulness (commonly known as “sleep loss”) should have an enduring negative impact on memory, especially given the brain’s general capacity to restore itself during an eventual “recovery sleep”. Recently, by recording from large populations of hippocampal neurons in behaving and sleepin

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 365 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.7 domain gate = 29%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "segregation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,106,977 in active NIH money across 2 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,106,977
Active projects
2
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 68 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,106,977 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-04.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “segregation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS147469-01 The impact of sleep pressure and timing on hippocampal reactivation and replay

    R01 · NINDS · $532,314 · May 4, 2026 to Mar 31, 2031

  • 5R01MH139216-02 Consolidation and interference of hippocampal spatial maps

    R01 · NIMH · $574,663 · Dec 15, 2024 to Nov 30, 2029

All active NIH projects for Kamran Diba ($1,106,977)
  • 5R01MH139216-02 Consolidation and interference of hippocampal spatial maps — $574,663, ends Nov 30, 2029
  • 1R01NS147469-01 The impact of sleep pressure and timing on hippocampal reactivation and replay — $532,314, ends Mar 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 4, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#146 Lab fit 29% · Adjacent Hiring: Strong Michigan Neuroscience

Lori L. Isom lab

Lori L. Isom · University of Michigan, Ann Arbor MI

Sudden Unexpected Death in Epilepsy (SUDEP) is a leading cause of death in patients with epilepsy. SUDEP mechanisms are not understood, although there is evidence to implicate apnea, autonomic dysfunction, and cardiac arrhythmias. Genes encoding voltage-gated sodium channel subunits are high SUDEP risk genes. Loss- of-function variants in SCN1A are linked to the Developmental and Epileptic Encephalopathy (DEE) Dravet syndrome (DS). Importantly, SCN1A is expressed in both heart and brain. Thus, we proposed that cardiac arrhythmias contribute to the mechanism of SUDEP in channelopathy-linked gen

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 289 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.7 domain gate = 29%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $1,946,840 in active NIH money across 4 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,946,840
Active projects
4
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 73 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,946,840 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2T32GM140223-06, which is outside this briefing's scope but is active NIH money for this PI.
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01HL178516-01A1 Neuro-cardiac Mechanisms of Sudden Unexpected Death in Epilepsy

    R01 · NHLBI · $765,515 · May 1, 2026 to Mar 31, 2030

All active NIH projects for Lori L. Isom ($1,946,840)
  • 1R01HL178516-01A1 Neuro-cardiac Mechanisms of Sudden Unexpected Death in Epilepsy — $765,515, ends Mar 31, 2030
  • 2T32GM140223-06 Interdepartmental Training in Pharmacological Sciences — $647,005, ends Jun 30, 2031
  • 1R61NS150122-01 Development of a SCN1B gene replacement therapy for DEE52 — $378,320, ends Aug 31, 2028
  • 1R03NS151500-01 Development of an epitope-tagged Nav1.1 transgenic mouse model — $156,000, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2026 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#147 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuroscience

Jack M Parent lab

Jack M Parent · University of Michigan, Ann Arbor MI

Sudden Unexpected Death in Epilepsy (SUDEP) is a leading cause of death in patients with epilepsy. SUDEP mechanisms are not understood, although there is evidence to implicate apnea, autonomic dysfunction, and cardiac arrhythmias. Genes encoding voltage-gated sodium channel subunits are high SUDEP risk genes. Loss- of-function variants in SCN1A are linked to the Developmental and Epileptic Encephalopathy (DEE) Dravet syndrome (DS). Importantly, SCN1A is expressed in both heart and brain. Thus, we proposed that cardiac arrhythmias contribute to the mechanism of SUDEP in channelopathy-linked gen

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 289 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 41% × 0.7 domain gate = 29%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $765,515 in active NIH money across 1 project, 3.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$765,515
Active projects
1
Runway left
3.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $765,515 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01HL178516-01A1 Neuro-cardiac Mechanisms of Sudden Unexpected Death in Epilepsy

    R01 · NHLBI · $765,515 · May 1, 2026 to Mar 31, 2030

All active NIH projects for Jack M Parent ($765,515)
  • 1R01HL178516-01A1 Neuro-cardiac Mechanisms of Sudden Unexpected Death in Epilepsy — $765,515, ends Mar 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2026 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#148 Lab fit 29% · Adjacent Hiring: Strong Atlanta Neuroscience

Vince D Calhoun lab

Vince D Calhoun · Georgia State University, Atlanta GA

Project Summary/Abstract In the field of Alzheimer's and related dementias (ADRD), while multimodal data collection is common, most approaches still separately analyze and then combine the data. There is much less work on methods that can perform joint decomposition of multimodal neuroimaging and genomic data, despite considerable promise. Most imaging genomic studies have focused either on candidate gene approaches or on univariate approaches to link neuroimaging and genomic data (e.g., polygenic risk scores). Even for genome wide studies, the vast majority of imaging genomic studies still re

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 737 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $5,257,231 in active NIH money across 6 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$5,257,231
Active projects
6
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $5,257,231 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years) — 1RM1DA065022-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG090597-02 Flexible multivariate models for linking multi-scale connectome and genome data in Alzheimer’s disease and related disorders

    R01 · NIA · $776,294 · Jun 1, 2025 to Feb 28, 2030

  • 5R01AG073949-05 Data driven dynamic activity/connectivity methods for early detection of Alzheimer’s

    R01 · NIA · $726,546 · Sep 1, 2021 to May 31, 2027

  • 5R01MH123610-05 Data-driven solutions for temporal, spatial, and spatiotemporal dynamic functional connectivity

    R01 · NIMH · $561,985 · Mar 19, 2021 to Jan 31, 2027

All active NIH projects for Vince D Calhoun ($5,257,231)
  • 1RM1DA065022-01 Pathways from Chronic Methamphetamine Use to Neurological Dysfunction in People with HIV: High-Dimensional Fusion of Systems Biology and Multimodal Neuroimaging — $2,183,030, ends Mar 31, 2031
  • 5R01AG090597-02 Flexible multivariate models for linking multi-scale connectome and genome data in Alzheimer’s disease and related disorders — $776,294, ends Feb 28, 2030
  • 5R01AG073949-05 Data driven dynamic activity/connectivity methods for early detection of Alzheimer’s — $726,546, ends May 31, 2027
  • 5R01EB006841-19 Multivariate methods for identifying multitask/multimodal brain imaging biomarkers — $610,340, ends Apr 30, 2029
  • 5R01MH123610-05 Data-driven solutions for temporal, spatial, and spatiotemporal dynamic functional connectivity — $561,985, ends Jan 31, 2027
  • 5P50DA056408-04 Data Harmonization and Analysis Core — $399,036, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#149 Lab fit 29% · Adjacent Hiring: Moderate Atlanta Neuroscience

Jingyu Liu lab

Jingyu Liu · Georgia State University, Atlanta GA

Project Summary/Abstract In the field of Alzheimer's and related dementias (ADRD), while multimodal data collection is common, most approaches still separately analyze and then combine the data. There is much less work on methods that can perform joint decomposition of multimodal neuroimaging and genomic data, despite considerable promise. Most imaging genomic studies have focused either on candidate gene approaches or on univariate approaches to link neuroimaging and genomic data (e.g., polygenic risk scores). Even for genome wide studies, the vast majority of imaging genomic studies still re

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 518 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,127,294 in active NIH money across 2 projects, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,127,294
Active projects
2
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,127,294 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG090597-02 Flexible multivariate models for linking multi-scale connectome and genome data in Alzheimer’s disease and related disorders

    R01 · NIA · $776,294 · Jun 1, 2025 to Feb 28, 2030

  • 5R01MH130595-04 Frontal-thalamo-cerebellar circuitry of attention deficit via imaging-genetic-environmental analyses

    R01 · NIMH · $351,000 · Aug 16, 2023 to May 31, 2028

All active NIH projects for Jingyu Liu ($1,127,294)
  • 5R01AG090597-02 Flexible multivariate models for linking multi-scale connectome and genome data in Alzheimer’s disease and related disorders — $776,294, ends Feb 28, 2030
  • 5R01MH130595-04 Frontal-thalamo-cerebellar circuitry of attention deficit via imaging-genetic-environmental analyses — $351,000, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#150 Lab fit 29% · Adjacent Hiring: Possible Michigan Neuroscience

William Joseph Chopik lab

William Joseph Chopik · Michigan State University, East Lansing MI

PROJECT SUMMARY Poor health and cognitive decline in older adulthood are significant public health challenges that profoundly impact individuals, their families, and society. In the United States, current estimates of the healthcare costs of Alzheimer’s disease (AD) are at $345 billion per year. This number will balloon to over $1 trillion per year by 2060 as the number of Americans living with AD will likely double to nearly 14 million. These stark numbers represent only a fraction of the burden of AD. It is crucial to identify potential risk factors to track the prevalence, emergence, and or

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 238 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $355,404 in active NIH money across 1 project, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$355,404
Active projects
1
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $355,404 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG089376-02 Cultural variation in the impact of spousal depressive symptoms on Alzheimer's Disease and physical health

    R01 · NIA · $355,404 · May 15, 2025 to Feb 28, 2030

All active NIH projects for William Joseph Chopik ($355,404)
  • 5R01AG089376-02 Cultural variation in the impact of spousal depressive symptoms on Alzheimer's Disease and physical health — $355,404, ends Feb 28, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 15, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#151 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuroscience

Briana Mezuk lab

Briana Mezuk · University of Michigan, Ann Arbor MI

SUMMARY It is critically important to identify modifiable determinants of cognitive health and functioning, particularly among racial/ethnic minority groups that have elevated risk of Alzheimer’s disease and related dementias (ADRD). Black Americans have 2-4 times the age-adjusted incidence of ADRD, with significantly earlier age of onset, relative to non-Hispanic Whites (NHW). However, there is a dearth of longitudinal studies examining risk and protective factors in early and middle-adulthood within the Black population to inform culturally-relevant prevention and intervention efforts. The g

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 330 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,862,943 in active NIH money across 5 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,862,943
Active projects
5
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,862,943 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years) — 5T32AG027708-17, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG087121-02 ADRD risk and resilience among Black Americans: A 20-year longitudinal study

    R01 · NIA · $1,523,835 · Feb 1, 2025 to Jan 31, 2030

All active NIH projects for Briana Mezuk ($2,862,943)
  • 5R01AG087121-02 ADRD risk and resilience among Black Americans: A 20-year longitudinal study — $1,523,835, ends Jan 31, 2030
  • 5R01MH128198-05 Aging, Major Life Transitions, and Suicide Risk — $774,927, ends Nov 30, 2027
  • 5T32AG027708-17 Interdisciplinary Research Training in Health and Aging — $327,919, ends Jul 31, 2030
  • 5R25MH136652-07 Summer Training Program in Integrative Methods for Mental and Physical Health — $215,281, ends Jan 31, 2028
  • 5P30AG015281-29 Michigan Center for Urban African American Aging Research - Analysis Core (AnC) — $20,981, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2025 · project period to Jan 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#152 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuroscience

Courtney S Thomas Tobin lab

Courtney S Thomas Tobin · University of Michigan, Ann Arbor MI

SUMMARY It is critically important to identify modifiable determinants of cognitive health and functioning, particularly among racial/ethnic minority groups that have elevated risk of Alzheimer’s disease and related dementias (ADRD). Black Americans have 2-4 times the age-adjusted incidence of ADRD, with significantly earlier age of onset, relative to non-Hispanic Whites (NHW). However, there is a dearth of longitudinal studies examining risk and protective factors in early and middle-adulthood within the Black population to inform culturally-relevant prevention and intervention efforts. The g

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 330 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,523,835 in active NIH money across 1 project, 3.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,523,835
Active projects
1
Runway left
3.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,523,835 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-01-31 (about 3.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG087121-02 ADRD risk and resilience among Black Americans: A 20-year longitudinal study

    R01 · NIA · $1,523,835 · Feb 1, 2025 to Jan 31, 2030

All active NIH projects for Courtney S Thomas Tobin ($1,523,835)
  • 5R01AG087121-02 ADRD risk and resilience among Black Americans: A 20-year longitudinal study — $1,523,835, ends Jan 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2025 · project period to Jan 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#153 Lab fit 29% · Adjacent Hiring: Strong Michigan Neuroscience

Lindsay C Kobayashi lab

Lindsay C Kobayashi · University of Michigan, Ann Arbor MI

PROJECT SUMMARY By 2050, over 75% of cases of Alzheimer’s disease and related dementias (ADRD) are expected to occur in low- and middle-income countries (LMICs), such as India, which is world’s most populous country with a population of >1.4 billion. Education is the strongest known modifiable protective factor for ADRD, yet ~50% of adults aged ≥45 in India have no formal education and will carry a heavy share of the future global dementia burden. Education is thought to protect against ADRD by promoting cognitive reserve, a theoretical construct representing between-person differences in the

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 501 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $4,697,076 in active NIH money across 6 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,697,076
Active projects
6
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,697,076 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG087965-01 Non-educational sources of later-life cognitive reserve and resilience among older adults with and without formal education in India

    RF1 · NIA · $2,222,489 · Sep 23, 2024 to Aug 31, 2027

  • 2R01AG070953-06 Socioeconomic, Cardiovascular, and Psychosocial Sources of Cross-National Variation in Cognitive Health Among Older Adults

    R01 · NIA · $655,139 · Apr 1, 2021 to Mar 31, 2031

All active NIH projects for Lindsay C Kobayashi ($4,697,076)
  • 1RF1AG087965-01 Non-educational sources of later-life cognitive reserve and resilience among older adults with and without formal education in India — $2,222,489, ends Aug 31, 2027
  • 2R01AG070953-06 Socioeconomic, Cardiovascular, and Psychosocial Sources of Cross-National Variation in Cognitive Health Among Older Adults — $655,139, ends Mar 31, 2031
  • 5U24AG065182-08 Research Network for the Harmonized Cognitive Assessment Protocol (HCAP): Years 6-10 — $598,172, ends Jun 30, 2029
  • 5R01AG069128-07 Cumulative socioeconomic exposures, cash transfer interventions, and later-life cognitive decline and dementia risk in a low-income region of South Africa — $517,818, ends May 31, 2029
  • 5R25AG095537-02 Best Practices for the Measurement and Analysis of Cognitive Data in the International Health and Retirement Study (HRS) Family and its Harmonized Cognitive Assessment Protocol (HCAP) — $375,539, ends May 31, 2030
  • 5T32AG027708-17 Interdisciplinary Research Training in Health and Aging — $327,919, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 23, 2024 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#154 Lab fit 29% · Adjacent Hiring: Unlikely Michigan Neuroscience

Mohammed Akaaboune lab

Mohammed Akaaboune · University of Michigan, Ann Arbor MI

Stable and efficient synaptic transmission depends largely on the maintenance of a high number/density of postsynaptic receptors at synaptic sites. At the neuromuscular junction (NMJ), the synapse between spinal motor neurons and skeletal muscle cells, the mechanisms that regulate the stability of postsynaptic nicotinic acetylcholine receptors (AChRs) over the lifetime of animals remain largely unknown. Recent studies from our lab showed that αkap, a non-kinase muscle anchoring protein encoded within the calcium/calmodulin kinase II α gene, plays an important role in regulating the stability o

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 243 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 42% × 0.7 domain gate = 29%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "ubiquitin".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $426,301 in active NIH money across 1 project, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$426,301
Active projects
1
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $426,301 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “ubiquitin”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS111041-05 The effect of muscle-specific anchoring protein on the biology of the Neuromuscular system

    R01 · NINDS · $426,301 · Apr 1, 2019 to Mar 31, 2027

All active NIH projects for Mohammed Akaaboune ($426,301)
  • 5R01NS111041-05 The effect of muscle-specific anchoring protein on the biology of the Neuromuscular system — $426,301, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2019 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#155 Lab fit 29% · Adjacent Hiring: Moderate Michigan Neuroscience

Esther M. Friedman lab

Esther M. Friedman · University of Michigan, Ann Arbor MI

Project Summary This application proposes to collect, process, and disseminate data in the 2025 and 2027 waves of the Panel Study of Income Dynamics (PSID), including a new supplement on caregiving and cognition in 2026, which will enhance information on cognitive precursors to and caregiving for Alzheimer’s Disease and Related Dementias (ADRD). The PSID is a longitudinal survey of a nationally representative sample of U.S. families that was begun in 1968. A cornerstone of the nation’s social science research infrastructure, PSID has collected 43 waves of data over 56 years on original familie

Lab fit breakdown — 29% weighted · Adjacent

Scored on enough lab text to read as a verdict. 275 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.82 domain gate = 29%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $15,490,428 in active NIH money across 2 projects, 3.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$15,490,428
Active projects
2
Runway left
3.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $15,490,428 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-01-31 (about 3.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 2RF1AG040213-16 Health, Caregiving, Cognition, and Well-being Over the Life Course and Across Multiple Generations

    RF1 · NIA · $15,345,206 · Sep 1, 2011 to Jan 31, 2030

All active NIH projects for Esther M. Friedman ($15,490,428)
  • 2RF1AG040213-16 Health, Caregiving, Cognition, and Well-being Over the Life Course and Across Multiple Generations — $15,345,206, ends Jan 31, 2030
  • 5P30AG012846-32 External Innovative Network Core — $145,222, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2011 · project period to Jan 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#156 Lab fit 28% · Adjacent Hiring: Moderate Atlanta Neuroscience

Stephen Nicholas Housley lab

Stephen Nicholas Housley · Georgia Institute of Technology, Atlanta GA

From growth, homeostasis, and regeneration, the nervous system is responsible for orchestrating and maintaining complex biologic processes in health and disease. It is therefore no surprise that the nervous system is emerging as a critical regulator of cancer. Recent data demonstrates that brain cancers establish bidirectional communication with their neuronal counterparts, creating cancer-neuronal circuits that promote tumor growth, invasion, and therapeutic resistance. These data highlight an underappreciated aspect of cancer biology and emphasize that cancer-neuron interactions are pivotal.

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 67% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.7 domain gate = 28%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".
  • Axonal transport and neuronal injury assays Lab text mentions "anterograde".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $523,554 in active NIH money across 1 project, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$523,554
Active projects
1
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $523,554 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-06.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 67%

    Matched 3 of 7 profile areas (20 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “anterograde”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01CA315100-01 Mapping and Manipulating Cancer-Associated Neuronal Networks

    R01 · NCI · $523,554 · Aug 6, 2026 to Jul 31, 2031

All active NIH projects for Stephen Nicholas Housley ($523,554)
  • 1R01CA315100-01 Mapping and Manipulating Cancer-Associated Neuronal Networks — $523,554, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 6, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#157 Lab fit 28% · Adjacent Hiring: Moderate Michigan Neuroscience

William T Birdsong lab

William T Birdsong · University of Michigan, Ann Arbor MI

Project Summary/ Abstract Opioids like morphine are the most effective pain relieving drugs available but their rewarding properties lead to misuse. The rewarding and analgesic properties of opioids are mediated by activation of mu opioid receptors (MOR). Hyperalgesia is an exaggerated pain perception in response to a stimulus that is normally mildly uncomfortable. Hyperalgesia occurs when opioid-dependent people discontinue opioid use, known as opioid withdrawal-induced hyperalgesia (OWIH). Opioids also relieve this hyperalgesia providing motivation for continued opioid use and dose escalatio

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 258 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 40% × 0.7 domain gate = 28%. No real disease overlap — weighted mean discounted 30%.

What matches

  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunofluoresc".
  • Sequencing, variant and splicing analysis Lab text mentions "allele".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $595,171 in active NIH money across 1 project, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$595,171
Active projects
1
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $595,171 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunofluoresc”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DA062636-01A1 Functional anatomy, physiology and behavioral responses mediated by mu opioid receptor signaling on medial thalamic neurons.

    R01 · NIDA · $595,171 · May 1, 2026 to Feb 28, 2031

All active NIH projects for William T Birdsong ($595,171)
  • 1R01DA062636-01A1 Functional anatomy, physiology and behavioral responses mediated by mu opioid receptor signaling on medial thalamic neurons. — $595,171, ends Feb 28, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2026 · project period to Feb 28, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#158 Lab fit 28% · Adjacent Hiring: Moderate Michigan Neuro + ophtho

Joshua Robert Ehrlich lab

Joshua Robert Ehrlich · University of Michigan, Ann Arbor MI

Kenya’s population is aging rapidly, with the number of adults aged 60 and older projected to increase 4- fold in the next 30 years. However, there is little population level data from Kenya or neighboring countries to inform economic and public health planning. Our team seeks to address this gap through the development of the Longitudinal Study of Health and Ageing in Kenya (LOSHAK-Core), which joins a growing global network of harmonized panel studies of health, economics, and aging modelled on the U.S. Health and Retirement Study (HRS). Likewise, the LOSHAK-Harmonized Cognitive Assessment P

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 585 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.82 domain gate = 28%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • In vivo ocular imaging and functional readouts Lab text mentions "visual acuity".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,883,608 in active NIH money across 4 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,883,608
Active projects
4
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,883,608 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “visual acuity”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG093721-02S1 The Longitudinal Study of Health and Ageing in Kenya (LOSHAK): A Population study of Health, Wellbeing, Economics, and AD/ADRD in Older Kenyan Adults

    R01 · NIA · $3,207,366 · Aug 15, 2025 to Jun 30, 2030

  • 5R01EY034479-04 Vision Impairment in the National Health and Aging Trends Study

    R01 · NEI · $652,638 · Sep 30, 2023 to Jun 30, 2028

All active NIH projects for Joshua Robert Ehrlich ($4,883,608)
  • 3R01AG093721-02S1 The Longitudinal Study of Health and Ageing in Kenya (LOSHAK): A Population study of Health, Wellbeing, Economics, and AD/ADRD in Older Kenyan Adults — $3,207,366, ends Jun 30, 2030
  • 4R33AG089063-03 Sensory Aging, Late-Life Wellbeing, and ADRD Research Infrastructure to Catalyze Practice and Policy — $785,100, ends Jul 31, 2029
  • 5R01EY034479-04 Vision Impairment in the National Health and Aging Trends Study — $652,638, ends Jun 30, 2028
  • 5D43TW012027-05 Building Non-Communicable Eye Disease Research Capacity in India — $238,504, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2025 · project period to Jun 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#159 Lab fit 28% · Adjacent Hiring: Moderate Atlanta Neuroscience

Anke Huels lab

Anke Huels · Emory University, Atlanta GA

Abstract Exposures to ambient air pollution, especially fine particulate matter (PM2.5), have been associated with increased risks of many chronic illnesses, including Alzheimer’s Disease and related dementias (AD/ADRD). Identification and understanding the role of modifiable risk factors is essential for AD disease prevention. Despite the observed epidemiological evidence, three central and unsolved questions are 1) what components of PM2.5 (e.g., sulfate, nitrate, ammonium, elemental carbon, organic carbon, metals, etc.) are most neurotoxic, 2) the role of other ubiquitous air pollutants (ca

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 849 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.82 domain gate = 28%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,538,664 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,538,664
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,538,664 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG087250-03 Air pollution, the blood and brain metabolome and their effects on Alzheimer's disease and related dementias

    R01 · NIA · $764,329 · Sep 15, 2024 to Apr 30, 2029

  • 3U01AG088425-03S1 IMPACT-ADRD: Investigating the Multi-omics Perturbations Associated with Complex Environmental Toxicants and their Contribution to Alzheimer's Disease and Related Dementias

    U01 · NIA · $109,034 · Aug 15, 2024 to Jul 31, 2029

  • 5R01AG079170-05 Air pollution and early signs of dementia

    R01 · NIA · $611,378 · Sep 30, 2022 to Aug 31, 2027

All active NIH projects for Anke Huels ($3,538,664)
  • 5U01AG088425-03 IMPACT-ADRD: Investigating the Multi-omics Perturbations Associated with Complex Environmental Toxicants and their Contribution to Alzheimer's Disease and Related Dementias — $2,162,957, ends Jul 31, 2029
  • 5R01AG087250-03 Air pollution, the blood and brain metabolome and their effects on Alzheimer's disease and related dementias — $764,329, ends Apr 30, 2029
  • 5R01AG079170-05 Air pollution and early signs of dementia — $611,378, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#160 Lab fit 28% · Adjacent Hiring: Moderate Atlanta Neuroscience

Donghai Liang lab

Donghai Liang · Emory University, Atlanta GA

Abstract Exposures to ambient air pollution, especially fine particulate matter (PM2.5), have been associated with increased risks of many chronic illnesses, including Alzheimer’s Disease and related dementias (AD/ADRD). Identification and understanding the role of modifiable risk factors is essential for AD disease prevention. Despite the observed epidemiological evidence, three central and unsolved questions are 1) what components of PM2.5 (e.g., sulfate, nitrate, ammonium, elemental carbon, organic carbon, metals, etc.) are most neurotoxic, 2) the role of other ubiquitous air pollutants (ca

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 553 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.82 domain gate = 28%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,586,189 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,586,189
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,586,189 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG087250-03 Air pollution, the blood and brain metabolome and their effects on Alzheimer's disease and related dementias

    R01 · NIA · $764,329 · Sep 15, 2024 to Apr 30, 2029

  • 3U01AG088425-03S1 IMPACT-ADRD: Investigating the Multi-omics Perturbations Associated with Complex Environmental Toxicants and their Contribution to Alzheimer's Disease and Related Dementias

    U01 · NIA · $109,034 · Aug 15, 2024 to Jul 31, 2029

All active NIH projects for Donghai Liang ($3,586,189)
  • 5U01AG088425-03 IMPACT-ADRD: Investigating the Multi-omics Perturbations Associated with Complex Environmental Toxicants and their Contribution to Alzheimer's Disease and Related Dementias — $2,162,957, ends Jul 31, 2029
  • 5R01AG087250-03 Air pollution, the blood and brain metabolome and their effects on Alzheimer's disease and related dementias — $764,329, ends Apr 30, 2029
  • 5R01ES035738-03 The Omics and Mixtures Integration on Traffic exposure and Preterm Birth (OMIT-PTB) Study — $658,903, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#161 Lab fit 28% · Adjacent Hiring: Possible Atlanta Neuroscience

Liang Zhao lab

Liang Zhao · Emory University, Atlanta GA

Alzheimer's Disease (AD) is increasingly becoming an immense economic and social challenge. By 2050, it's projected that 13.8 million Americans will be living with AD, and the total annual expenditures for health, long- term care, and hospice services for those with AD and other dementias could surge to $1.2 trillion. Developing predictive artificial intelligent (AI) models to assist in the diagnosis and prognosis of the disease is critically important for patient management. However, current AI models for studying Alzheimer’s Disease often suffer from explainability challenges, and the effect

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 264 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.82 domain gate = 28%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $970,417 in active NIH money across 2 projects, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$970,417
Active projects
2
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $970,417 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG089806-03 Explainable and Ethical AI for Studying Alzheimer's Disease

    R01 · NIA · $679,906 · Aug 1, 2024 to Apr 30, 2029

All active NIH projects for Liang Zhao ($970,417)
  • 5R01AG089806-03 Explainable and Ethical AI for Studying Alzheimer's Disease — $679,906, ends Apr 30, 2029
  • 5R01CA297856-03 SCH: Visual explanation-guided learning for human-AI collaborative abdominal cancer diagnostic imaging — $290,511, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#162 Lab fit 28% · Adjacent Hiring: Possible Atlanta Neuroscience

Felipe Garcia Quiroz lab

Felipe Garcia Quiroz · Emory University, Atlanta GA

Project Summary/Abstract Intrinsically-disordered proteins (IDPs) are drivers of intracellular self-assembly. Powered by highly multivalent interactions, IDPs organize subcellular assemblies (biomolecular condensates) governed by liquid-liquid phase separation (LLPS) dynamics. From genomic organization to synaptic plasticity, biomolecular condensates influence wide-ranging cellular mechanisms. Despite these exciting insights, the biophysical and physiological properties of the underlying IDP-assemblies remain poorly understood. This knowledge gap is pervasive because existing tools to study ID

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 157 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.82 domain gate = 28%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "organoid")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $939,000 in active NIH money across 1 project, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$939,000
Active projects
1
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $939,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4DP2GM149749-02 Multifunctional phase sensors for probing and manipulation of intracellular biomolecular condensates

    DP2 · NIGMS · $939,000 · Sep 1, 2022 to Aug 31, 2027

All active NIH projects for Felipe Garcia Quiroz ($939,000)
  • 4DP2GM149749-02 Multifunctional phase sensors for probing and manipulation of intracellular biomolecular condensates — $939,000, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#163 Lab fit 28% · Adjacent Hiring: Moderate Atlanta Neuroscience

Hui Mao lab

Hui Mao · Emory University, Atlanta GA

Project Summary Alzheimer’s disease (AD) is a major healthcare and social-economic burden. With effective treatment yet to be developed, the early detection at the prodromal stage and surveillance of the progression are the best approach to control and intervene AD development. While non-invasive positron emission tomography (PET) can measure amyloid-β peptides (Aβs) and microtubule tau proteins in the brain to confirm the onset of AD, the availability of imaging equipment, diagnostic accuracy of single Aβ or tau specific radiotracer and the cost and exposure of radioactive materials limit ima

Lab fit breakdown — 28% weighted · Adjacent

Scored on enough lab text to read as a verdict. 284 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.82 domain gate = 28%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "radiotracer")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,890,597 in active NIH money across 5 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,890,597
Active projects
5
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,890,597 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 5 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years) — 5U01EB036001-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG067736-05 High-sensitivity Immunomagnetic System for "Liquid Biopsy" of Alzheimer's Disease

    R01 · NIA · $555,212 · Feb 1, 2021 to Dec 31, 2026

All active NIH projects for Hui Mao ($2,890,597)
  • 5R42AG078718-03 Development of "Imagnostix": A Liquid Biopsy System for Alzheimer's Disease — $811,413, ends May 31, 2028
  • 5U01EB036001-02 Fast high-resolution simultaneous metabolic and multiparametric imaging of the whole brain — $649,356, ends Jul 31, 2030
  • 5R01AG067736-05 High-sensitivity Immunomagnetic System for "Liquid Biopsy" of Alzheimer's Disease — $555,212, ends Dec 31, 2026
  • 5R01CA261251-05 Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer — $472,215, ends Jun 30, 2027
  • 1R21CA303380-01A1 Development of an F-18 Imaging Agent to Measure Glioma IDH1mut Expression — $402,401, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2021 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#164 Lab fit 27% · Adjacent Hiring: Possible Michigan Neuroscience

Travis Walton lab

Travis Walton · Van Andel Institute, Grand Rapids MI

Project Summary Microtubules (MTs) and intermediate filaments (IFs) are two main components of the cytoskeleton in eukaryotic cells, each with unique structural and regulatory roles. Interactions between MTs and IFs are crucial for maintaining cellular shape, stability, and organization. Despite their wide importance in biology, exactly how MTs and IFs interact at the molecular level remains unclear. A major barrier to elucidating these interactions is the strong context-dependency of cytoskeletal arrangement and function across tissues, cell types, and subcellular locations. MTs and IFs are s

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 170 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 67% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $528,000 in active NIH money across 1 project, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$528,000
Active projects
1
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $528,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 67%

    Matched 3 of 7 profile areas (20 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM160317-02 Revealing the Molecular Basis of Microtubule-Intermediate Filament Interactions.

    R35 · NIGMS · $528,000 · Aug 9, 2025 to May 31, 2030

All active NIH projects for Travis Walton ($528,000)
  • 5R35GM160317-02 Revealing the Molecular Basis of Microtubule-Intermediate Filament Interactions. — $528,000, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 9, 2025 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#165 Lab fit 27% · Adjacent Hiring: Moderate Michigan Neuroscience

Euisik Yoon lab

Euisik Yoon · University of Michigan, Ann Arbor MI

Project Summary Significance: While exploration of brain mapping has been moving forward at an unprecedented scale and steady innovations in optogenetics have provided a toolset for identifying and manipulating of circuit components, still electrophysiology tools for monitoring and perturbing targeted neurons in multiple local circuits in the behaving animal are lagging. Understanding how local circuits perform in the brain requires high- density recording from a statistically representative fraction of neurons and targeted cell-specific perturbation of the circuit components. This grant appli

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 435 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,380,231 in active NIH money across 2 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,380,231
Active projects
2
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,380,231 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • +5 Brand-new (Type 1) project, not a renewal — 5R01NS142069-02 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS142069-02 Artifact-free Micro-LED Optoelectrode for Multi-color Neuromodulation

    R01 · NINDS · $542,645 · Jun 1, 2025 to Apr 30, 2030 · Type 1 (new)

  • 1RF1NS133978-01 Reconfigurable 3D Origami Probes for Multi-modal Neural Interface

    RF1 · NINDS · $3,837,586 · Sep 15, 2023 to Aug 31, 2027

All active NIH projects for Euisik Yoon ($4,380,231)
  • 1RF1NS133978-01 Reconfigurable 3D Origami Probes for Multi-modal Neural Interface — $3,837,586, ends Aug 31, 2027
  • 5R01NS142069-02 Artifact-free Micro-LED Optoelectrode for Multi-color Neuromodulation — $542,645, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2025 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#166 Lab fit 27% · Adjacent Hiring: Moderate Michigan Neuroscience

Changyang Linghu lab

Changyang Linghu · University of Michigan, Ann Arbor MI

Abstract Many fundamental questions in neuroscience and neurological disorders, such as those associated with learning, memory, sleep, aging, and disease progression, would benefit greatly from a technology that enables brain-wide single-cell readout of signaling activities and gene expression changes over extended time periods (over weeks, months, to even years). Current single-cell physiology recording methods require external interfacing to live cells, either optically (via fluorescent probes plus microscopy) or electrically (via electrical probes). It has been a major challenge to perform

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 198 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 47% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "protein engineering")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,996,493 in active NIH money across 2 projects, 4.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,996,493
Active projects
2
Runway left
4.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,996,493 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-04-30 (about 4.6 years) — 1R01NS144823-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 47%

    Matched 2 of 7 profile areas (14 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1DP2MH140133-01 Temporally scalable recording of brain-wide single-cell physiology

    DP2 · NIMH · $1,345,424 · Sep 10, 2024 to Sep 9, 2027

All active NIH projects for Changyang Linghu ($1,996,493)
  • 1DP2MH140133-01 Temporally scalable recording of brain-wide single-cell physiology — $1,345,424, ends Sep 9, 2027
  • 1R01NS144823-01A1 Spatially Multiplexed Imaging of Complex Signaling Networks — $651,069, ends Apr 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 10, 2024 · project period to Sep 9, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#167 Lab fit 27% · Adjacent Hiring: Moderate Michigan Neuroscience

Xianshuang Liu lab

Xianshuang Liu · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

Abstract Veterans and the general public with traumatic brain injury (TBI) have a high risk of developing posttraumatic stress disorder (PTSD) and other psychiatric disorders, such as anxiety and depression. The pathophysiological basis that contributes to comorbid PTSD and other psychiatric disorders following TBI is not yet understood, and there are currently few effective treatments for comorbid TBI/PTSD. Serotonergic dysfunction and neuroinflammation are strongly associated with TBI and psychiatric disorders. Gut microbiota dysfunction induces inflammation and affects tryptophan metabolism

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 506 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Axonal transport and neuronal injury assays Lab text mentions "neurite".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,018,538 in active NIH money across 2 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,018,538
Active projects
2
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,018,538 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “neurite”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS133347-03 Investigating the role of gut-derived extracellular vesicles in PTSD following TBI

    R01 · NINDS · $463,308 · Sep 5, 2024 to Aug 31, 2029

  • 5R01DK135970-03 Investigating the role of gut extracellular vesicles in diabetic peripheral neuropathy

    R01 · NIDDK · $555,230 · Mar 1, 2024 to Jan 31, 2028

All active NIH projects for Xianshuang Liu ($1,018,538)
  • 5R01DK135970-03 Investigating the role of gut extracellular vesicles in diabetic peripheral neuropathy — $555,230, ends Jan 31, 2028
  • 5R01NS133347-03 Investigating the role of gut-derived extracellular vesicles in PTSD following TBI — $463,308, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 5, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#168 Lab fit 27% · Adjacent Hiring: Moderate Atlanta Neuroscience

Xiao Hu lab

Xiao Hu · Emory University, Atlanta GA

Project Summary Poststroke cognitive impairment (PSCI) was found to be common in various research studies. PSCI is ideally recognized through cognitive screening and test but they are not standard clinical practices and hence stroke recovery and prevention of recurrent strokes may be undermined by concurrent but poorly recognized cognitive issues, e.g., patient compliance to follow blood pressure control medication may be poorer among those with PSCI. Therefore, a significant unmet need for optimizing poststroke care is to recognize patients at high risk of PSCI to tailor for them an appropria

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 287 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $9,096,136 in active NIH money across 3 projects, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$9,096,136
Active projects
3
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $9,096,136 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3RF1NS139325-01S1 Using AI on Routine Clinical and Imaging Data from Acute Stroke Encounter to Predict Post-Stroke Vascular Contributions to Cognitive Impairment (AI - RESPECT)

    RF1 · NINDS · $234,750 · Sep 1, 2024 to Jul 31, 2027

All active NIH projects for Xiao Hu ($9,096,136)
  • 3OT2OD032701-01S3 Bridge2AI: Patient-Focused Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AI — $6,109,654, ends Nov 30, 2026
  • 1RF1NS139325-01 Using AI on Routine Clinical and Imaging Data from Acute Stroke Encounter to Predict Post-Stroke Vascular Contributions to Cognitive Impairment (AI - RESPECT) — $2,340,263, ends Jul 31, 2027
  • 5R01HL166233-04 Novel Algorithm and Data Strategies to detect and Predict atrial fibrillation for post-stroke patients (NADSP) — $646,219, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#169 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Fadi Basil Nahab lab

Fadi Basil Nahab · Emory University, Atlanta GA

Project Summary Poststroke cognitive impairment (PSCI) was found to be common in various research studies. PSCI is ideally recognized through cognitive screening and test but they are not standard clinical practices and hence stroke recovery and prevention of recurrent strokes may be undermined by concurrent but poorly recognized cognitive issues, e.g., patient compliance to follow blood pressure control medication may be poorer among those with PSCI. Therefore, a significant unmet need for optimizing poststroke care is to recognize patients at high risk of PSCI to tailor for them an appropria

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 287 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $2,340,263 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,340,263
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,340,263 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3RF1NS139325-01S1 Using AI on Routine Clinical and Imaging Data from Acute Stroke Encounter to Predict Post-Stroke Vascular Contributions to Cognitive Impairment (AI - RESPECT)

    RF1 · NINDS · $234,750 · Sep 1, 2024 to Jul 31, 2027

All active NIH projects for Fadi Basil Nahab ($2,340,263)
  • 1RF1NS139325-01 Using AI on Routine Clinical and Imaging Data from Acute Stroke Encounter to Predict Post-Stroke Vascular Contributions to Cognitive Impairment (AI - RESPECT) — $2,340,263, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#170 Lab fit 27% · Adjacent Hiring: Moderate Atlanta Neuroscience

Huiwen Xu lab

Huiwen Xu · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Alzheimer’s special care units (SCUs) are a promising care model for nursing home residents with Alzheimer's Disease & Related Dementias (ADRD). SCUs provide higher quality care and improve outcomes for residents with ADRD. Our preliminary analysis further found that, in facilities with an SCU, the disparities in 3-month hospitalization rates and pressure ulcers between Hispanic and White residents were eliminated or greatly reduced. Despite the benefits of SCUs, racial and ethnic minority residents are less likely to access SCUs than White residents, suggesting that l

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 499 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,313,769 in active NIH money across 3 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,313,769
Active projects
3
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,313,769 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years) — 1R01AG104879-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG087296-03 Alzheimer's Special Care Units in Nursing Homes: Racial and Ethnic Disparities, and Resident Outcomes

    R01 · NIA · $394,184 · Sep 1, 2024 to May 31, 2028

  • 5R01AG081282-04 The effectiveness and consequences of visitation bans in nursing homes

    R01 · NIA · $383,929 · Jun 1, 2023 to Jan 31, 2027

All active NIH projects for Huiwen Xu ($1,313,769)
  • 1R01AG104879-01 Understand the Determinants and Quality Implications of Agency Staff Use in Nursing Homes: A Mixed Methods Study — $535,656, ends Jun 30, 2030
  • 5R01AG087296-03 Alzheimer's Special Care Units in Nursing Homes: Racial and Ethnic Disparities, and Resident Outcomes — $394,184, ends May 31, 2028
  • 5R01AG081282-04 The effectiveness and consequences of visitation bans in nursing homes — $383,929, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#171 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Robert E Gross lab

Robert E Gross · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Epilepsy is one of the most prevalent neurological disorders. Patients with epilepsy experience abnormal brain activity causing seizures or periods of unusual behavior, sensations, and often loss of awareness or consciousness. Deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) is an approved therapy that effectively reduces seizures in many patients with drug resistant epilepsy, but very rarely leads to all-important complete freedom from disabling seizures. This gap in treatment effectiveness may stem from limited understanding of the mechanism u

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 227 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $515,875 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$515,875
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $515,875 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS129984-03 Deconstructing Antiseizure Mechanisms of Anterior Thalamic Nucleus Electrical Stimulation

    R01 · NINDS · $515,875 · Aug 20, 2024 to Jun 30, 2029

All active NIH projects for Robert E Gross ($515,875)
  • 5R01NS129984-03 Deconstructing Antiseizure Mechanisms of Anterior Thalamic Nucleus Electrical Stimulation — $515,875, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 2024 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#172 Lab fit 27% · Adjacent Hiring: Not enough data Michigan Neuroscience

Michael Thomas Roberts lab

Michael Thomas Roberts · University of Michigan, Ann Arbor MI

Our long-term goal is to determine how cholinergic signaling drives adaptive sound processing in the auditory midbrain and how this computational flexibility is altered in auditory gating disorders, hearing loss, and aging. As the midbrain link between the auditory brainstem and forebrain, the inferior colliculus (IC) is a critical processing center that influences which auditory information gets presented to the forebrain. Computations in the IC are modulated by cholinergic projections from brainstem cholinergic systems, including a dense projection from the pedunculopontine tegmentum (PPT).

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 235 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "patch clamp")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 10 of 100 points
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DC021416-03 Mechanisms of Cholinergic Signaling in the Inferior Colliculus

    R01 · NIDCD · $582,712 · Aug 1, 2024 to Apr 30, 2029

Newest award started Aug 1, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#173 Lab fit 27% · Adjacent Hiring: Possible Michigan Neuroscience

Amara E Ezeamama lab

Amara E Ezeamama · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

The global burden of Alzheimer’s dementia and related disorders (ADRD) is growing in tandem with the demographic transition toward an aged society where older adults ≥65 years old that are more vulnerable to ADRD constitute a larger share of the general population. The fastest increase in ADRD and aging adults is occurring in sub-Saharan Africa where persons 50+ years old living with chronic HIV infection (OPH+) on combination antiretroviral therapy represent as much as 20% of older adults in some settings. OPH+ are at further risk of adverse cognitive outcomes and potentially ADRD due to HIV-

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 343 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $516,660 in active NIH money across 1 project, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$516,660
Active projects
1
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $516,660 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG087191-03S1 Vitamin D and Gut Microbiota and Dementia Risk in Older Adults with Chronic HIV infection and Demographically Matched Community Controls

    R01 · NIA · $281,093 · Jul 15, 2024 to Apr 30, 2029

All active NIH projects for Amara E Ezeamama ($516,660)
  • 5R01AG087191-03 Vitamin D and Gut Microbiota and Dementia Risk in Older Adults with Chronic HIV infection and Demographically Matched Community Controls — $516,660, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#174 Lab fit 27% · Adjacent Hiring: Moderate Michigan Neuroscience

Bruno Giordani lab

Bruno Giordani · University of Michigan, East Lansing MI

The global burden of Alzheimer’s dementia and related disorders (ADRD) is growing in tandem with the demographic transition toward an aged society where older adults ≥65 years old that are more vulnerable to ADRD constitute a larger share of the general population. The fastest increase in ADRD and aging adults is occurring in sub-Saharan Africa where persons 50+ years old living with chronic HIV infection (OPH+) on combination antiretroviral therapy represent as much as 20% of older adults in some settings. OPH+ are at further risk of adverse cognitive outcomes and potentially ADRD due to HIV-

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 598 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,564,806 in active NIH money across 2 projects, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,564,806
Active projects
2
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,564,806 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG087191-03S1 Vitamin D and Gut Microbiota and Dementia Risk in Older Adults with Chronic HIV infection and Demographically Matched Community Controls

    R01 · NIA · $281,093 · Jul 15, 2024 to Apr 30, 2029

  • 5R01AG068338-05 Identification of cognitive decline and dementia: Prediction by everyday driving behaviors and physiological responses

    R01 · NIA · $1,048,146 · Sep 15, 2020 to May 31, 2027

All active NIH projects for Bruno Giordani ($1,564,806)
  • 5R01AG068338-05 Identification of cognitive decline and dementia: Prediction by everyday driving behaviors and physiological responses — $1,048,146, ends May 31, 2027
  • 5R01AG087191-03 Vitamin D and Gut Microbiota and Dementia Risk in Older Adults with Chronic HIV infection and Demographically Matched Community Controls — $516,660, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2024 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#175 Lab fit 27% · Adjacent Hiring: Moderate Atlanta Neuroscience

Eric John Sundberg lab

Eric John Sundberg · Emory University, Atlanta GA

Antibodies are critical components of the adaptive immune system. While their simplest mechanism of action is neutralization mediated by their hypervariable Fab domains, most of their functional effects are a result of their constant Fc domains engaging host Fc receptors to recruit and stimulate the immune system. For IgG antibodies, Fc domains engage Fc γ receptors (FcγRs) and complement C1q to induce antibody-mediated effector functions that direct the immune response. A conserved N-linked glycan in the IgG Fc domain at residue Asn297 is overwhelmingly the most important molecular determinan

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 246 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on protein and antibody engineering Antibody/protein engineering programme; nothing on the CV covers molecule design or engineering. (matched on "monoclonal")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,562,079 in active NIH money across 3 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,562,079
Active projects
3
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,562,079 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5R01AI149297-07, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG085587-03 Deciphering the IgG glycosylation code of Alzheimer's Disease

    R01 · NIA · $547,556 · Feb 1, 2024 to Jan 31, 2029

All active NIH projects for Eric John Sundberg ($1,562,079)
  • 5R01AI149297-07 Engineering IgG-specific endoglycosidases to selectively defeat effector functions — $642,532, ends Apr 30, 2030
  • 5R01AG085587-03 Deciphering the IgG glycosylation code of Alzheimer's Disease — $547,556, ends Jan 31, 2029
  • 5R01GM148075-04 Gatekeeping glycan metabolism in the human gut microbiome — $371,991, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2024 · project period to Jan 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#176 Lab fit 27% · Adjacent Hiring: Moderate Michigan Ophthalmology

Linda D Hazlett lab

Linda D Hazlett · Wayne State University, Detroit MI

Summary Airborne particulate matter with a diameter of <10µm (PM10) is a major global airborne pollutant, with an irritant effect on mucous membranes, causing serious health (cardiovascular and respiratory) and economic outcomes. Pertinent to our studies, clinical evidence has shown that exposure to PM10 is linked to increased emergency room visits for keratitis and dry eye and conjunctivitis exacerbate the problem. Unfortunately, no studies have mechanistically investigated the effect of PM10 on the eye and the link/mechanisms leading to increased microbial infection. Therefore, the long-term

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 242 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,118,644 in active NIH money across 2 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,118,644
Active projects
2
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,118,644 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years) — 5P30EY004068-43, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035231-04 Airborne Particulates, Corneal Oxidative Stress and Infection

    R01 · NEI · $394,376 · Sep 30, 2023 to Jun 30, 2027

All active NIH projects for Linda D Hazlett ($1,118,644)
  • 5P30EY004068-43 Core Grant for Vision Research — $724,268, ends Jul 31, 2029
  • 5R01EY035231-04 Airborne Particulates, Corneal Oxidative Stress and Infection — $394,376, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2023 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#177 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Marina Sorrentino Hernandes lab

Marina Sorrentino Hernandes · Emory University, Atlanta GA

PROJECT SUMMARY The blood–brain barrier (BBB) is a term used to describe a series of properties possessed by the vasculature of the central nervous system (CNS) that play a critical role in maintaining a precisely regulated microenvironment for optimal neuronal signaling. The essential physiological functions of the BBB in supporting brain homeostasis are manifested within its most critical component, brain microvascular endothelial cells (ECs). Diminished EC barrier function and the consequent increase in vascular permeability significantly contribute to tissue damage, intracerebral hemorrhag

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 307 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "single-cell rna".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on structural biology Structure-determination lab (cryo-EM/crystallography). Her protein work is western blotting and mass spectrometry sample analysis, not structure solving. (matched on "protein structure")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,149,826 in active NIH money across 2 projects, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,149,826
Active projects
2
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,149,826 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “single-cell rna”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS127964-04 Poldip2 and the Brain Endothelial Barrier Function: Understanding Mechanisms that Regulate the Blood Brain Barrier Integrity

    R01 · NINDS · $472,758 · Sep 21, 2023 to May 31, 2028

All active NIH projects for Marina Sorrentino Hernandes ($1,149,826)
  • 5R01HL169373-03 Molecular mechanisms relating Poldip2 to endothelial permeability — $677,068, ends Mar 31, 2028
  • 5R01NS127964-04 Poldip2 and the Brain Endothelial Barrier Function: Understanding Mechanisms that Regulate the Blood Brain Barrier Integrity — $472,758, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 21, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#178 Lab fit 27% · Adjacent Hiring: Moderate Michigan Neuroscience

Hwajung Choi lab

Hwajung Choi · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT The number of people with Alzheimer’s disease and related dementias (ADRD) in the US will increase substantially, imposing a tremendous burden on patients, families, and the healthcare system. To inform the discussion of developing a sustainable and effective care system for people with ADRD, a better understanding of family care availability is critically important because it profoundly impacts care utilization and care costs at the onset and over the course of ADRD. The family care network/dynamics may have become more complicated in recent decades with increasing st

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 476 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,336,507 in active NIH money across 3 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,336,507
Active projects
3
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,336,507 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years).
  • +5 Brand-new (Type 1) project, not a renewal — 4RF1AG083037-02 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4RF1AG083037-02 Developing and evaluating new measures of family availability to provide care to people with dementia

    RF1 · NIA · $1,258,031 · Sep 1, 2023 to Aug 31, 2028 · Type 1 (new)

  • 5R01AG075002-05 The effects of the pandemic on formal and informal care among adults with dementia

    R01 · NIA · $529,334 · Sep 15, 2022 to May 31, 2027

All active NIH projects for Hwajung Choi ($2,336,507)
  • 4RF1AG083037-02 Developing and evaluating new measures of family availability to provide care to people with dementia — $1,258,031, ends Aug 31, 2028
  • 5R01AG080491-04 Implications of residential location in midlife disability and cognitive functioning among the poor vs. rich: within the US and cross-country comparisons — $549,142, ends Nov 30, 2027
  • 5R01AG075002-05 The effects of the pandemic on formal and informal care among adults with dementia — $529,334, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Aug 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#179 Lab fit 27% · Adjacent Hiring: Possible Michigan Neuroscience

Elham Mahmoudi lab

Elham Mahmoudi · University of Michigan, Ann Arbor MI

Project Summary/Abstract Medicare is the primary health insurance for older adults (65+) living in the U.S. Eligible beneficiaries must choose between two different plan types: traditional Medicare (TM) and Medicare Advantage (MA). MA enrollment has doubled in the last decade, currently covering about 45% of all Medicare beneficiaries. This growth has been driven, in part, by an increasing proportion of Black and Hispanic MA enrollees. While evidence suggests that some MA patient populations receive better-quality care and experience fewer disparities, it is unknown whether this is true for Me

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 245 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $712,990 in active NIH money across 1 project, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$712,990
Active projects
1
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $712,990 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG082856-03 Racial/Ethnic Disparities in Health Care and Challenges in Insurance Plan Choices among Older People with Alzheimer’s Disease and Related Dementia: A Mixed Methods Study of Medicare Options

    R01 · NIA · $712,990 · Aug 1, 2023 to Apr 30, 2029

All active NIH projects for Elham Mahmoudi ($712,990)
  • 5R01AG082856-03 Racial/Ethnic Disparities in Health Care and Challenges in Insurance Plan Choices among Older People with Alzheimer’s Disease and Related Dementia: A Mixed Methods Study of Medicare Options — $712,990, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2023 · project period to Apr 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#180 Lab fit 27% · Adjacent Hiring: Possible Michigan Neuroscience

Courtney A. Polenick lab

Courtney A. Polenick · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Persons living with dementia (PLWD) frequently experience sleep problems (e.g., trouble falling and staying asleep), which may reduce psychological well-being and exacerbate cognitive decline. PLWD are often supported by their spouses or cohabiting partners who are themselves at increased risk of sleep problems, psychological distress, and cognitive impairment. Spouses shape one another’s health and well-being in the context of aging and chronic illness. However, ADRD care research has primarily focused on caregivers’ own sleep, well-being, and cognitive function, limiting know

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 240 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $724,363 in active NIH money across 1 project, 2.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$724,363
Active projects
1
Runway left
2.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $724,363 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-01-31 (about 2.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG082025-03 Daily Experiences Among Couples Living With Early-Stage Dementia: Implications for Daily Sleep and Long-Term Well-Being and Cognitive Function

    R01 · NIA · $724,363 · May 15, 2023 to Jan 31, 2029

All active NIH projects for Courtney A. Polenick ($724,363)
  • 5R01AG082025-03 Daily Experiences Among Couples Living With Early-Stage Dementia: Implications for Daily Sleep and Long-Term Well-Being and Cognitive Function — $724,363, ends Jan 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 15, 2023 · project period to Jan 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#181 Lab fit 27% · Adjacent Hiring: Unlikely Michigan Ophthalmology

Taosheng Liu lab

Taosheng Liu · Michigan State University, East Lansing MI

PROJECT SUMMARY The environment contains far more information than the brain can process at once. Visual attention helps us cope with such information overload by selectively processing relevant information. In many situations, humans need to select arbitrary features in a scene. Theories of attention have proposed that such selection is mediated by a priority representation that encodes the relative importance of each visual stimulus in the scene. However, much remains unknown regarding how the brain computes and maintains attentional priority for features. Our long-term goal is to understand

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 241 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $384,162 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$384,162
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $384,162 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY032071-04 Representation of attentional priority for visual features in the human brain

    R01 · NEI · $384,162 · Sep 30, 2022 to Jun 30, 2027

All active NIH projects for Taosheng Liu ($384,162)
  • 5R01EY032071-04 Representation of attentional priority for visual features in the human brain — $384,162, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#182 Lab fit 27% · Adjacent Hiring: Unlikely Michigan Neuroscience

Phillip Eleas Vlisides lab

Phillip Eleas Vlisides · University of Michigan, Ann Arbor MI

TITLE: CAFFEINE AND POSTOPERATIVE NEUROCOGNITIVE RECOVERY PROJECT SUMMARY Delirium is a distressing clinical syndrome characterized by failure of basic cognitive functions that affects approximately 20-50% of older surgical patients. Delirium during surgical recovery is associated with increased mortality, increased healthcare expenditures, and future cognitive and functional decline. Moreover, there is pathophysiologic overlap between delirium and Alzheimer’s Disease-Related Dementias; patients experiencing delirium demonstrate increased risk of future dementia. Unfortunately, the underlying

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 223 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "segregation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $548,019 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$548,019
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $548,019 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “segregation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG075005-05 Caffeine and Postoperative Neurocognitive Recovery

    R01 · NIA · $548,019 · Aug 2, 2022 to Apr 30, 2027

All active NIH projects for Phillip Eleas Vlisides ($548,019)
  • 5R01AG075005-05 Caffeine and Postoperative Neurocognitive Recovery — $548,019, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 2, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#183 Lab fit 27% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Tiandong Leng lab

Tiandong Leng · Morehouse School of Medicine, Atlanta GA

PROJECT SUMMARY The overall objectives for this application are to determine the role of cholesterol metabolic enzyme CYP46A1 and its metabolite 24S-hydroxycholesterol (24S-HC) in ischemic stroke. Our central hypothesis is that activation of CYP46A1 results in increased production of 24S-HC, which contributes to ischemic brain injury through potentiation of NMDAR. To test our hypothesis, we will use a combination of in vitro and in vivo stroke models along with electrophysiology, calcium imaging and transgenic mice to pursue the following three specific aims: Aim 1. Determine the role of CYP46

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 225 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 39% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".
  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "mass spectrometr".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $355,000 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$355,000
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $355,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “mass spectrometr”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS128018-05 The role of cholesterol metabolic enzyme CYP46A1 and its metabolite 24S-hydroxycholesterol in ischemic stroke.

    R01 · NINDS · $355,000 · Jun 1, 2022 to May 31, 2027

All active NIH projects for Tiandong Leng ($355,000)
  • 5R01NS128018-05 The role of cholesterol metabolic enzyme CYP46A1 and its metabolite 24S-hydroxycholesterol in ischemic stroke. — $355,000, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#184 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Hang Lu lab

Hang Lu · Georgia Institute of Technology, Atlanta GA

Project Summary Anatomical atlases are spatial reference maps of cells in tissues/organs/brains and provide structure information for a wide range of biological analyses. The anatomical atlas of C. elegans nervous system is the only atlas for the entire nervous system of an animal with a resolution of all neuronal classes. However, built on a limited dataset and manual annotations, the standard atlas is insufficient in capturing biological variabilities, inaccurate and difficult to use for cell identification routinely, and only applicable for wildtype adult. While several heroic efforts of ge

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 225 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "c. elegans".
  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • In vivo ocular imaging and functional readouts Lab text mentions "in vivo imaging".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,144,782 in active NIH money across 2 projects, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,144,782
Active projects
2
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,144,782 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-01-31 (about 1.3 years) — 5R01AG082039-04, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “c. elegans”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH130064-04 Modularly built, complete, coordinate- and template-free brain atlases

    R01 · NIMH · $626,649 · Feb 10, 2022 to Jan 31, 2027

All active NIH projects for Hang Lu ($1,144,782)
  • 5R01MH130064-04 Modularly built, complete, coordinate- and template-free brain atlases — $626,649, ends Jan 31, 2027
  • 5R01AG082039-04 Inferring multi-scale dynamics underlying behavior in aging C. elegans — $518,133, ends Jan 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 10, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#185 Lab fit 27% · Adjacent Hiring: Possible Michigan Neuroscience

Patrick J Mueller lab

Patrick J Mueller · Wayne State University, Detroit MI

Physical inactivity is a major independent risk factor for cardiovascular disease (CVD) and is now considered the leading cause of premature death (Blair, 2009). Rates of physical inactivity continue to increase along with health care costs to treat CVD. Despite these disturbing trends, the mechanisms by which a sedentary lifestyle leads to CVD are not fully known. CVD is associated with increased sympathetic nervous system activity and overactivity of a brainstem region known as the rostral ventrolateral medulla (RVLM) (Sved et al., 2003;Guyenet, 2006). Sympathoexcitatory responses to direct

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 247 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • CRISPR / conditional knockout genetics Lab text mentions "gene targeting".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $618,391 in active NIH money across 1 project, 0.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$618,391
Active projects
1
Runway left
0.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $618,391 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-11-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “gene targeting”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01HL161233-04 Contribution of neuroplasticity in the rostral ventrolateral medulla to physical inactivity-related cardiovascular disease

    R01 · NHLBI · $618,391 · Dec 1, 2021 to Nov 30, 2026

All active NIH projects for Patrick J Mueller ($618,391)
  • 5R01HL161233-04 Contribution of neuroplasticity in the rostral ventrolateral medulla to physical inactivity-related cardiovascular disease — $618,391, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 1, 2021 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#186 Lab fit 27% · Adjacent Hiring: Possible Michigan Neuroscience

Noreen F Rossi lab

Noreen F Rossi · Wayne State University, Detroit MI

Physical inactivity is a major independent risk factor for cardiovascular disease (CVD) and is now considered the leading cause of premature death (Blair, 2009). Rates of physical inactivity continue to increase along with health care costs to treat CVD. Despite these disturbing trends, the mechanisms by which a sedentary lifestyle leads to CVD are not fully known. CVD is associated with increased sympathetic nervous system activity and overactivity of a brainstem region known as the rostral ventrolateral medulla (RVLM) (Sved et al., 2003;Guyenet, 2006). Sympathoexcitatory responses to direct

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 247 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • CRISPR / conditional knockout genetics Lab text mentions "gene targeting".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,244,475 in active NIH money across 2 projects, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,244,475
Active projects
2
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,244,475 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • CRISPR / conditional knockout genetics — lab text says “gene targeting”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01HL161233-04 Contribution of neuroplasticity in the rostral ventrolateral medulla to physical inactivity-related cardiovascular disease

    R01 · NHLBI · $618,391 · Dec 1, 2021 to Nov 30, 2026

All active NIH projects for Noreen F Rossi ($1,244,475)
  • 5R01HL163844-04 Impact of Dietary Fructose and High Salt Diet on Neurocardiovascular and Renal Function — $626,084, ends Mar 31, 2027
  • 5R01HL161233-04 Contribution of neuroplasticity in the rostral ventrolateral medulla to physical inactivity-related cardiovascular disease — $618,391, ends Nov 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 1, 2021 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#187 Lab fit 27% · Adjacent Hiring: Moderate Michigan Neuroscience

Shelly Beth Flagel lab

Shelly Beth Flagel · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT Stimuli (cues) in the environment associated with reward can motivate normal behavior, bringing one in close proximity to valuable resources (e.g. food); but they can also gain inordinate control over behavior, as is the case with addiction. The ability of reward cues to motivate behavior occurs through Pavlovian learning processes. When a discrete cue is repeatedly paired with presentation of a reward, it can acquire the ability to act as a predictor, but can also acquire incentive motivational properties. In individuals with addiction, cues that have been previously

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 238 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "viral vector".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,328,806 in active NIH money across 4 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,328,806
Active projects
4
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,328,806 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years) — 5R25NS107159-08, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “viral vector”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA054094-05 Probing the role of a hypothalamic-thalamic-striatal circuit in cue-driven behaviors

    R01 · NIDA · $533,722 · Sep 30, 2021 to Jul 31, 2027

All active NIH projects for Shelly Beth Flagel ($1,328,806)
  • 5R01DA054094-05 Probing the role of a hypothalamic-thalamic-striatal circuit in cue-driven behaviors — $533,722, ends Jul 31, 2027
  • 5R34DA061925-02 Building an “AI Forest” to identify the social and environmental factors underlying complex behavioral traits in wild primates. — $279,522, ends Feb 28, 2027
  • 5T32DA007281-30 NIDA Training Program in Neuroscience — $272,616, ends Jun 30, 2027
  • 5R25NS107159-08 Enhancing Mentoring, Agency, and Training Across the Neuroscience Graduate Education Continuum — $242,946, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2021 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#188 Lab fit 27% · Adjacent Hiring: Strong Michigan Neuroscience

Scott Pletcher lab

Scott Pletcher · University of Michigan, Ann Arbor MI

Project Summary Unrelenting growth in the number of elderly in our society and the resulting impact on the prevalence of age-related disease will have dramatic economic and health-related consequences over the next two decades. Although the causes and consequences of many diseases, including cancer and dementia, are slowly being unraveled, the mechanisms that underlie advanced age as the most significant risk factor associated with these disease states are relatively unknown. This is an important issue because single interventions that impact mechanisms of aging would be expected to ameliorate

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 817 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Non-rodent animal models Lab text mentions "drosophila".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "screening program")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,842,732 in active NIH money across 4 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,842,732
Active projects
4
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,842,732 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4R37AG051649-11 Modulation of aging through mechanisms of nutrient demand and reward

    R37 · NIA · $463,128 · Sep 1, 2021 to Mar 31, 2031

  • 2R01AG030593-16 Modulation of aging by Sensory Perception

    R01 · NIA · $455,571 · Jun 1, 2007 to Aug 31, 2029

  • 4RF1AG030593-18 Modulation of aging by Sensory Perception

    RF1 · NIA · $1,272,365 · Jun 1, 2007 to Aug 31, 2029

All active NIH projects for Scott Pletcher ($2,842,732)
  • 4RF1AG030593-18 Modulation of aging by Sensory Perception — $1,272,365, ends Aug 31, 2029
  • 5T32AG000114-42 Career Training in the Biology of Aging — $562,696, ends Jun 30, 2030
  • 5R33AG078428-05 Systems and methods for molecular dissection of socio-environmental effects on aging — $544,543, ends Aug 31, 2027
  • 4R37AG051649-11 Modulation of aging through mechanisms of nutrient demand and reward — $463,128, ends Mar 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#189 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Whitney Lee Wharton lab

Whitney Lee Wharton · Emory University, Atlanta GA

Women are more likely than men to develop Alzheimer's disease (AD), and available research suggests this is not only because they have a longer life expectancy than men. This increased risk is likely due, in part, to fluctuating sex hormones across the lifespan. Sex hormones likely have direct actions on AD brain biomarkers (Aβ and tau levels), as well as indirect actions via inflammation, sleep disruptions, and reduced brain blood flow and volume, all of which are independent risk factors for AD. African Americans –men and women– are also at increased risk for AD vs. Caucasians. As such, mech

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 311 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.82 domain gate = 27%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Sequencing, variant and splicing analysis Lab text mentions "allele".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $676,171 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$676,171
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $676,171 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “allele”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG066203-05 Role of estradiol and related hormones on inflammation, sleep, and risks for Alzheimer's disease

    R01 · NIA · $676,171 · Sep 15, 2019 to Jun 30, 2027

All active NIH projects for Whitney Lee Wharton ($676,171)
  • 5R01AG066203-05 Role of estradiol and related hormones on inflammation, sleep, and risks for Alzheimer's disease — $676,171, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2019 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#190 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Gennady S Cymbalyuk lab

Gennady S Cymbalyuk · Georgia State University, Atlanta GA

Project Summary / Abstract The long-term goal of this project is to elucidate the basic cellular, molecular, and physiological mechanisms of cold nociception. Thermosensory nociception is a specialized form of somatosensation, essential to the survival of all metazoans, that alerts the organism to potential environmental dangers coupled with pain sensation thereby serving as a protective mechanism for driving adaptive behavioral responses to safeguard against incipient damage. Despite this importance, the fundamental cellular, molecular, and physiological bases of cold nociception remain incom

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 242 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Calcium and mechanosensitive channel signalling Lab text mentions "ion channel".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $613,692 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$613,692
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $613,692 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS115209-08 Molecular and Computational Dissection of Cold Nociception

    R01 · NINDS · $613,692 · Jul 15, 2019 to Jul 31, 2029

All active NIH projects for Gennady S Cymbalyuk ($613,692)
  • 5R01NS115209-08 Molecular and Computational Dissection of Cold Nociception — $613,692, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2019 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#191 Lab fit 27% · Adjacent Hiring: Possible Atlanta Neuroscience

Daniel N Cox lab

Daniel N Cox · Georgia State University, Atlanta GA

Project Summary / Abstract The long-term goal of this project is to elucidate the basic cellular, molecular, and physiological mechanisms of cold nociception. Thermosensory nociception is a specialized form of somatosensation, essential to the survival of all metazoans, that alerts the organism to potential environmental dangers coupled with pain sensation thereby serving as a protective mechanism for driving adaptive behavioral responses to safeguard against incipient damage. Despite this importance, the fundamental cellular, molecular, and physiological bases of cold nociception remain incom

Lab fit breakdown — 27% weighted · Adjacent

Scored on enough lab text to read as a verdict. 242 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 38% × 0.7 domain gate = 27%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Calcium and mechanosensitive channel signalling Lab text mentions "ion channel".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $613,692 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$613,692
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $613,692 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Calcium and mechanosensitive channel signalling — lab text says “ion channel”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS115209-08 Molecular and Computational Dissection of Cold Nociception

    R01 · NINDS · $613,692 · Jul 15, 2019 to Jul 31, 2029

All active NIH projects for Daniel N Cox ($613,692)
  • 5R01NS115209-08 Molecular and Computational Dissection of Cold Nociception — $613,692, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2019 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#192 Lab fit 26% · Adjacent Hiring: Moderate Atlanta Neuroscience New award

Johnathan Lucas Mckay lab

Johnathan Lucas Mckay · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Parkinson's disease (PD) is the second-most common neurodegenerative condition, affecting over 10 million people worldwide. Misdiagnosis rates of PD range from 15% to 24%. Limited access to PD care is common, especially in rural areas. In the United States (US), only 9% of PD patients see specialists, while most receive care from general neurologists or primary care providers. Mental health care is crucial for PD patients due to the significant burden of psychiatric symptoms, which often go unrecognized and untreated. Barriers include stigma, lack of social support, in

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 375 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $618,523 in active NIH money across 1 project, 4.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$618,523
Active projects
1
Runway left
4.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $618,523 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-08-31 (about 4.9 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146515-01A1 Scalable and Affordable Artificial Intelligence-driven Clinical Decision Support for Movement Disorders

    R01 · NINDS · $618,523 · Sep 1, 2026 to Aug 31, 2031

All active NIH projects for Johnathan Lucas Mckay ($618,523)
  • 1R01NS146515-01A1 Scalable and Affordable Artificial Intelligence-driven Clinical Decision Support for Movement Disorders — $618,523, ends Aug 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Aug 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#193 Lab fit 26% · Adjacent Hiring: Strong Atlanta Neuroscience New award

Matthew Gombolay lab

Matthew Gombolay · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT Successful implementation of deep brain stimulation (DBS) for treatment of Parkinson’s disease (PD) hinges on appropriate selection of stimulation parameters (contact configuration, amplitude, pulse width, frequency) to maximize therapeutic benefit and minimize side effects. There is an urgent need to develop more efficient pro- gramming methods to expand DBS access while maintaining and potentially improving clinical outcomes. Ob- jective and rapidly measurable electrophysiologic biomarkers now exist that could guide automated selection of stimulation parameters using

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 265 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,214,627 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,214,627
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,214,627 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01NS146703-01A1 Automated programming for personalized deep brain stimulation in Parkinsons disease

    R01 · NINDS · $635,512 · Sep 1, 2026 to Jun 30, 2031

All active NIH projects for Matthew Gombolay ($2,214,627)
  • 2R01HL157457-04 Intelligent Perfusion Digital Twin to Improve Patient Safety and Quality in Cardiac Surgery — $875,418, ends Apr 30, 2030
  • 5R01EB036877-02 An Artificial Intelligence Coaching System to Improve Surgical Performance in Urologic Endoscopy — $703,697, ends Feb 28, 2029
  • 1R01NS146703-01A1 Automated programming for personalized deep brain stimulation in Parkinsons disease — $635,512, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2026 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#194 Lab fit 26% · Adjacent Hiring: Moderate Atlanta Neuroscience

Miranda Annette Moore lab

Miranda Annette Moore · Emory University, Atlanta GA

The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population Abstract. Americans living in rural areas, compared to their urban and suburban counterparts, are disproportionately affected by shortages of health care resources, resulting in poorer health status and health outcomes. The prevalence and impact of dementia and other chronic illnesses is and will continue to be higher in rural America. Rural-dwelling persons living with dementia illnesses (PLWD) and the friends and family (caregivers)

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 266 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $651,391 in active NIH money across 1 project, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$651,391
Active projects
1
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $651,391 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-18.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG099377-01 The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population

    R01 · NIA · $651,391 · Aug 18, 2026 to Jul 31, 2031

All active NIH projects for Miranda Annette Moore ($651,391)
  • 1R01AG099377-01 The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population — $651,391, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 18, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#195 Lab fit 26% · Adjacent Hiring: Strong Atlanta Neuroscience

Molly M Perkins lab

Molly M Perkins · Emory University, Atlanta GA

The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population Abstract. Americans living in rural areas, compared to their urban and suburban counterparts, are disproportionately affected by shortages of health care resources, resulting in poorer health status and health outcomes. The prevalence and impact of dementia and other chronic illnesses is and will continue to be higher in rural America. Rural-dwelling persons living with dementia illnesses (PLWD) and the friends and family (caregivers)

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 550 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,528,169 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,528,169
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,528,169 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-18.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01AG099377-01 The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population

    R01 · NIA · $651,391 · Aug 18, 2026 to Jul 31, 2031

  • 5R01AG069114-03 Investigating Informal Caregivers' Involvement in End-of-Life Care among Assisted Living Residents with Advanced Dementia and its Influence on Resident and Caregiver Outcomes

    R01 · NIA · $706,597 · Jun 1, 2021 to May 31, 2027

All active NIH projects for Molly M Perkins ($2,528,169)
  • 5P30AG064200-08 Roybal Center for Dementia Family Caregiver Mastery — $1,170,181, ends May 31, 2029
  • 5R01AG069114-03 Investigating Informal Caregivers' Involvement in End-of-Life Care among Assisted Living Residents with Advanced Dementia and its Influence on Resident and Caregiver Outcomes — $706,597, ends May 31, 2027
  • 1R01AG099377-01 The Rural Family Dementia Caregivers (RFD Caregivers) Program: Developing Caregiving Knowledge and Skills for a Disproportionately Burdened Caregiver Population — $651,391, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 18, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#196 Lab fit 26% · Adjacent Hiring: Moderate Michigan Neuroscience

J. Devin Mcauley lab

J. Devin Mcauley · University of Michigan, Ann Arbor MI

Treatment options for stuttering remain severely limited, with reported success rates of current interventions for children who stutter failing to exceed natural (unassisted) recovery rates. There is a significant need to develop novel treatments informed by an updated neuroscientific understanding of stuttering. Systematic empirical work as well as theoretical perspectives have pointed to an association between deficits in the basal ganglia thalamocortical (BGTC) network and the onset and persistence of stuttering. A key function supported by the BGTC network is timing and initiation of speec

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 192 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $648,923 in active NIH money across 1 project, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$648,923
Active projects
1
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $648,923 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-07-20.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DC023753-01 Digital rhythm games for stuttering intervention

    R01 · NIDCD · $648,923 · Jul 20, 2026 to Jun 30, 2031

All active NIH projects for J. Devin Mcauley ($648,923)
  • 1R01DC023753-01 Digital rhythm games for stuttering intervention — $648,923, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 20, 2026 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#197 Lab fit 26% · Adjacent Hiring: Strong Michigan Neuroscience

Helen Carmon Spink Meier lab

Helen Carmon Spink Meier · University of Michigan, Ann Arbor MI

Alzheimer’s disease and related dementias (ADRD) are a growing public health burden and understanding modifiable ADRD causes is a national priority. Many classes of environmental chemicals, such as pesticides and per- and polyfluoroalkyl substances (PFASs) contain known neurotoxicants and are thus likely to contribute to ADRD risk, but we lack prospective data with appropriate temporality (exposures measured years before cognitive outcomes) in large and representative populations. Leveraging stored biospecimens from one of the largest, longitudinal, population-based United States cohorts, the

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,886,721 in active NIH money across 3 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,886,721
Active projects
3
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,886,721 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-04-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01AG096517-01 Environmental Exposures and ADRD in the Health and Retirement Study Cohort

    R01 · NIA · $1,703,843 · Apr 1, 2026 to Jan 31, 2031

All active NIH projects for Helen Carmon Spink Meier ($2,886,721)
  • 1R01AG096517-01 Environmental Exposures and ADRD in the Health and Retirement Study Cohort — $1,703,843, ends Jan 31, 2031
  • 5U01HD110063-05 The longitudinal impact of the COVID-19 pandemic and related multi-level mitigation and contextual factors on health and socioeconomic outcomes of individuals and families from a vulnerable population — $597,961, ends Apr 30, 2027
  • 5R01AG080401-04 The impact of redlining and place-based factors on health at mid-life — $584,917, ends Dec 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2026 · project period to Jan 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#198 Lab fit 26% · Adjacent Hiring: Possible Atlanta Neuroscience

Thota Ganesh lab

Thota Ganesh · Emory University, Atlanta GA

Lay Summary Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Currently, about 6.5 million Americans are living with AD. Alzheimer’s and other dementias are estimated to cost the US $321 billion per year and this number is expected to 1 trillion by 2050, yet no small molecule therapeutic agent on the horizon that clearly alters the disease progression and inevitable cognitive decline. The small molecule drugs and anti-bodies that have been developed based on the amyloid cascade hypothesis showed a limited (if any) disease modifying benefit so far. Thus, it would be very

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 361 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on medicinal chemistry and radiotracer development Chemistry-driven programme (probe or radiotracer development) rather than disease-mechanism cell biology. (matched on "drug discovery")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,871,028 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,871,028
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,871,028 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5U01AG088113-03 Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease

    U01 · NIA · $1,871,028 · Sep 20, 2024 to Jun 30, 2029

All active NIH projects for Thota Ganesh ($1,871,028)
  • 5U01AG088113-03 Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease — $1,871,028, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 20, 2024 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#199 Lab fit 26% · Adjacent Hiring: Possible Michigan Neuroscience

Michael Patrick Flynn lab

Michael Patrick Flynn · University of Michigan, Ann Arbor MI

Project Summary Over the decades, various neurotechnologies have made significant advancements to meet the highest priority goals enumerated in the BRAIN 2025 Report. However, each tool development has been driven by a certain type of specific modalities in the target brain region, cell type, and limited experiments and has focused on scaling in a narrow domain. While the utility of such tools has uniquely served one modality, neuroscience experiments are inherently limited by the breadth of observations available. It is known that brain activities and status are affected by biophysiological p

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 213 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.7 domain gate = 26%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $3,837,586 in active NIH money across 1 project, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,837,586
Active projects
1
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,837,586 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1NS133978-01 Reconfigurable 3D Origami Probes for Multi-modal Neural Interface

    RF1 · NINDS · $3,837,586 · Sep 15, 2023 to Aug 31, 2027

All active NIH projects for Michael Patrick Flynn ($3,837,586)
  • 1RF1NS133978-01 Reconfigurable 3D Origami Probes for Multi-modal Neural Interface — $3,837,586, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2023 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#200 Lab fit 26% · Adjacent Hiring: Unlikely Michigan Ophthalmology

Carlo Piermarocchi lab

Carlo Piermarocchi · Michigan State University, East Lansing MI

My long-term research goal is to develop data-driven mathematical models to understand and control cell differentiation. My lab’s approach integrates single-cell transcriptomics data in a mathematical model, the Hopfield model, to describe the signaling dynamics in gene networks and simulate the effect of perturbations on sets of target genes. Originally developed as a mathematical model of the brain, the Hopfield model allows for a direct mapping of associative memory patterns into dynamical attractor states in a network, so that the system can recover a host of memories using partial informa

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 230 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 21% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.82 domain gate = 26%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $374,715 in active NIH money across 1 project, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$374,715
Active projects
1
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $374,715 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 21%

    Matched 1 of 6 profile areas (6 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM149261-04 Network models of differentiation landscapes for angiogenesis and hematopoiesis

    R35 · NIGMS · $374,715 · Sep 1, 2023 to Aug 31, 2028

All active NIH projects for Carlo Piermarocchi ($374,715)
  • 5R35GM149261-04 Network models of differentiation landscapes for angiogenesis and hematopoiesis — $374,715, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Aug 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#201 Lab fit 26% · Adjacent Hiring: Unlikely Michigan Neuroscience

Stefanie Galban lab

Stefanie Galban · University of Michigan, Ann Arbor MI

Understanding the role of cancer stem cells (CSCs) in diffuse intrinsic pontine glioma (DIPG) is crucial for preventing treatment resistance and tumor progression and for devising therapies that may prolong the lives of the 200-400 pediatric DIPG patients diagnosed each year. Radiotherapy remains the standard of care, but tumors recur in 100% of patients, resulting in dismal patient survival of 8-11 months. Over 250 clinical trials have failed to move these numbers. Mechanistic research is urgently needed to understand the underlying biology of CSCs and how they drive treatment resistance to d

Lab fit breakdown — 26% weighted · Adjacent

Scored on enough lab text to read as a verdict. 329 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 37% × 0.7 domain gate = 26%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $439,778 in active NIH money across 1 project, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$439,778
Active projects
1
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $439,778 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS131515-04 Epigenetically regulated stemness program and stem cell niche as targets in pediatric DIPG

    R01 · NINDS · $439,778 · Jun 1, 2023 to Apr 30, 2028

All active NIH projects for Stefanie Galban ($439,778)
  • 5R01NS131515-04 Epigenetically regulated stemness program and stem cell niche as targets in pediatric DIPG — $439,778, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#202 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience New award

Christian Richard Burgess lab

Christian Richard Burgess · University of Michigan, Ann Arbor MI

Project summary Sleep is a fundamental behavior that is tightly regulated by the brain. Dysregulation of this neural circuitry results in disordered sleep, costing an estimated ~$90 billion per year in excess healthcare costs in the US. Sleep is made up of distinct phases: non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. REM sleep, associated with high cortical activity and muscle atonia, is homeostatically regulated and serves many important physiological functions. The neural circuits that govern REM sleep are central to several sleep disorders, including narcolepsy and REM

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 260 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $532,242 in active NIH money across 1 project, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$532,242
Active projects
1
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $532,242 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-14.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01NS150237-01 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01NS150237-01 Identifying neural circuits regulating entrance into REM sleep

    R01 · NINDS · $532,242 · Sep 14, 2026 to Jun 30, 2031 · Type 1 (new)

All active NIH projects for Christian Richard Burgess ($532,242)
  • 1R01NS150237-01 Identifying neural circuits regulating entrance into REM sleep — $532,242, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 14, 2026 · project period to Jun 30, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#203 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Xuefei Huang lab

Xuefei Huang · Michigan State University, East Lansing MI

Proteoglycans (PGs) play important roles in many biological processes including inflammatory responses, cancer development, immune modulation, and Alzheimer’s disease. PGs are comprised of heparan sulfate or chondroitin sulfate glycosaminoglycan chains covalently attached to the core protein through tetrasaccharide linkers. Traditionally, the biological functions of PGs are believed to be dominated by the glycosaminoglycan chains attached. However, it has become increasingly appreciated that the core protein can significantly impact glycan activities. Both the core protein and the GAG chains s

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 150 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,952,130 in active NIH money across 3 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,952,130
Active projects
3
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,952,130 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R35GM158263-02 Syntheses of homogeneous proteoglycan like glycopeptide and glycoprotein libraries for microarray studies

    R35 · NIGMS · $392,500 · Aug 10, 2025 to Jul 31, 2030

All active NIH projects for Xuefei Huang ($1,952,130)
  • 5R01AI182419-02 Deciphering the amine/acetylation code of PNAG through comprehensive libraries of synthetic oligosaccharides for effective anti-microbial vaccines — $795,733, ends Oct 31, 2029
  • 5R01AI190348-02 Carbohydrate based multi-component vaccine against Bordetella pertussis — $763,897, ends Apr 30, 2030
  • 5R35GM158263-02 Syntheses of homogeneous proteoglycan like glycopeptide and glycoprotein libraries for microarray studies — $392,500, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 10, 2025 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#204 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Mellanie V Springer lab

Mellanie V Springer · University of Michigan, Ann Arbor MI

Vascular cognitive impairment and dementia (VCID) after stroke increases risk for death and is highly disabling. New-onset VCID after stroke is common, affecting as many as one-third of stroke survivors. There are currently no treatments recommended to reduce VCID risk. Interventions to reduce risk of incident VCID after stroke are critically needed. One simple, inexpensive, accessible intervention that holds promise for VCID prevention among stroke patients is cognitively stimulating activities (such as reading, doing crossword puzzles, and word games). The performance of cognitively stimulat

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 202 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $819,479 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$819,479
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $819,479 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS140071-02 Determining modifiable factors for post-stroke Vascular Cognitive Impairment and Dementia

    R01 · NINDS · $576,047 · Aug 4, 2025 to Jul 31, 2030

All active NIH projects for Mellanie V Springer ($819,479)
  • 5R01NS140071-02 Determining modifiable factors for post-stroke Vascular Cognitive Impairment and Dementia — $576,047, ends Jul 31, 2030
  • 5K01NS117555-05 Partnering with an Urban Safety Net Hospital to Deliver Stroke Preparedness in the Emergency Department — $243,432, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 4, 2025 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#205 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Honglei Chen lab

Honglei Chen · Henry Ford Health + Michigan State University Health Sciences, East Lansing MI

Abstract Many pesticides are neurotoxic, and high exposures may have long-term neurodegenerative consequences. However, empirical evidence on the association between pesticides and Alzheimer’s disease and related dementias (ADRD) is preliminary and inconsistent. This project will identify links between pesticide exposure and markers across the ADRD neurodegeneration continuum, from preclinical biomarkers to clinical diagnosis. The study will be conducted among rural farmers, the group with particularly high pesticide exposure. The central hypothesis is that high pesticide exposure will increas

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 571 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,226,608 in active NIH money across 2 projects, 3.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,226,608
Active projects
2
Runway left
3.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,226,608 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-01-31 (about 3.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG091698-02 Pesticide Use and Markers of ADRD Neurodegeneration among US Farmers

    R01 · NIA · $2,730,619 · Mar 15, 2025 to Jan 31, 2030

  • 5R01AG071517-05 Poor sense of smell and the health of older adults

    R01 · NIA · $495,989 · Jun 15, 2022 to Feb 28, 2027

All active NIH projects for Honglei Chen ($3,226,608)
  • 5R01AG091698-02 Pesticide Use and Markers of ADRD Neurodegeneration among US Farmers — $2,730,619, ends Jan 31, 2030
  • 5R01AG071517-05 Poor sense of smell and the health of older adults — $495,989, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 15, 2025 · project period to Jan 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#206 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Lauren Beth Gerlach lab

Lauren Beth Gerlach · University of Michigan, Ann Arbor MI

PROJECT ABSTRACT Nursing homes are an important location of care for patients with dementia, who are at high risk for medication-related harms. Antiepileptic medications such as valproic acid and gabapentin are commonly prescribed off-label to patients with dementia to treat symptoms such as behavioral disturbances and pain despite limited evidence that these medications are effective in treating such conditions. Our work has found that the prescribing of antiepileptics has doubled over the past decade, now prescribed to over 40% of nursing home residents with dementia. The growth in antiepile

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 258 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $858,415 in active NIH money across 2 projects, 3.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$858,415
Active projects
2
Runway left
3.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $858,415 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-11-30 (about 3.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG087073-02 National study of antiepileptic use among patients with dementia in long-term care

    R01 · NIA · $693,535 · Feb 1, 2025 to Nov 30, 2029

All active NIH projects for Lauren Beth Gerlach ($858,415)
  • 5R01AG087073-02 National study of antiepileptic use among patients with dementia in long-term care — $693,535, ends Nov 30, 2029
  • 5K23AG066864-05 Medicating distress: Use of psychotropic medications among patients with dementia receiving hospice care — $164,880, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2025 · project period to Nov 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#207 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Sung-hee Lee lab

Sung-hee Lee · University of Michigan, Ann Arbor MI

Two of the strategic research directions of the National Institute on Aging (NIA) are: 1) improving understanding of Alzheimer’s Disease and Related Dementias (ADRD) and 2) understanding heterogeneity of health conditions to improve the health of all older adult populations. Achieving these goals requires data across subpopulations, particularly groups associated with races, ethnicities and languages, as the aging U.S. population is projected to be more heterogenous on these dimensions. More national aging research data are needed beyond Latinos, non-Latino Whites, and non-Latino Blacks who ar

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 300 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,556,298 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,556,298
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,556,298 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG082080-02 Improving Alzheimer’s Disease and Related Dementias Population-Based Research Data Capacity for All through Nationally Representative Hybrid Sampling.

    R01 · NIA · $1,168,016 · Apr 1, 2024 to Jun 30, 2030

All active NIH projects for Sung-hee Lee ($1,556,298)
  • 5R01AG082080-02 Improving Alzheimer’s Disease and Related Dementias Population-Based Research Data Capacity for All through Nationally Representative Hybrid Sampling. — $1,168,016, ends Jun 30, 2030
  • 5U24AG077012-05 Network for Advancing Methodological Research in Longitudinal Studies of Aging — $388,282, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2024 · project period to Jun 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#208 Lab fit 25% · Adjacent Hiring: Strong Atlanta Neuroscience

Fikri Birey lab

Fikri Birey · Emory University, Atlanta GA

ABSTRACT Assembly of the brain relies upon spatiotemporally coordinated action of a small number of intracellular signaling pathways, which together govern an astonishingly wide array of processes, ranging from cell differentiation to tissue morphogenesis. How a handful of pathways can provide the precision and specificity required for the emergence of complex tissue structure and function that unfold over long periods of time, such as those of the human brain, has been a long-standing question in developmental biology. Even though landmark studies in developmental genetics, biochemistry and s

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 286 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • CRISPR / conditional knockout genetics Lab text mentions "crispr".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Calcium and mechanosensitive channel signalling Lab text mentions "mechanotransduc".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,493,341 in active NIH money across 4 projects, 4.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,493,341
Active projects
4
Runway left
4.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,493,341 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-04-30 (about 4.6 years) — 1R01MH140260-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • CRISPR / conditional knockout genetics — lab text says “crispr”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Calcium and mechanosensitive channel signalling — lab text says “mechanotransduc”Her side: Her current UCI arm on trabecular meshwork calcium channels — chronic ER stress and impaired TRPV4 signalling — described in the research profile as active and unpublished.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH133612-03 Elucidating the Signaling Landscapes Underlying Cellular and Regional Specification During Human Brain Development

    R01 · NIMH · $760,493 · Feb 1, 2024 to Nov 30, 2028

All active NIH projects for Fikri Birey ($3,493,341)
  • 1S10OD038233-01 Acquisition of an automated robotic culture system for organoid generation, maintenance, and phenotyping — $1,521,607, ends May 14, 2027
  • 1R01MH140260-01A1 hiPSC and Progenitor Heterogeneity as Predictors of Variability in 3D Human Neural Differentiation — $780,866, ends Apr 30, 2031
  • 5R01MH133612-03 Elucidating the Signaling Landscapes Underlying Cellular and Regional Specification During Human Brain Development — $760,493, ends Nov 30, 2028
  • 1R21MH144466-01 Multiplexed Functional Mapping of CACNA1C Disease Variants in hiPSC-Derived Neurons — $430,375, ends Jul 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 1, 2024 · project period to Nov 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#209 Lab fit 25% · Adjacent Hiring: Moderate Atlanta Neuroscience

Candace L. Floyd lab

Candace L. Floyd · Emory University, Atlanta GA

Project Summary/ Abstract The goal of this project is to develop and validate a porcine model of spinal cord injury-induced neuropathic pain (SCI-NP). Most previous research in SCI-NP has been conducted in rodent models which have significantly advanced knowledge of mechanisms and drug discovery but have shortcomings which limit accurate prediction of analgesic efficacy in human clinical populations. Thus, a model that is more similar to humans in anatomy, size, metabolism, physiology, and pharmacokinetics/dynamics is needed to advance development of new therapies. We hypothesize that a porcin

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 273 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Non-rodent animal models Lab text mentions "porcine".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histopatholog".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,344,505 in active NIH money across 3 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,344,505
Active projects
3
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,344,505 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years).
  • +5 Brand-new (Type 1) project, not a renewal — 4RF1NS135504-02 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “porcine”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histopatholog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 4RF1NS135504-02 Development and validation of a porcine model of spinal cord injury-induced neuropathic pain

    RF1 · NINDS · $2,344,505 · Sep 21, 2023 to Aug 31, 2028 · Type 1 (new)

All active NIH projects for Candace L. Floyd ($2,344,505)
  • 4RF1NS135504-02 Development and validation of a porcine model of spinal cord injury-induced neuropathic pain — $2,344,505, ends Aug 31, 2028
  • 5I50BX005878-06 PRECISE-TBI: PRE Clinical lnteragency research resourcE-TBI — unknown, ends Nov 30, 2027
  • 5I01BX005203-06 Evaluation of 6SHG/EM1 as a treatment for spinal cord injury-induced neuropathic pain in a pig model — unknown, ends Sep 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 21, 2023 · project period to Aug 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#210 Lab fit 25% · Adjacent Hiring: Strong Atlanta Neuroscience

Nicholas Thomas Seyfried lab

Nicholas Thomas Seyfried · Emory University, Atlanta GA

Project Summary Lewy body dementia (LBD), a class of disorders comprising Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), features aggressive cognitive and neuropsychiatric decline without cure or effective mitigating therapies. Driving the clinical challenges surrounding LBD is a poor understanding of the pathophysiology underlying its clinical deterioration and a desperate lack of diagnostic, progressive, and therapeutic biomarkers. Neuropathological evidence suggests that corticolimbic synucleinopathy is closely linked to the aggressive dementia of LBD and that effec

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 284 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 30% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $18,196,225 in active NIH money across 6 projects, 4.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$18,196,225
Active projects
6
Runway left
4.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $18,196,225 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-08-31 (about 4.9 years) — 1U19AG097398-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5U01NS128433-04 Novel Protein Biomarkers of Corticolimbic Pathophysiology in Lewy body Dementia

    U01 · NINDS · $1,794,006 · Sep 15, 2022 to Jun 30, 2028

All active NIH projects for Nicholas Thomas Seyfried ($18,196,225)
  • 1U19AG097398-01 TARGET-AD: A Precision Medicine Framework for Alzheimer’s Disease — $8,231,369, ends Aug 31, 2031
  • 1RF1NS139948-01 VCID CWOW: Identifying Novel Targets to Treat Cerebral Amyloid Angiopathy — $5,949,022, ends Aug 31, 2027
  • 5U01NS128433-04 Novel Protein Biomarkers of Corticolimbic Pathophysiology in Lewy body Dementia — $1,794,006, ends Jun 30, 2028
  • 5R01AG075820-05 Neuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer's disease. — $948,518, ends May 31, 2027
  • 5R01AG061800-07 Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease — $767,130, ends Nov 30, 2029
  • 5P30AG066511-07 Biomarker Core — $506,180, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2022 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#211 Lab fit 25% · Adjacent Hiring: Possible Michigan Neuroscience

Louis Tuong Chinh Dang lab

Louis Tuong Chinh Dang · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Epilepsy is a major cause of morbidity, mortality, disability, and expense, and affects over 470,000 children in the U.S. While many medications to control seizures have been developed, about 30% of patients do not respond to medications, and to date, there are no medications that can prevent or halt the progression of epilepsy. Recently, many genetic causes of epilepsy have been identified, providing insights into pathways involved in epileptogenesis. Mutations causing hyperactivity of the mTOR pathway (so-called “mTORpathies”) have emerged as an important cause of cerebral ma

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 280 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 63% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Histology, IHC and confocal / electron microscopy Lab text mentions "immunohistochem".
  • Molecular biology, biochemistry and proteomics Lab text mentions "single-cell rna".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $862,061 in active NIH money across 2 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$862,061
Active projects
2
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $862,061 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years) — 1R21MH144311-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 63%

    Matched 3 of 7 profile areas (19 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “immunohistochem”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “single-cell rna”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS127829-05 Elucidating pathogenic mechanisms in STRADA-related brain malformation and epilepsy

    R01 · NINDS · $433,061 · Aug 15, 2022 to Jun 30, 2027

All active NIH projects for Louis Tuong Chinh Dang ($862,061)
  • 5R01NS127829-05 Elucidating pathogenic mechanisms in STRADA-related brain malformation and epilepsy — $433,061, ends Jun 30, 2027
  • 1R21MH144311-01 Gene dosage, synaptic neotony, and neurodevelopmental disorders — $429,000, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#212 Lab fit 25% · Adjacent Hiring: Not enough data Michigan Neuroscience

Courtney Elaine Stewart lab

Courtney Elaine Stewart · Veterans Education And Research Association Of Michigan, Ann Arbor MI

Abstract Loss of stability and falls is a major risk factor for injury and death in older adults. Previously overlooked, lifetime noise exposure has been shown to cause damage to the vestibular periphery; although, animal models and human studies that can provide a mechanistic basis connecting noise-induced vestibular dysfunction and age-related fall risk are limited. The vestibular system plays a critical role in detection of head movements and orientation with respect to gravity and is essential for normal vision and postural control. Due to their anatomical proximity to the cochlea, the oto

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 312 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 3 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ocular".
  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Not enough data Not enough data: active NIH award total unknown, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
unknown
Active projects
unknown
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 0 of 100 points
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: Total active NIH award dollars could not be retrieved for this PI.
  • Unknown: Active project count unavailable.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ocular”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG073157-05 Effects of Noise Exposure Across the Lifespan on Balance and Stability in Older Adults

    R01 · NIA · $539,911 · Sep 30, 2021 to May 31, 2027

Newest award started Sep 30, 2021 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#213 Lab fit 25% · Adjacent Hiring: Moderate Atlanta Neuroscience

Jennifer Marie Spangle lab

Jennifer Marie Spangle · Emory University, Atlanta GA

Project Summary Glioblastoma (GBM) is the most common and deadliest primary brain tumor in adults. Recent work continues to support the idea that this cancer (like many others) echoes the proliferation and differentiation programs from earlier developmental stages. The possibility that neurological cancers like GBM are essentially `locked in' to a developmental program and retain the controls that instruct these cell populations during development opens new and exciting opportunities. Furthermore, it places an emphasis on the need to identify the molecular triggers that govern the transition o

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 228 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 32% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • CRISPR / conditional knockout genetics Lab text mentions "knock-out".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "mutation".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,363,935 in active NIH money across 4 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,363,935
Active projects
4
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 48 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,363,935 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-07-31 (about 1.8 years) — 5R35GM150587-04, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 32%

    Matched 1 of 5 profile areas (9 of 28 weight to saturation).

    • CRISPR / conditional knockout genetics — lab text says “knock-out”Her side: CRISPR/Cas9 gene editing listed under molecular biology skills; first-author FEBS J review on CRISPR for ocular disease; conditional autophagy-deficient RGC mice in her 2026 paper.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “mutation”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS123562-05 Shared mechanisms of astrocyte maturation in development and glioblastoma

    R01 · NINDS · $394,688 · Sep 30, 2021 to Jun 30, 2027

All active NIH projects for Jennifer Marie Spangle ($1,363,935)
  • 1R21CA307807-01 Leveraging radiation to sensitize breast cancers to T-DXd — $402,401, ends Mar 31, 2028
  • 5R01NS123562-05 Shared mechanisms of astrocyte maturation in development and glioblastoma — $394,688, ends Jun 30, 2027
  • 5R35GM150587-04 Role of novel histone modifications and variants in transcriptional regulation — $383,937, ends Jul 31, 2028
  • 5R21CA286273-02 Mapping the origin of HER2 plasticity in breast cancer — $182,909, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#214 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Paul Michael Jenkins lab

Paul Michael Jenkins · University of Michigan, Ann Arbor MI

Voltage-gated sodium channels (NaVs) are fundamental for the control of neuronal excitability, with classical roles in action potential (AP) initiation and propagation. Decades of work have shown that APs are initiated by NaVs clustered at the axon initial segment (AIS) and propagated to release sites by NaVs along axons, at times clustered within nodes of Ranvier (NoR). We and others have shown that NaVs are also critical for other aspects of neuron excitability, including integration of synaptic activity in dendritic compartments. Individual neurons express multiple NaV channel α subunit sub

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 228 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 37% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 36% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".
  • Sequencing, variant and splicing analysis Lab text mentions "exome".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $915,200 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$915,200
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $915,200 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years) — 2R01MH126960-06, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 37%

    Matched 2 of 7 profile areas (11 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.
    • Sequencing, variant and splicing analysis — lab text says “exome”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01MH126960-06S1 Convergent mechanisms for neurodevelopmental disorder genes

    R01 · NIMH · $86,029 · May 14, 2021 to Feb 28, 2027

All active NIH projects for Paul Michael Jenkins ($915,200)
  • 2R01MH126960-06 Convergent mechanisms for neurodevelopmental disorder genes — $759,200, ends Jul 31, 2031
  • 1R03NS151500-01 Development of an epitope-tagged Nav1.1 transgenic mouse model — $156,000, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 14, 2021 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#215 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Frederick Kofi Korley lab

Frederick Kofi Korley · University of Michigan, Ann Arbor MI

Project Summary / Abstract Traumatic Brain Injury (TBI) is a major cause of death and disability both in the United States and worldwide. This proposal focuses on persons with severe TBI (those with prolonged unresponsiveness [Glasgow Coma Scale < 8]). Severe TBI affects nearly 27,000 persons in the United States each year. These patients experience high mortality and require sophisticated care in intensive care units estimated at up to $244 billion dollars each year. There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical bar

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 263 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neuroprotect".
  • Non-rodent animal models Lab text mentions "porcine".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,328,134 in active NIH money across 3 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,328,134
Active projects
3
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,328,134 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years) — 5R38HL177788-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neuroprotect”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “porcine”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS114251-05 Biomarkers in the Hyperbaric Oxygen in Brain Injury Treatment Trial

    R01 · NINDS · $562,877 · Sep 15, 2020 to Aug 31, 2027

All active NIH projects for Frederick Kofi Korley ($2,328,134)
  • 5U01NS095926-07 Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial — $1,557,915, ends Jun 30, 2029
  • 5R01NS114251-05 Biomarkers in the Hyperbaric Oxygen in Brain Injury Treatment Trial — $562,877, ends Aug 31, 2027
  • 5R38HL177788-02 Michigan Emergency Medicine Physician-Scientist StARR Training Program — $207,342, ends Jun 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2020 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#216 Lab fit 25% · Adjacent Hiring: Possible Michigan Neuroscience

Eleanor Josephine Clowney lab

Eleanor Josephine Clowney · University of Michigan, Ann Arbor MI

Summary Olfactory circuits allow past experiences--during evolution or within an individual’s life--to generate predictions of future conditions. Odorant receptors are among the largest animal gene families yet are dwarfed by the complexity of odor space. Representations afforded by the number of receptors are expanded through combi- natorial connectivity in higher olfactory centers, where individual neurons receive inputs from multiple odorant receptor channels. Two kinds of representations are critical to allow animals to avoid danger and exploit re- sources: Hard-wired connectivity patterns

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 217 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Non-rodent animal models Lab text mentions "drosophila".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "histolog".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $467,147 in active NIH money across 1 project, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$467,147
Active projects
1
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $467,147 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “histolog”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 2R01DC018032-06A1 Generation and manipulation of combinatorial connectivity in olfactory perception

    R01 · NIDCD · $467,147 · Mar 1, 2020 to Mar 31, 2031

All active NIH projects for Eleanor Josephine Clowney ($467,147)
  • 2R01DC018032-06A1 Generation and manipulation of combinatorial connectivity in olfactory perception — $467,147, ends Mar 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2020 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#217 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Aditya S Pandey lab

Aditya S Pandey · University of Michigan, Ann Arbor MI

Title: Novel Ultrasonic Technique for the Treatment of Hemorrhagic Stroke Project Summary This grant is a renewal of our previous R01 (NS108042) to develop neuronavigation-guided transcranial histotripsy (NaviTH) as the most minimally invasive, safe, and effective method for treatment of Intracerebral hemorrhage (ICH) to date. ICH is the most common type of hemorrhagic stroke caused by the rupture of vessels resulting in formation of a clot inside the brain. Standard clinical ICH treatments, including medical management and craniotomy-based surgery, have not shown improvements in patient outco

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 64% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 55% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Non-rodent animal models Lab text mentions "porcine".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,019,221 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,019,221
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,019,221 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 64%

    Matched 3 of 5 profile areas (18 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.
    • Non-rodent animal models — lab text says “porcine”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 55%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • Three or more years left in the project period — lab text says “award record”

    Not found: R01-class award that can carry a postdoc line; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01NS108042-07 Novel Ultrasonic Technique for the Treatment of Hemorrhagic Stroke

    U01 · NINDS · $668,221 · Sep 30, 2018 to Jun 30, 2030

All active NIH projects for Aditya S Pandey ($1,019,221)
  • 5U01NS108042-07 Novel Ultrasonic Technique for the Treatment of Hemorrhagic Stroke — $668,221, ends Jun 30, 2030
  • 5R01NS131514-02 Human Intracerebral Hemorrhage: Impact of Hematoma Size, Hemolysis and Iron Overload on Edema and White Matter Survival by MRI — $351,000, ends Nov 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2018 · project period to Jun 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#218 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Zhen Xu lab

Zhen Xu · University of Michigan, Ann Arbor MI

Title: Novel Ultrasonic Technique for the Treatment of Hemorrhagic Stroke Project Summary This grant is a renewal of our previous R01 (NS108042) to develop neuronavigation-guided transcranial histotripsy (NaviTH) as the most minimally invasive, safe, and effective method for treatment of Intracerebral hemorrhage (ICH) to date. ICH is the most common type of hemorrhagic stroke caused by the rupture of vessels resulting in formation of a clot inside the brain. Standard clinical ICH treatments, including medical management and craniotomy-based surgery, have not shown improvements in patient outco

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 4 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 64% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 55% · weight 15%
Geography 100% · weight 10%

Weighted mean 35% × 0.7 domain gate = 25%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Non-rodent animal models Lab text mentions "porcine".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,408,868 in active NIH money across 4 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,408,868
Active projects
4
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,408,868 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 64%

    Matched 3 of 5 profile areas (18 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.
    • Non-rodent animal models — lab text says “porcine”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 55%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • Three or more years left in the project period — lab text says “award record”

    Not found: R01-class award that can carry a postdoc line; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01NS108042-07 Novel Ultrasonic Technique for the Treatment of Hemorrhagic Stroke

    U01 · NINDS · $668,221 · Sep 30, 2018 to Jun 30, 2030

All active NIH projects for Zhen Xu ($2,408,868)
  • 5U01NS108042-07 Novel Ultrasonic Technique for the Treatment of Hemorrhagic Stroke — $668,221, ends Jun 30, 2030
  • 5R01EB037129-02 Transcranial MRI- and Ultrasound- guided histotripsy (tcMR-USgHt) system — $611,682, ends Dec 31, 2028
  • 5R01HL141967-07 Integrated Dual-frequency Ultrasound Catheter for Accelerated Sonothrombolysis (iDUCAS) — $587,968, ends Mar 31, 2028
  • 5R01EB034399-04 Ultrasound-guided Ultra-steerable Histotripsy Array System for Non-invasive treatment of Soft Tissue Sarcoma — $540,997, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2018 · project period to Jun 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#219 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Jessica Faul lab

Jessica Faul · University of Michigan, Ann Arbor MI

This competing continuation proposal for Years 35-40 of the Health and Retirement Study (HRS) cooperative agreement, including the Harmonized Cognitive Assessment Protocol (HCAP) sub-study, is in response to NIA RFA #AG-24-010. The primary aim of the HRS and HCAP is to design, collect and distribute longitudinal multi-disciplinary data to support research on aging, Alzheimer’s Disease and Related Dementias (ADRD), and the health and well-being of the older population. This proposal seeks to collect three additional waves of HRS panel data, one follow-up wave of HCAP data, continue collection o

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 369 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 55% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $38,802,289 in active NIH money across 6 projects, 3.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$38,802,289
Active projects
6
Runway left
3.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $38,802,289 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-12-31 (about 3.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 55%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • Three or more years left in the project period — lab text says “award record”

    Not found: R01-class award that can carry a postdoc line; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01AG009740-37 Health and Retirement Study: Yrs 35-40

    U01 · NIA · $32,538,512 · Sep 25, 1990 to Dec 31, 2029

All active NIH projects for Jessica Faul ($38,802,289)
  • 5U01AG009740-37 Health and Retirement Study: Yrs 35-40 — $32,538,512, ends Dec 31, 2029
  • 4RF1AG079554-04 Genotyping the Understanding America Study to generate novel opportunities for research on cognitive functioning and dementia — $4,573,376, ends May 31, 2028
  • 5R01AG071071-05 Biological Aging Across the Life Course: Harmonizing Cohort Biospecimen Archives — $586,208, ends Feb 28, 2027
  • 5R01AG068937-05 Social Circumstances and Epigenomics Promoting Health in Three Countries — $562,444, ends Apr 30, 2027
  • 5R24AG054365-09 Network on Biomarker Collection and Measurement in Population Studies of Aging: 2022-2027 — $391,629, ends Mar 31, 2028
  • 5R25AG053227-10 Genomics for Social Scientists: 2022-2027 — $150,120, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 25, 1990 · project period to Dec 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#220 Lab fit 25% · Adjacent Hiring: Moderate Michigan Neuroscience

Kenneth M Langa lab

Kenneth M Langa · University of Michigan, Ann Arbor MI

This competing continuation proposal for Years 35-40 of the Health and Retirement Study (HRS) cooperative agreement, including the Harmonized Cognitive Assessment Protocol (HCAP) sub-study, is in response to NIA RFA #AG-24-010. The primary aim of the HRS and HCAP is to design, collect and distribute longitudinal multi-disciplinary data to support research on aging, Alzheimer’s Disease and Related Dementias (ADRD), and the health and well-being of the older population. This proposal seeks to collect three additional waves of HRS panel data, one follow-up wave of HCAP data, continue collection o

Lab fit breakdown — 25% weighted · Adjacent

Scored on enough lab text to read as a verdict. 369 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 55% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.82 domain gate = 25%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $33,136,684 in active NIH money across 2 projects, 3.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$33,136,684
Active projects
2
Runway left
3.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $33,136,684 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2029-12-31 (about 3.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 55%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • Three or more years left in the project period — lab text says “award record”

    Not found: R01-class award that can carry a postdoc line; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01AG009740-37 Health and Retirement Study: Yrs 35-40

    U01 · NIA · $32,538,512 · Sep 25, 1990 to Dec 31, 2029

All active NIH projects for Kenneth M Langa ($33,136,684)
  • 5U01AG009740-37 Health and Retirement Study: Yrs 35-40 — $32,538,512, ends Dec 31, 2029
  • 5U24AG065182-08 Research Network for the Harmonized Cognitive Assessment Protocol (HCAP): Years 6-10 — $598,172, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 25, 1990 · project period to Dec 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#221 Lab fit 24% · Adjacent Hiring: Moderate Michigan Neuroscience New award

Stephen William Peter Kemp lab

Stephen William Peter Kemp · University of Michigan, Ann Arbor MI

PROJECT SUMMARY The global prevalence of chronic pain is estimated at approximately 20% of the population, and the economic costs are greater than those of cancer, HIV, and cardiovascular diseases combined. Neuropathic pain is the most severely disabling type of chronic pain resulting from amputation, with associated health care costs estimated to be greater than $600 billion annually. Opioid drugs, while effective for many types of chronic pain, are limited due to the risks of overdose and abuse. In addition, opioids have decreased analgesia in pain of neuropathic origin, particularly in symp

Lab fit breakdown — 24% weighted · Adjacent

Scored on enough lab text to read as a verdict. 273 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 54% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.7 domain gate = 24%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $779,997 in active NIH money across 1 project, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$779,997
Active projects
1
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $779,997 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-15.
  • +5 Brand-new (Type 1) project, not a renewal — 1R01DA067337-01 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 54%

    Matched 2 of 5 profile areas (15 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DA067337-01 Allosteric Modulators for the Treatment of Neuroma Pain

    R01 · NIDA · $779,997 · Sep 15, 2026 to Jul 31, 2031 · Type 1 (new)

All active NIH projects for Stephen William Peter Kemp ($779,997)
  • 1R01DA067337-01 Allosteric Modulators for the Treatment of Neuroma Pain — $779,997, ends Jul 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#222 Lab fit 24% · Adjacent Hiring: Strong Michigan Neuroscience New award

Kristen Culbert lab

Kristen Culbert · Michigan State University, East Lansing MI

PROJECT SUMMARY Women show a heightened risk for psychosis in midlife that is not observed in men. In our ongoing R01 project, we have shown that perimenopausal changes in ovarian hormones (estrogen, progesterone) contribute to the midlife increase in psychosis risk. These findings substantially increase our understanding of midlife psychosis risk in women. However, the picture is critically incomplete. Not every woman develops psychosis during the hormonal changes of perimenopause. Only a subset of women develops these debilitating symptoms, and a crucial next step in this high-priority area

Lab fit breakdown — 24% weighted · Adjacent

Scored on enough lab text to read as a verdict. 230 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.7 domain gate = 24%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,277,160 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,277,160
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,277,160 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-08.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01MH140527-01A1 Gene x Ovarian Hormone Interactions in Perimenopausal Risk for Psychosis

    R01 · NIMH · $796,106 · Sep 8, 2026 to Jul 31, 2031

All active NIH projects for Kristen Culbert ($2,277,160)
  • 1R01MH144712-01 Phenotypic and Genetic Effects of Endogenous Testosterone on Binge Eating in Women — $800,361, ends Apr 30, 2031
  • 1R01MH140527-01A1 Gene x Ovarian Hormone Interactions in Perimenopausal Risk for Psychosis — $796,106, ends Jul 31, 2031
  • 5R01MH128196-05 Hormonal Mechanisms of Perimenopausal Risk for Psychosis in Women — $680,693, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 8, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#223 Lab fit 24% · Adjacent Hiring: Strong Michigan Neuroscience New award

Kelly L Klump lab

Kelly L Klump · Michigan State University, East Lansing MI

PROJECT SUMMARY Women show a heightened risk for psychosis in midlife that is not observed in men. In our ongoing R01 project, we have shown that perimenopausal changes in ovarian hormones (estrogen, progesterone) contribute to the midlife increase in psychosis risk. These findings substantially increase our understanding of midlife psychosis risk in women. However, the picture is critically incomplete. Not every woman develops psychosis during the hormonal changes of perimenopause. Only a subset of women develops these debilitating symptoms, and a crucial next step in this high-priority area

Lab fit breakdown — 24% weighted · Adjacent

Scored on enough lab text to read as a verdict. 230 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.7 domain gate = 24%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,277,160 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,277,160
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 80 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,277,160 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-08.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01MH140527-01A1 Gene x Ovarian Hormone Interactions in Perimenopausal Risk for Psychosis

    R01 · NIMH · $796,106 · Sep 8, 2026 to Jul 31, 2031

All active NIH projects for Kelly L Klump ($2,277,160)
  • 1R01MH144712-01 Phenotypic and Genetic Effects of Endogenous Testosterone on Binge Eating in Women — $800,361, ends Apr 30, 2031
  • 1R01MH140527-01A1 Gene x Ovarian Hormone Interactions in Perimenopausal Risk for Psychosis — $796,106, ends Jul 31, 2031
  • 5R01MH128196-05 Hormonal Mechanisms of Perimenopausal Risk for Psychosis in Women — $680,693, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 8, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#224 Lab fit 24% · Adjacent Hiring: Strong Michigan Neuroscience New award

Katharine Natasha Thakkar lab

Katharine Natasha Thakkar · Michigan State University, East Lansing MI

PROJECT SUMMARY Women show a heightened risk for psychosis in midlife that is not observed in men. In our ongoing R01 project, we have shown that perimenopausal changes in ovarian hormones (estrogen, progesterone) contribute to the midlife increase in psychosis risk. These findings substantially increase our understanding of midlife psychosis risk in women. However, the picture is critically incomplete. Not every woman develops psychosis during the hormonal changes of perimenopause. Only a subset of women develops these debilitating symptoms, and a crucial next step in this high-priority area

Lab fit breakdown — 24% weighted · Adjacent

Scored on enough lab text to read as a verdict. 456 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.7 domain gate = 24%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".
  • Sequencing, variant and splicing analysis Lab text mentions "genotype".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $1,870,667 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,870,667
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 73 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,870,667 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-07-31 (about 4.8 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-09-08.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “genotype”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01MH140527-01A1 Gene x Ovarian Hormone Interactions in Perimenopausal Risk for Psychosis

    R01 · NIMH · $796,106 · Sep 8, 2026 to Jul 31, 2031

  • 5R01MH121417-05 Visual perception as a window onto prediction anomalies in schizophrenia

    R01 · NIMH · $393,868 · Apr 1, 2021 to Jan 31, 2027

All active NIH projects for Katharine Natasha Thakkar ($1,870,667)
  • 1R01MH140527-01A1 Gene x Ovarian Hormone Interactions in Perimenopausal Risk for Psychosis — $796,106, ends Jul 31, 2031
  • 5R01MH128196-05 Hormonal Mechanisms of Perimenopausal Risk for Psychosis in Women — $680,693, ends Jan 31, 2027
  • 5R01MH121417-05 Visual perception as a window onto prediction anomalies in schizophrenia — $393,868, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 8, 2026 · project period to Jul 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#225 Lab fit 24% · Adjacent Hiring: Moderate Michigan Neuroscience

Benjamin Joseph Murdock lab

Benjamin Joseph Murdock · University of Michigan, Ann Arbor MI

ABSTRACT Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with no cure, and although inflammation plays a significant role in the disease, gaps remain in leveraging this knowledge for personalized clinical outcome models and personalized therapeutics. Peripheral blood immune profiles—defined as the total numbers and activation states of specific peripheral immune cells—reflect overall inflammation, but methodologic gaps exist to characterize these immune profiles given limitations in conventional flow cytometry, hampering its widespread use for ALS. The long-term goal

Lab fit breakdown — 24% weighted · Adjacent

Scored on enough lab text to read as a verdict. 398 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 75% · weight 15%
Geography 100% · weight 10%

Weighted mean 34% × 0.7 domain gate = 24%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "induced pluripotent")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,015,683 in active NIH money across 2 projects, 2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,015,683
Active projects
2
Runway left
2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,015,683 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-09-29 (about 2 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2025-09-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 75%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Three or more years left in the project period; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1U01TS000351-01 Spectral flow cytometry identifies new immune signatures that provide personalized ALS risk and progression biomarkers and therapeutic targets

    U01 · ATSDR · $500,000 · Sep 30, 2025 to Sep 29, 2028

  • 5R01NS120926-05 Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures

    R01 · NINDS · $515,683 · May 15, 2021 to Feb 28, 2027

All active NIH projects for Benjamin Joseph Murdock ($1,015,683)
  • 5R01NS120926-05 Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures — $515,683, ends Feb 28, 2027
  • 1U01TS000351-01 Spectral flow cytometry identifies new immune signatures that provide personalized ALS risk and progression biomarkers and therapeutic targets — $500,000, ends Sep 29, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2025 · project period to Sep 29, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#226 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Deborah Allison Levine lab

Deborah Allison Levine · University of Michigan, Ann Arbor MI

Project Summary/Abstract A significant gap in understanding is how suboptimal control of hyperglycemia from type 2 diabetes (T2DM) and prediabetes, particularly in young adults (18-45), influences later-life cognitive decline and Alzheimer’s dis- ease and related dementias (ADRD) risk. This gap is a critical barrier to developing T2DM prevention and management interventions for reducing vascular contributions to cognitive impairment and dementia (VCID). Hyperglycemia increasingly develops in younger adults and may impair their cognition. The central hypothesis is that higher cumulative hypergl

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 286 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $2,380,018 in active NIH money across 1 project, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,380,018
Active projects
1
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,380,018 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1NS136499-01 Type 2 Diabetes Mellitus and Vascular Contributions to Cognitive Impairment and Dementia (T2DM-VCID)

    RF1 · NINDS · $2,380,018 · Sep 18, 2024 to Aug 31, 2027

All active NIH projects for Deborah Allison Levine ($2,380,018)
  • 1RF1NS136499-01 Type 2 Diabetes Mellitus and Vascular Contributions to Cognitive Impairment and Dementia (T2DM-VCID) — $2,380,018, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 18, 2024 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#227 Lab fit 23% · Adjacent Hiring: Possible Atlanta Neuroscience

James K Rilling lab

James K Rilling · Emory University, Atlanta GA

Project Summary An estimated 5.8 million Americans age 65 and older are living with Alzheimer’s dementia in 2020. The majority of these individuals are cared for at home by family members. Caring for people living with dementia (PLWD) can be very stressful, and is associated with negative mental health outcomes, including depression and anxiety. The chronic stress of caregiving has also been associated with increased levels of proinflammatory biomarkers, which mediate many of the chronic diseases of aging. High levels of cognitive empathy have been associated with lower levels of subjective st

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 256 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "randomized")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $723,742 in active NIH money across 1 project, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$723,742
Active projects
1
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $723,742 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 3R01AG087216-02S1 Effect of Cognitive Empathy Training on Dementia Caregivers

    R01 · NIA · $48,509 · Sep 15, 2024 to Aug 31, 2029

All active NIH projects for James K Rilling ($723,742)
  • 5R01AG087216-03 Effect of Cognitive Empathy Training on Dementia Caregivers — $723,742, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#228 Lab fit 23% · Adjacent Hiring: Moderate Atlanta Neuroscience

Mi-kyung Song lab

Mi-kyung Song · Emory University, Atlanta GA

ABSTRACT In 2021, approximately 11 million Americans provided unpaid care to an adult with Alzheimer’s disease and related dementias (ADRD), which was estimated to be 16 billion hours of assistance valued at $271.6 billion. Over 65% of older adults with dementia in the community rely on 2 or more family members or friends to meet their needs, ranging from basic activities of daily living to self-care activities and care decisions. Yet, most caregiving research has been focused on the roles and care burden, including psychosocial and physical health, of a single primary caregiver. Given the agi

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 240 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,067,345 in active NIH money across 2 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,067,345
Active projects
2
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,067,345 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years) — 5R01DK142681-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG082300-03 Informal Caregiving Networks of Older Adults with Dementia

    R01 · NIA · $1,291,767 · Sep 15, 2024 to May 31, 2029

All active NIH projects for Mi-kyung Song ($2,067,345)
  • 5R01AG082300-03 Informal Caregiving Networks of Older Adults with Dementia — $1,291,767, ends May 31, 2029
  • 5R01DK142681-02 Longitudinal Study of Quality of Everyday Life Experience among Home Dialysis Patients and Their Family Caregivers — $775,578, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#229 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Noelle E. Carlozzi lab

Noelle E. Carlozzi · University of Michigan, Ann Arbor MI

ABSTRACT Financial hardship (including financial stress, financial strain, asset depletion, and financial toxicity) is a highly relevant construct among the 5.7 million people with a diagnosis of Alzheimer’s disease and Alzheimer’s disease related dementias (ADRD) and their caregiving unit. In 2022, the total lifetime cost of care for a patient with ADRD was estimated at more than $400K with ~208K of which are borne out directly by the family of the person with ADRD— either through out-of-pocket health expenses, long-term care expenses or from the value of unpaid care. In addition, few familie

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 538 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,560,637 in active NIH money across 2 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,560,637
Active projects
2
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,560,637 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • +5 Brand-new (Type 1) project, not a renewal — 4RF1AG083030-02 is flagged as a new project by NIH.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4R01AG088345-03 Financial stress, financial strain, asset depletion, and financial toxicity: New measures to characterize the financial impact that dementia has on families

    R01 · NIA · $2,145,184 · Sep 1, 2024 to Jun 30, 2029

  • 4RF1AG083030-02 Capturing the complexities of informal caregiver networks: New measures to improve outcomes for informal care partners of people living with Alzheimer’s disease and related dementias (AD/ADRD)

    RF1 · NIA · $1,415,453 · Sep 1, 2023 to Aug 31, 2028 · Type 1 (new)

All active NIH projects for Noelle E. Carlozzi ($3,560,637)
  • 4R01AG088345-03 Financial stress, financial strain, asset depletion, and financial toxicity: New measures to characterize the financial impact that dementia has on families — $2,145,184, ends Jun 30, 2029
  • 4RF1AG083030-02 Capturing the complexities of informal caregiver networks: New measures to improve outcomes for informal care partners of people living with Alzheimer’s disease and related dementias (AD/ADRD) — $1,415,453, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2024 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#230 Lab fit 23% · Adjacent Hiring: Possible Atlanta Neuroscience

Cassie S Mitchell lab

Cassie S Mitchell · Georgia Institute of Technology, Atlanta GA

Project Summary/Abstract The Laboratory for Pathology Dynamics was founded on the principle that pathology is multifactorial, multi- scalar, and driven by complex interacting dynamics. This proposal builds and applies new predictive medicine technology that enables multifactorial, multi-scalar data integration to identify disease causes, develop cures, and optimize patient care. Key knowledge gaps addressed include: 1.) integration of siloed relationships for interactive literature-based discovery across 33+ million journal articles, including the development of a comprehensive biomedical know

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 187 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "artificial intelligence")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $366,688 in active NIH money across 1 project, 2.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$366,688
Active projects
1
Runway left
2.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $366,688 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-03-31 (about 2.5 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R35GM152245-03 Integrative predictive medicine to identify disease causes, develop cures, and optimize patient care

    R35 · NIGMS · $366,688 · May 1, 2024 to Mar 31, 2029

All active NIH projects for Cassie S Mitchell ($366,688)
  • 5R35GM152245-03 Integrative predictive medicine to identify disease causes, develop cures, and optimize patient care — $366,688, ends Mar 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2024 · project period to Mar 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#231 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Susan Anne Bell lab

Susan Anne Bell · University of Michigan, Ann Arbor MI

PROJECT ABSTRACT Background: There is a critical need to understand how disasters such as hurricanes affect older adults living with Alzheimer’s disease and related dementias (ADRD). For older adults living with ADRD, the disruption in critical supportive services and overall normal patterns of daily living caused by a disaster can be highly disorienting and result in immediate changes in health and well-being, leading to functional decline and even death. Our existing program of research is dedicated to examining the effects of disasters on health outcomes among older adults, with the goal of

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 243 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "health services")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,765,141 in active NIH money across 2 projects, 4.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,765,141
Active projects
2
Runway left
4.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,765,141 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-01-31 (about 4.3 years) — 1R01AG092567-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG083768-01 Preventing Deaths Among Older Americans with Alzheimer’s Disease and Other Related Dementias Exposed to Hurricanes

    RF1 · NIA · $2,107,715 · Sep 1, 2023 to Aug 31, 2027

All active NIH projects for Susan Anne Bell ($2,765,141)
  • 1RF1AG083768-01 Preventing Deaths Among Older Americans with Alzheimer’s Disease and Other Related Dementias Exposed to Hurricanes — $2,107,715, ends Aug 31, 2027
  • 1R01AG092567-01A1 Healthcare Readiness for Rural Older Adults with Critical Illness During Disasters — $657,426, ends Jan 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#232 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Matthew A Davis lab

Matthew A Davis · University of Michigan, Ann Arbor MI

PROJECT ABSTRACT Background: There is a critical need to understand how disasters such as hurricanes affect older adults living with Alzheimer’s disease and related dementias (ADRD). For older adults living with ADRD, the disruption in critical supportive services and overall normal patterns of daily living caused by a disaster can be highly disorienting and result in immediate changes in health and well-being, leading to functional decline and even death. Our existing program of research is dedicated to examining the effects of disasters on health outcomes among older adults, with the goal of

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 243 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "health services")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,276,068 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,276,068
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,276,068 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1AG083768-01 Preventing Deaths Among Older Americans with Alzheimer’s Disease and Other Related Dementias Exposed to Hurricanes

    RF1 · NIA · $2,107,715 · Sep 1, 2023 to Aug 31, 2027

All active NIH projects for Matthew A Davis ($2,276,068)
  • 1RF1AG083768-01 Preventing Deaths Among Older Americans with Alzheimer’s Disease and Other Related Dementias Exposed to Hurricanes — $2,107,715, ends Aug 31, 2027
  • 5P30AG066582-07 Core E. External Research Resources Support Core — $168,353, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Aug 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#233 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Huda Akil lab

Huda Akil · University of Michigan, Ann Arbor MI

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Substance abuse disorders (SUDs) are a major challenge to individuals and society and are caused by the interplay between genetic factors that shape vulnerability to drug addiction and environmental variables that can trigger and affect the course of these disorders. The goal of this project is to uncover the genetic and genomic mechanisms underlying the propensity for drug seeking and drug addiction. Evidence shows that the vast inter-individual differences in v

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 328 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rats".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $842,899 in active NIH money across 1 project, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$842,899
Active projects
1
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $842,899 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rats”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01DA043098-09 Genetics of novelty seeking and propensity for drug abuse in outbred rats

    U01 · NIDA · $842,899 · Sep 1, 2023 to Jun 30, 2028

All active NIH projects for Huda Akil ($842,899)
  • 5U01DA043098-09 Genetics of novelty seeking and propensity for drug abuse in outbred rats — $842,899, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#234 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Jun Li lab

Jun Li · University of Michigan, Ann Arbor MI

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Substance abuse disorders (SUDs) are a major challenge to individuals and society and are caused by the interplay between genetic factors that shape vulnerability to drug addiction and environmental variables that can trigger and affect the course of these disorders. The goal of this project is to uncover the genetic and genomic mechanisms underlying the propensity for drug seeking and drug addiction. Evidence shows that the vast inter-individual differences in v

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 328 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rats".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $842,899 in active NIH money across 1 project, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$842,899
Active projects
1
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $842,899 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rats”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01DA043098-09 Genetics of novelty seeking and propensity for drug abuse in outbred rats

    U01 · NIDA · $842,899 · Sep 1, 2023 to Jun 30, 2028

All active NIH projects for Jun Li ($842,899)
  • 5U01DA043098-09 Genetics of novelty seeking and propensity for drug abuse in outbred rats — $842,899, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#235 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Stanley J Watson lab

Stanley J Watson · University of Michigan, Ann Arbor MI

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Substance abuse disorders (SUDs) are a major challenge to individuals and society and are caused by the interplay between genetic factors that shape vulnerability to drug addiction and environmental variables that can trigger and affect the course of these disorders. The goal of this project is to uncover the genetic and genomic mechanisms underlying the propensity for drug seeking and drug addiction. Evidence shows that the vast inter-individual differences in v

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 328 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 40% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rats".
  • Molecular biology, biochemistry and proteomics Lab text mentions "transcriptom".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $842,899 in active NIH money across 1 project, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$842,899
Active projects
1
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $842,899 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rats”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 40%

    Matched 2 of 7 profile areas (12 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “transcriptom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01DA043098-09 Genetics of novelty seeking and propensity for drug abuse in outbred rats

    U01 · NIDA · $842,899 · Sep 1, 2023 to Jun 30, 2028

All active NIH projects for Stanley J Watson ($842,899)
  • 5U01DA043098-09 Genetics of novelty seeking and propensity for drug abuse in outbred rats — $842,899, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#236 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Marco Angrisani lab

Marco Angrisani · University of Michigan, Ann Arbor MI

Project Summary Up to 36 million Americans provide caregiving to adults with functional limitations and approximately 16.1 million provide informal caregiving to people with Alzheimer’s disease and related dementias (ADRD). Given the rising number of older adults with health problems and ADRD and the accompanying shortage and cost of paid caregivers, family and other unpaid caregivers are increasingly vital in the long-term care of older adults. Caregiving is often shared across multiple social partners across the life course, across generations within family, extended family, stepfamily and n

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 265 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $962,900 in active NIH money across 1 project, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$962,900
Active projects
1
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $962,900 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG083097-04 UAS-CLEAR: A new nationally representative longitudinal study of caregiving experiences and well-being across the lifecourse

    R01 · NIA · $962,900 · Aug 15, 2023 to Apr 30, 2028

All active NIH projects for Marco Angrisani ($962,900)
  • 5R01AG083097-04 UAS-CLEAR: A new nationally representative longitudinal study of caregiving experiences and well-being across the lifecourse — $962,900, ends Apr 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#237 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Kira S Birditt lab

Kira S Birditt · University of Michigan, Ann Arbor MI

Project Summary Up to 36 million Americans provide caregiving to adults with functional limitations and approximately 16.1 million provide informal caregiving to people with Alzheimer’s disease and related dementias (ADRD). Given the rising number of older adults with health problems and ADRD and the accompanying shortage and cost of paid caregivers, family and other unpaid caregivers are increasingly vital in the long-term care of older adults. Caregiving is often shared across multiple social partners across the life course, across generations within family, extended family, stepfamily and n

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 265 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,617,574 in active NIH money across 2 projects, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,617,574
Active projects
2
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,617,574 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years) — 5R01DC022921-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG083097-04 UAS-CLEAR: A new nationally representative longitudinal study of caregiving experiences and well-being across the lifecourse

    R01 · NIA · $962,900 · Aug 15, 2023 to Apr 30, 2028

All active NIH projects for Kira S Birditt ($1,617,574)
  • 5R01AG083097-04 UAS-CLEAR: A new nationally representative longitudinal study of caregiving experiences and well-being across the lifecourse — $962,900, ends Apr 30, 2028
  • 5R01DC022921-02 Promoting hearing aid use: The roles of social networks and daily interpersonal processes — $654,674, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#238 Lab fit 23% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Nicholas M Boulis lab

Nicholas M Boulis · Emory University, Atlanta GA

PROJECT SUMMARY/ABSTRACT This project aims to develop, validate, and translate a novel class of nerve guidance conduits (NGCs) for the surgical repair and healing of large defects in thick peripheral nerves by restoring their continuity and functions. The research team includes an innovative and productive expert in nanotechnology from the Department of Biomedical Engineering at the Georgia Institute of Technology and a top neurosurgeon and scientist from the Department of Neurosurgery at Emory University School of Medicine. Guided by the anatomic structure of peripheral nerve, as well as the

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 43% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Non-rodent animal models Lab text mentions "porcine".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $0 in active NIH money across 0 projects, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$0
Active projects
0
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 5 of 100 points
  • 0 Under $250K of active NIH award money — NIH RePORTER reports only $0 active.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “porcine”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 43%

    Matched 2 of 7 profile areas (13 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.
    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS126183-02 Hierarchically-Structured Conduits with Programmed Release of Neurotrophic Factors for Repairing Large Defects in Thick Nerves

    R01 · NINDS · $391,821 · May 15, 2023 to Apr 30, 2028

Newest award started May 15, 2023 · project period to Apr 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#239 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Laura B Zahodne lab

Laura B Zahodne · University of Michigan, Ann Arbor MI

Risk of Alzheimer’s disease and related dementias (ADRD) is higher for Black older adults than for White older adults. This disparity is not fully explained by commonly measured individual risk factors such as education, apolipoprotein-epsilon 4, or medical comorbidities. Thus, there is a critical need to identify additional modifiable targets at multiple levels to reduce ADRD disparities in line with NIA’s Strategic Directions for Research and the NIA Health Disparities Framework. The overall goal of this longitudinal study (N=700; 50% Black) is to identify new, modifiable pathways to reduce

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 545 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "health services")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,282,484 in active NIH money across 3 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,282,484
Active projects
3
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,282,484 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years) — 5P30AG059300-09, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG082307-04 Mechanisms of ADRD risk disparities in the Michigan Cognitive Aging Project

    R01 · NIA · $741,260 · Apr 1, 2023 to Jan 31, 2028

  • 5R01AG070951-05 Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans

    R01 · NIA · $839,547 · Apr 1, 2021 to Mar 31, 2027

All active NIH projects for Laura B Zahodne ($2,282,484)
  • 5R01AG070951-05 Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans — $839,547, ends Mar 31, 2027
  • 5R01AG082307-04 Mechanisms of ADRD risk disparities in the Michigan Cognitive Aging Project — $741,260, ends Jan 31, 2028
  • 5P30AG059300-09 MI Center for Contextual Factors in Alzheimer's Disease (MCCFAD) Yrs 6-10 — $701,677, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2023 · project period to Jan 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#240 Lab fit 23% · Adjacent Hiring: Moderate Atlanta Neuroscience

Jalayne J Arias lab

Jalayne J Arias · Georgia State University, Atlanta GA

It is a pivotal time for Alzheimer’s disease and related dementias (ADRD) research to harness data sharing and accelerate therapeutic discovery. Data sharing is important to advance research because it supports large data sets that are more representative of the population, increasing the ability to detect generalizable contributors to disease. Sharing data increases efficiency by allowing investigators to build upon each other’s work and prevents redundant data generation. For of these reasons, the National Institutes of Health has committed to promoting data sharing to accelerate research in

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 224 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $693,021 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$693,021
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $693,021 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years) — 5R13AG087669-03, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG080093-04 Identifying barriers to optimizing data sharing and accelerate discovery in Alzheimer’s disease and related dementia research

    R01 · NIA · $493,021 · Feb 15, 2023 to Nov 30, 2027

All active NIH projects for Jalayne J Arias ($693,021)
  • 5R01AG080093-04 Identifying barriers to optimizing data sharing and accelerate discovery in Alzheimer’s disease and related dementia research — $493,021, ends Nov 30, 2027
  • 1U13AG092165-01A1 A Scientific Retreat to Address Ethical Challenges in Data and Sample Sharing to Advance Neurodegenerative Research — $150,000, ends Jul 31, 2028
  • 5R13AG087669-03 Career Development for Legally Trained Interdisciplinary Researchers in Aging and Health Sciences — $50,000, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 15, 2023 · project period to Nov 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#241 Lab fit 23% · Adjacent Hiring: Unlikely Michigan Neuroscience

Susanne Brummelte lab

Susanne Brummelte · Wayne State University, Detroit MI

Opioid use disorder (OUD) is a global epidemic affecting a high proportion of child-bearing women. The drastic 4-fold increase in OUD among pregnant women from 1999-2014 has promoted opioid maintenance therapies (OMT) such as buprenorphine (BUP) to mitigate effects associated with opioid abuse. BUP is a mixed (partial mu-receptor agonist/kappa-receptor antagonist) semi-synthetic OMT that produces better infant outcomes after gestational treatment as compared to other OMTs (i.e. methadone). However, effects of BUP on pregnant women transitioning to motherhood is not well understood. Endogenous

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 307 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "microbiome")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $563,141 in active NIH money across 2 projects, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$563,141
Active projects
2
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $563,141 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA052386-05 The effects of gestational opioid exposure on the maternal brain, behavior and microbiome

    R01 · NIDA · $332,141 · Aug 1, 2022 to May 31, 2027

All active NIH projects for Susanne Brummelte ($563,141)
  • 5R01DA052386-05 The effects of gestational opioid exposure on the maternal brain, behavior and microbiome — $332,141, ends May 31, 2027
  • 5R21DA062066-02 Understanding the effects of gestational fentanyl exposure on external morphology, neonatal opioid withdrawal, and brain volume, morphology and neurochemistry of offspring — $231,000, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#242 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Geoffrey Jonathan Hoffman lab

Geoffrey Jonathan Hoffman · University of Michigan, Ann Arbor MI

ABSTRACT The scope of Alzheimer’s disease and related Dementias (ADRD) in the United States is unprecedented, affecting 14 million Americans at an annual cost of $200 billion.1,2 Addressing the needs of patients with ADRD requires substantial long-term behavioral and social care supports not typically available under traditional fee- for-service insurance. Due to their cognitive limitations, older patients with ADRD may not know that other potentially beneficial insurance options are available to them. Managed care products may be expected to improve patient outcomes while restraining health c

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 243 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "caregiver")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,014,941 in active NIH money across 2 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,014,941
Active projects
2
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,014,941 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years) — 1R01AG094634-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG074944-04 The impact of Medicare managed care on older patients with dementia and their family caregivers.

    R01 · NIA · $334,640 · Jun 15, 2022 to May 31, 2027

All active NIH projects for Geoffrey Jonathan Hoffman ($1,014,941)
  • 1R01AG094634-01A1 Effects of Medicare's wage index on patient access and hospital care quality for older Medicare beneficiaries — $680,301, ends Mar 31, 2031
  • 5R01AG074944-04 The impact of Medicare managed care on older patients with dementia and their family caregivers. — $334,640, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 15, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#243 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Natalie Colabianchi lab

Natalie Colabianchi · University of Michigan, Ann Arbor MI

The development of neurological conditions as people age is a major public health issue. While many individual risk factors have been identified as predictors of both vascular contributions to cognitive impairment and dementia (VCID), as well as stroke, these individual factors do not fully explain the likelihood of developing these outcomes. School, neighborhood, and regional characteristics are three factors hypothesized to be important in the development of VCID and stroke, yet few studies exist in this area. Across the disciplines of chronic disease, life course, and spatial epidemiology,

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 256 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $747,189 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$747,189
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $747,189 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 4R01NS127606-02 Examining school, neighborhood, and regional characteristics associated with VCID and stroke in the REGARDS study

    R01 · NINDS · $747,189 · May 1, 2022 to Apr 30, 2027

All active NIH projects for Natalie Colabianchi ($747,189)
  • 4R01NS127606-02 Examining school, neighborhood, and regional characteristics associated with VCID and stroke in the REGARDS study — $747,189, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2022 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#244 Lab fit 23% · Adjacent Hiring: Strong Michigan Neuroscience

Grace A Noppert lab

Grace A Noppert · University of Michigan, Ann Arbor MI

While risk factors for cognitive decline and Alzheimer’s Disease and related dementias (ADRD) have been widely studied, there is still much unknown about the biological pathways that lead to ADRD. This project seeks to improve our understanding of the pathophysiology of cognitive decline and ADRD by examining the role of peripheral immunosenescence in these processes. A major gap in existing research is a lack of longitudinal studies that can establish an etiologic link between peripheral immunosenescence and development of incident ADRD. In addition, there are few population-based studies exa

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 279 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,479,531 in active NIH money across 3 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,479,531
Active projects
3
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,479,531 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 1R01AG109115-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG075719-05 Immunosenescence, socioeconomic differences and dementia in the US aging population

    R01 · NIA · $730,721 · Mar 1, 2022 to Nov 30, 2026

All active NIH projects for Grace A Noppert ($3,479,531)
  • 1R01AG109115-01 The National Neighborhood Data Archive: A Resource to Understand Health Risk & Resilience for Aging in The United States — $2,114,183, ends Jun 30, 2031
  • 5R01AG075719-05 Immunosenescence, socioeconomic differences and dementia in the US aging population — $730,721, ends Nov 30, 2026
  • 5U01NR020556-05 A National Neighborhood Data Resource to Understand the Health and Socioeconomic Impacts of the 2020 Pandemic in the United States — $634,627, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2022 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#245 Lab fit 23% · Adjacent Hiring: Moderate Atlanta Neuroscience

Javier E Stern lab

Javier E Stern · Georgia State University, Atlanta GA

Neurovascular coupling (NVC) links increases in neuronal activity with a rapid and spatially restricted increase in local blood flow. Knowledge on the cellular mechanisms driving NVC has been focused on transient exteroceptive sensory stimulation and limited to superficial dorsal brain areas (cortex). Thus, less is understood on NVC dynamics of deeper brain regions, which can be activated by slow, sustained, and widespread stimuli (e.g., physiological disturbances of bodily homeostasis). Derangement in homeostatic processes is a key driver of pathological mechanisms in prevalent diseases such

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 242 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 68% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • AAV / lentiviral delivery and gene therapy Lab text mentions "adeno-associated".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,600,919 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,600,919
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,600,919 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years) — 5R01MH135553-03, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 68%

    Matched 2 of 5 profile areas (19 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • AAV / lentiviral delivery and gene therapy — lab text says “adeno-associated”Her side: Co-author on lentiviral CRISPR delivery lowering IOP (Sci Rep 2024); book chapter on viral vector-induced ocular hypertension in mice; intraocular injection listed as a skill.

    Not found: CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01HL162575-04 Inverse neurovascular coupling in the hypothalamus and its role in positive feedback regulation of Vasopressin neurons in health and disease

    R01 · NHLBI · $671,936 · Dec 1, 2021 to Nov 30, 2026

All active NIH projects for Javier E Stern ($1,600,919)
  • 5R01MH135553-03 Sexually Dimorphic Vasopressin Circuits in the Control of Social Interest — $731,379, ends Jun 30, 2029
  • 5R01HL162575-04 Inverse neurovascular coupling in the hypothalamus and its role in positive feedback regulation of Vasopressin neurons in health and disease — $671,936, ends Nov 30, 2026
  • 5R21DA062844-02 Lasting effects of early resource scarcity on cortical astrocyte structure and function — $197,604, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 1, 2021 · project period to Nov 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#246 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Nicolaas Ida Bohnen lab

Nicolaas Ida Bohnen · University of Michigan, Ann Arbor MI

Abstract The management of dopamine resistant postural instability and gait difficulties (PIGD) features, such as falls, represents perhaps the most important unmet clinical need in persons with Parkinson's disease (PD) and is a major cause for reduced quality of life. The loss of functional abilities and quality of life associated with the emergence of PIGD is further compromised by coinciding emergence of cognitive decline and dementia. This may reflect progressive non-dopaminergic pathologies, such as cholinergic system changes. Vestibular impairment, in particular more chronic bilateral ve

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 264 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "neurodegener".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $599,350 in active NIH money across 2 projects, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$599,350
Active projects
2
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $599,350 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years) — 5I01RX003397-05, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “neurodegener”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG073100-05 Central cholinergic presbyvestibulopathy network changes and imbalance in Parkinson's disease and older persons

    R01 · NIA · $599,350 · Sep 30, 2021 to May 31, 2027

All active NIH projects for Nicolaas Ida Bohnen ($599,350)
  • 5R01AG073100-05 Central cholinergic presbyvestibulopathy network changes and imbalance in Parkinson's disease and older persons — $599,350, ends May 31, 2027
  • 5I01RX003397-05 Vestibulopathy, imbalance and gait disturbances in Parkinson disease — unknown, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2021 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#247 Lab fit 23% · Adjacent Hiring: Possible Atlanta Neuroscience

Michael Goodman lab

Michael Goodman · Emory University, Atlanta GA

The goal of this proposal is to expand and extend the ongoing longitudinal Study of Transition, Outcomes & Gender (STRONG), which is identified from the electronic medical records of three large integrated health care systems: Kaiser Permanente Georgia, Kaiser Permanente Southern California, and Kaiser Permanente Northern California. The study now includes 6,459 members with an index date (first evidence of eligibility status) from 2006 through 2014. The cohort is matched on year of birth, race/ethnicity, site, and membership year at initial presentation (index date) with up to 10 male and 10

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $617,252 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$617,252
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $617,252 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG066956-05 An expanded national cohort study of transgender people

    R01 · NIA · $617,252 · Sep 15, 2021 to May 31, 2027

All active NIH projects for Michael Goodman ($617,252)
  • 5R01AG066956-05 An expanded national cohort study of transgender people — $617,252, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2021 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#248 Lab fit 23% · Adjacent Hiring: Possible Atlanta Neuroscience

Tulay Adali lab

Tulay Adali · Georgia State University, Atlanta GA

Project Summary/Abstract The development of biomarkers for identifying preclinical or prodromal Alzheimer’s disorder are of great in- terest. While some initial results based on resting fMRI have been presented, accuracy, robustness, and relia- bility are still relatively low. One highly promising direction is the development of dynamic functional activity and functional connectivity approaches. These approaches have been shown to be especially promising most likely due to the highly dynamic nature of the brain and the unconstrained nature of resting fMRI. Currently, there are no methods that

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 465 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,288,531 in active NIH money across 2 projects, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,288,531
Active projects
2
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,288,531 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG073949-05 Data driven dynamic activity/connectivity methods for early detection of Alzheimer’s

    R01 · NIA · $726,546 · Sep 1, 2021 to May 31, 2027

  • 5R01MH123610-05 Data-driven solutions for temporal, spatial, and spatiotemporal dynamic functional connectivity

    R01 · NIMH · $561,985 · Mar 19, 2021 to Jan 31, 2027

All active NIH projects for Tulay Adali ($1,288,531)
  • 5R01AG073949-05 Data driven dynamic activity/connectivity methods for early detection of Alzheimer’s — $726,546, ends May 31, 2027
  • 5R01MH123610-05 Data-driven solutions for temporal, spatial, and spatiotemporal dynamic functional connectivity — $561,985, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#249 Lab fit 23% · Adjacent Hiring: Possible Atlanta Neuroscience

Nelson K Steenland lab

Nelson K Steenland · Emory University, Atlanta GA

Dementia is a major public health challenge with substantial economic and social burden, affecting more than 47 million people worldwide. Alzheimer's disease (AD) constitutes about two-thirds of dementia cases and is the sixth leading cause of death in the United States, and the only diagnosis among the top 10 that cannot be cured. There is a pressing need to support Alzheimer's disease and related dementias (AD/ADRD) patients by identifying novel and modifiable risk factors that may reduce morbidity. Emerging evidence suggests that air pollution – in particular fine particulate matter (PM2.5)

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 296 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,122,416 in active NIH money across 3 projects, 0.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,122,416
Active projects
3
Runway left
0.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,122,416 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-02-28.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01AG074357-05 Air Pollution and Alzheimer's Disease and Related Dementias: A National Study

    R01 · NIA · $658,273 · Sep 1, 2021 to Jan 31, 2027

All active NIH projects for Nelson K Steenland ($1,122,416)
  • 5R01AG074357-05 Air Pollution and Alzheimer's Disease and Related Dementias: A National Study — $658,273, ends Jan 31, 2027
  • 5U01TW010107-10 Building U.S. Research Capacity Through International Environmental Health Science on Air Pollution, Cardiorespiratory Disease, and Alzheimer’s Disease (Research U01) — $286,954, ends Feb 28, 2027
  • 5U2RTW010114-10 GEOHealth Hub Peru: Building U.S. Research Capacity Through International Environmental Health Science on Air Pollution, Cardiorespiratory Disease, and Alzheimer’s Disease (Research Training U2R) — $177,189, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2021 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#250 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Kristine J. Ajrouch lab

Kristine J. Ajrouch · University of Michigan, Ann Arbor MI

Project Summary Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans The incidence of Alzheimer’s disease and related dementia (ADRD) is higher in Black Americans and Hispanics than in non-Hispanic Whites, but data on Arab Americans have been virtually absent from research on brain and cognitive aging. The unique experiences of this understudied group have the potential to clarify knowledge of ADRD disparities related to ethnicity, immigrant and social factors. The proposed project leverages the first prevalence study of ADRD among Arab Americans (AG057510) to examine b

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 267 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,541,224 in active NIH money across 2 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,541,224
Active projects
2
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,541,224 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years) — 5P30AG059300-09, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG070951-05 Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans

    R01 · NIA · $839,547 · Apr 1, 2021 to Mar 31, 2027

All active NIH projects for Kristine J. Ajrouch ($1,541,224)
  • 5R01AG070951-05 Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans — $839,547, ends Mar 31, 2027
  • 5P30AG059300-09 MI Center for Contextual Factors in Alzheimer's Disease (MCCFAD) Yrs 6-10 — $701,677, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2021 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#251 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Toni Claudette Antonucci lab

Toni Claudette Antonucci · University of Michigan, Ann Arbor MI

Project Summary Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans The incidence of Alzheimer’s disease and related dementia (ADRD) is higher in Black Americans and Hispanics than in non-Hispanic Whites, but data on Arab Americans have been virtually absent from research on brain and cognitive aging. The unique experiences of this understudied group have the potential to clarify knowledge of ADRD disparities related to ethnicity, immigrant and social factors. The proposed project leverages the first prevalence study of ADRD among Arab Americans (AG057510) to examine b

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 267 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "disparit")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,541,224 in active NIH money across 2 projects, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,541,224
Active projects
2
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,541,224 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years) — 5P30AG059300-09, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG070951-05 Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans

    R01 · NIA · $839,547 · Apr 1, 2021 to Mar 31, 2027

All active NIH projects for Toni Claudette Antonucci ($1,541,224)
  • 5R01AG070951-05 Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans — $839,547, ends Mar 31, 2027
  • 5P30AG059300-09 MI Center for Contextual Factors in Alzheimer's Disease (MCCFAD) Yrs 6-10 — $701,677, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2021 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#252 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Yi Lu Murphey lab

Yi Lu Murphey · University of Michigan, Ann Arbor MI

As the population continues to age and rates of late-life cognitive impairment rise, early detection of cognitive impairment is increasingly important for the timely implementation of interventions and safety initiatives. This may be particularly important in individuals found to have high brain amyloid burden, putting them at particular risk for Alzheimer’s disease and related disorders (ADRD) of the brain. Performance changes in challenging, complex, high-stakes daily activities, such as driving, and accompanying physiological responses may together provide an inexpensive avenue for early de

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 255 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,048,146 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,048,146
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 33 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,048,146 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG068338-05 Identification of cognitive decline and dementia: Prediction by everyday driving behaviors and physiological responses

    R01 · NIA · $1,048,146 · Sep 15, 2020 to May 31, 2027

All active NIH projects for Yi Lu Murphey ($1,048,146)
  • 5R01AG068338-05 Identification of cognitive decline and dementia: Prediction by everyday driving behaviors and physiological responses — $1,048,146, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2020 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#253 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Carol C Persad lab

Carol C Persad · University of Michigan, Ann Arbor MI

As the population continues to age and rates of late-life cognitive impairment rise, early detection of cognitive impairment is increasingly important for the timely implementation of interventions and safety initiatives. This may be particularly important in individuals found to have high brain amyloid burden, putting them at particular risk for Alzheimer’s disease and related disorders (ADRD) of the brain. Performance changes in challenging, complex, high-stakes daily activities, such as driving, and accompanying physiological responses may together provide an inexpensive avenue for early de

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 255 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,048,146 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,048,146
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 33 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,048,146 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG068338-05 Identification of cognitive decline and dementia: Prediction by everyday driving behaviors and physiological responses

    R01 · NIA · $1,048,146 · Sep 15, 2020 to May 31, 2027

All active NIH projects for Carol C Persad ($1,048,146)
  • 5R01AG068338-05 Identification of cognitive decline and dementia: Prediction by everyday driving behaviors and physiological responses — $1,048,146, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2020 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#254 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Lewis B Morgenstern lab

Lewis B Morgenstern · University of Michigan, Ann Arbor MI

Abstract With the continued growth and aging of the Mexican American (MA) population in the United States, we will see a tremendous expansion of Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) in this important group. Understanding and reducing the impact of AD/ADRD in MAs is an important priority for public health and policy making. Currently, there is a critical gap in our understanding of the depth and determinants of disparities in AD/ADRD over time, and potential ways to lessen the impact of these disorders in MA communities. AD/ADRD affects not only the patient, b

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "questionnaire")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,139,846 in active NIH money across 2 projects, 1.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,139,846
Active projects
2
Runway left
1.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,139,846 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-04-30 (about 1.6 years) — 5R37NS038916-28, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG069148-05 Critical Decision Making in Alzheimer's Disease and Related Dementias in Mexican Americans

    R01 · NIA · $733,331 · Sep 15, 2020 to Apr 30, 2027

All active NIH projects for Lewis B Morgenstern ($2,139,846)
  • 5R37NS038916-28 Brain Attack Surveillance in Corpus Christi (BASIC) Project — $1,406,515, ends Apr 30, 2028
  • 5R01AG069148-05 Critical Decision Making in Alzheimer's Disease and Related Dementias in Mexican Americans — $733,331, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2020 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#255 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Darin B Zahuranec lab

Darin B Zahuranec · University of Michigan, Ann Arbor MI

Abstract With the continued growth and aging of the Mexican American (MA) population in the United States, we will see a tremendous expansion of Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) in this important group. Understanding and reducing the impact of AD/ADRD in MAs is an important priority for public health and policy making. Currently, there is a critical gap in our understanding of the depth and determinants of disparities in AD/ADRD over time, and potential ways to lessen the impact of these disorders in MA communities. AD/ADRD affects not only the patient, b

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "questionnaire")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,292,178 in active NIH money across 2 projects, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,292,178
Active projects
2
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,292,178 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG069148-05 Critical Decision Making in Alzheimer's Disease and Related Dementias in Mexican Americans

    R01 · NIA · $733,331 · Sep 15, 2020 to Apr 30, 2027

All active NIH projects for Darin B Zahuranec ($1,292,178)
  • 5R01AG069148-05 Critical Decision Making in Alzheimer's Disease and Related Dementias in Mexican Americans — $733,331, ends Apr 30, 2027
  • 5R01NR019268-05 Comprehensive Outcome Assessment after Severe Acute Brain Injury: Advanced Symptoms and End-of-Life Care Needs — $558,847, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2020 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#256 Lab fit 23% · Adjacent Hiring: Moderate Michigan Neuroscience

Erin Bakshis Ware lab

Erin Bakshis Ware · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Alzheimer’s disease and its related dementias (ADRD) represent the leading terminal forms of dementia affecting a growing number of aging adults in the United States. Biomarkers of ADRD risk, particularly among susceptible populations (ADRD risk is disproportionately high among minorities, women, rural inhabitants, and people with lower education), represent a critical knowledge gap. Thus, studies with sufficient sample sizes, concurrently assessing multiple characteristics, such as educational attainment, environment, social, behavioral, lifestyle, geographic, biology, and epi

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 283 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "dementia".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,944,899 in active NIH money across 4 projects, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,944,899
Active projects
4
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 63 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,944,899 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years) — 1R01AG097804-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “dementia”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG067592-05 DNA Methylation,Genetics, and Modifiable Risk Factors of Dementia in a Nationally Representative, Multi-Ethnic Cohort

    R01 · NIA · $736,487 · May 15, 2020 to Mar 31, 2027

All active NIH projects for Erin Bakshis Ware ($1,944,899)
  • 1R01AG097804-01 From Cells to Society: Using Epigenetics to Understand Brain Vulnerability to Delirium and Cognitive Decline — $761,496, ends Feb 28, 2031
  • 5R01AG067592-05 DNA Methylation,Genetics, and Modifiable Risk Factors of Dementia in a Nationally Representative, Multi-Ethnic Cohort — $736,487, ends Mar 31, 2027
  • 5P2CHD041028-25 Development Core — $296,796, ends Apr 30, 2027
  • 5R25AG053227-10 Genomics for Social Scientists: 2022-2027 — $150,120, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 15, 2020 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#257 Lab fit 23% · Adjacent Hiring: Unlikely Atlanta Neuroscience

Vishnu D Suppiramaniam lab

Vishnu D Suppiramaniam · Kennesaw State University, Kennesaw GA

Project Abstract Cannabis is one of the most illicit drugs used during pregnancy, and with increased legalization, use during pregnancy is expected to rise. Clinical studies have shown prenatal cannabinoid exposure (PCE) results in residual cognitive deficits in offspring. Despite the rise in PCE, there is little understanding of a comprehensive mechanistic pathway responsible for learning and memory deficits associated with PCE. Our long-range goal is to understand how PCE affects cognition, and the goal of this proposal is to dissect the molecular mechanisms of memory and synaptic plasticity

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 241 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Molecular biology, biochemistry and proteomics Lab text mentions "signaling pathway".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $295,850 in active NIH money across 1 project, 0.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$295,850
Active projects
1
Runway left
0.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $295,850 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-02-28.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “signaling pathway”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01DA046723-05 Elucidation of molecular mechanisms of prenatal cannabinoid exposure: Identification of targets and therapies.

    R01 · NIDA · $295,850 · Apr 15, 2020 to Feb 28, 2027

All active NIH projects for Vishnu D Suppiramaniam ($295,850)
  • 5R01DA046723-05 Elucidation of molecular mechanisms of prenatal cannabinoid exposure: Identification of targets and therapies. — $295,850, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 15, 2020 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#258 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Thad A Polk lab

Thad A Polk · University of Michigan, Ann Arbor MI

Project Summary/Abstract A growing body of research has found that neural representations are less distinctive in older relative to younger adults, a phenomenon known as age-related neural dedifferentiation. Neural dedifferentiation has been associated with many of the behavioral impairments typically observed in healthy aging, and evidence collected by our group during the original funding period has found a strong relationship between neural dedifferentiation and gamma-aminobutyric acid (GABA), the brain’s major inhibitory neurotransmitter. Specifically, we found that GABA levels are lower i

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 217 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "alzheimer".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $684,779 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$684,779
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $684,779 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “alzheimer”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG050523-10 Investigating age-related neural dedifferentiation longitudinally and in Alzheimer’s pathology

    R01 · NIA · $684,779 · May 15, 2016 to May 31, 2027

All active NIH projects for Thad A Polk ($684,779)
  • 5R01AG050523-10 Investigating age-related neural dedifferentiation longitudinally and in Alzheimer’s pathology — $684,779, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 15, 2016 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#259 Lab fit 23% · Adjacent Hiring: Moderate Atlanta Neuroscience

Michael Robert Borich lab

Michael Robert Borich · Emory University, Atlanta GA

Our long-term goal is to advance our neuromechanical understanding of balance impairments in Parkinson’s disease (PD) to enable mechanistic, personalized treatments to improve balance and reduce falls. In this renewal, we seek to identify cortical activity metrics related to perceptual, cognitive, and muscle activity impairments in PD, all of which we showed in the prior funding period to be associated with balance impairments and/or fall history. Here we seek to understand neural circuit dysfunction underlying interactions between non-motor and motor symptoms of PD that lead to balance impair

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 254 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 29% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.82 domain gate = 23%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Neurodegeneration and neuroprotection Lab text mentions "parkinson".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "predictive model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,871,953 in active NIH money across 4 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,871,953
Active projects
4
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,871,953 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 29%

    Matched 1 of 6 profile areas (8 of 28 weight to saturation).

    • Neurodegeneration and neuroprotection — lab text says “parkinson”Her side: CV research interests list "Retinal ganglion cell degeneration and neuroprotection"; her UCI focus includes neuroprotection and mitochondrial homeostasis.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01HD046922-18 Neuromechanical modeling of postural responses: Cortical mechanisms of balance impairments in Parkinson's disease

    R01 · NICHD · $637,313 · Apr 1, 2004 to Aug 31, 2029

All active NIH projects for Michael Robert Borich ($1,871,953)
  • 5R01HD046922-18 Neuromechanical modeling of postural responses: Cortical mechanisms of balance impairments in Parkinson's disease — $637,313, ends Aug 31, 2029
  • 5R01AG072756-05 Individual-specific engagement of cortical resources for standing balance control in aging and post stroke — $570,043, ends Mar 31, 2027
  • 5U24NS107234-08 NIH StrokeNet- Regional Coordinating Stroke Centers for year 2023 — $403,365, ends Nov 30, 2028
  • 5T32EB025816-08 Training in Computational Neural Engineering — $261,232, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2004 · project period to Aug 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#260 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Vaibhav A. Diwadkar lab

Vaibhav A. Diwadkar · Wayne State University, Detroit MI

PROJECT SUMMARY/ABSTRACT This is a competitive renewal of grant award R01MH59299, enhanced by significant new in vivo multi-modal functional imaging directions (1H fMRS and fMRI). These innovations facilitate a never-before attempted understanding of specific aspects of dysfunctional neurobiology in youth with Obsessive Compulsive Disorder (OCD). OCD is a severe, prevalent, and chronically disabling disorder emerging during childhood/adolescence (80% of cases) with well-delineated clinical phenomenology/nosology. However, the relationship between the clinical phenomenology and modes of brain d

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 249 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $600,800 in active NIH money across 1 project, 0.1 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$600,800
Active projects
1
Runway left
0.1 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $600,800 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-10-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH059299-24 Multimodal Investigation of Excitatory/Inhibitory Imbalances and Network Dysfunction Related to Motor Control in OCD Youth: ¹H fMRS and fMRI Applications

    R01 · NIMH · $600,800 · Aug 20, 1999 to Oct 30, 2026

All active NIH projects for Vaibhav A. Diwadkar ($600,800)
  • 5R01MH059299-24 Multimodal Investigation of Excitatory/Inhibitory Imbalances and Network Dysfunction Related to Motor Control in OCD Youth: ¹H fMRS and fMRI Applications — $600,800, ends Oct 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 1999 · project period to Oct 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#261 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

David R Rosenberg lab

David R Rosenberg · Wayne State University, Detroit MI

PROJECT SUMMARY/ABSTRACT This is a competitive renewal of grant award R01MH59299, enhanced by significant new in vivo multi-modal functional imaging directions (1H fMRS and fMRI). These innovations facilitate a never-before attempted understanding of specific aspects of dysfunctional neurobiology in youth with Obsessive Compulsive Disorder (OCD). OCD is a severe, prevalent, and chronically disabling disorder emerging during childhood/adolescence (80% of cases) with well-delineated clinical phenomenology/nosology. However, the relationship between the clinical phenomenology and modes of brain d

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 249 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $600,800 in active NIH money across 1 project, 0.1 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$600,800
Active projects
1
Runway left
0.1 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $600,800 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-10-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH059299-24 Multimodal Investigation of Excitatory/Inhibitory Imbalances and Network Dysfunction Related to Motor Control in OCD Youth: ¹H fMRS and fMRI Applications

    R01 · NIMH · $600,800 · Aug 20, 1999 to Oct 30, 2026

All active NIH projects for David R Rosenberg ($600,800)
  • 5R01MH059299-24 Multimodal Investigation of Excitatory/Inhibitory Imbalances and Network Dysfunction Related to Motor Control in OCD Youth: ¹H fMRS and fMRI Applications — $600,800, ends Oct 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 1999 · project period to Oct 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#262 Lab fit 23% · Adjacent Hiring: Possible Michigan Neuroscience

Jeffrey A Stanley lab

Jeffrey A Stanley · Wayne State University, Detroit MI

PROJECT SUMMARY/ABSTRACT This is a competitive renewal of grant award R01MH59299, enhanced by significant new in vivo multi-modal functional imaging directions (1H fMRS and fMRI). These innovations facilitate a never-before attempted understanding of specific aspects of dysfunctional neurobiology in youth with Obsessive Compulsive Disorder (OCD). OCD is a severe, prevalent, and chronically disabling disorder emerging during childhood/adolescence (80% of cases) with well-delineated clinical phenomenology/nosology. However, the relationship between the clinical phenomenology and modes of brain d

Lab fit breakdown — 23% weighted · Adjacent

Scored on enough lab text to read as a verdict. 249 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 33% × 0.7 domain gate = 23%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $600,800 in active NIH money across 1 project, 0.1 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$600,800
Active projects
1
Runway left
0.1 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $600,800 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-10-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH059299-24 Multimodal Investigation of Excitatory/Inhibitory Imbalances and Network Dysfunction Related to Motor Control in OCD Youth: ¹H fMRS and fMRI Applications

    R01 · NIMH · $600,800 · Aug 20, 1999 to Oct 30, 2026

All active NIH projects for Jeffrey A Stanley ($600,800)
  • 5R01MH059299-24 Multimodal Investigation of Excitatory/Inhibitory Imbalances and Network Dysfunction Related to Motor Control in OCD Youth: ¹H fMRS and fMRI Applications — $600,800, ends Oct 30, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 1999 · project period to Oct 30, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#263 Lab fit 22% · Adjacent Hiring: Strong Michigan Neuroscience

Joshua James Emrick lab

Joshua James Emrick · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT Odontogenic pain, also known as toothache, is the most common form of orofacial pain across the world. Most commonly, odontogenic pain stems from inflammation of the tooth pulp following either bacterial infection or iatrogenic damage. While this pain will resolve with clinical intervention that removes the peripheral insult and dental pulp (e.g., root canal or extraction), it may be accompanied by substantial mechanical and thermal allodynia that is not alleviated by local anesthesia. We continue to lack safe approaches to achieve effective, immediate analgesia toward

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 231 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "bacterial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $4,349,544 in active NIH money across 2 projects, 4.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,349,544
Active projects
2
Runway left
4.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 75 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,349,544 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-05-31 (about 4.7 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-08-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DE035109-01A1 Defining the cells, circuits, and phenotypes of odontogenic pain

    R01 · NIDCR · $600,214 · Aug 1, 2026 to May 31, 2031

All active NIH projects for Joshua James Emrick ($4,349,544)
  • 4UC2AR082197-02 Neural Architecture of the Murine and Human Temporomandibular Joint — $3,749,330, ends Aug 31, 2027
  • 1R01DE035109-01A1 Defining the cells, circuits, and phenotypes of odontogenic pain — $600,214, ends May 31, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2026 · project period to May 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#264 Lab fit 22% · Adjacent Hiring: Moderate Atlanta Neuroscience

Alexandra Cohen lab

Alexandra Cohen · Emory University, Atlanta GA

Project Summary/Abstract Neuropsychiatric disorders often emerge during childhood and adolescence, and many involve maladaptive learning and memory. Persistent memories of salient positive or negative events can contribute to the onset and maintenance of disorders like addiction and anxiety; yet we lack a mechanistic account of how affective experiences drive selective memory prioritization throughout development. Dopaminergic and noradrenergic projections to the hippocampus have been implicated in long-term memory for emotion-related events and research in nonhuman animal models suggests that

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 235 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $821,349 in active NIH money across 2 projects, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$821,349
Active projects
2
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $821,349 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-13.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1R01MH141201-01 Dopaminergic and noradrenergic mechanisms of emotion-related memory over development

    R01 · NIMH · $628,380 · May 13, 2026 to Feb 28, 2031

All active NIH projects for Alexandra Cohen ($821,349)
  • 1R01MH141201-01 Dopaminergic and noradrenergic mechanisms of emotion-related memory over development — $628,380, ends Feb 28, 2031
  • 5K01DA053438-06 Neurocognitive mechanisms of reward - motivated memory persistence across age — $192,969, ends Feb 28, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 13, 2026 · project period to Feb 28, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026

#265 Lab fit 22% · Adjacent Hiring: Possible Michigan Neuroscience

Cheng-yu Lee lab

Cheng-yu Lee · University of Michigan, Ann Arbor MI

Intermediate progenitors are stem cell progeny that undergo limited proliferation to increase the generation of differentiated cells per asymmetric stem cell division. Subsets of stem cells appear to have the capability to further expand the generation of intermediate progenitors via transit-amplifying cell types while other subsets do not. It is unclear whether the competency to amplify the generation of intermediate progenitors is encoded in the lineage-specific gene regulatory program or is a general stem cell functionality that can undergo controlled activation. In addition, stem cell func

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 213 words of lab text were scored, matching 3 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 29% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Human donor tissue, primary and explant culture Lab text mentions "ex vivo".
  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "single-cell rna".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $413,082 in active NIH money across 1 project, 2.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$413,082
Active projects
1
Runway left
2.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $413,082 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-05-31 (about 2.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 29%

    Matched 2 of 5 profile areas (8 of 28 weight to saturation).

    • Human donor tissue, primary and explant culture — lab text says “ex vivo”Her side: Primary cell culture of human and mouse ocular tissue, explant culture and adult stem cell isolation; donor-eye cohorts across her three TM papers.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “single-cell rna”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS134942-03 Regulation of generation and functions of intermediate progenitors

    R01 · NINDS · $413,082 · Jul 1, 2024 to May 31, 2029

All active NIH projects for Cheng-yu Lee ($413,082)
  • 5R01NS134942-03 Regulation of generation and functions of intermediate progenitors — $413,082, ends May 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2024 · project period to May 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#266 Lab fit 22% · Adjacent Hiring: Unlikely Atlanta Neuroscience

James Q Zheng lab

James Q Zheng · Emory University, Atlanta GA

Project Summary Chemical synapses are composed of paired pre- and post-synaptic terminals. Most of the excitatory synapses reside on dendritic spines, a type of dendritic protrusion that hosts neurotransmitter receptors and other postsynaptic specializations. Synapses are plastic and undergo short- and long-term modifications during developmental refinement of neuronal circuitry, as well as during learning and memory. Synaptic modifications involve both pre- and post-synaptic changes. At the postsynaptic site, directed trafficking of neurotransmitter receptors to and from the membrane surface

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 219 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 47% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Histology, IHC and confocal / electron microscopy Lab text mentions "microscopy".
  • Molecular biology, biochemistry and proteomics Lab text mentions "biochemi".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $548,622 in active NIH money across 1 project, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$548,622
Active projects
1
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $548,622 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2027-12-31 (about 1.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 47%

    Matched 2 of 7 profile areas (14 of 30 weight to saturation).

    • Histology, IHC and confocal / electron microscopy — lab text says “microscopy”Her side: Cryo and paraffin sectioning, histopathology, immunohistochemistry, confocal microscopy and transmission electron microscopy are all listed CV skills.
    • Molecular biology, biochemistry and proteomics — lab text says “biochemi”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH133798-03 Actin Cytoskeleton in Postsynaptic Structure and Function

    R01 · NIMH · $548,622 · Jun 3, 2024 to Dec 31, 2027

All active NIH projects for James Q Zheng ($548,622)
  • 5R01MH133798-03 Actin Cytoskeleton in Postsynaptic Structure and Function — $548,622, ends Dec 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 3, 2024 · project period to Dec 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#267 Lab fit 22% · Adjacent Hiring: Possible Michigan Neuroscience

Ada Eban-rothschild lab

Ada Eban-rothschild · University of Michigan, Ann Arbor MI

Project Summary Despite the overall reduced responsiveness to external stimuli during sleep, incoming sounds are processed by a highly active and broadly projecting auditory system. Moreover, not only the acoustic aspects of sounds are processed during sleep but also their associated meaning, as evidenced by a higher likelihood of awakening from novel and meaningful sounds as compared to familiar and meaningless sounds. These and other findings suggest that there is ongoing semantic neural processing during sleep, yet the underlying brain circuits and neurophysiological mechanisms remain poorl

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 393 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $999,215 in active NIH money across 2 projects, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$999,215
Active projects
2
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $999,215 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS129874-04 The neural mechanisms and mnemonic consequences of sound processing during sleep

    R01 · NINDS · $495,150 · Jul 15, 2023 to May 31, 2028

  • 5R01NS131821-04 The functions of dopamine signaling during sleep in memory

    R01 · NINDS · $504,065 · Apr 1, 2023 to Jan 31, 2028

All active NIH projects for Ada Eban-rothschild ($999,215)
  • 5R01NS131821-04 The functions of dopamine signaling during sleep in memory — $504,065, ends Jan 31, 2028
  • 5R01NS129874-04 The neural mechanisms and mnemonic consequences of sound processing during sleep — $495,150, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#268 Lab fit 22% · Adjacent Hiring: Possible Michigan Neuroscience

Gideon Rothschild lab

Gideon Rothschild · University of Michigan, Ann Arbor MI

Project Summary Despite the overall reduced responsiveness to external stimuli during sleep, incoming sounds are processed by a highly active and broadly projecting auditory system. Moreover, not only the acoustic aspects of sounds are processed during sleep but also their associated meaning, as evidenced by a higher likelihood of awakening from novel and meaningful sounds as compared to familiar and meaningless sounds. These and other findings suggest that there is ongoing semantic neural processing during sleep, yet the underlying brain circuits and neurophysiological mechanisms remain poorl

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 393 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 32% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".
  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $999,215 in active NIH money across 2 projects, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$999,215
Active projects
2
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $999,215 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS129874-04 The neural mechanisms and mnemonic consequences of sound processing during sleep

    R01 · NINDS · $495,150 · Jul 15, 2023 to May 31, 2028

  • 5R01NS131821-04 The functions of dopamine signaling during sleep in memory

    R01 · NINDS · $504,065 · Apr 1, 2023 to Jan 31, 2028

All active NIH projects for Gideon Rothschild ($999,215)
  • 5R01NS131821-04 The functions of dopamine signaling during sleep in memory — $504,065, ends Jan 31, 2028
  • 5R01NS129874-04 The neural mechanisms and mnemonic consequences of sound processing during sleep — $495,150, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#269 Lab fit 22% · Adjacent Hiring: Moderate Michigan Neuroscience

Suzanne M Moenter lab

Suzanne M Moenter · University of Michigan, Ann Arbor MI

Project Summary Gonadotropin-releasing hormone (GnRH) neurons form the final common central pathway regulating fertility. Properly patterned GnRH release is required for fertility and is often disrupted in women with polycystic ovary syndrome (PCOS). Hyperandrogenic PCOS affects ~8-10% of women. In these women, there is a persistent high frequency of luteinizing hormone (LH), and likely GnRH, release. Prenatally androgenized (PNA) mice have neuroendocrine phenotypes similar to women with PCOS, including high LH pulse frequency, and can be used to study mechanisms of this increase. Pathophysiol

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 510 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,585,459 in active NIH money across 4 projects, 2.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,585,459
Active projects
4
Runway left
2.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,585,459 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 4 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-04-30 (about 2.6 years) — 5T32HD079342-13, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01HD104345-05 Development of the GnRH neuronal network and effects of prenatal androgen exposure

    R01 · NICHD · $434,312 · May 1, 2021 to Jan 31, 2027

  • 5R01HD041469-25 Central Actions of Estrogens: Effects on GnRH Neurons

    R01 · NICHD · $411,522 · Feb 11, 2002 to May 31, 2028

All active NIH projects for Suzanne M Moenter ($1,585,459)
  • 5R37HD034860-30 Cellular and molecular bases for rhythmic GnRH release — $568,853, ends May 31, 2027
  • 5R01HD104345-05 Development of the GnRH neuronal network and effects of prenatal androgen exposure — $434,312, ends Jan 31, 2027
  • 5R01HD041469-25 Central Actions of Estrogens: Effects on GnRH Neurons — $411,522, ends May 31, 2028
  • 5T32HD079342-13 Career Training in Reproductive Biology — $170,772, ends Apr 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2021 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#270 Lab fit 22% · Adjacent Hiring: Possible Atlanta Neuroscience

Muhannad Bakir lab

Muhannad Bakir · Emory University, Atlanta GA

Despite recent advances in technology for recording and modulating neural activity, current methods for measuring and manipulating the nervous system’s motor output lag far behind in terms of scale and resolution. The control of skeletal motor output is mediated by “motor units”, each consisting of a single motor neuron and the muscle fibers it activates to generate muscle force and produce body movements. Because each “spike” (action potential) in a motor neuron reliably evokes a single spike in its target muscle fibers, spikes recorded from muscle provide high-resolution readouts of motor ne

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 617 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Non-rodent animal models Lab text mentions "nonhuman primate".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "survey")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $575,943 in active NIH money across 1 project, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$575,943
Active projects
1
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $575,943 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS109237-07 Next-Generation Tools to Measure and Manipulate Muscle Activity Across Species and Behaviors

    R01 · NINDS · $575,943 · Jun 15, 2019 to Apr 30, 2030

All active NIH projects for Muhannad Bakir ($575,943)
  • 5R01NS109237-07 Next-Generation Tools to Measure and Manipulate Muscle Activity Across Species and Behaviors — $575,943, ends Apr 30, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 15, 2019 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#271 Lab fit 22% · Adjacent Hiring: Moderate Atlanta Neuroscience

Samuel Sober lab

Samuel Sober · Emory University, Atlanta GA

Despite recent advances in technology for recording and modulating neural activity, current methods for measuring and manipulating the nervous system’s motor output lag far behind in terms of scale and resolution. The control of skeletal motor output is mediated by “motor units”, each consisting of a single motor neuron and the muscle fibers it activates to generate muscle force and produce body movements. Because each “spike” (action potential) in a motor neuron reliably evokes a single spike in its target muscle fibers, spikes recorded from muscle provide high-resolution readouts of motor ne

Lab fit breakdown — 22% weighted · Adjacent

Scored on enough lab text to read as a verdict. 617 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 31% × 0.7 domain gate = 22%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".
  • Non-rodent animal models Lab text mentions "nonhuman primate".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "survey")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,959,298 in active NIH money across 3 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,959,298
Active projects
3
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 58 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,959,298 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS109237-07 Next-Generation Tools to Measure and Manipulate Muscle Activity Across Species and Behaviors

    R01 · NINDS · $575,943 · Jun 15, 2019 to Apr 30, 2030

All active NIH projects for Samuel Sober ($1,959,298)
  • 5U24NS126936-04 Center for Advanced Muscle BioElectronics (CAMBER) — $848,798, ends May 31, 2028
  • 5R01NS109237-07 Next-Generation Tools to Measure and Manipulate Muscle Activity Across Species and Behaviors — $575,943, ends Apr 30, 2030
  • 1R56NS147432-01A1 The role of Renshaw cells and recurrent inhibition during motor behaviors — $534,557, ends Aug 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 15, 2019 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#272 Lab fit 21% · Low fit Hiring: Unlikely Michigan Neuro + ophtho

Susmit Suvas lab

Susmit Suvas · Wayne State University, Detroit MI

Herpes stromal keratitis (HSK) is a leading cause of infection-induced vision loss in the United States. The HSK develops in response to corneal herpes simplex virus-1 (HSV-1) infection. Recurrent corneal HSV-1 infection can cause the persistence of innate immune cells, such as monocytes, neutrophils, and effector CD4 T cells in the corneal stroma of the infected cornea. As the accumulation of neutrophils and effector CD4 T cells in the HSK cornea plays a pivotal role in orchestrating the tissue damage, the strategies to manipulate the stay of infiltrating immune cells in the HSK cornea are an

Lab fit breakdown — 21% weighted · Low fit

Scored on enough lab text to read as a verdict. 244 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 30% × 0.7 domain gate = 21%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".
  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on infection and immunology Infection/immunology focus. Her neurodegeneration work does not include host-pathogen or immunology assays. (matched on "infection")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $385,000 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$385,000
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $385,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY035540-04 CXCR4: A potential therapeutic target in HSK

    R01 · NEI · $385,000 · Sep 1, 2023 to May 31, 2027

All active NIH projects for Susmit Suvas ($385,000)
  • 5R01EY035540-04 CXCR4: A potential therapeutic target in HSK — $385,000, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2023 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#273 Lab fit 21% · Low fit Hiring: Moderate Michigan Neuroscience

Kenn R Oldham lab

Kenn R Oldham · University of Michigan, Ann Arbor MI

Project Summary The goal of this work is to achieve high-speed optical fluorescence imaging of 3D brain volume in moving, behaving mice, using miniature scanning mirrors in an implantable, fiber-coupled microscope. Existing implantable microscopes for neural imaging primarily image a single focal plane or may alter image depth using scanning mechanisms that are slow and/or reduce the optical resolution. Scanning mirrors based on microelectromechanical system (MEMS) technology can be placed near the objective lens of fiber-coupled miniature microscopes, and achieve very high scanning frequencie

Lab fit breakdown — 21% weighted · Low fit

Scored on enough lab text to read as a verdict. 226 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 30% × 0.7 domain gate = 21%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "lens".
  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,215,122 in active NIH money across 3 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,215,122
Active projects
3
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,215,122 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years) — 5P41EB035084-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “lens”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1NS131063-01 Implantable 3D fluorescence imaging with high-speed, addressable laser scanning in moving mice

    RF1 · NINDS · $1,696,857 · Jun 1, 2023 to May 31, 2027

All active NIH projects for Kenn R Oldham ($3,215,122)
  • 1RF1NS131063-01 Implantable 3D fluorescence imaging with high-speed, addressable laser scanning in moving mice — $1,696,857, ends May 31, 2027
  • 5P41EB035084-02 Microsystems-Based Imaging Systems — $1,302,368, ends Apr 30, 2030
  • 5T32EB032756-04 Acute and Critical Care Engineering (ACCE) Training Program — $215,897, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2023 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#274 Lab fit 21% · Low fit Hiring: Unlikely Michigan Neuroscience

Monica Dus lab

Monica Dus · University of Michigan, Ann Arbor MI

PROJECT SUMMARY During eating animals modulate the size of meals by associating sensory cues with rewarding qualities of food. This process is central to the control of food intake and is impaired in humans and animals exposed to high fat and sugar diets. The neural mechanisms through which food associations 1) regulate meal size and 2) are perturbed by this dietary environment, however, remain poorly understood. This lack of knowledge has hindered progress in uncovering the underlying causes of obesity and, thus, in curbing the spread of metabolic disease. Here we propose to use the D. melano

Lab fit breakdown — 21% weighted · Low fit

Scored on enough lab text to read as a verdict. 267 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 13% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 30% × 0.7 domain gate = 21%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • In vivo ocular imaging and functional readouts Lab text mentions "in vivo imaging".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $308,368 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$308,368
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $308,368 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 13%

    Matched 1 of 7 profile areas (4 of 30 weight to saturation).

    • In vivo ocular imaging and functional readouts — lab text says “in vivo imaging”Her side: OCT retinal imaging, PERG/ERG functional vision testing and intraocular pressure measurement are listed CV skills.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK130875-05 Neural determinants on meal size in invertebrate models of obesity

    R01 · NIDDK · $308,368 · Sep 1, 2022 to Jun 30, 2027

All active NIH projects for Monica Dus ($308,368)
  • 5R01DK130875-05 Neural determinants on meal size in invertebrate models of obesity — $308,368, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#275 Lab fit 21% · Low fit Hiring: Unlikely Michigan Ophthalmology

Karl Boynton Seydel lab

Karl Boynton Seydel · Michigan State University, East Lansing MI

This project aims to identify the targets and features of antibody responses that determine the outcome of malaria infection in young African children. It uses Systems Serology, combining multi-dimensional antibody profiling with machine learning, to study responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), the dominant antigen on the surface of malaria infected erythrocytes (IEs). Some PfEMP1 types are implicated in cerebral malaria (CM); others may lead to asymptomatic parasitemia (AP). Asymptomatic infections contribute to ongoing malaria transmission. Understanding

Lab fit breakdown — 21% weighted · Low fit

Scored on enough lab text to read as a verdict. 271 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 21% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 26% × 0.82 domain gate = 21%. Thin disease overlap — weighted mean discounted 18%.

What matches

  • Retina, photoreceptors and RPE Lab text mentions "retina".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $173,457 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$173,457
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 5 of 100 points
  • 0 Under $250K of active NIH award money — NIH RePORTER reports only $173,457 active.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 21%

    Matched 1 of 6 profile areas (6 of 28 weight to saturation).

    • Retina, photoreceptors and RPE — lab text says “retina”Her side: Retinal flat mounts, OCT retinal imaging and PERG/ERG in her technical skills; retinal work across all three training centres.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AI165595-05S1 Identifying functional antibody responses that protect against malaria in children

    R01 · NIAID · $158,782 · Aug 15, 2022 to Jul 31, 2027

All active NIH projects for Karl Boynton Seydel ($173,457)
  • 5R01AI165595-05 Identifying functional antibody responses that protect against malaria in children — $173,457, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2022 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#276 Lab fit 20% · Low fit Hiring: Moderate Michigan Neuroscience

Paul Frederick Kramer lab

Paul Frederick Kramer · University of Michigan, Ann Arbor MI

Project Summary Dopamine (DA) release from terminal axons in the striatum is crucial for regulating movement and associative learning. Dysregulation of DA release contributes to substance use disorders like nicotine use disorder (NUD), leading to significant health impacts in the United States. DA release in the striatum is controlled by the regulation of action potential (AP) firing in dopaminergic (DAergic) cell bodies as well as inputs onto DAergic axons in the terminal region of the striatum. Decades of research have brought insight into the somatic mechanisms regulating AP initiation, but

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 220 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 20% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Axonal transport and neuronal injury assays Lab text mentions "axon".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $386,301 in active NIH money across 1 project, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$386,301
Active projects
1
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $386,301 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-05-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 20%

    Matched 1 of 7 profile areas (6 of 30 weight to saturation).

    • Axonal transport and neuronal injury assays — lab text says “axon”Her side: Axonal transport is named in her UCI research focus and is the subject of the JCI Insight 2025 paper she co-authored.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01DA065668-01 Axonal Mechanisms Regulating Dopamine Release

    R01 · NIDA · $386,301 · May 1, 2026 to Feb 28, 2031

All active NIH projects for Paul Frederick Kramer ($386,301)
  • 1R01DA065668-01 Axonal Mechanisms Regulating Dopamine Release — $386,301, ends Feb 28, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2026 · project period to Feb 28, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#277 Lab fit 20% · Low fit Hiring: Moderate Michigan Neuroscience

Pierre F Apostolides lab

Pierre F Apostolides · University of Michigan, Ann Arbor MI

Project Summary/Abstract Associative learning is a fundamental cornerstone of behavior and cognition, but the underlying neural mechanisms remain poorly understood. In vertebrates, the inferior colliculus (IC) is a layered, midbrain hub important for sound localization, speech perception, and a potential site of plasticity for associative auditory learning. Indeed, classic studies in avians showed that neurons of the external “shell” IC layers have a substantial capacity for plasticity of auditory space maps. Additionally, early mammalian studies suggested that lesions of the analogous shell I

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 218 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,522,225 in active NIH money across 2 projects, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,522,225
Active projects
2
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,522,225 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years) — 2R01DC019090-06A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1RF1MH141903-01 Midbrain Signals for Differential Reinforcement Learning

    RF1 · NIMH · $2,908,921 · Sep 22, 2025 to Sep 21, 2029

All active NIH projects for Pierre F Apostolides ($3,522,225)
  • 1RF1MH141903-01 Midbrain Signals for Differential Reinforcement Learning — $2,908,921, ends Sep 21, 2029
  • 2R01DC019090-06A1 Learning Related Plasticity in Mammalian Sound Localization Circuits — $613,304, ends Feb 28, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 22, 2025 · project period to Sep 21, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#278 Lab fit 20% · Low fit Hiring: Possible Atlanta Neuroscience

Hannah Choi lab

Hannah Choi · Georgia Institute of Technology, Atlanta GA

To understand the world around us, we use body movement to actively probe for information. For instance, you might grasp each object in your bag in turn, until you recognize your keys by their texture and shape. To do this, the brain must synthesize sensory and motor signals to generate an internal model of the world and to guide adaptive action. In this project, we will determine how neural circuits in the sensory and motor cortex implement those computations by combining theory- and data-driven modeling (led by PI Choi) with experiments in mice (led by PI Rodgers). Our overall hypothesis is

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 203 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "predictive model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $376,833 in active NIH money across 1 project, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$376,833
Active projects
1
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $376,833 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS147739-02 CRCNS: The Circuit Mechanism of Sensorimotor Predictive Processing for Active Touch

    R01 · NINDS · $376,833 · Sep 1, 2025 to Aug 31, 2030

All active NIH projects for Hannah Choi ($376,833)
  • 5R01NS147739-02 CRCNS: The Circuit Mechanism of Sensorimotor Predictive Processing for Active Touch — $376,833, ends Aug 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2025 · project period to Aug 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#279 Lab fit 20% · Low fit Hiring: Moderate Atlanta Neuroscience

Christopher Rodgers lab

Christopher Rodgers · Emory University, Atlanta GA

To understand the world around us, we use body movement to actively probe for information. For instance, you might grasp each object in your bag in turn, until you recognize your keys by their texture and shape. To do this, the brain must synthesize sensory and motor signals to generate an internal model of the world and to guide adaptive action. In this project, we will determine how neural circuits in the sensory and motor cortex implement those computations by combining theory- and data-driven modeling (led by PI Choi) with experiments in mice (led by PI Rodgers). Our overall hypothesis is

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 203 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "predictive model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $906,552 in active NIH money across 3 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$906,552
Active projects
3
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $906,552 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS147739-02 CRCNS: The Circuit Mechanism of Sensorimotor Predictive Processing for Active Touch

    R01 · NINDS · $376,833 · Sep 1, 2025 to Aug 31, 2030

All active NIH projects for Christopher Rodgers ($906,552)
  • 5R01NS147739-02 CRCNS: The Circuit Mechanism of Sensorimotor Predictive Processing for Active Touch — $376,833, ends Aug 31, 2030
  • 5R34NS137017-02 Wirelessly Recording and Manipulating Neural Activity to Study the Sensorimotor Dynamics of Free Behavior — $337,720, ends Jul 31, 2027
  • 5R21DC019711-03 Central auditory pathways for integrating auditory input with head position during active sound localization in mice — $191,999, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2025 · project period to Aug 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#280 Lab fit 20% · Low fit Hiring: Moderate Atlanta Neuroscience

Aaron John Young lab

Aaron John Young · Georgia Institute of Technology, Atlanta GA

Mobility serves as a surrogate for well-being with age-related limits to walking function that include: increased energy cost and decreased speed. In 2021, the National Institute on Aging convened interdisciplinary scientists to identify multi-scale mechanisms for mobility impairments in aging and identified multiple factors contributing to elevated metabolic cost and reduced walking speed. A foundational age-related difference in walking function emerged - the so called ‘distal to proximal shift’ in neuromechanical effort. Older walkers rely more on proximal hip rather than distal ankle muscl

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 249 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 33% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Autophagy, mitophagy and organelle quality control Lab text mentions "mitochondri".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $4,681,814 in active NIH money across 3 projects, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$4,681,814
Active projects
3
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $4,681,814 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 33%

    Matched 1 of 7 profile areas (10 of 30 weight to saturation).

    • Autophagy, mitophagy and organelle quality control — lab text says “mitochondri”Her side: Her central research contribution: conditional autophagy loss in RGCs causing organelle accumulation; UCI focus also names ER stress and mitochondrial homeostasis.

    Not found: Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1RF1AG096055-01 Identifying Multi-Scale Mechanisms for Age-Related Increase in Metabolic Cost of Walking

    RF1 · NIA · $3,224,215 · Aug 15, 2025 to Jul 31, 2029

All active NIH projects for Aaron John Young ($4,681,814)
  • 1RF1AG096055-01 Identifying Multi-Scale Mechanisms for Age-Related Increase in Metabolic Cost of Walking — $3,224,215, ends Jul 31, 2029
  • 4DP2HD111709-02 A new framework for self-adaptive artificial intelligence to personalize assistance for patients using robotic exoskeletons and prostheses — $944,400, ends Aug 31, 2027
  • 5R01HD113598-03 Personalized Hip vs Ankle Exoskeleton Assistance with Biofeedback to Enhance Mobility Post-Stroke — $513,199, ends Jan 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2025 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#281 Lab fit 20% · Low fit Hiring: Possible Atlanta Neuroscience

Annaelle Devergnas lab

Annaelle Devergnas · Emory University, Atlanta GA

SUMMARY The objective of this proposal is to investigate how temporal lobe (TL) seizures with different onset patterns propagate through the basal ganglia (BG) and to evaluate the implication of this circuit in the control of TL seizures. TL epilepsy is the most common form of focal epilepsy and a third of the patients do not respond to drug therapy. Resective surgery and deep brain stimulation can be effective, however, only some patients are eligible and very few become seizure free. There is then a clear need for better and more individualized epilepsy treatments based on a rigorous underst

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 226 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "animal model".
  • Non-rodent animal models Lab text mentions "nonhuman primate".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $650,773 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$650,773
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $650,773 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “nonhuman primate”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS136529-03 Impact of seizure onset pattern on temporal lobe seizure propagation through the basal ganglia

    R01 · NINDS · $650,773 · Sep 11, 2024 to Jul 31, 2029

All active NIH projects for Annaelle Devergnas ($650,773)
  • 5R01NS136529-03 Impact of seizure onset pattern on temporal lobe seizure propagation through the basal ganglia — $650,773, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 11, 2024 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#282 Lab fit 20% · Low fit Hiring: Possible Atlanta Neuroscience

Anita Vani Devineni lab

Anita Vani Devineni · Emory University, Atlanta GA

Our sense of taste is critical in helping us decide what to eat. Altered taste perception is associated with obesity and eating disorders, suggesting that dysregulation of taste processing may contribute to these conditions. Understanding how the taste system flexibly transforms sensory input into behavior thus represents a fundamental question underlying feeding decisions across healthy and disordered states. Two key questions underpin the mechanisms of taste processing: how are neuronal responses to taste transformed along the taste pathway, and how do these responses drive behavior? Studies

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 195 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 46% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".
  • Non-rodent animal models Lab text mentions "drosophila".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $377,953 in active NIH money across 1 project, 2.2 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$377,953
Active projects
1
Runway left
2.2 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $377,953 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-11-30 (about 2.2 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 46%

    Matched 2 of 5 profile areas (13 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.
    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01DC021478-03 Dissecting the first layer of central taste processing in Drosophila

    R01 · NIDCD · $377,953 · Dec 1, 2023 to Nov 30, 2028

All active NIH projects for Anita Vani Devineni ($377,953)
  • 5R01DC021478-03 Dissecting the first layer of central taste processing in Drosophila — $377,953, ends Nov 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 1, 2023 · project period to Nov 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#283 Lab fit 20% · Low fit Hiring: Possible Atlanta Neuroscience

Boris I Prilutsky lab

Boris I Prilutsky · Georgia Institute of Technology, Atlanta GA

Whether it is walking, playing sports/recreation, eating/drinking or mating, moving is essential to having a high quality of life. Traumatic spinal cord injury (SCI) is a catastrophic event that completely alters a person’s life, with a high cost to the health care system and the highest out-of-pocket expenses for individuals. Symptoms include weakened muscles, loss of sensation, and with the most severe injuries, complete motor paralysis. However, after SCI, the spinal sensorimotor circuits located below the injury remain largely intact and can be activated by pharmacology and/or electrical s

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 275 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "animal model".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "biomechanic")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $542,369 in active NIH money across 1 project, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$542,369
Active projects
1
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $542,369 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-07-31 (about 3.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “animal model”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS110550-07 Limb coordination during locomotion before and after spinal cord injury

    R01 · NINDS · $542,369 · Feb 15, 2020 to Jul 31, 2030

All active NIH projects for Boris I Prilutsky ($542,369)
  • 5R01NS110550-07 Limb coordination during locomotion before and after spinal cord injury — $542,369, ends Jul 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 15, 2020 · project period to Jul 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#284 Lab fit 20% · Low fit Hiring: Possible Michigan Neuroscience

Robert John Wessells lab

Robert John Wessells · Wayne State University, Detroit MI

Project Summary Endurance exercise is a highly effective intervention for ensuring healthy metabolism and maintaining healthy function during aging, but is unavailable to patients with illnesses or injuries that restrict their movement. Here, we follow up on previous discoveries from the fruit fly model system showing that stimulation of octopamine secretion from the brain acts through receptors in muscle and fat to coordinate benefits of exercise in sedentary animals. Here, we propose to identify genetic factors that mediate increased neuronal branching in the exercising brain (Aim 1), elucid

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 218 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 11% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 28% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Non-rodent animal models Lab text mentions "drosophila".
  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $420,380 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$420,380
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $420,380 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-06-30 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 11%

    Matched 1 of 5 profile areas (3 of 28 weight to saturation).

    • Non-rodent animal models — lab text says “drosophila”Her side: No non-rodent model appears anywhere in the CV; scored low so a zebrafish or primate lab is not credited with an overlap she does not have.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG059683-08 Octpamine controls adaptation to endurance exercise in Drosophila

    R01 · NIA · $420,380 · Sep 30, 2018 to Jun 30, 2029

All active NIH projects for Robert John Wessells ($420,380)
  • 5R01AG059683-08 Octpamine controls adaptation to endurance exercise in Drosophila — $420,380, ends Jun 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2018 · project period to Jun 30, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#285 Lab fit 20% · Low fit Hiring: Moderate Michigan Neuroscience

Brian D. Gulbransen lab

Brian D. Gulbransen · Michigan State University, East Lansing MI

PROJECT SUMMARY Experiencing gut inflammation imparts long-lasting effects on the neural control of gut motility that contribute to persistent gut motility issues in irritable bowel syndrome and inflammatory bowel disease. Intestinal motility is governed by neural circuits in the enteric nervous system (ENS) and changes in how enteric motility neurocircuits function play a central role in post-inflammatory gut dysfunction. The underlying mechanisms remain poorly understood. Enteric glia surround enteric neurons and regulate gut motility through effects on neuronal excitability and neuroinflamm

Lab fit breakdown — 20% weighted · Low fit

Scored on enough lab text to read as a verdict. 200 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 29% × 0.7 domain gate = 20%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $957,067 in active NIH money across 2 projects, 3.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$957,067
Active projects
2
Runway left
3.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $957,067 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-04-30 (about 3.6 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK103723-12 Regulation of enteric motor neurocircuits by enteric glia in health and disease

    R01 · NIDDK · $502,932 · Jul 15, 2015 to Apr 30, 2030

All active NIH projects for Brian D. Gulbransen ($957,067)
  • 5R01DK103723-12 Regulation of enteric motor neurocircuits by enteric glia in health and disease — $502,932, ends Apr 30, 2030
  • 5R01DK120862-07 Enteric glia and visceral pain — $454,135, ends Feb 28, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2015 · project period to Apr 30, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#286 Lab fit 19% · Low fit Hiring: Possible Michigan Neuroscience

Lora M. Cope lab

Lora M. Cope · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT This proposal leverages recent advancements in translational neuroscience and represents a critical step in the effort to further our understanding of individual differences in addiction liability, one of the most challenging and important questions in substance use research. This question is particularly relevant during emerging adulthood because that is when risk factors and rates of substance use and substance use disorder are high relative to other age groups. One of the most well-validated models of addiction based on animal models, incentive-sensitization theory,

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 244 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rodent".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $701,998 in active NIH money across 1 project, 2.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$701,998
Active projects
1
Runway left
2.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $701,998 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-07-31 (about 2.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rodent”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA058010-03 Neurobehavioral signatures of sign- and goal-tracking in emerging adults: Translation of a preclinical model

    R01 · NIDA · $701,998 · Sep 30, 2024 to Jul 31, 2029

All active NIH projects for Lora M. Cope ($701,998)
  • 5R01DA058010-03 Neurobehavioral signatures of sign- and goal-tracking in emerging adults: Translation of a preclinical model — $701,998, ends Jul 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2024 · project period to Jul 31, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#287 Lab fit 19% · Low fit Hiring: Unlikely Michigan Neuroscience

Jianping Fu lab

Jianping Fu · University of Michigan, Ann Arbor MI

Project Summary A Fully Patterned Human Neural Tube Model Using Microfluidics The development of vertebrate central nervous system (CNS) begins with the formation of neural tube (NT) and its regional patterning to generate neuronal subtypes along the rostral (R)-caudal (C) and dorsal (D)- ventral (V) axes. Regional patterning of the human NT is a tightly regulated process, deviation from which can result in neurodevelopmental disorders and may lead to distinct neurological and psychiatric diseases later in life. Regional patterning of the human NT remains incompletely understood due to limited

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 263 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on human iPSC and organoid models Lab relies on iPSC or organoid systems. Her stem cell experience is adult tissue-derived — human trabecular meshwork stem cells isolated from donor eyes — with no iPSC or organoid work on the CV. (matched on "organoid")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $523,443 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$523,443
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $523,443 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS129850-04 A Fully Patterned Human Neural Tube Model Using Microfluidics

    R01 · NINDS · $523,443 · Aug 15, 2023 to May 31, 2028

All active NIH projects for Jianping Fu ($523,443)
  • 5R01NS129850-04 A Fully Patterned Human Neural Tube Model Using Microfluidics — $523,443, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 15, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#288 Lab fit 19% · Low fit Hiring: Unlikely Atlanta Neuroscience

Malavika Murugan lab

Malavika Murugan · Emory University, Atlanta GA

PROJECT SUMMARY Most mammals, including humans, navigate a life motivated and shaped by a drive to seek rewards such as food, water, and social interactions. Social stimuli can act as positive reinforcers, driving animals to pursue and interact with other members of their own species (e.g., people regularly hanging out with friends or a mouse repeatedly visiting to investigate a novel conspecific). Significantly, deficits in motivation to seek socially rewarding stimuli and deficits in social reward processing are associated with several disorders, such as Autism Spectrum Disorders. While the

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 204 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $377,953 in active NIH money across 1 project, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$377,953
Active projects
1
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $377,953 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-01-31 (about 1.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH130755-04 Prefrontal circuits in processing social versus non-social rewards

    R01 · NIMH · $377,953 · Apr 3, 2023 to Jan 31, 2028

All active NIH projects for Malavika Murugan ($377,953)
  • 5R01MH130755-04 Prefrontal circuits in processing social versus non-social rewards — $377,953, ends Jan 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 3, 2023 · project period to Jan 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#289 Lab fit 19% · Low fit Hiring: Unlikely Michigan Neuroscience

George Alexander Mashour lab

George Alexander Mashour · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Perioperative neurocognitive disorder (PND) is a common, debilitating, and distressing complication in surgical patients over the age of 65. Sleep disorders or insufficient sleep are highly prevalent among surgical patients and sleep disturbances are an important factor associated with the development of PND. However, there are scarce mechanistic studies or data on the precise relationship between disrupted sleep and cognitive impairment after surgery and anesthesia. The preoptic region of the hypothalamus is a critical node for the control of sleep onset and sleep homeostasis.

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 239 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $500,665 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$500,665
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $500,665 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG078134-04 Role of preoptic hypothalamus in sleep-dependent cognition after surgery and general anesthesia

    R01 · NIA · $500,665 · Aug 20, 2022 to May 31, 2027

All active NIH projects for George Alexander Mashour ($500,665)
  • 5R01AG078134-04 Role of preoptic hypothalamus in sleep-dependent cognition after surgery and general anesthesia — $500,665, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#290 Lab fit 19% · Low fit Hiring: Unlikely Michigan Neuroscience

Giancarlo Vanini lab

Giancarlo Vanini · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Perioperative neurocognitive disorder (PND) is a common, debilitating, and distressing complication in surgical patients over the age of 65. Sleep disorders or insufficient sleep are highly prevalent among surgical patients and sleep disturbances are an important factor associated with the development of PND. However, there are scarce mechanistic studies or data on the precise relationship between disrupted sleep and cognitive impairment after surgery and anesthesia. The preoptic region of the hypothalamus is a critical node for the control of sleep onset and sleep homeostasis.

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 239 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $500,665 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$500,665
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $500,665 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01AG078134-04 Role of preoptic hypothalamus in sleep-dependent cognition after surgery and general anesthesia

    R01 · NIA · $500,665 · Aug 20, 2022 to May 31, 2027

All active NIH projects for Giancarlo Vanini ($500,665)
  • 5R01AG078134-04 Role of preoptic hypothalamus in sleep-dependent cognition after surgery and general anesthesia — $500,665, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 20, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#291 Lab fit 19% · Not enough lab text to score reliably Hiring: Possible Atlanta Neuroscience

Audrey Sederberg lab

Audrey Sederberg · Georgia Institute of Technology, Atlanta GA

Project Summary A key goal in neuroscience is determining how microcircuit structure predicts circuit function. An intriguing idea, supported by some theoretical models, is that variation in microcircuit composition supports functional specialization. This theory has received support from the observation of a correlation between gradients in circuit properties (receptor expression densities; inhibitory cell types) and in measurements of average intrinsic timescales of recorded activity across cortical areas. However, other theories show how observed hierarchies of timescales can emerge in the

Lab fit breakdown — 19% weighted · Not enough lab text to score reliably

Not enough lab text to score reliably. 100 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is under the 120-word bar and it did not fire 4 terms across all 3 evidence dimensions, so most of her profile was never tested. The percentage is a floor set by how little was written, not a judgement about the fit.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,202,160 in active NIH money across 2 projects, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,202,160
Active projects
2
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,202,160 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 7RF1MH130413-02 Investigating the microcircuit determinants of neural population activity through comparative analysis of latent dynamics across cortical areas in the mouse

    RF1 · NIMH · $812,529 · Aug 1, 2022 to May 31, 2027

All active NIH projects for Audrey Sederberg ($1,202,160)
  • 7RF1MH130413-02 Investigating the microcircuit determinants of neural population activity through comparative analysis of latent dynamics across cortical areas in the mouse — $812,529, ends May 31, 2027
  • 5R01NS123842-05 Flexible normalization in ferret V1: computational modeling and 2-photon imaging — $389,631, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2022 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#292 Lab fit 19% · Low fit Hiring: Possible Atlanta Neuroscience

Michael Tilghman Treadway lab

Michael Tilghman Treadway · Emory University, Atlanta GA

Project Summary/Abstract Major Depressive Disorder (MDD) is a devastating clinical disorder and the leading cause of disability worldwide. Adolescence is a key developmental period during which risk for the development of depression is greatest. Behavioral Activation (BA) psychotherapy has emerged as a first-line treatment for adolescent depression, yet the underlying neurobiological mechanisms that mediate treatment efficacy remain unclear. Understanding these target mechanisms is fundamental to developing novel adaptations of BA, augmenting other treatments with BA, and designing new interve

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 428 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,674,768 in active NIH money across 3 projects, 0.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,674,768
Active projects
3
Runway left
0.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,674,768 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-02-28.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH126985-05 Multi-level Mechanisms of Behavioral Activation Therapy for Adolescent Depression

    R01 · NIMH · $744,561 · May 3, 2022 to Feb 28, 2027

  • 3R01MH126083-03S1 Glutamatergic adaptation to stress as a mechanism for anhedonia and treatment response with ketamine

    R01 · NIMH · $58,580 · Mar 1, 2022 to Dec 31, 2026

All active NIH projects for Michael Tilghman Treadway ($1,674,768)
  • 5R01MH126985-05 Multi-level Mechanisms of Behavioral Activation Therapy for Adolescent Depression — $744,561, ends Feb 28, 2027
  • 5R01MH126083-05 Glutamatergic adaptation to stress as a mechanism for anhedonia and treatment response with ketamine — $730,815, ends Dec 31, 2026
  • 5R25MH101079-10 Emory Psychiatry Clinical Scientist Training Program (CSTP) — $199,392, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 3, 2022 · project period to Feb 28, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#293 Lab fit 19% · Low fit Hiring: Possible Michigan Neuroscience

Shane R Crandall lab

Shane R Crandall · Michigan State University, East Lansing MI

PROJECT SUMMARY Nearly all sensory signals enter the neocortex by way of the thalamus, and the sensory cortex, in turn, distributes this information to several downstream cortical and subcortical areas. A prominent but often neglected feature of the sensory cortex is numerous feedback projections from other cortical areas. This key organizational feature of the brain implies that the ongoing activities in other cortical regions may influence local information processing and the outputs of the sensory cortex. Indeed, corticocortical communication is thought to mediate cognitive processes such a

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 204 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "in vivo".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $815,959 in active NIH money across 2 projects, 1.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$815,959
Active projects
2
Runway left
1.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $815,959 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-08-31 (about 1.9 years) — 1R21NS147529-01A1, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “in vivo”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS117636-05 Dynamic properties of neural circuits in the forebrain

    R01 · NINDS · $384,209 · Apr 1, 2022 to Mar 31, 2027

All active NIH projects for Shane R Crandall ($815,959)
  • 1R21NS147529-01A1 VIP Interneuron Dysfunction in Tuberous Sclerosis Complex — $431,750, ends Aug 31, 2028
  • 5R01NS117636-05 Dynamic properties of neural circuits in the forebrain — $384,209, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2022 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#294 Lab fit 19% · Low fit Hiring: Unlikely Michigan Neuroscience

Alexandra H. Veenema lab

Alexandra H. Veenema · Michigan State University, East Lansing MI

PROJECT SUMMARY Social play is a highly rewarding behavior and important for social skill development as has been demonstrated for human children and juvenile rats. Children with autism spectrum disorder (ASD) exhibit social play deficits, which contributes to their lifelong social dysfunction. ASD is more prevalent in males than in females, suggest- ing sex differences in the etiology of ASD. Developing effective means to restore social play in children with ASD will improve their lifelong social functioning, but this requires better understanding of the neural basis of social play and potent

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 225 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "rats".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $382,451 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$382,451
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $382,451 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2026-12-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “rats”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH125806-05 Oxytocin neural circuitry involvement in juvenile social play

    R01 · NIMH · $382,451 · Mar 15, 2022 to Dec 31, 2026

All active NIH projects for Alexandra H. Veenema ($382,451)
  • 5R01MH125806-05 Oxytocin neural circuitry involvement in juvenile social play — $382,451, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 15, 2022 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#295 Lab fit 19% · Low fit Hiring: Strong Atlanta Neuroscience

Eric Gerald Krause lab

Eric Gerald Krause · Georgia State University, Atlanta GA

Project Summary Stressful life events are linked to the etiology of cardiovascular disease (CVD), which is the leading cause of death in the U.S. The mechanisms by which stress causes pathophysiology contributing to CVD are poorly understood and effective therapeutics that relieve stress and improve cardiovascular health are lacking. A premise of this proposal is that exploration of the neural circuits controlling the perception of stress may provide insight towards mechanisms underlying CVD and interventions aimed at its reversal. Causally-linking patterns of neural activity to stress and the

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 212 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,387,859 in active NIH money across 3 projects, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,387,859
Active projects
3
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,387,859 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years) — 1R01DK148119-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R35HL150750-07 Interrogating stress-relieving neural circuits to alleviate cardiovascular disease

    R35 · NHLBI · $917,281 · Feb 5, 2020 to Dec 31, 2026

All active NIH projects for Eric Gerald Krause ($2,387,859)
  • 5R35HL150750-07 Interrogating stress-relieving neural circuits to alleviate cardiovascular disease — $917,281, ends Dec 31, 2026
  • 1R01DK148119-01 Targeting stress axes to enhance the efficacy of weight loss therapeutics — $802,008, ends Feb 28, 2031
  • 5R01AT013166-02 Blunted mechanosensation of the heart and gut as a mediator of pathogenesis conferred by chronic social subjugation — $668,570, ends Nov 30, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Feb 5, 2020 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#296 Lab fit 19% · Low fit Hiring: Strong Atlanta Neuroscience

Annette Diane De Kloet lab

Annette Diane De Kloet · Georgia State University, Atlanta GA

Project Summary Despite therapeutic advances, ~20% of patients with hypertension have uncontrolled high blood pressure, a condition that is associated with dysfunction in brain cardiovascular control centers. Therefore, there is a critical need to understand the neural pathways involved in cardiovascular regulation and how their dysfunction contributes to high blood pressure. This is particularly important for hypertension that is induced by chronic social stress, a major problem in today’s world, which involves activation of neuroendocrine and autonomic mechanisms. Our previous studies using

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 227 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mouse".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,090,904 in active NIH money across 3 projects, 4.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,090,904
Active projects
3
Runway left
4.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,090,904 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-02-28 (about 4.4 years) — 1R01DK148119-01, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mouse”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01HL136595-08 Angiotensin-sensitive neurons in the nucleus of the solitary tract mediate social stress induced hypertension

    R01 · NHLBI · $620,326 · Dec 1, 2017 to Dec 31, 2026

All active NIH projects for Annette Diane De Kloet ($2,090,904)
  • 1R01DK148119-01 Targeting stress axes to enhance the efficacy of weight loss therapeutics — $802,008, ends Feb 28, 2031
  • 5R01AT013166-02 Blunted mechanosensation of the heart and gut as a mediator of pathogenesis conferred by chronic social subjugation — $668,570, ends Nov 30, 2029
  • 5R01HL136595-08 Angiotensin-sensitive neurons in the nucleus of the solitary tract mediate social stress induced hypertension — $620,326, ends Dec 31, 2026

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 1, 2017 · project period to Dec 31, 2026 · roster/posting last verified date unknown · first seen Sep 22, 2026

#297 Lab fit 19% · Low fit Hiring: Moderate Michigan Neuroscience

Gina Marie Leinninger lab

Gina Marie Leinninger · Michigan State University, East Lansing MI

PROJECT SUMMARY Obesity and chronic pain frequently occur together, which is exacerbated by current pain medications that induce further weight gain. Our limited understanding of the common neurobiological factor(s) underlying obesity and pain is a major knowledge gap preventing design of effective treatment strategies. The neuropeptide Neurotensin (Nts) acts centrally to promote analgesia and weight loss, hence, augmenting Nts signaling could combat comorbid obesity and chronic pain. Yet, the endogenous source of Nts and the signaling mechanisms mediating these effects remained elusive. Over

Lab fit breakdown — 19% weighted · Low fit

Scored on enough lab text to read as a verdict. 206 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 36% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 27% × 0.7 domain gate = 19%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Mouse / rodent in vivo models Lab text mentions "mice".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of crispr / conditional knockout genetics Nothing in the grant text or lab description touches crispr / conditional knockout genetics, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $916,076 in active NIH money across 2 projects, 4.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$916,076
Active projects
2
Runway left
4.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $916,076 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-06-30 (about 4.8 years) — 2T32GM142521-06, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 36%

    Matched 1 of 5 profile areas (10 of 28 weight to saturation).

    • Mouse / rodent in vivo models — lab text says “mice”Her side: Animal models section of the CV: mouse genetics and breeding, transgenic mouse models, IOP measurement, intraocular injections, ocular dissection.

    Not found: AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK103808-12 Role of Lateral Hypothalamic Neurotensin Neurons in Energy Balance

    R01 · NIDDK · $484,739 · Sep 15, 2014 to Jan 31, 2028

All active NIH projects for Gina Marie Leinninger ($916,076)
  • 5R01DK103808-12 Role of Lateral Hypothalamic Neurotensin Neurons in Energy Balance — $484,739, ends Jan 31, 2028
  • 2T32GM142521-06 Integrative Pharmacological Sciences Training Program (IPSTP) — $431,337, ends Jun 30, 2031

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2014 · project period to Jan 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#298 Lab fit 18% · Low fit Hiring: Possible Atlanta Neuroscience

David Ryan Goldsmith lab

David Ryan Goldsmith · Emory University, Atlanta GA

Project Summary The CNS mechanisms underlying motivational deficits in patients with schizophrenia are poorly understood. These deficits significantly contribute to negative symptoms, which are strongly related to poor functional outcomes and nonresponse to antipsychotic therapies. Data from our group and others have shown that increased peripheral inflammatory markers, such as tumor necrosis factor (TNF), are associated with motivational deficits and negative symptoms in patients with schizophrenia. Regarding the mechanisms involved, our data indicate that in patients with schizophrenia, TNF

Lab fit breakdown — 18% weighted · Low fit

Scored on enough lab text to read as a verdict. 255 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 26% × 0.7 domain gate = 18%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Molecular biology, biochemistry and proteomics Lab text mentions "gene expression".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $784,589 in active NIH money across 2 projects, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$784,589
Active projects
2
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $784,589 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2027-12-31 (about 1.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “gene expression”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH131910-04 Targeting Inflammation-Induced Changes in Brain Reward Signaling and Motivational Deficits in Patients with Schizophrenia Using an Anti-Inflammatory Challenge

    R01 · NIMH · $585,197 · Mar 1, 2023 to Dec 31, 2027

All active NIH projects for David Ryan Goldsmith ($784,589)
  • 5R01MH131910-04 Targeting Inflammation-Induced Changes in Brain Reward Signaling and Motivational Deficits in Patients with Schizophrenia Using an Anti-Inflammatory Challenge — $585,197, ends Dec 31, 2027
  • 5R25MH101079-10 Emory Psychiatry Clinical Scientist Training Program (CSTP) — $199,392, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2023 · project period to Dec 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#299 Lab fit 18% · Low fit Hiring: Unlikely Atlanta Neuroscience

Hyder A Jinnah lab

Hyder A Jinnah · Emory University, Atlanta GA

PROJECT SUMMARY The dystonias are a group of disorders characterized by excessive involuntary muscle contractions leading to spasms and abnormal movements. Any region of the body may be affected. One of the most commonly affected regions is the upper face, leading to blepharospasm (BL). Patients experience a number of distinct but overlapping problems that include spasms of the muscles around the eyes, excessive blinking, eyelid fluttering, impaired eyelid opening, and spread to the lower face or jaw. Traditionally, BL has been viewed as a relatively homogeneous disorder, differing only in gra

Lab fit breakdown — 18% weighted · Low fit

Scored on enough lab text to read as a verdict. 191 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 26% × 0.7 domain gate = 18%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $364,194 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$364,194
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $364,194 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-06-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS119831-04 Deep phenotyping in blepharospasm

    R01 · NINDS · $364,194 · Sep 29, 2021 to Jun 30, 2027

All active NIH projects for Hyder A Jinnah ($364,194)
  • 5R01NS119831-04 Deep phenotyping in blepharospasm — $364,194, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 29, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#300 Lab fit 18% · Low fit Hiring: Possible Atlanta Neuroscience

Woon-hong Yeo lab

Woon-hong Yeo · Georgia Institute of Technology, Atlanta GA

PROJECT SUMMARY The dystonias are a group of disorders characterized by excessive involuntary muscle contractions leading to spasms and abnormal movements. Any region of the body may be affected. One of the most commonly affected regions is the upper face, leading to blepharospasm (BL). Patients experience a number of distinct but overlapping problems that include spasms of the muscles around the eyes, excessive blinking, eyelid fluttering, impaired eyelid opening, and spread to the lower face or jaw. Traditionally, BL has been viewed as a relatively homogeneous disorder, differing only in gra

Lab fit breakdown — 18% weighted · Low fit

Scored on enough lab text to read as a verdict. 191 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 23% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 26% × 0.7 domain gate = 18%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Molecular biology, biochemistry and proteomics Lab text mentions "proteom".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,379,320 in active NIH money across 3 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,379,320
Active projects
3
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 43 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,379,320 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 23%

    Matched 1 of 7 profile areas (7 of 30 weight to saturation).

    • Molecular biology, biochemistry and proteomics — lab text says “proteom”Her side: Western blotting, protein analysis, RT-PCR, gene expression analysis and mass spectrometry sample preparation in the CV's molecular biology section.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS119831-04 Deep phenotyping in blepharospasm

    R01 · NINDS · $364,194 · Sep 29, 2021 to Jun 30, 2027

All active NIH projects for Woon-hong Yeo ($1,379,320)
  • 5R01ES033241-04 Sensor Hardware and Intelligent Tools for Assessing the Health Effects of Heat Exposure — $596,842, ends Jun 30, 2027
  • 1R21EB037156-01 Real-Time Monitoring and Automated Electrolyte Repletion Using Ion-Selective, Sensor-Integrated Central Venous Catheters — $418,284, ends Aug 31, 2027
  • 5R01NS119831-04 Deep phenotyping in blepharospasm — $364,194, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 29, 2021 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#301 Lab fit 17% · Low fit Hiring: Moderate Michigan Neuroscience

Alexander Weigard lab

Alexander Weigard · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT Neurocognitive abilities relevant to adaptive decision making and self-regulation (e.g., inhibition, working memory) mature from childhood through adolescence and play a critical role in the emergence of psychopathology. However, one-to-one mappings between these abilities and risk for specific psychiatric diagnoses have been elusive. The field’s struggle to identify such mappings is nonetheless consistent with high rates of comorbidity among disorders and the presence of a general factor for psychopathology (“p-factor”) suggesting many etiological mechanisms have a br

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "computational model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $958,155 in active NIH money across 2 projects, 4.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$958,155
Active projects
2
Runway left
4.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 60 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $958,155 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +20 Four or more years of project period left — Longest project period runs to 2031-03-31 (about 4.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-06-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 1R01MH135879-01A1 Evaluating efficiency of evidence accumulation as a neurodevelopmental mechanism of transdiagnostic risk for psychopathology: a computational model-based approach

    R01 · NIMH · $761,595 · Jun 1, 2026 to Mar 31, 2031

All active NIH projects for Alexander Weigard ($958,155)
  • 1R01MH135879-01A1 Evaluating efficiency of evidence accumulation as a neurodevelopmental mechanism of transdiagnostic risk for psychopathology: a computational model-based approach — $761,595, ends Mar 31, 2031
  • 5K23DA051561-05 Leveraging computational models of neurocognition to improve predictions about individual youths' risk for substance use disorders — $196,560, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2026 · project period to Mar 31, 2031 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#302 Lab fit 17% · Low fit Hiring: Strong Atlanta Neuroscience

Eva Dyer lab

Eva Dyer · Georgia Institute of Technology, Atlanta GA

ABSTRACT Studying multi-animal interactions is crucial for understanding cognitive mechanisms underlying social behaviors and decision-making processes. Observing collective behaviors can reveal the neural basis of social bonding, aggression, and cooperation. However, current methods for automating multi-animal behavior analysis are often too simplistic and may neglect interactions, context, and the complexity of multi-animal behavior. Here we argue that understanding complex animal behaviors requires breaking them down into fundamental units, and then forming an understanding of how these uni

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 196 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $2,918,700 in active NIH money across 2 projects, 3.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,918,700
Active projects
2
Runway left
3.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,918,700 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-04-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1RF1MH140429-01A1 Multiscale Models for Understanding Multi-Animal Interactions and Intent

    RF1 · NIMH · $2,596,724 · Apr 1, 2026 to Mar 31, 2030

All active NIH projects for Eva Dyer ($2,918,700)
  • 1RF1MH140429-01A1 Multiscale Models for Understanding Multi-Animal Interactions and Intent — $2,596,724, ends Mar 31, 2030
  • 5R34DA059510-02 A modeling framework and arena for measuring contextual influences of behavior — $321,976, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2026 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026

#303 Lab fit 17% · Low fit Hiring: Strong Atlanta Neuroscience

Anqi Wu lab

Anqi Wu · Georgia Institute of Technology, Atlanta GA

ABSTRACT Studying multi-animal interactions is crucial for understanding cognitive mechanisms underlying social behaviors and decision-making processes. Observing collective behaviors can reveal the neural basis of social bonding, aggression, and cooperation. However, current methods for automating multi-animal behavior analysis are often too simplistic and may neglect interactions, context, and the complexity of multi-animal behavior. Here we argue that understanding complex animal behaviors requires breaking them down into fundamental units, and then forming an understanding of how these uni

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 196 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 90% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Strong Strong: $3,507,661 in active NIH money across 2 projects, 3.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,507,661
Active projects
2
Runway left
3.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 70 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,507,661 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-03-31 (about 3.5 years).
  • +10 Award started within the last 12 months — 1 award in this snapshot started on or after 2026-04-01.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 90%

    3 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”
    • Award started within the last 12 months — lab text says “award record”

    Not found: Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 1RF1MH140429-01A1 Multiscale Models for Understanding Multi-Animal Interactions and Intent

    RF1 · NIMH · $2,596,724 · Apr 1, 2026 to Mar 31, 2030

All active NIH projects for Anqi Wu ($3,507,661)
  • 1RF1MH140429-01A1 Multiscale Models for Understanding Multi-Animal Interactions and Intent — $2,596,724, ends Mar 31, 2030
  • 5U01NS131810-03 Integrative circuit dissection in the behaving nonhuman primate — $910,937, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 1, 2026 · project period to Mar 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#304 Lab fit 17% · Low fit Hiring: Unlikely Atlanta Neuroscience

Shihao Ji lab

Shihao Ji · Georgia State University, Atlanta GA

Abstract/Summary: Attention deficit (AD) is a reported concern across mental health and neurological disorders. It exists as an extreme condition of a continuously distributed trait in the general population. AD as a key component of ADHD is often associated with impairments in multiple neurocognitive domains, particularly in attention/vigilance, working memory, processing speed, and response variability. To date, most investigations on AD focus on frontal-parietal circuity, and less is known about the frontal-thalamo-cerebellar circuitry (FCC) relates to AD. To extend our knowledge on neural

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 246 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $351,000 in active NIH money across 1 project, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$351,000
Active projects
1
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $351,000 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH130595-04 Frontal-thalamo-cerebellar circuitry of attention deficit via imaging-genetic-environmental analyses

    R01 · NIMH · $351,000 · Aug 16, 2023 to May 31, 2028

All active NIH projects for Shihao Ji ($351,000)
  • 5R01MH130595-04 Frontal-thalamo-cerebellar circuitry of attention deficit via imaging-genetic-environmental analyses — $351,000, ends May 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 16, 2023 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#305 Lab fit 17% · Low fit Hiring: Unlikely Michigan Neuroscience

Daniel Louis Hertz lab

Daniel Louis Hertz · University of Michigan, Ann Arbor MI

Abstract Several anticancer agents cause a side effect known as peripheral neuropathy that can permanently diminish patient’s functional ability and quality of life. Since there are no effective strategies to prevent or treat peripheral neuropathy, clinical practice guidelines recommend withholding or dose-reducing chemotherapy, which reduces patient survival. Clinical and lifestyle factors do not adequately predict risk of taxane-induced peripheral neuropathy (TIPN). Therefore, there is a critical need to validate clinically useful and mechanistically informative predictive TIPN biomarkers in

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 235 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $484,606 in active NIH money across 1 project, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$484,606
Active projects
1
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $484,606 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2027-12-31 (about 1.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R37CA277043-04 Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy

    R37 · NCI · $484,606 · Jan 1, 2023 to Dec 31, 2027

All active NIH projects for Daniel Louis Hertz ($484,606)
  • 5R37CA277043-04 Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy — $484,606, ends Dec 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 1, 2023 · project period to Dec 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#306 Lab fit 17% · Low fit Hiring: Unlikely Michigan Neuroscience

Meghna S Trivedi lab

Meghna S Trivedi · University of Michigan, Ann Arbor MI

Abstract Several anticancer agents cause a side effect known as peripheral neuropathy that can permanently diminish patient’s functional ability and quality of life. Since there are no effective strategies to prevent or treat peripheral neuropathy, clinical practice guidelines recommend withholding or dose-reducing chemotherapy, which reduces patient survival. Clinical and lifestyle factors do not adequately predict risk of taxane-induced peripheral neuropathy (TIPN). Therefore, there is a critical need to validate clinically useful and mechanistically informative predictive TIPN biomarkers in

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 235 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $484,606 in active NIH money across 1 project, 1.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$484,606
Active projects
1
Runway left
1.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 20 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $484,606 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2027-12-31 (about 1.3 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R37CA277043-04 Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy

    R37 · NCI · $484,606 · Jan 1, 2023 to Dec 31, 2027

All active NIH projects for Meghna S Trivedi ($484,606)
  • 5R37CA277043-04 Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy — $484,606, ends Dec 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jan 1, 2023 · project period to Dec 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#307 Lab fit 17% · Low fit Hiring: Possible Atlanta Ophthalmology

Brian Patrick Brooks lab

Brian Patrick Brooks · Emory University, Atlanta GA

ABSTRACT Congenital defects of the eye occur in approximately 5 per 10,000 live births. While there is a paucity of epidemiologic information about these conditions, there is a growing awareness of the long-term complications among children with these malformations. Among the more common visually threatening congenital eye defects are anophthalmia (total absence of the globe); microphthalmia (anomalously small eye in the orbit); and coloboma (failure of the closure of the fetal fissure). Collectively, these defects are referred to as MAC complex and are considered part of an embryologic contin

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 248 words of lab text were scored, matching 2 of her 18 profile terms (saturation needs 10) across 2 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "ophthalm".
  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $851,567 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$851,567
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $851,567 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “ophthalm”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 7U01EY032403-05 Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children (MAGIC) Study

    U01 · NEI · $851,567 · May 1, 2021 to Apr 30, 2027

All active NIH projects for Brian Patrick Brooks ($851,567)
  • 7U01EY032403-05 Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children (MAGIC) Study — $851,567, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started May 1, 2021 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#308 Lab fit 17% · Low fit Hiring: Possible Michigan Neuroscience

Brooke Ingersoll lab

Brooke Ingersoll · Michigan State University, East Lansing MI

PROJECT SUMMARY Despite strong consensus that early, specialized intervention for children with Autism Spectrum Disorder (ASD) can have a dramatic impact on outcomes, the U.S. health system’s capacity to provide such services is severely challenged by the rapid rise in ASD prevalence. The long-term goal is to improve outcomes for children with early signs of ASD by increasing the capacity to provide appropriately specialized treatment within an existing infrastructure: the Part C Early Intervention (EI) service delivery system. Part C is publicly funded, available in all areas, and serves chil

Lab fit breakdown — 17% weighted · Low fit

Scored on enough lab text to read as a verdict. 296 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 17% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 24% × 0.7 domain gate = 17%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Sequencing, variant and splicing analysis Lab text mentions "variant".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $604,061 in active NIH money across 1 project, 0.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$604,061
Active projects
1
Runway left
0.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $604,061 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-05-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 17%

    Matched 1 of 7 profile areas (5 of 30 weight to saturation).

    • Sequencing, variant and splicing analysis — lab text says “variant”Her side: Whole exome and Sanger sequencing plus RNA splicing analysis in the CV; first-author KIZ dual-mechanism variant paper and a book chapter on exonic splicing variants.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH122725-05 2/4: Improving the Part C Early Intervention Service Delivery System for Children with ASD: A Randomized Clinical Trial

    R01 · NIMH · $604,061 · Jun 1, 2020 to May 31, 2027

All active NIH projects for Brooke Ingersoll ($604,061)
  • 5R01MH122725-05 2/4: Improving the Part C Early Intervention Service Delivery System for Children with ASD: A Randomized Clinical Trial — $604,061, ends May 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2020 · project period to May 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#309 Lab fit 16% · Low fit Hiring: Possible Michigan Ophthalmology

Maria Anneke Woodward lab

Maria Anneke Woodward · University of Michigan, Ann Arbor MI

PROJECT SUMMARY/ABSTRACT Microbial keratitis (MK) is an emergent, painful infection of the cornea and a leading cause of worldwide blindness. A key modifiable driver of vision loss in MK is the lack of a reliable, rapid, and effective strategy to identify the causative organism at disease presentation. Point-of-care tests are not available, are experimental, and are cost-prohibitive. The lack of point-of-care organism identification leads clinicians to be unsure about treatments, affecting patient outcomes. There is a critical need for developing practical, widely available strategies to rapid

Lab fit breakdown — 16% weighted · Low fit

Scored on enough lab text to read as a verdict. 268 words of lab text were scored, matching 1 of her 18 profile terms (saturation needs 10) across 1 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 11% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 23% × 0.7 domain gate = 16%. No real disease overlap — weighted mean discounted 30%.

What matches

  • Other ocular tissue (cornea, lens, sclera, uvea) Lab text mentions "cornea".

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "deep learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $701,363 in active NIH money across 2 projects, 1.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$701,363
Active projects
2
Runway left
1.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 35 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $701,363 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-05-31 (about 1.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 11%

    Matched 1 of 6 profile areas (3 of 28 weight to saturation).

    • Other ocular tissue (cornea, lens, sclera, uvea) — lab text says “cornea”Her side: First-author corneal endothelium storage study (Indian J Ophthalmol 2019) from her eye-banking work.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01EY036418-03 Automated Quantitative Ulcer Analysis (AQUA): Diagnosing Organism Types

    R01 · NEI · $628,401 · Sep 30, 2024 to May 31, 2028

All active NIH projects for Maria Anneke Woodward ($701,363)
  • 5R01EY036418-03 Automated Quantitative Ulcer Analysis (AQUA): Diagnosing Organism Types — $628,401, ends May 31, 2028
  • 5P30EY007003-40 Data Integrity Core — $72,962, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2024 · project period to May 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#310 Lab fit 15% · Low fit Hiring: Possible Atlanta Neuroscience

Vanessa Brown lab

Vanessa Brown · Emory University, Atlanta GA

Anxiety and related disorders are common and impairing; in particular, avoidance is a highly detrimental component of anxiety that is poorly understood. To better understand and treat avoidance, a theory of avoidance that can account for experimental findings and translate across species is needed. This application proposes to use an interdisciplinary approach to combine neural and behavioral data to validate a novel computational model of avoidance, to test differences in avoidance behavior in people with clinically impairing anxiety and avoidance using this model, and to test whether model-p

Lab fit breakdown — 15% weighted · Low fit

Scored on enough lab text to read as a verdict. 220 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 22% × 0.7 domain gate = 15%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on biomechanics and computational modelling Lab is biomechanics/engineering-led. The CV lists no finite-element, tissue-mechanics or modelling work. (matched on "computational model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $781,027 in active NIH money across 1 project, 3.7 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$781,027
Active projects
1
Runway left
3.7 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $781,027 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-05-31 (about 3.7 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH139780-02 Quantifying neural signatures of multi-step avoidance behavior in anxiety

    R01 · NIMH · $781,027 · Aug 1, 2025 to May 31, 2030

All active NIH projects for Vanessa Brown ($781,027)
  • 5R01MH139780-02 Quantifying neural signatures of multi-step avoidance behavior in anxiety — $781,027, ends May 31, 2030

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2025 · project period to May 31, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#311 Lab fit 15% · Low fit Hiring: Moderate Atlanta Neuro + ophtho

Bilal Haider lab

Bilal Haider · Georgia Institute of Technology, Atlanta GA

Sensory processing is a way to understand the nervous system in action. Behavioral context strongly affects sensory processing. For example, a brief visual stimulus is easier to detect if it appears in a predictable spatial location. This attention to visual space strongly enhances neural and behavioral responses to stimuli in those locations, and is thought to rely on feedback activity from cognitive areas in frontal cortex across multiple areas of visual cortex. The detailed neural mechanisms that allow cognitive control of multiple visual brain areas remain unknown. Addressing this gap requ

Lab fit breakdown — 15% weighted · Low fit

Scored on enough lab text to read as a verdict. 425 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 80% · weight 15%
Geography 100% · weight 10%

Weighted mean 22% × 0.7 domain gate = 15%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $859,592 in active NIH money across 2 projects, 3.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$859,592
Active projects
2
Runway left
3.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 45 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $859,592 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-02-28 (about 3.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 80%

    2 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”
    • Three or more years left in the project period — lab text says “award record”

    Not found: Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01EY036078-02 Functional organization and spatial resolution of attentional feedback from frontal to visual cortex

    R01 · NEI · $465,689 · Mar 1, 2025 to Feb 28, 2030

  • 4R01NS132288-02 Tracking Flow of Attention in Visual Circuits Across the Brain

    R01 · NINDS · $393,903 · Sep 13, 2023 to Aug 31, 2028

All active NIH projects for Bilal Haider ($859,592)
  • 5R01EY036078-02 Functional organization and spatial resolution of attentional feedback from frontal to visual cortex — $465,689, ends Feb 28, 2030
  • 4R01NS132288-02 Tracking Flow of Attention in Visual Circuits Across the Brain — $393,903, ends Aug 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2025 · project period to Feb 28, 2030 · roster/posting last verified date unknown · first seen Sep 22, 2026 (baseline snapshot)

#312 Lab fit 14% · Low fit Hiring: Possible Atlanta Neuroscience

Jiayu Chen lab

Jiayu Chen · Georgia State University, Atlanta GA

Project Summary This proposal aims to address the lack of sex-specific research in psychosis, which hinders the development of sex-informed risk detection and tailored interventions that hold strong promise to improve the outcome of psychotic disorders (PDs) and reduce their substantial clinical and economical burden. However, the current diagnostic systems primarily rely on specific symptoms that may not yet be present in the prodromal stage, and do not consider sex differences. This has motivated a shift towards neurobiological and genetic markers that are known to show recognizable psychosi

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 291 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $472,543 in active NIH money across 1 project, 2.1 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$472,543
Active projects
1
Runway left
2.1 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $472,543 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-10-31 (about 2.1 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH136665-02 Sex-Specific Psychosis Biotypes: Informed Data-driven Neurobiological and Genomic Markers for Early Risk Detection

    R01 · NIMH · $472,543 · Dec 13, 2024 to Oct 31, 2028

All active NIH projects for Jiayu Chen ($472,543)
  • 5R01MH136665-02 Sex-Specific Psychosis Biotypes: Informed Data-driven Neurobiological and Genomic Markers for Early Risk Detection — $472,543, ends Oct 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 13, 2024 · project period to Oct 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#313 Lab fit 14% · Low fit Hiring: Possible Atlanta Neuroscience

Armin Iraji lab

Armin Iraji · Georgia State University, Atlanta GA

Project Summary This proposal aims to address the lack of sex-specific research in psychosis, which hinders the development of sex-informed risk detection and tailored interventions that hold strong promise to improve the outcome of psychotic disorders (PDs) and reduce their substantial clinical and economical burden. However, the current diagnostic systems primarily rely on specific symptoms that may not yet be present in the prodromal stage, and do not consider sex differences. This has motivated a shift towards neurobiological and genetic markers that are known to show recognizable psychosi

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 291 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $472,543 in active NIH money across 1 project, 2.1 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$472,543
Active projects
1
Runway left
2.1 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 25 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $472,543 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-10-31 (about 2.1 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH136665-02 Sex-Specific Psychosis Biotypes: Informed Data-driven Neurobiological and Genomic Markers for Early Risk Detection

    R01 · NIMH · $472,543 · Dec 13, 2024 to Oct 31, 2028

All active NIH projects for Armin Iraji ($472,543)
  • 5R01MH136665-02 Sex-Specific Psychosis Biotypes: Informed Data-driven Neurobiological and Genomic Markers for Early Risk Detection — $472,543, ends Oct 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Dec 13, 2024 · project period to Oct 31, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#314 Lab fit 14% · Low fit Hiring: Possible Michigan Neuroscience

Elizabeth Duval lab

Elizabeth Duval · University of Michigan, Ann Arbor MI

Abstract Opioid medications have been widely prescribed in efforts to control medical and surgical pain, but opioid use disorder (OUD) has become a serious, prevalent, and costly public health problem. Identifying risk factors for the development of OUD after prescribed opioid use could help reduce serious injury and mortality-related outcomes, like overdose. Hippocampal (Hpc)-circuit based context processing is an important neuro-cognitive process associated with OUD. Evidence for context processing deficits is seen in psychiatric, substance use, and chronic pain populations. One major predic

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 263 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $620,551 in active NIH money across 1 project, 1.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$620,551
Active projects
1
Runway left
1.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 30 of 100 points
  • +20 $600K–$1M of active NIH award money — NIH RePORTER reports $620,551 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +5 One to two years of project period left — Longest project period runs to 2028-06-30 (about 1.8 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DA056415-04 A mechanistic investigation of risk factors for opioid use disorder: Examining hippocampal-based context-dependent learning and memory associated with adverse childhood experiences

    R01 · NIDA · $620,551 · Sep 15, 2023 to Jun 30, 2028

All active NIH projects for Elizabeth Duval ($620,551)
  • 5R01DA056415-04 A mechanistic investigation of risk factors for opioid use disorder: Examining hippocampal-based context-dependent learning and memory associated with adverse childhood experiences — $620,551, ends Jun 30, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 15, 2023 · project period to Jun 30, 2028 · roster/posting last verified date unknown · first seen Sep 22, 2026

#315 Lab fit 14% · Low fit Hiring: Moderate Michigan Neuroscience

Randy J Seeley lab

Randy J Seeley · University of Michigan, Ann Arbor MI

Abstract Obesity contributes to the development of type 2 diabetes and other chronic diseases, while weight loss ameliorates the risk for these maladies. Current medical therapies remain inadequate to combatting the ongoing US obesity epidemic, however- in part because some of the most promising obesity drugs promote aversive responses (e.g., nausea) that limit their therapeutic utility. To design improved obesity therapies, we must understand the mechanisms of action for and relationships among circuits that control food intake and that mediate nausea. The area postrema (AP) senses nutrients

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 229 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on cellular electrophysiology Lab's primary readout is cellular or unit electrophysiology. Her functional testing is whole-eye PERG/ERG; the CV shows no patch-clamp or electrode recording. (matched on "electrophysiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,747,667 in active NIH money across 6 projects, 3.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,747,667
Active projects
6
Runway left
3.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,747,667 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 6 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-06-30 (about 3.8 years) — 5P30DK089503-17, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01DK132008-04 Defining roles for area postrema neuron cell types in food intake and nausea

    R01 · NIDDK · $674,229 · Mar 10, 2023 to Jan 31, 2027

All active NIH projects for Randy J Seeley ($3,747,667)
  • 5P30DK089503-17 Michigan Nutrition Obesity Research Center — $1,169,992, ends Jun 30, 2030
  • 5R01DK132008-04 Defining roles for area postrema neuron cell types in food intake and nausea — $674,229, ends Jan 31, 2027
  • 5R01DK129360-04 The mTOR-ETV5 signaling in gastric X/A like cells and its role in hepatic lipid metabolism and steatosis — $576,286, ends Sep 30, 2026
  • 5R01DK139942-02 Nuclear ATP citrate lyase and ischemia/reperfusion injury in steatotic liver — $559,993, ends Jul 31, 2029
  • 5R01DK133140-04 Intestinal Reg3g as a mediator of dietary, pharmacological and surgical therapies for obesity and diabetes — $537,184, ends Apr 30, 2027
  • 5T32DK108740-09 Obesity & Gastrointestinal Surgery Research Training Program — $229,983, ends Mar 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 10, 2023 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#316 Lab fit 14% · Low fit Hiring: Possible Michigan Neuroscience

Rebecca Kaufman Sripada lab

Rebecca Kaufman Sripada · University of Michigan, Ann Arbor MI

Project Summary/Abstract Healthcare workers on the frontlines of the COVID-19 pandemic are experiencing unprecedented levels of stress and trauma exposure, resulting in exceptionally high rates (27-57%) of posttraumatic stress disorder (PTSD). Although Employee Assistance Programs (EAPs) have expanded their offerings to support healthcare workers during the pandemic, they lack the capacity to provide time-intensive first-line treatments for PTSD. To address this problem, the study team has adapted a standard first-line 12-session treatment into a brief, 4-6 session format (Prolonged Exposure f

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 312 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,446,498 in active NIH money across 2 projects, 0.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,446,498
Active projects
2
Runway left
0.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,446,498 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-08-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH126693-04 Reducing COVID-related PTSD symptoms in Frontline Healthcare Workers through Trauma-Focused Treatment in Employee Assistance Programs

    R01 · NIMH · $722,502 · Sep 1, 2022 to Jun 30, 2027

All active NIH projects for Rebecca Kaufman Sripada ($1,446,498)
  • 5R01MH125857-05 Testing Adaptive Interventions to Improve PTSD Treatment Outcomes in Federally Qualified Health Centers — $723,996, ends Aug 31, 2027
  • 5R01MH126693-04 Reducing COVID-related PTSD symptoms in Frontline Healthcare Workers through Trauma-Focused Treatment in Employee Assistance Programs — $722,502, ends Jun 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2022 · project period to Jun 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#317 Lab fit 14% · Low fit Hiring: Moderate Michigan Neuroscience

Chandra Sekhar Sripada lab

Chandra Sekhar Sripada · University of Michigan, Ann Arbor MI

Abstract Bipolar disorder is a serious chronic condition, and there is great interest in understanding brain-based mechanisms that contribute to disorder symptoms. In this proposal, we focus on one promising candidate: efficiency of evidence accumulation (EEA). EEA is measured in specialized models from computational psychiatry, and it quantifies a basic neurocognitive ability to accumulate information from a stimulus in noisy conditions in order to select appropriate responses. Substantial reductions in EEA are found in bipolar disorder, as well as other major psychiatric disorders, and they

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 564 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "predictive model")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,097,381 in active NIH money across 3 projects, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,097,381
Active projects
3
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,097,381 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01MH130348-05 Establishing Network Neuroscience Mechanisms of Efficiency of Evidence Accumulation in a Well-Characterized Sample with Bipolar Disorder: A Multi-Modal Clinical Imaging Study

    R01 · NIMH · $725,194 · Jun 1, 2022 to Mar 31, 2027

  • 5U01DA041106-12 9/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT U MICHIGAN

    U01 · NIDA · $2,040,687 · Sep 30, 2015 to Mar 31, 2027

All active NIH projects for Chandra Sekhar Sripada ($3,097,381)
  • 5U01DA041106-12 9/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT U MICHIGAN — $2,040,687, ends Mar 31, 2027
  • 5R01MH130348-05 Establishing Network Neuroscience Mechanisms of Efficiency of Evidence Accumulation in a Well-Characterized Sample with Bipolar Disorder: A Multi-Modal Clinical Imaging Study — $725,194, ends Mar 31, 2027
  • 5R01MH123458-05 Building a multi-factor etiological model of the emergence of general psychopathology (the "P factor") in adolescence with multi-modal neuroimaging in ABCD — $331,500, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jun 1, 2022 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#318 Lab fit 14% · Low fit Hiring: Unlikely Michigan Neuroscience

Adriene M. Beltz lab

Adriene M. Beltz · University of Michigan, Ann Arbor MI

Abstract Chronic pain during childhood and adolescence is a significant personal and societal burden, affecting 20–25% of youth. Unfortunately, treatment is difficult and long-term outcomes are poor, in part due to the limited understanding of how chronic pain manifests across the first two decades of life. Chronic widespread pain is common in adults, and often occurs in absence or not in proportion to tissue damage or inflammation. In adults, widespread pain is associated with altered processing in the central nervous system (CNS), is more common in females, and is accompanied by a cluster of

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $480,157 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$480,157
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $480,157 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-01-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NR020013-05 Behavioral and neurobiological predictors of widespread pain in early adolescence and sex-specific trajectories of pain during puberty

    R01 · NINR · $480,157 · Apr 12, 2022 to Jan 31, 2027

All active NIH projects for Adriene M. Beltz ($480,157)
  • 5R01NR020013-05 Behavioral and neurobiological predictors of widespread pain in early adolescence and sex-specific trajectories of pain during puberty — $480,157, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 12, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#319 Lab fit 14% · Low fit Hiring: Unlikely Michigan Neuroscience

Chelsea Kaplan lab

Chelsea Kaplan · University of Michigan, Ann Arbor MI

Abstract Chronic pain during childhood and adolescence is a significant personal and societal burden, affecting 20–25% of youth. Unfortunately, treatment is difficult and long-term outcomes are poor, in part due to the limited understanding of how chronic pain manifests across the first two decades of life. Chronic widespread pain is common in adults, and often occurs in absence or not in proportion to tissue damage or inflammation. In adults, widespread pain is associated with altered processing in the central nervous system (CNS), is more common in females, and is accompanied by a cluster of

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 270 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "cohort study")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $480,157 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$480,157
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $480,157 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-01-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NR020013-05 Behavioral and neurobiological predictors of widespread pain in early adolescence and sex-specific trajectories of pain during puberty

    R01 · NINR · $480,157 · Apr 12, 2022 to Jan 31, 2027

All active NIH projects for Chelsea Kaplan ($480,157)
  • 5R01NR020013-05 Behavioral and neurobiological predictors of widespread pain in early adolescence and sex-specific trajectories of pain during puberty — $480,157, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Apr 12, 2022 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#320 Lab fit 14% · Low fit Hiring: Unlikely Michigan Neuroscience

Nora E. Fritz lab

Nora E. Fritz · Wayne State University, Ann Arbor MI

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects approximately 1 million people in the US and is the #1 cause of non-traumatic disability in young adults. Cognitive dysfunction, including deficits in processing speed, visual memory, verbal fluency, working memory, and executive functioning, is one of the most common problems in MS. Cognitive dysfunction in MS exerts a dire impact on many aspects of health-related quality of life. Unfortunately, progress in developing preventative, compensatory and restorative interventions for cognitive dysfunction in MS

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $582,753 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$582,753
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $582,753 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01HD102337-05 Optimizing detection and prediction of changes in cognitive function in multiple sclerosis with novel ambulatory assessment methods

    R01 · NICHD · $582,753 · Aug 1, 2021 to Jul 31, 2027

All active NIH projects for Nora E. Fritz ($582,753)
  • 5R01HD102337-05 Optimizing detection and prediction of changes in cognitive function in multiple sclerosis with novel ambulatory assessment methods — $582,753, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2021 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#321 Lab fit 14% · Low fit Hiring: Moderate Michigan Neuroscience

Anna Louise Kratz lab

Anna Louise Kratz · University of Michigan, Ann Arbor MI

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects approximately 1 million people in the US and is the #1 cause of non-traumatic disability in young adults. Cognitive dysfunction, including deficits in processing speed, visual memory, verbal fluency, working memory, and executive functioning, is one of the most common problems in MS. Cognitive dysfunction in MS exerts a dire impact on many aspects of health-related quality of life. Unfortunately, progress in developing preventative, compensatory and restorative interventions for cognitive dysfunction in MS

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 261 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $1,322,454 in active NIH money across 3 projects, 2.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,322,454
Active projects
3
Runway left
2.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 53 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,322,454 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-08-31 (about 2.9 years) — 5K24AT012644-03, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01HD102337-05 Optimizing detection and prediction of changes in cognitive function in multiple sclerosis with novel ambulatory assessment methods

    R01 · NICHD · $582,753 · Aug 1, 2021 to Jul 31, 2027

All active NIH projects for Anna Louise Kratz ($1,322,454)
  • 5R01AT011341-05 Mechanisms of cannabidiol in persons with MS: the role of sleep and pain phenotype — $612,796, ends Apr 30, 2027
  • 5R01HD102337-05 Optimizing detection and prediction of changes in cognitive function in multiple sclerosis with novel ambulatory assessment methods — $582,753, ends Jul 31, 2027
  • 5K24AT012644-03 Patient Oriented Research and Mentoring in Multidisciplinary Chronic Pain Treatments — $126,905, ends Aug 31, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Aug 1, 2021 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#322 Lab fit 14% · Low fit Hiring: Possible Michigan Neuroscience

Margaret Takako Hicken lab

Margaret Takako Hicken · University of Michigan, Ann Arbor MI

Inequalities in healthy aging are across racial groups are well-documented; the research literature on these inequalities in chronic conditions and cognitive impairment among older adults is growing. Neighborhood context has emerged as a potentially powerful determinant of these inequalities in aging-related health conditions, including cognitive decline, and may be a key intervention site. Neighborhoods include both social and environmental exposures important for healthy aging. Evidence indicates inequalities across racial groups in exposure to neighborhood social resources and air pollution

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 202 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "epidemiolog")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $1,153,793 in active NIH money across 2 projects, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$1,153,793
Active projects
2
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 38 of 100 points
  • +28 $1M–$2M of active NIH award money — NIH RePORTER reports $1,153,793 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3R01AG074887-05S1 DNA methylation in context: Population patterns in social adversity and sensitivity to the health impact of air pollution

    R01 · NIA · $164,411 · Jul 15, 2021 to Apr 30, 2027

All active NIH projects for Margaret Takako Hicken ($1,153,793)
  • 5R01MD016244-05 Social patterns in sleep deficiencies: The role of stress in the workplace — $577,444, ends Apr 30, 2027
  • 5R01AG074887-05 DNA methylation in context: Population patterns in social adversity and sensitivity to the health impact of air pollution — $576,349, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 15, 2021 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#323 Lab fit 14% · Low fit Hiring: Unlikely Atlanta Neuroscience

Vincent D Costa lab

Vincent D Costa · Emory University, Atlanta GA

Project Summary The explore-exploit dilemma refers to the challenge of deciding when to forego choices with known consequences to explore new opportunities and learn more about them. Managing this trade-off is a fundamental component of behavioral flexibility. Excessive exploration or exploitation impedes learning and results in poor choices leading to undesired outcomes. Explore-exploit decision making is understudied in psychiatry despite its ecological validity and relevance in understanding disorders characterized by inflexible behaviors. One reason for this is we have not identified if th

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 177 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $586,111 in active NIH money across 1 project, 0.6 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$586,111
Active projects
1
Runway left
0.6 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $586,111 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-04-30.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 7R01MH125824-05 Neurocomputational mechanisms of explore-exploit decision making in prefrontal and motivational neural circuits

    R01 · NIMH · $586,111 · Jul 1, 2021 to Apr 30, 2027

All active NIH projects for Vincent D Costa ($586,111)
  • 7R01MH125824-05 Neurocomputational mechanisms of explore-exploit decision making in prefrontal and motivational neural circuits — $586,111, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2021 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#324 Lab fit 14% · Low fit Hiring: Unlikely Michigan Neuroscience

William Charles Stacey lab

William Charles Stacey · University of Michigan, Ann Arbor MI

PROJECT SUMMARY Epilepsy is one of the world’s most prevalent diseases, yet the rate of uncontrolled seizures has not changed in decades. One of the reasons for this is our limited understanding of seizure mechanisms, and so one of the main goals of epilepsy research is to identify new biomarkers to help us understand the nature of the disease. Recent technological advancements now allow us to monitor brain activity with much higher resolution, which have led to the identification of promising potential biomarkers such as High Frequency Oscillations (HFOs). Unfortunately, clinicians still have

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 222 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $462,821 in active NIH money across 1 project, 0.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$462,821
Active projects
1
Runway left
0.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $462,821 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-01-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS094399-10 Characterizing High Frequency Oscillations as an epilepsy biomarker with Big Data tools

    R01 · NINDS · $462,821 · Sep 1, 2015 to Jan 31, 2027

All active NIH projects for William Charles Stacey ($462,821)
  • 5R01NS094399-10 Characterizing High Frequency Oscillations as an epilepsy biomarker with Big Data tools — $462,821, ends Jan 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 1, 2015 · project period to Jan 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#325 Lab fit 14% · Low fit Hiring: Unlikely Atlanta Neuroscience

Ying Guo lab

Ying Guo · Emory University, Atlanta GA

Project Summary/Abstract Recent mental health studies have led to an expanded depth of multimodal brain imaging data, clinical assessments and physiological data. In addition, longitudinal studies have become increasingly important to capture the trajectory of disease progression, treatment response and relapse. This wealth of datasets provides an unprecedented opportunity for crosscutting investigations. However, much-needed statistical methods for exploring discoveries are lacking. In particular, there has been very limited development of advanced statistical methods for several important ob

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 280 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $517,733 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$517,733
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $517,733 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH105561-09 Statistical ICA Methods for Analysis and Integration of Multi-dimensional Data

    R01 · NIMH · $517,733 · Sep 25, 2014 to Jul 31, 2027

All active NIH projects for Ying Guo ($517,733)
  • 5R01MH105561-09 Statistical ICA Methods for Analysis and Integration of Multi-dimensional Data — $517,733, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 25, 2014 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#326 Lab fit 14% · Low fit Hiring: Unlikely Atlanta Neuroscience

Jian Kang lab

Jian Kang · University of Michigan, Atlanta GA

Project Summary/Abstract Recent mental health studies have led to an expanded depth of multimodal brain imaging data, clinical assessments and physiological data. In addition, longitudinal studies have become increasingly important to capture the trajectory of disease progression, treatment response and relapse. This wealth of datasets provides an unprecedented opportunity for crosscutting investigations. However, much-needed statistical methods for exploring discoveries are lacking. In particular, there has been very limited development of advanced statistical methods for several important ob

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 280 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "neural network")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $517,733 in active NIH money across 1 project, 0.8 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$517,733
Active projects
1
Runway left
0.8 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $517,733 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-07-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01MH105561-09 Statistical ICA Methods for Analysis and Integration of Multi-dimensional Data

    R01 · NIMH · $517,733 · Sep 25, 2014 to Jul 31, 2027

All active NIH projects for Jian Kang ($517,733)
  • 5R01MH105561-09 Statistical ICA Methods for Analysis and Integration of Multi-dimensional Data — $517,733, ends Jul 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 25, 2014 · project period to Jul 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#327 Lab fit 14% · Low fit Hiring: Moderate Atlanta Neuroscience

Daniel L Drane lab

Daniel L Drane · Emory University, Atlanta GA

Project Summary: We have conducted the largest prospective comparative study of laser amygdalohippocampotomy (SLAH), a minimally invasive procedure ablating the amygdalo-hippocampal complex (AHC) versus selective and standard open resection (OR) epilepsy surgery (N=425+). We demonstrated that SLAH is superior to OR in 1-year cognitive outcomes in adults (including episodic verbal memory & perceptual (semantic) recognition or name retrieval of objects/faces), while achieving comparable seizure control. We will extend our analysis longitudinally in an unprecedented manner (5-10 year outcome) lev

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 240 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $2,177,850 in active NIH money across 2 projects, 2.3 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,177,850
Active projects
2
Runway left
2.3 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 55 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,177,850 across this PI's active projects.
  • +10 Two concurrent NIH projects — 2 active NIH projects listed.
  • +10 Two to three years of project period left — Longest project period runs to 2028-12-31 (about 2.3 years) — 5R01MH118514-08, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Atlanta is one of the two target regions.

    • Atlanta is a target metro — lab text says “Atlanta”
Awards in this snapshot
  • 5R01NS088748-10 Dissecting the Cognitive Roles of Hippocampus and Other Temporal Lobe Structures in Patients Undergoing Epilepsy Surgery

    R01 · NINDS · $563,717 · Jul 1, 2014 to Apr 30, 2027

All active NIH projects for Daniel L Drane ($2,177,850)
  • 5R01MH118514-08 National Neuropsychological Network (NNN) — $1,614,133, ends Dec 31, 2028
  • 5R01NS088748-10 Dissecting the Cognitive Roles of Hippocampus and Other Temporal Lobe Structures in Patients Undergoing Epilepsy Surgery — $563,717, ends Apr 30, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2014 · project period to Apr 30, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#328 Lab fit 14% · Low fit Hiring: Unlikely Michigan Neuroscience

Eishi Asano lab

Eishi Asano · Wayne State University, Detroit MI

We will determine the utility of a novel brain mapping technique for epilepsy presurgical evaluation, referred to as 'six-dimensional (6D) dynamic tractography'. This innovative program animates the rapid neural propagations along MRI-defined, 3D white matter tracts that connect regions supporting cognitive functions. Specifically, it will use event-related high gamma activity to localize the regions supporting specific linguistic functions and compute the velocity and strength of neural propagations based on the latency and amplitude of early neural responses to single-pulse electrical stimul

Lab fit breakdown — 14% weighted · Low fit

Scored on enough lab text to read as a verdict. 237 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 65% · weight 15%
Geography 100% · weight 10%

Weighted mean 20% × 0.7 domain gate = 14%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on AI, machine learning and big-data analysis Core methodology is AI / machine learning. Her record is wet-lab molecular and cell biology; the only computational work on the CV is sequence and splicing analysis. (matched on "machine learning")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Unlikely Unlikely: $473,627 in active NIH money across 1 project, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$473,627
Active projects
1
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 15 of 100 points
  • +10 $250K–$600K of active NIH award money — NIH RePORTER reports $473,627 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 65%

    1 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”
    • R01-class award that can carry a postdoc line — lab text says “award record”

    Not found: Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5R01NS064033-15 Functional brain mapping in pediatric neurosurgery

    R01 · NINDS · $473,627 · Mar 1, 2009 to Mar 31, 2027

All active NIH projects for Eishi Asano ($473,627)
  • 5R01NS064033-15 Functional brain mapping in pediatric neurosurgery — $473,627, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Mar 1, 2009 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

#329 Lab fit 11% · Low fit Hiring: Moderate Michigan Neuroscience

Lori Shutter lab

Lori Shutter · University of Michigan, Ann Arbor MI

Project Summary/Abstract . Traumatic brain injury (TBI) is a major cause of death and disability. Of the 3.5 million Americans who sustain a TBI every year, approximately 27,000 experience prolonged traumatic coma, the most severe form of TBI. Less than 20% of these patients make a good recovery, and most are left with life-long disabilities. ICU management of severe TBI focuses on monitoring intracranial pressure (ICP), but data from recently conducted randomized clinical trials indicate that this approach is overly simplistic. Another approach is to monitor the partial pressure of oxygen in

Lab fit breakdown — 11% weighted · Low fit

Scored on enough lab text to read as a verdict. 271 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 16% × 0.7 domain gate = 11%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $3,858,572 in active NIH money across 1 project, 2.4 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$3,858,572
Active projects
1
Runway left
2.4 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 50 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $3,858,572 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • +10 Two to three years of project period left — Longest project period runs to 2029-02-28 (about 2.4 years).
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3U01NS099046-06S4 Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3)

    U01 · NINDS · $37,500 · Jul 1, 2018 to Feb 28, 2029

All active NIH projects for Lori Shutter ($3,858,572)
  • 2U01NS099046-06 Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3) — $3,858,572, ends Feb 28, 2029

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2018 · project period to Feb 28, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#330 Lab fit 11% · Low fit Hiring: Moderate Michigan Neuroscience

Robert Silbergleit lab

Robert Silbergleit · University of Michigan, Ann Arbor MI

Project Summary/Abstract . Traumatic brain injury (TBI) is a major cause of death and disability. Of the 3.5 million Americans who sustain a TBI every year, approximately 27,000 experience prolonged traumatic coma, the most severe form of TBI. Less than 20% of these patients make a good recovery, and most are left with life-long disabilities. ICU management of severe TBI focuses on monitoring intracranial pressure (ICP), but data from recently conducted randomized clinical trials indicate that this approach is overly simplistic. Another approach is to monitor the partial pressure of oxygen in

Lab fit breakdown — 11% weighted · Low fit

Scored on enough lab text to read as a verdict. 271 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 16% × 0.7 domain gate = 11%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "clinical trial")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Moderate Moderate: $9,526,770 in active NIH money across 3 projects, 3.9 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$9,526,770
Active projects
3
Runway left
3.9 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 65 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $9,526,770 across this PI's active projects.
  • +15 Three or more concurrent NIH projects — 3 active NIH projects listed.
  • +15 Three to four years of project period left — Longest project period runs to 2030-08-31 (about 3.9 years) — 4UH3NS131532-02, which is outside this briefing's scope but is active NIH money for this PI.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 3U01NS099046-06S4 Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3)

    U01 · NINDS · $37,500 · Jul 1, 2018 to Feb 28, 2029

All active NIH projects for Robert Silbergleit ($9,526,770)
  • 4UH3NS131532-02 Ketamine Add-On for Established Status Epilepticus Treatment Trial (KESETT) — $5,668,197, ends Aug 31, 2030
  • 2U01NS099046-06 Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3) — $3,858,572, ends Feb 28, 2029
  • 5U24NS100659-09 Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Clinical Coordinating Center (CCC) — $1, ends Jan 31, 2028

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Jul 1, 2018 · project period to Feb 28, 2029 · roster/posting last verified date unknown · first seen Sep 22, 2026

#331 Lab fit 11% · Low fit Hiring: Possible Michigan Neuroscience

Mary M Heitzeg lab

Mary M Heitzeg · University of Michigan, Ann Arbor MI

Abstract Adolescent Brain Cognitive Development (ABCD) is the largest long-term study of brain development and child health in the United States. The ABCD Research Consortium consists of 21 research sites across the country, a Coordinating Center, and a Data Analysis and Informatics Resource Center. In its first five years, under RFA- DA-15-015, ABCD enrolled a diverse sample of 11,878 9-10 year olds from across the consortium, and will track their biological and behavioral development through adolescence into young adulthood. All participants received a comprehensive baseline assessment, incl

Lab fit breakdown — 11% weighted · Low fit

Scored on enough lab text to read as a verdict. 327 words of lab text were scored, matching 0 of her 18 profile terms (saturation needs 10) across 0 of 3 evidence dimensions. That is past the 120-word bar, so a term this text does not mention counts as a genuine absence and the percentage reads as a verdict.

Disease & domain overlap 0% · weight 30%
Model systems 0% · weight 20%
Techniques & readouts 0% · weight 25%
Seniority & capacity fit 40% · weight 15%
Geography 100% · weight 10%

Weighted mean 16% × 0.7 domain gate = 11%. No real disease overlap — weighted mean discounted 30%.

What matches

Nothing in this award overlaps her profile terms.

What’s missing

  • No evidence of glaucoma, iop and trabecular meshwork Nothing in the grant text or lab description touches glaucoma, iop and trabecular meshwork, one of her core areas.
  • No evidence of retinal ganglion cells and the optic nerve Nothing in the grant text or lab description touches retinal ganglion cells and the optic nerve, one of her core areas.
  • No evidence of mouse / rodent in vivo models Nothing in the grant text or lab description touches mouse / rodent in vivo models, one of her core areas.
  • No evidence of aav / lentiviral delivery and gene therapy Nothing in the grant text or lab description touches aav / lentiviral delivery and gene therapy, one of her core areas.
  • No evidence of autophagy, mitophagy and organelle quality control Nothing in the grant text or lab description touches autophagy, mitophagy and organelle quality control, one of her core areas.
  • Lab leans on clinical trials, epidemiology and health services This is a human-subjects, trials or health-services project rather than a bench lab. Her human-subject work is molecular genetics of patient cohorts and donor-eye analysis, not trial conduct or population screening. (matched on "participants")

Lab composition · Not researched

Unknown — this lab has not been researched.

No roster research has been carried out for this lab. Roster and posting research was prioritised by match score, so lower-scoring labs were left unchecked rather than filled in with guesses.

Posting · No posting advertised

Not checked for this lab.

No job-board check has been run for this lab.

Can they afford to hire her?

Possible Possible: $2,040,687 in active NIH money across 1 project, 0.5 years of project period left, lab size unknown, no advertised opening.

Active NIH money
$2,040,687
Active projects
1
Runway left
0.5 yrs
Known lab size
unknown
Show the reasoning and the underlying awards
Hiring signals — 40 of 100 points
  • +35 Over $2M of active NIH award money — NIH RePORTER reports $2,040,687 across this PI's active projects.
  • +5 One active NIH project — 1 active NIH project listed.
  • 0 Under a year of project period left — Longest project period ends 2027-03-31.
  • Unknown: No job-board check has been run for this lab.
  • Unknown: Current lab size is unknown — no usable public roster.
Per-dimension evidence
  • Disease & domain overlap — 0%

    No overlap found with any of Yogapriya's 6 disease & domain overlap areas.

    Not found: Glaucoma, IOP and trabecular meshwork; Retinal ganglion cells and the optic nerve; Neurodegeneration and neuroprotection; Retina, photoreceptors and RPE; Inherited retinal disease and ocular gene therapy; Other ocular tissue (cornea, lens, sclera, uvea)

  • Model systems — 0%

    No overlap found with any of Yogapriya's 5 model systems areas.

    Not found: Mouse / rodent in vivo models; AAV / lentiviral delivery and gene therapy; CRISPR / conditional knockout genetics; Human donor tissue, primary and explant culture; Non-rodent animal models

  • Techniques & readouts — 0%

    No overlap found with any of Yogapriya's 7 techniques & readouts areas.

    Not found: Autophagy, mitophagy and organelle quality control; Histology, IHC and confocal / electron microscopy; Molecular biology, biochemistry and proteomics; Axonal transport and neuronal injury assays; Sequencing, variant and splicing analysis; In vivo ocular imaging and functional readouts; Calcium and mechanosensitive channel signalling

  • Seniority & capacity fit — 40%

    0 of 4 capacity conditions met on top of the 40-point baseline for an active NIH award.

    • Active NIH-funded lab — lab text says “active NIH award”

    Not found: R01-class award that can carry a postdoc line; Three or more years left in the project period; Award started within the last 12 months; Advertised opening at one of her three target levels

  • Geography — 100%

    Michigan is one of the two target regions.

    • Michigan is a target metro — lab text says “Michigan”
Awards in this snapshot
  • 5U01DA041106-12 9/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT U MICHIGAN

    U01 · NIDA · $2,040,687 · Sep 30, 2015 to Mar 31, 2027

All active NIH projects for Mary M Heitzeg ($2,040,687)
  • 5U01DA041106-12 9/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT U MICHIGAN — $2,040,687, ends Mar 31, 2027

Read from NIH RePORTER on Sep 23, 2026.

Newest award started Sep 30, 2015 · project period to Mar 31, 2027 · roster/posting last verified date unknown · first seen Sep 22, 2026

Index — the 433 labs in this view

Each name links to that lab's entry. The index follows the filters so the count above can be checked against the names it stands for; tick the box to list every lab in the snapshot regardless.

  • Aaron John Young — Georgia Institute of Technology, Atlanta · lab fit 20% · not yet researched
  • Abigail Fahim — University of Michigan, Michigan · lab fit 73% · not yet researched
  • Ada Eban-rothschild — University of Michigan, Michigan · lab fit 22% · not yet researched
  • Aditya S Pandey — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Adriana Galvan — Emory University, Atlanta · lab fit 44% · not yet researched
  • Adriene M. Beltz — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Ahmed S Ibrahim — Wayne State University, Michigan · lab fit 47% · not yet researched
  • Alberto Stolfi — Georgia Institute of Technology, Atlanta · lab fit 37% · not yet researched
  • Alexander Weigard — University of Michigan, Michigan · lab fit 17% · not yet researched
  • Alexandra Cohen — Emory University, Atlanta · lab fit 22% · not yet researched
  • Alexandra H. Veenema — Michigan State University, Michigan · lab fit 19% · not yet researched
  • Alexandre Dasilva — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Alfred J Robison — Michigan State University, Michigan · lab fit 41% · not yet researched
  • Allan I Levey — Emory University, Atlanta · lab fit 41% · not yet researched
  • Amanda Noel Leggett — Wayne State University, Michigan · lab fit 30% · not yet researched
  • Amara E Ezeamama — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 27% · not yet researched
  • Ambar Kulshreshtha — Emory University, Atlanta · lab fit 31%
  • Ana Marie Daugherty — Wayne State University, Michigan · lab fit 40% · not yet researched
  • Anant Krishna Paravastu — Georgia Institute of Technology, Atlanta · lab fit 38% · not yet researched
  • Andreas S Bommarius — Georgia Institute of Technology, Atlanta · lab fit 43% · not yet researched
  • Andrew Frederick Brouwer — University of Michigan, Michigan · lab fit 29%
  • Andrew Fx Goldberg — Oakland University, Michigan · lab fit 53% · not yet researched
  • Andrew H Miller — Emory University, Atlanta · lab fit 36% · not yet researched
  • Andrew J. Feola — Emory University, Atlanta · lab fit 36% · no NIH award matched · not yet researched
  • Andrew P Escayg — Emory University, Atlanta · lab fit 53%
  • Andrew P Lieberman — University of Michigan, Michigan · lab fit 57% · not yet researched
  • Angela M Mabb — Georgia State University, Atlanta · lab fit 49% · not yet researched
  • Anita H. Corbett — Emory University, Atlanta · lab fit 31% · not yet researched
  • Anita Vani Devineni — Emory University, Atlanta · lab fit 20% · not yet researched
  • Anjali Sharma — University of Michigan, Michigan · lab fit 63%
  • Anke Huels — Emory University, Atlanta · lab fit 28% · not yet researched
  • Anna Louise Kratz — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Anna Moszczynska — Wayne State University, Michigan · lab fit 46% · not yet researched
  • Annabelle Catherine Singer — Georgia Institute of Technology, Atlanta · lab fit 43% · not yet researched
  • Annaelle Devergnas — Emory University, Atlanta · lab fit 20% · not yet researched
  • Anne Watson Draelos — University of Michigan, Michigan · lab fit 54% · not yet researched
  • Annette Diane De Kloet — Georgia State University, Atlanta · lab fit 19% · not yet researched
  • Anqi Wu — Georgia Institute of Technology, Atlanta · lab fit 17% · not yet researched
  • Anupam Patgiri — Emory University, Atlanta · lab fit 49% · not yet researched
  • Armin Iraji — Georgia State University, Atlanta · lab fit 14% · not yet researched
  • Ashok Kumar — Wayne State University, Michigan · lab fit 83% · not yet researched
  • Audrey Sederberg — Georgia Institute of Technology, Atlanta · lab fit 19% · not yet researched
  • Avanti Gokhale — Emory University, Atlanta · lab fit 49% · not yet researched
  • Benjamin Herschel Singer — University of Michigan, Michigan · lab fit 34% · not yet researched
  • Benjamin Joseph Murdock — University of Michigan, Michigan · lab fit 24% · not yet researched
  • Benjamin Michael Hampstead — University of Michigan, Michigan · lab fit 35% · not yet researched
  • Benjamin Neal Combs — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 49% · not yet researched
  • Bilal Haider — Georgia Institute of Technology, Atlanta · lab fit 15% · not yet researched
  • Bing Yao — Emory University, Atlanta · lab fit 42% · not yet researched
  • Bing Ye — University of Michigan, Michigan · lab fit 39% · not yet researched
  • Bingzhong Xue — Georgia State University, Atlanta · lab fit 34% · not yet researched
  • Blaine Russell Roberts — Emory University, Atlanta · lab fit 55% · not yet researched
  • Bo Liang — Emory University, Atlanta · lab fit 43% · not yet researched
  • Boris I Prilutsky — Georgia Institute of Technology, Atlanta · lab fit 20% · not yet researched
  • Brendon O Watson — University of Michigan, Michigan · lab fit 55%
  • Brett Andrew Mccray — University of Michigan, Michigan · lab fit 37% · not yet researched
  • Brian D. Gulbransen — Michigan State University, Michigan · lab fit 20% · not yet researched
  • Brian Patrick Brooks — Emory University, Atlanta · lab fit 17% · not yet researched
  • Briana Mezuk — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Brooke Ingersoll — Michigan State University, Michigan · lab fit 17% · not yet researched
  • Bruce A. Berkowitz — Wayne State University, Michigan · lab fit 77% · not yet researched
  • Bruno Giordani — University of Michigan, Michigan · lab fit 27% · not yet researched
  • C Ross Ethier — Emory University, Atlanta · lab fit 66%
  • Candace C. Fleischer — Emory University, Atlanta · lab fit 33% · not yet researched
  • Candace L. Floyd — Emory University, Atlanta · lab fit 25% · not yet researched
  • Carl J Koschmann — University of Michigan, Michigan · lab fit 44% · not yet researched
  • Carlo Piermarocchi — Michigan State University, Michigan · lab fit 26% · not yet researched
  • Carol C Persad — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Carolyn A Harris — Wayne State University, Michigan · lab fit 30% · not yet researched
  • Carolyn Kay Clevenger — Emory University, Atlanta · lab fit 30% · not yet researched
  • Carrie Ferrario — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Cassie S Mitchell — Georgia Institute of Technology, Atlanta · lab fit 23% · not yet researched
  • Catherine Cook Kaczorowski — University of Michigan, Michigan · lab fit 63%
  • Chandra Sekhar Sripada — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Changyang Linghu — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Chelsea Kaplan — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Cheng-yu Lee — University of Michigan, Michigan · lab fit 22% · not yet researched
  • Christian Richard Burgess — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Christina Donata Cota — Georgia Institute of Technology, Atlanta · lab fit 37% · not yet researched
  • Christina Gavegnano — Emory University, Atlanta · lab fit 34% · not yet researched
  • Christopher Rodgers — Emory University, Atlanta · lab fit 20% · not yet researched
  • Claire-anne N Gutekunst — Emory University, Atlanta · lab fit 37% · not yet researched
  • Colin Fred Greineder — University of Michigan, Michigan · lab fit 52% · not yet researched
  • Courtney A. Polenick — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Courtney Elaine Stewart — Veterans Education And Research Association Of Michigan, Michigan · lab fit 25% · not yet researched
  • Courtney S Thomas Tobin — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Craig Forest — Georgia Institute of Technology, Atlanta · lab fit 34% · not yet researched
  • Dana M Spence — Michigan State University, Michigan · lab fit 31% · not yet researched
  • Daniel A Lawrence — University of Michigan, Michigan · lab fit 34% · not yet researched
  • Daniel J. Klionsky — University of Michigan, Michigan · lab fit 39% · not yet researched
  • Daniel L Drane — Emory University, Atlanta · lab fit 14% · not yet researched
  • Daniel Louis Hertz — University of Michigan, Michigan · lab fit 17% · not yet researched
  • Daniel N Cox — Georgia State University, Atlanta · lab fit 27% · not yet researched
  • Daniel T. Hass — Emory University, Atlanta · lab fit 16% · no NIH award matched · not yet researched
  • Dao-qi Zhang — Oakland University, Michigan · lab fit 57% · not yet researched
  • Darin B Zahuranec — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Darren John Moore — Van Andel Institute, Michigan · lab fit 59%
  • David Gilbert Lynn — Emory University, Atlanta · lab fit 43% · not yet researched
  • David P Olson — University of Michigan, Michigan · lab fit 31% · not yet researched
  • David R Rosenberg — Wayne State University, Michigan · lab fit 23% · not yet researched
  • David Ryan Goldsmith — Emory University, Atlanta · lab fit 18% · not yet researched
  • David Weinshenker — Emory University, Atlanta · lab fit 48% · not yet researched
  • Dawen Cai — University of Michigan, Michigan · lab fit 42% · not yet researched
  • Deborah Allison Levine — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Deepta Ghate — Emory University, Atlanta · lab fit 25% · no NIH award matched · not yet researched
  • Deqiang Qiu — Emory University, Atlanta · lab fit 42% · not yet researched
  • Dolly Ann Padovani-claudio — University of Michigan, Michigan · lab fit 42%
  • Donghai Liang — Emory University, Atlanta · lab fit 28% · not yet researched
  • Dongshan Yang — University of Michigan, Michigan · lab fit 67%
  • Donna M. Martin — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Donovan T Maust — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Dorairaj Prabhakaran — Emory University, Atlanta · lab fit 36% · not yet researched
  • Ebrahim Haroon — Emory University, Atlanta · lab fit 30% · not yet researched
  • Eishi Asano — Wayne State University, Michigan · lab fit 14% · not yet researched
  • Eldon Geisert — Emory University, Atlanta · lab fit 16% · no NIH award matched · not yet researched
  • Eleanor Josephine Clowney — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Elham Mahmoudi — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Elizabeth Berger — Wayne State University, Michigan · lab fit 29%
  • Elizabeth Duval — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Eric Gerald Krause — Georgia State University, Atlanta · lab fit 19% · not yet researched
  • Eric John Sundberg — Emory University, Atlanta · lab fit 27% · not yet researched
  • Erica Marlis Werner — Emory University, Atlanta · lab fit 49% · not yet researched
  • Erica Sawyer Levitt — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Erik C.b. Johnson — Emory University, Atlanta · lab fit 40% · not yet researched
  • Erin Bakshis Ware — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Esther M. Friedman — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Euisik Yoon — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Eva Dyer — Georgia Institute of Technology, Atlanta · lab fit 17% · not yet researched
  • Eva Lucille Feldman — University of Michigan, Michigan · lab fit 58%
  • Fadi Basil Nahab — Emory University, Atlanta · lab fit 27% · not yet researched
  • Felipe Garcia Quiroz — Emory University, Atlanta · lab fit 28% · not yet researched
  • Fikri Birey — Emory University, Atlanta · lab fit 25% · not yet researched
  • Firas Kobaissy — Morehouse School of Medicine, Atlanta · lab fit 30% · not yet researched
  • Frederick Kofi Korley — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Fu-shin X Yu — Wayne State University, Michigan · lab fit 36% · not yet researched
  • Gabriel Corfas — University of Michigan, Michigan · lab fit 34% · not yet researched
  • Garrett B. Stanley — Georgia Institute of Technology, Atlanta · lab fit 30% · not yet researched
  • Gary J Bassell — Emory University, Atlanta · lab fit 73% · not yet researched
  • Gennady S Cymbalyuk — Georgia State University, Atlanta · lab fit 27% · not yet researched
  • Geoffrey G Murphy — University of Michigan, Michigan · lab fit 34% · not yet researched
  • Geoffrey Jonathan Hoffman — University of Michigan, Michigan · lab fit 23% · not yet researched
  • George Alexander Mashour — University of Michigan, Michigan · lab fit 19% · not yet researched
  • Giancarlo Vanini — University of Michigan, Michigan · lab fit 19% · not yet researched
  • Gideon Rothschild — University of Michigan, Michigan · lab fit 22% · not yet researched
  • Gina Marie Leinninger — Michigan State University, Michigan · lab fit 19% · not yet researched
  • Grace A Noppert — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Greg Thurber — University of Michigan, Michigan · lab fit 32% · not yet researched
  • Gregory Stephen Sawicki — Georgia Institute of Technology, Atlanta · lab fit 36% · not yet researched
  • Hang Lu — Georgia Institute of Technology, Atlanta · lab fit 27% · not yet researched
  • Hang Shi — Georgia State University, Atlanta · lab fit 34% · not yet researched
  • Hannah Choi — Georgia Institute of Technology, Atlanta · lab fit 20% · not yet researched
  • Hans Grossniklaus — Emory University, Atlanta · lab fit 9% · no NIH award matched · not yet researched
  • Hayley S Mcloughlin — University of Michigan, Michigan · lab fit 72% · not yet researched
  • Helen Carmon Spink Meier — University of Michigan, Michigan · lab fit 26% · not yet researched
  • Henry L Paulson — University of Michigan, Michigan · lab fit 34% · not yet researched
  • Honglei Chen — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 25% · not yet researched
  • Huda Akil — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Hui Mao — Emory University, Atlanta · lab fit 28% · not yet researched
  • Huilin Li — Van Andel Institute, Michigan · lab fit 49% · not yet researched
  • Huiwen Xu — Emory University, Atlanta · lab fit 27% · not yet researched
  • Hwajung Choi — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Hyder A Jinnah — Emory University, Atlanta · lab fit 18% · not yet researched
  • Hyeokhyen Kwon — Emory University, Atlanta · lab fit 26%
  • Irene Yang — Emory University, Atlanta · lab fit 31% · not yet researched
  • J. Devin Mcauley — University of Michigan, Michigan · lab fit 26% · not yet researched
  • Jack M Parent — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Jailson Brito Querido — University of Michigan, Michigan · lab fit 33% · not yet researched
  • Jalayne J Arias — Georgia State University, Atlanta · lab fit 23% · not yet researched
  • James D Weiland — University of Michigan, Michigan · lab fit 73% · not yet researched
  • James J Lah — Emory University, Atlanta · lab fit 40% · not yet researched
  • James J. Moon — University of Michigan, Michigan · lab fit 34% · not yet researched
  • James K Rilling — Emory University, Atlanta · lab fit 23% · not yet researched
  • James Q Zheng — Emory University, Atlanta · lab fit 22% · not yet researched
  • Javier E Stern — Georgia State University, Atlanta · lab fit 23% · not yet researched
  • Jayanth Ramadoss — Wayne State University, Michigan · lab fit 36% · not yet researched
  • Jeffrey A Stanley — Wayne State University, Michigan · lab fit 23% · not yet researched
  • Jeffrey H Boatright — Emory University, Atlanta · lab fit 77% · not yet researched
  • Jennifer C Felger — Emory University, Atlanta · lab fit 36% · not yet researched
  • Jennifer Marie Spangle — Emory University, Atlanta · lab fit 25% · not yet researched
  • Jessica Faul — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Jessica Shantha — Emory University, Atlanta · lab fit 30%
  • Jian Kang — University of Michigan, Atlanta · lab fit 14% · not yet researched
  • Jianping Fu — University of Michigan, Michigan · lab fit 19% · not yet researched
  • Jiayu Chen — Georgia State University, Atlanta · lab fit 14% · not yet researched
  • Jiayu Zhou — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Jie Jiang — Emory University, Atlanta · lab fit 73% · not yet researched
  • Jie Xu — University of Michigan, Michigan · lab fit 40% · not yet researched
  • Jillian Nydam Pearring — University of Michigan, Michigan · lab fit 65% · not yet researched
  • Jin He — Michigan State University, Michigan · lab fit 30% · not yet researched
  • Jingjing Yang — Emory University, Atlanta · lab fit 35% · not yet researched
  • Jingyu Liu — Georgia State University, Atlanta · lab fit 29% · not yet researched
  • Joanna H Mattis — University of Michigan, Michigan · lab fit 39% · not yet researched
  • John Nickerson — Emory University, Atlanta · lab fit 22% · no NIH award matched · not yet researched
  • Johnathan Lucas Mckay — Emory University, Atlanta · lab fit 26% · not yet researched
  • Jonathan K. Stiles — Morehouse School of Medicine, Atlanta · lab fit 38% · not yet researched
  • Jonathan Lifshitz — University of Michigan, Michigan · lab fit 45% · not yet researched
  • Joongkyu Park — Wayne State University, Michigan · lab fit 38% · not yet researched
  • Joseph Wider — University of Michigan, Michigan · lab fit 45%
  • Joshua James Emrick — University of Michigan, Michigan · lab fit 22% · not yet researched
  • Joshua Robert Ehrlich — University of Michigan, Michigan · lab fit 28% · not yet researched
  • Joshua Welch — University of Michigan, Michigan · lab fit 52% · not yet researched
  • Julia E. Richards — University of Michigan, Michigan · lab fit 22% · no NIH award matched · not yet researched
  • Jun Hee Kim — University of Michigan, Michigan · lab fit 41% · not yet researched
  • Jun Li — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Justin Adam Colacino — University of Michigan, Michigan · lab fit 43% · not yet researched
  • Kabayam M Venkat Narayan — Emory University, Atlanta · lab fit 36% · not yet researched
  • Kamran Diba — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Kanishka Thiran Jayasundera — University of Michigan, Michigan · lab fit 39% · not yet researched
  • Karin List — Wayne State University, Michigan · lab fit 55%
  • Karl Boynton Seydel — Michigan State University, Michigan · lab fit 21% · not yet researched
  • Katharine Natasha Thakkar — Michigan State University, Michigan · lab fit 24% · not yet researched
  • Kathy Steece-collier — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 57% · not yet researched
  • Kelly Bakulski — University of Michigan, Michigan · lab fit 51%
  • Kelly L Klump — Michigan State University, Michigan · lab fit 24% · not yet researched
  • Ken Berglund — Emory University, Atlanta · lab fit 34% · not yet researched
  • Ken Inoki — University of Michigan, Michigan · lab fit 45% · not yet researched
  • Ken W Hepburn — Emory University, Atlanta · lab fit 33% · not yet researched
  • Kenn R Oldham — University of Michigan, Michigan · lab fit 21% · not yet researched
  • Kenneth H Moberg — Emory University, Atlanta · lab fit 31% · not yet researched
  • Kenneth M Langa — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Kenneth Yu-chung Kwan — University of Michigan, Michigan · lab fit 34% · not yet researched
  • Kin Sing Stephen Lee — Michigan State University, Michigan · lab fit 34% · not yet researched
  • Kira S Birditt — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Kristen Culbert — Michigan State University, Michigan · lab fit 24% · not yet researched
  • Kristine J. Ajrouch — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Laura B Zahodne — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Laura Elske Maria Wisse — Wayne State University, Michigan · lab fit 40% · not yet researched
  • Lauren Beth Gerlach — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Lena H Ting — Emory University, Atlanta · lab fit 30% · not yet researched
  • Lev Prasov — University of Michigan, Michigan · lab fit 75%
  • Lewis B Morgenstern — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Li Zhang — Henry Ford Health System, Michigan · lab fit 34% · not yet researched
  • Lian Li — Emory University, Atlanta · lab fit 48%
  • Liang Zhao — Emory University, Atlanta · lab fit 28% · not yet researched
  • Lih-shen Chin — Emory University, Atlanta · lab fit 41% · not yet researched
  • Linda D Hazlett — Wayne State University, Michigan · lab fit 27% · not yet researched
  • Lindsay C Kobayashi — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Lindsey Blake De Lott — University of Michigan, Michigan · lab fit 46%
  • Lois S Weisman — University of Michigan, Michigan · lab fit 32% · not yet researched
  • Lora M. Cope — University of Michigan, Michigan · lab fit 19% · not yet researched
  • Lori L. Isom — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Lori Shutter — University of Michigan, Michigan · lab fit 11% · not yet researched
  • Louis Tuong Chinh Dang — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Machelle T. Pardue — Emory University, Atlanta · lab fit 72% · not yet researched
  • Maik Huettemann — Wayne State University, Michigan · lab fit 36% · not yet researched
  • Malavika Murugan — Emory University, Atlanta · lab fit 19% · not yet researched
  • Manojkumar A Puthenveedu — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Mar M Sanchez — Emory University, Atlanta · lab fit 37% · not yet researched
  • Marco Angrisani — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Margaret Takako Hicken — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Maria Anneke Woodward — University of Michigan, Michigan · lab fit 16% · not yet researched
  • Maria C Alvarado — Emory University, Atlanta · lab fit 48% · not yet researched
  • Maria G Castro — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Marianna Sadagurski — Wayne State University, Michigan · lab fit 57% · not yet researched
  • Marina Sorrentino Hernandes — Emory University, Atlanta · lab fit 27% · not yet researched
  • Martin G Myers — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Mary M Heitzeg — University of Michigan, Michigan · lab fit 11% · not yet researched
  • Matthew A Davis — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Matthew Gombolay — Emory University, Atlanta · lab fit 26% · not yet researched
  • Matthew J.m. Rowan — Emory University, Atlanta · lab fit 62% · not yet researched
  • Matthew Richard Chapman — University of Michigan, Michigan · lab fit 39% · not yet researched
  • Matthias Christof Truttmann — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Maureen Agnes Sartor — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Meghna S Trivedi — University of Michigan, Michigan · lab fit 17% · not yet researched
  • Mellanie V Springer — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Mi-kyung Song — Emory University, Atlanta · lab fit 23% · not yet researched
  • Michael Girard — Emory University, Atlanta · lab fit 81%
  • Michael Goodman — Emory University, Atlanta · lab fit 23% · not yet researched
  • Michael Henderson — Van Andel Institute, Michigan · lab fit 52% · not yet researched
  • Michael Landowski — Wayne State University, Michigan · lab fit 77%
  • Michael Mark Alexander Sutton — University of Michigan, Michigan · lab fit 37% · not yet researched
  • Michael Patrick Flynn — University of Michigan, Michigan · lab fit 26% · not yet researched
  • Michael Robert Borich — Emory University, Atlanta · lab fit 23% · not yet researched
  • Michael Roland Williams — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 36% · not yet researched
  • Michael Thomas Roberts — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Michael Tilghman Treadway — Emory University, Atlanta · lab fit 19% · not yet researched
  • Michal R Zochowski — University of Michigan, Michigan · lab fit 33% · not yet researched
  • Michelle L Hastings — University of Michigan, Michigan · lab fit 55% · not yet researched
  • Michelle Suzanne Mazei-robison — Michigan State University, Michigan · lab fit 41% · not yet researched
  • Mijin Kim — Georgia Institute of Technology, Atlanta · lab fit 44% · not yet researched
  • Min-hao Kuo — Michigan State University, Michigan · lab fit 42% · not yet researched
  • Ming Li — University of Michigan, Michigan · lab fit 54% · not yet researched
  • Miranda Annette Moore — Emory University, Atlanta · lab fit 26% · not yet researched
  • Miriam H Meisler — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Mohamed Al-sayed Al-shabrawey — Oakland University, Michigan · lab fit 55% · not yet researched
  • Mohammad Ejaz Ahmed — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 46% · not yet researched
  • Mohammed Akaaboune — University of Michigan, Michigan · lab fit 29% · not yet researched
  • Molly M Perkins — Emory University, Atlanta · lab fit 26% · not yet researched
  • Monica Dus — University of Michigan, Michigan · lab fit 21% · not yet researched
  • Muhannad Bakir — Emory University, Atlanta · lab fit 22% · not yet researched
  • Natalie Colabianchi — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Neera Tewari-singh — Michigan State University, Michigan · lab fit 53% · not yet researched
  • Nelson K Steenland — Emory University, Atlanta · lab fit 23% · not yet researched
  • Nicholas M Boulis — Emory University, Atlanta · lab fit 23% · not yet researched
  • Nicholas Thomas Seyfried — Emory University, Atlanta · lab fit 25% · not yet researched
  • Nicolaas Ida Bohnen — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Noelle E. Carlozzi — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Nora E. Fritz — Wayne State University, Michigan · lab fit 14% · not yet researched
  • Norbert E Kaminski — Michigan State University, Michigan · lab fit 34% · not yet researched
  • Noreen F Rossi — Wayne State University, Michigan · lab fit 27% · not yet researched
  • Norman Scheel — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 26%
  • Omar Jamil Ahmed — University of Michigan, Michigan · lab fit 30% · not yet researched
  • P. Michael Iuvone — Emory University, Atlanta · lab fit 16% · no NIH award matched · not yet researched
  • Patrick J Mueller — Wayne State University, Michigan · lab fit 27% · not yet researched
  • Paul Frederick Kramer — University of Michigan, Michigan · lab fit 20% · not yet researched
  • Paul Michael Jenkins — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Paula Anne Newman-casey — University of Michigan, Michigan · lab fit 36%
  • Paulette B. Goforth — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Peng Jin — Emory University, Atlanta · lab fit 34% · not yet researched
  • Peter K Todd — University of Michigan, Michigan · lab fit 41% · not yet researched
  • Peter M Tessier — University of Michigan, Michigan · lab fit 52%
  • Philip D King — University of Michigan, Michigan · lab fit 32% · not yet researched
  • Phillip Eleas Vlisides — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Phyllis I Hanson — University of Michigan, Michigan · lab fit 38% · not yet researched
  • Pierre F Apostolides — University of Michigan, Michigan · lab fit 20% · not yet researched
  • Qiang Zhu — Van Andel Institute, Michigan · lab fit 43%
  • Quan Jiang — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 30% · not yet researched
  • Rajesh Rao — University of Michigan, Michigan · lab fit 30% · no NIH award matched · not yet researched
  • Randy A. Hall — Emory University, Atlanta · lab fit 30% · not yet researched
  • Randy J Seeley — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Raquel L Lieberman — Georgia Institute of Technology, Atlanta · lab fit 68% · not yet researched
  • Ravi Allada — University of Michigan, Michigan · lab fit 35% · not yet researched
  • Rebecca Kaufman Sripada — University of Michigan, Michigan · lab fit 14% · not yet researched
  • Rebecca Knickmeyer — Michigan State University, Michigan · lab fit 31% · not yet researched
  • Reece Mazade — Emory University, Atlanta · lab fit 50%
  • Renee D Read — Emory University, Atlanta · lab fit 48% · not yet researched
  • Renu A. Kowluru — Wayne State University, Michigan · lab fit 57% · not yet researched
  • Richard D Dix — Georgia State University, Atlanta · lab fit 45% · not yet researched
  • Richard David Wainford — Emory University, Atlanta · lab fit 30% · not yet researched
  • Richard F Keep — University of Michigan, Michigan · lab fit 49% · not yet researched
  • Robert E Gross — Emory University, Atlanta · lab fit 27% · not yet researched
  • Robert John Wessells — Wayne State University, Michigan · lab fit 20% · not yet researched
  • Robert Silbergleit — University of Michigan, Michigan · lab fit 11% · not yet researched
  • Roman Jeno Giger — University of Michigan, Michigan · lab fit 48% · not yet researched
  • Ryan David Mohan — Wayne State University, Michigan · lab fit 43% · not yet researched
  • Ryan Insolera — Wayne State University, Michigan · lab fit 39% · not yet researched
  • Ryan Thummel — Wayne State University, Michigan · lab fit 58%
  • S. Alexandra Burt — Michigan State University, Michigan · lab fit 34% · not yet researched
  • Saima Rathore — Emory University, Atlanta · lab fit 35%
  • Sami Barmada — University of Michigan, Michigan · lab fit 52% · not yet researched
  • Samuel Sober — Emory University, Atlanta · lab fit 22% · not yet researched
  • Sara J Aton — University of Michigan, Michigan · lab fit 33% · not yet researched
  • Sarah Elizabeth Vordenberg — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Sarah L Veatch — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Saravanan Venkatachalam — Wayne State University, Michigan · lab fit 31% · not yet researched
  • Sayantan Datta — Emory University, Atlanta · lab fit 23% · no NIH award matched · not yet researched
  • Scott Pletcher — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Seong Su Kang — Emory University, Atlanta · lab fit 43% · not yet researched
  • Shane R Crandall — Michigan State University, Michigan · lab fit 19% · not yet researched
  • Shannon Leigh Gourley — Emory University, Atlanta · lab fit 47% · not yet researched
  • Shanthi K Srinivasan — Emory University, Atlanta · lab fit 36% · not yet researched
  • Shella D Keilholz — Emory University, Atlanta · lab fit 30% · not yet researched
  • Shelly Beth Flagel — University of Michigan, Michigan · lab fit 27% · not yet researched
  • Sherry Day — University of Michigan, Michigan · lab fit 39% · not yet researched
  • Shigeki Iwase — University of Michigan, Michigan · lab fit 31% · not yet researched
  • Shihao Ji — Georgia State University, Atlanta · lab fit 17% · not yet researched
  • Shina Caroline Lynn Kamerlin — Georgia Institute of Technology, Atlanta · lab fit 38% · not yet researched
  • Shirley Zhang — Emory University, Atlanta · lab fit 49% · not yet researched
  • Shreesh Raj Sammi — Michigan State University, Michigan · lab fit 49% · not yet researched
  • Shunbin Xu — Wayne State University, Michigan · lab fit 48% · not yet researched
  • Sidhartha Tan — Wayne State University, Michigan · lab fit 40% · not yet researched
  • Sokol Todi — Wayne State University, Michigan · lab fit 43% · not yet researched
  • Soo-eun Chang — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Stanislav Y Emelianov — Georgia Institute of Technology, Atlanta · lab fit 40% · not yet researched
  • Stanley J Watson — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Stefanie Galban — University of Michigan, Michigan · lab fit 26% · not yet researched
  • Stella M Papa — Emory University, Atlanta · lab fit 47%
  • Stephen F Traynelis — Emory University, Atlanta · lab fit 40% · not yet researched
  • Stephen Goutman — University of Michigan, Michigan · lab fit 37% · not yet researched
  • Stephen Matthew Cain — University of Michigan, Michigan · lab fit 33% · not yet researched
  • Stephen Nicholas Housley — Georgia Institute of Technology, Atlanta · lab fit 28% · not yet researched
  • Stephen William Peter Kemp — University of Michigan, Michigan · lab fit 24% · not yet researched
  • Steven H Liang — Emory University, Atlanta · lab fit 50%
  • Stuart A Batterman — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Sung Kyun Park — University of Michigan, Michigan · lab fit 33% · not yet researched
  • Sung-hee Lee — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Susan Anne Bell — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Susan V Brooks — University of Michigan, Michigan · lab fit 45% · not yet researched
  • Susanne Brummelte — Wayne State University, Michigan · lab fit 23% · not yet researched
  • Susmit Suvas — Wayne State University, Michigan · lab fit 21% · not yet researched
  • Suvarna Alladi — Emory University, Atlanta · lab fit 36% · not yet researched
  • Suzanne M Moenter — University of Michigan, Michigan · lab fit 22% · not yet researched
  • Svjetlana Miocinovic — Emory University, Atlanta · lab fit 40%
  • Swathi Yadlapalli — University of Michigan, Michigan · lab fit 48% · not yet researched
  • Taosheng Liu — Michigan State University, Michigan · lab fit 27% · not yet researched
  • Taraz G. Lee — University of Michigan, Michigan · lab fit 30%
  • Terrone L Rosenberry — Georgia Institute of Technology, Atlanta · lab fit 38% · not yet researched
  • Thackery Ian Brown — Georgia Institute of Technology, Atlanta · lab fit 33% · not yet researched
  • Thad A Polk — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Thanh Hoang — University of Michigan, Michigan · lab fit 52% · no NIH award matched · not yet researched
  • Thomas Joseph Wubben — University of Michigan, Michigan · lab fit 70%
  • Thomas L Kukar — Emory University, Atlanta · lab fit 41% · not yet researched
  • Thomas Wichmann — Emory University, Atlanta · lab fit 41% · not yet researched
  • Thota Ganesh — Emory University, Atlanta · lab fit 26% · not yet researched
  • Tiandong Leng — Morehouse School of Medicine, Atlanta · lab fit 27% · not yet researched
  • Timothy C Cope — Georgia Institute of Technology, Atlanta · lab fit 36% · not yet researched
  • Timothy Robert Sampson — Emory University, Atlanta · lab fit 36% · not yet researched
  • Todd E Golde — Emory University, Atlanta · lab fit 61%
  • Tomomi Ichinose — Wayne State University, Michigan · lab fit 40% · not yet researched
  • Toni Claudette Antonucci — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Travis Walton — Van Andel Institute, Michigan · lab fit 27% · not yet researched
  • Tulay Adali — Georgia State University, Atlanta · lab fit 23% · not yet researched
  • Tzumin Lee — University of Michigan, Michigan · lab fit 36% · not yet researched
  • Ursula H. Jakob — University of Michigan, Michigan · lab fit 45% · not yet researched
  • Vaibhav A. Diwadkar — Wayne State University, Michigan · lab fit 23% · not yet researched
  • Vanessa Brown — Emory University, Atlanta · lab fit 15% · not yet researched
  • Vasiliki Michopoulos — Emory University, Atlanta · lab fit 30% · not yet researched
  • Vince D Calhoun — Georgia State University, Atlanta · lab fit 29% · not yet researched
  • Vincent D Costa — Emory University, Atlanta · lab fit 14% · not yet researched
  • Vishnu D Suppiramaniam — Kennesaw State University, Atlanta · lab fit 23% · not yet researched
  • Viswanathan Mohan — Emory University, Atlanta · lab fit 36% · not yet researched
  • Wei Li — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 33% · not yet researched
  • Wenjing Wang — University of Michigan, Michigan · lab fit 44% · not yet researched
  • Whitney Lee Wharton — Emory University, Atlanta · lab fit 27% · not yet researched
  • William Charles Stacey — University of Michigan, Michigan · lab fit 14% · not yet researched
  • William Joseph Chopik — Michigan State University, Michigan · lab fit 29% · not yet researched
  • William T Birdsong — University of Michigan, Michigan · lab fit 28% · not yet researched
  • Woon-hong Yeo — Georgia Institute of Technology, Atlanta · lab fit 18% · not yet researched
  • Xianshuang Liu — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 27% · not yet researched
  • Xiao Hu — Emory University, Atlanta · lab fit 27% · not yet researched
  • Xuefei Huang — Michigan State University, Michigan · lab fit 25% · not yet researched
  • Yang Yang — Van Andel Institute, Michigan · lab fit 55%
  • Ye Xiong — Henry Ford Health + Michigan State University Health Sciences, Michigan · lab fit 38% · not yet researched
  • Yi Lu Murphey — University of Michigan, Michigan · lab fit 23% · not yet researched
  • Ying Guo — Emory University, Atlanta · lab fit 14% · not yet researched
  • Yoland Smith — Emory University, Atlanta · lab fit 41% · not yet researched
  • Yona R Levites — Emory University, Atlanta · lab fit 61% · not yet researched
  • Yu Wang — University of Michigan, Michigan · lab fit 30% · not yet researched
  • Yue Feng — Emory University, Atlanta · lab fit 42% · not yet researched
  • Zachary Thomas Mceachin — Emory University, Atlanta · lab fit 39% · not yet researched
  • Zhen Xu — University of Michigan, Michigan · lab fit 25% · not yet researched
  • Zhexing Wen — Emory University, Atlanta · lab fit 62% · not yet researched
  • Zixu Mao — Emory University, Atlanta · lab fit 56%